gamma-aminobutyric acid has been researched along with Pain in 743 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We hypothesized that the addition of coenzyme Q10 (CoQ10) to pregabalin might be helpful in improving symptoms in patients suffering from painful diabetic neuropathy (PDN)." | 9.51 | Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial. ( Amini, P; Mehrpooya, M; Mirjalili, M; Mohammadi, Y; Sajedi, F, 2022) |
| "On the intent‑to‑treat population (ITT) analysis, the CoQ10 + pregabalin regimen resulted in significantly greater pain relief than the placebo + pregabalin regimen." | 9.51 | Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial. ( Amini, P; Mehrpooya, M; Mirjalili, M; Mohammadi, Y; Sajedi, F, 2022) |
| "05 mol/L GABA, 1% lidocaine) was investigated for the amelioration of pain and sensitivity induced by application of capsaicin (1%, 2 min) to the tongue of thirty healthy male and female subjects in this four-session, randomized, placebo-controlled, double-blinded, cross-over study." | 9.27 | γ-Aminobutyric acid (GABA) oral rinse reduces capsaicin-induced burning mouth pain sensation: An experimental quantitative sensory testing study in healthy subjects. ( Arendt-Nielsen, L; Cairns, BE; Wang, K; Zhang, Y, 2018) |
| "Capsaicin-induced burning tongue pain and decreases in WDT and HPT can be ameliorated by rinsing the mouth with lidocaine and GABA solutions." | 9.27 | γ-Aminobutyric acid (GABA) oral rinse reduces capsaicin-induced burning mouth pain sensation: An experimental quantitative sensory testing study in healthy subjects. ( Arendt-Nielsen, L; Cairns, BE; Wang, K; Zhang, Y, 2018) |
| "Capsaicin application on the tongue evoked burning pain with a peak of 4." | 9.27 | γ-Aminobutyric acid (GABA) oral rinse reduces capsaicin-induced burning mouth pain sensation: An experimental quantitative sensory testing study in healthy subjects. ( Arendt-Nielsen, L; Cairns, BE; Wang, K; Zhang, Y, 2018) |
| "Rinsing the mouth with an oral GABA containing solution ameliorated burning pain and increased heat sensitivity produced by application of capsaicin to the tongue." | 9.27 | γ-Aminobutyric acid (GABA) oral rinse reduces capsaicin-induced burning mouth pain sensation: An experimental quantitative sensory testing study in healthy subjects. ( Arendt-Nielsen, L; Cairns, BE; Wang, K; Zhang, Y, 2018) |
| " Nonetheless, pain intensity reduction is achieved with 50% of the minimum required gabapentin dose alone (800 to 1600 mg/d) in classic NDD trials." | 9.22 | Clinical Trial Assessing the Efficacy of Gabapentin Plus B Complex (B1/B12) versus Pregabalin for Treating Painful Diabetic Neuropathy. ( Aguilar Navarro, S; Mimenza Alvarado, A, 2016) |
| "HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G)." | 9.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "This pilot study is the first prospective randomized trial of gabapentin for RIM-related pain." | 9.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "Pregabalin has been used for the treatment of pain." | 9.22 | A Validated Fluorometric Method for the Rapid Determination of Pregabalin in Human Plasma Applied to Patients With Pain. ( Kawakami, J; Naito, T; Yagi, T; Yoshikawa, N, 2016) |
| "To assess effects of pregabalin on colonic compliance, sensory and motor functions in patients with constipation-predominant irritable bowel syndrome." | 9.19 | Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome. ( Burton, D; Busciglio, I; Camilleri, M; Iturrino, J; Zinsmeister, AR, 2014) |
| "In a pilot, double-blind, placebo-controlled, parallel-group study, we tested oral pregabalin, 200mg, in 18 patients with constipation-predominant irritable bowel syndrome." | 9.19 | Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome. ( Burton, D; Busciglio, I; Camilleri, M; Iturrino, J; Zinsmeister, AR, 2014) |
| "Pregabalin, 200mg, might not reduce distension-related colonic pain in constipation-predominant irritable bowel syndrome patients." | 9.19 | Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome. ( Burton, D; Busciglio, I; Camilleri, M; Iturrino, J; Zinsmeister, AR, 2014) |
| "In prior studies, pregabalin reduced rectal or colonic pain in patients with irritable bowel syndrome and healthy adults, suggesting reduction of afferent function." | 9.19 | Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome. ( Burton, D; Busciglio, I; Camilleri, M; Iturrino, J; Zinsmeister, AR, 2014) |
| "The intradermal capsaicin pain model has been used to evaluate analgesic effects of a variety of drugs." | 9.19 | Determination of the effective dose of pregabalin on human experimental pain using the sequential up-down method. ( Wallace, MS; Wong, W, 2014) |
| "Using the Dixon sequential up-down method, the ED50 of pregabalin on intradermal capsaicin induced pain was successfully calculated (252 mg) using only 13 subjects." | 9.19 | Determination of the effective dose of pregabalin on human experimental pain using the sequential up-down method. ( Wallace, MS; Wong, W, 2014) |
| "Based on the obtained data, prophylactic lornoxicam controlled postendodontic treatment pain more effectively than did the placebo drugs, and gabapentin was more effective in controlling the pain than either lornoxicam or the placebo." | 9.19 | Analgesic efficacy of prophylactic gabapentin and lornoxicam in preventing postendodontic pain. ( Aktuna, S; Işik, B; Turan, A; Yaman, S, 2014) |
| "This multicentre, double-blind, parallel-group study in diabetic peripheral neuropathic pain addressed whether, in patients not responding to standard doses of duloxetine or pregabalin, combining both medications is superior to increasing each drug to its maximum recommended dose." | 9.17 | Duloxetine and pregabalin: high-dose monotherapy or their combination? The "COMBO-DN study"--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. ( Bouhassira, D; Cruccu, G; Freynhagen, R; Lledo, A; Schacht, A; Skljarevski, V; Tesfaye, S; Tölle, T; Wilhelm, S, 2013) |
| "Gabapentin is increasingly being used for the treatment of postoperative pain and a variety of psychiatric diseases, including chronic anxiety disorders." | 9.17 | Gabapentin reduces preoperative anxiety and pain catastrophizing in highly anxious patients prior to major surgery: a blinded randomized placebo-controlled trial. ( Clarke, H; Katz, J; Katznelson, R; Kirkham, KR; Ko, R; Ma, M; Mitsakakis, N; Orser, BA; Snyman, A, 2013) |
| " Following ethics approval and informed consent, 50 female patients with a 0-10 numeric rating scale (NRS) anxiety score of greater than or equal to 5/10 consented to receive either gabapentin 1,200 mg (n = 25) or placebo (n = 25) prior to surgery." | 9.17 | Gabapentin reduces preoperative anxiety and pain catastrophizing in highly anxious patients prior to major surgery: a blinded randomized placebo-controlled trial. ( Clarke, H; Katz, J; Katznelson, R; Kirkham, KR; Ko, R; Ma, M; Mitsakakis, N; Orser, BA; Snyman, A, 2013) |
| "Administration of gabapentin 1,200 mg prior to surgery reduces preoperative NRS anxiety scores and pain catastrophizing scores and increases sedation prior to entering the operating room." | 9.17 | Gabapentin reduces preoperative anxiety and pain catastrophizing in highly anxious patients prior to major surgery: a blinded randomized placebo-controlled trial. ( Clarke, H; Katz, J; Katznelson, R; Kirkham, KR; Ko, R; Ma, M; Mitsakakis, N; Orser, BA; Snyman, A, 2013) |
| "To study the effects of pregabalin on development of secondary oesophageal hypersensitivity in healthy humans." | 9.16 | Randomised clinical trial: pregabalin attenuates the development of acid-induced oesophageal hypersensitivity in healthy volunteers - a placebo-controlled study. ( Aziz, Q; Chua, YC; Jafari, J; Knowles, CH; Ng, KS; Sharma, A; Surguy, S; Yazaki, E, 2012) |
| "Pregabalin attenuates development of secondary hypersensitivity in the proximal oesophagus after distal oesophageal acidification; it may thus have a role in treatment of patients with proven oesophageal pain hypersensitivity." | 9.16 | Randomised clinical trial: pregabalin attenuates the development of acid-induced oesophageal hypersensitivity in healthy volunteers - a placebo-controlled study. ( Aziz, Q; Chua, YC; Jafari, J; Knowles, CH; Ng, KS; Sharma, A; Surguy, S; Yazaki, E, 2012) |
| "To assess the effect of pregabalin on polysomnographic (PSG) measures of sleep and patient-rated sleep, tiredness, and pain in fibromyalgia patients." | 9.16 | Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study. ( Bhadra, P; Lankford, DA; Resnick, EM; Roth, T; Whalen, E, 2012) |
| "Patients with fibromyalgia treated with pregabalin had statistically significant and meaningful improvements in sleep, as assessed by PSG." | 9.16 | Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study. ( Bhadra, P; Lankford, DA; Resnick, EM; Roth, T; Whalen, E, 2012) |
| "This study compared the effects of pregabalin (300 mg) and the tetracycline antibiotic and glial attenuator minocycline (400 mg) on capsaicin-induced spontaneous pain, flare, allodynia and hyperalgesia in patients with unilateral sciatica on both their affected and unaffected leg." | 9.16 | The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica. ( Briggs, N; Gentgall, M; Hutchinson, MR; Rolan, P; Sumracki, NM; Williams, DB, 2012) |
| "Patients with unilateral sciatica have heightened responses to intradermal capsaicin compared to pain-free volunteers." | 9.16 | The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica. ( Briggs, N; Gentgall, M; Hutchinson, MR; Rolan, P; Sumracki, NM; Williams, DB, 2012) |
| "It cannot be concluded that minocycline is unsuitable for further evaluation as an anti-neuropathic pain drug as pregabalin, our positive control, failed to reduce capsaicin-induced neuropathic pain." | 9.16 | The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica. ( Briggs, N; Gentgall, M; Hutchinson, MR; Rolan, P; Sumracki, NM; Williams, DB, 2012) |
| "Pregabalin, a high-affinity ligand for α2δ subunits of voltage-gated calcium channels, is a novel pharmacotherapy for chronic pain, partial seizures, and other disorders." | 9.15 | Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. ( Bockbrader, HN; Burger, P; Corrigan, BW; Knapp, L, 2011) |
| "Using nonlinear mixed-effect modeling, 5,583 plasma pregabalin concentration-time samples from 1,723 subjects were analyzed: 2,868 samples from healthy volunteers or subjects with renal impairment (n = 123), 1,513 from patients with partial seizures (n = 626), and 1,202 from patients with chronic pain (n = 974)." | 9.15 | Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. ( Bockbrader, HN; Burger, P; Corrigan, BW; Knapp, L, 2011) |
| "Pregabalin CL/F is related to CLcr, and this relationship is similar among healthy volunteers and patients with either partial seizures or chronic pain disorders." | 9.15 | Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. ( Bockbrader, HN; Burger, P; Corrigan, BW; Knapp, L, 2011) |
| "Pregabalin has demonstrated efficacy in several forms of neuropathic pain, but its long-term efficacy in central post-stroke pain (CPSP) is unproven." | 9.15 | Safety and efficacy of pregabalin in patients with central post-stroke pain. ( Bashford, G; Cheung, R; Dror, V; Kim, JS; Martin, A; Murphy, KT, 2011) |
| "In a randomized, double-blind, placebo-controlled, two-session crossover study the effect of a single oral dose of pregabalin (150 mg) on pain and allodynia was evaluated in 8 subjects with herpes zoster." | 9.15 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| "Compared to an earlier study of gabapentin 900 mg for acute zoster pain and allodynia that followed a nearly identical protocol, pregabalin had a similar effect on pain and was well tolerated, with no difference from placebo on sleepiness." | 9.15 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| "The effect of pregabalin on acute herpes zoster pain has not been previously evaluated." | 9.15 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| "Over 6 hours of observation, pain decreased by a mean of 33% with pregabalin and 14% with placebo (p < 0." | 9.15 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| "This randomised, double-blind, placebo-controlled trial assessed the efficacy and tolerability of pregabalin to alleviate the neuropathic component of moderate to severe burn pain." | 9.15 | Pregabalin in severe burn injury pain: a double-blind, randomised placebo-controlled trial. ( Cabot, PJ; Cramond, T; Doecke, J; Gray, P; Kirby, J; Smith, MT; Williams, B, 2011) |
| "Treatment with trazodone significantly improved global fibromyalgia severity, sleep quality, and depression, as well as pain interference with daily activities although without showing a direct effect on bodily pain." | 9.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| "Although trazodone is frequently used by fibromyalgia patients, its efficacy on this disease has not been adequately studied." | 9.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| " Trazodone, flexibly dosed (50-300 mg/day), was administered to 66 fibromyalgia patients during 12 weeks; 41 patients who completed the treatment accepted to receive pregabalin, also flexibly dosed (75-450 mg/day), added to trazodone treatment for an additional 12-week period." | 9.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| "Trazodone significantly improved fibromyalgia severity and associated symptomatology." | 9.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| " If effective, pregabalin, whose beneficial effects on pain and sleep quality in fibromyalgia have been demonstrated, could complement the antidepressant and anxiolytic effects of trazodone." | 9.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| "This study evaluates the efficacy and tolerability of long-term controlled-release (CR) oxycodone + pregabalin in patients with non-cancer pain, in a real-life setting." | 9.15 | Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study. ( Gatti, A; Longo, G; Sabato, AF; Sabato, E, 2011) |
| "Patients (n = 1,051) with chronic uncontrolled non-cancer pain received CR oxycodone + pregabalin for 1 year." | 9.15 | Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study. ( Gatti, A; Longo, G; Sabato, AF; Sabato, E, 2011) |
| "The combination of CR oxycodone + pregabalin could represent a valuable long-term therapeutic addition to existing pharmacological options for the treatment of non-cancer pain." | 9.15 | Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study. ( Gatti, A; Longo, G; Sabato, AF; Sabato, E, 2011) |
| "Gabapentin has demonstrated efficacy in clinical trials as a pre-emptive analgesic and in acute postoperative pain management." | 9.15 | Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia. ( Marashi, SH; Nadjafi, A; Panah Khahi, M; Yaghooti, AA, 2011) |
| "The pain score was significantly lower in the gabapentin group at two hours post surgery (p-value is 0." | 9.15 | Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia. ( Marashi, SH; Nadjafi, A; Panah Khahi, M; Yaghooti, AA, 2011) |
| "Pre-emptive use of gabapentin 300 mg orally significantly decreases postoperative pain two hours after surgery." | 9.15 | Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia. ( Marashi, SH; Nadjafi, A; Panah Khahi, M; Yaghooti, AA, 2011) |
| "To evaluate the adequacy of a low-dose combination of oxycodone and paracetamol (acetaminophen) in patients with multimodal, chronic, non-malignant pain using the Pain Management Index (PMI)." | 9.14 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "In patients with PHN and painful DPN failing to respond to monotherapy, combination therapy with 5% lidocaine medicated plaster and pregabalin provides additional clinically relevant pain relief and is safe and well-tolerated." | 9.14 | Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "To compare efficacy and safety of 5% lidocaine medicated plaster with pregabalin in patients with post-herpetic neuralgia (PHN) or painful diabetic polyneuropathy (DPN)." | 9.14 | 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| " Data are reported from the initial 4-week comparative phase, in which adults with PHN or painful DPN received either topical 5% lidocaine medicated plaster applied to the most painful skin area or twice-daily pregabalin capsules titrated to effect according to the Summary of Product Characteristics." | 9.14 | 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "Effects of pregabalin (PGB) on patient-reported health outcomes were assessed in 65 PGB-naive subjects with trigeminal neuralgia refractory to previous analgesic therapy in a prospective, multicentre observational study carried out in primary care." | 9.14 | Patient-reported outcomes in subjects with painful trigeminal neuralgia receiving pregabalin: evidence from medical practice in primary care settings. ( Martínez, S; Navarro, A; Pérez, C; Rejas, J; Saldaña, MT, 2009) |
| "To compare the efficacy and safety of pregabalin and amitriptyline in alleviating pain associated with diabetic peripheral neuropathy." | 9.14 | Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. ( Bansal, D; Bhansali, A; Chakrabarti, A; Dutta, P; Hota, D, 2009) |
| "Good, moderate and mild pain relief were noted in 21 (48%), 6 (13%) and 7 (15%) patients on pregabalin and 15 (34%), 5 (11%) and 12 (27%) patients on amitriptyline, respectively, by patient's global assessment of efficacy and safety." | 9.14 | Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. ( Bansal, D; Bhansali, A; Chakrabarti, A; Dutta, P; Hota, D, 2009) |
| "The aim of this randomized double-blind, placebo-controlled, parallel-group study was to evaluate the efficacy, safety, and tolerability of pregabalin in combination with oxycodone or placebo, in patients with either postherpetic neuralgia (PHN) or painful diabetic neuropathy (PDN)." | 9.14 | A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. ( Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010) |
| "The clinical usefulness of gabapentin in combination with opioids for Japanese patients with neuropathic cancer pain was assessed in an open-label, single-center, prospective study." | 9.14 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| "Although gabapentin might be regarded as a promising new adjuvant analgesic for neuropathic cancer pain, our results indicated that the decrease in pain score was of minimal clinical benefit." | 9.14 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| "Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally." | 9.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Low-dose gabapentin-imipramine significantly decreased the total pain score and daily paroxysmal pain episodes." | 9.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Low-dose gabapentin-antidepressant combination with opioids was effective in managing neuropathic cancer pain without severe adverse effects." | 9.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "This study compared the efficacy and safety of tramadol/acetaminophen (T/A) and gabapentin in the management of painful diabetic neuropathy." | 9.14 | Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. ( Baik, SH; Cha, BY; Kim, CH; Kim, DS; Ko, KS; Ko, SH; Kwon, HS; Lee, JH; Mok, JO; Noh, JH; Park, IB; Park, TS; Son, HS; Yu, JM, 2010) |
| "This study suggests that the T/A combination treatment is as effective as gabapentin in the treatment of painful diabetic neuropathy in patients with Type 2 diabetes." | 9.14 | Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. ( Baik, SH; Cha, BY; Kim, CH; Kim, DS; Ko, KS; Ko, SH; Kwon, HS; Lee, JH; Mok, JO; Noh, JH; Park, IB; Park, TS; Son, HS; Yu, JM, 2010) |
| "The objective of this study was to evaluate the effect of patients' characteristics at baseline on the magnitude of pain response to pregabalin in patients with fibromyalgia." | 9.14 | Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics. ( Emir, B; Murphy, TK; Petersel, DL; Whalen, E, 2010) |
| "Data from four randomized, multicenter, placebo-controlled clinical studies of pregabalin in patients with fibromyalgia were used for the analysis." | 9.14 | Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics. ( Emir, B; Murphy, TK; Petersel, DL; Whalen, E, 2010) |
| "The magnitude of response to pregabalin in terms of changes in pain may depend on age, pain, and sleep levels at baseline in patients with fibromyalgia." | 9.14 | Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics. ( Emir, B; Murphy, TK; Petersel, DL; Whalen, E, 2010) |
| "Recent consensus guidelines recommend pregabalin as a first-tier treatment for painful diabetic peripheral neuropathy (DPN)." | 9.13 | Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. ( Arezzo, JC; Lamoreaux, L; Pauer, L; Rosenstock, J, 2008) |
| "Pregabalin 600 mg/d (300 mg BID) effectively reduced pain, was well tolerated, and had no statistically significant or clinically meaningful effect on NC in patients with painful DPN." | 9.13 | Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. ( Arezzo, JC; Lamoreaux, L; Pauer, L; Rosenstock, J, 2008) |
| "Intradermal (ID) capsaicin injection in humans induces spontaneous pain, flare, primary hyperalgesia, secondary hyperalgesia, and allodynia." | 9.13 | Effect of morphine and pregabalin compared with diphenhydramine hydrochloride and placebo on hyperalgesia and allodynia induced by intradermal capsaicin in healthy male subjects. ( Baxendale, J; Bolognese, J; Calder, N; Connell, J; Cummings, C; Herman, G; Kehler, A; Wang, H, 2008) |
| "To evaluate the efficacy and safety of pregabalin for symptomatic relief of pain associated with fibromyalgia (FM) and for management of FM." | 9.13 | A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. ( Arnold, LM; Florian, H; Martin, SA; Mease, PJ; Russell, IJ; Sharma, U; Young, JP, 2008) |
| "Patients in all pregabalin groups showed statistically significant improvement in endpoint mean pain score and in PGIC response compared with placebo." | 9.13 | A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. ( Arnold, LM; Florian, H; Martin, SA; Mease, PJ; Russell, IJ; Sharma, U; Young, JP, 2008) |
| "Pregabalin at 300, 450, and 600 mg/day was efficacious and safe for treatment of pain associated with FM." | 9.13 | A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. ( Arnold, LM; Florian, H; Martin, SA; Mease, PJ; Russell, IJ; Sharma, U; Young, JP, 2008) |
| " The risk of phantom pain (gabapentin vs." | 9.12 | A randomized study of the effects of gabapentin on postamputation pain. ( Finnerup, NB; Jensen, TS; Keller, J; Kramp, S; Nikolajsen, L; Vimtrup, AS, 2006) |
| "Gabapentin administered in the first 30 postoperative days after amputation does not reduce the incidence or intensity of postamputation pain." | 9.12 | A randomized study of the effects of gabapentin on postamputation pain. ( Finnerup, NB; Jensen, TS; Keller, J; Kramp, S; Nikolajsen, L; Vimtrup, AS, 2006) |
| "Gabapentin, an oral non-opioid analgesic, has been used to decrease pain after a variety of surgical procedures." | 9.12 | Premedication with gabapentin: the effect on tourniquet pain and quality of intravenous regional anesthesia. ( Karamanlioglu, B; Pamukçu, Z; Turan, A; White, PF, 2007) |
| " However, tourniquet pain scores at 30, 40, 50, and 60 min after cuff inflation were lower in the gabapentin group (P < 0." | 9.12 | Premedication with gabapentin: the effect on tourniquet pain and quality of intravenous regional anesthesia. ( Karamanlioglu, B; Pamukçu, Z; Turan, A; White, PF, 2007) |
| "To assess the efficacy and safety of gabapentin in patients with fibromyalgia." | 9.12 | Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. ( Arnold, LM; Bishop, F; Goldenberg, DL; Hess, EV; Hudson, JI; Keck, PE; Lalonde, JK; Sandhu, HS; Stanford, KE; Stanford, SB; Welge, JA, 2007) |
| "A 12-week, randomized, double-blind study was designed to compare gabapentin (1,200-2,400 mg/day) (n=75 patients) with placebo (n=75 patients) for efficacy and safety in treating pain associated with fibromyalgia." | 9.12 | Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. ( Arnold, LM; Bishop, F; Goldenberg, DL; Hess, EV; Hudson, JI; Keck, PE; Lalonde, JK; Sandhu, HS; Stanford, KE; Stanford, SB; Welge, JA, 2007) |
| "Gabapentin (1,200-2,400 mg/day) is safe and efficacious for the treatment of pain and other symptoms associated with fibromyalgia." | 9.12 | Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. ( Arnold, LM; Bishop, F; Goldenberg, DL; Hess, EV; Hudson, JI; Keck, PE; Lalonde, JK; Sandhu, HS; Stanford, KE; Stanford, SB; Welge, JA, 2007) |
| "Gabapentin-treated patients displayed a significantly greater improvement in the BPI average pain severity score (P=0." | 9.12 | Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. ( Arnold, LM; Bishop, F; Goldenberg, DL; Hess, EV; Hudson, JI; Keck, PE; Lalonde, JK; Sandhu, HS; Stanford, KE; Stanford, SB; Welge, JA, 2007) |
| "To estimate the cost-effectiveness of branded pregabalin (PGB) versus generic gabapentin (GBP) in patients with neuropathic pain (NeP) due to painful diabetic polyneuropathy (DPN) or post-herpetic neuralgia (PHN) in Spain." | 9.12 | Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007) |
| "According with data used in this modeling in patients with NeP due to DPN and/or PHN, PGB was shown to be more cost-effective than generic gabapentin in Spain." | 9.12 | Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007) |
| "To test the hypotheses that both amitriptyline and gabapentin are more effective in relieving neuropathic pain than an active placebo, diphenhydramine." | 9.12 | Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. ( Courtade, D; Fiess, RN; Holmes, SA; Loubser, PG; Rintala, DH; Tastard, LV, 2007) |
| "Amitriptyline is more efficacious in relieving neuropathic pain than diphenhydramine at or below the level of spinal cord injury in people who have considerable depressive symptomatology." | 9.12 | Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. ( Courtade, D; Fiess, RN; Holmes, SA; Loubser, PG; Rintala, DH; Tastard, LV, 2007) |
| "To determine the analgesic effect of the addition of gabapentin to opioids in the management of neuropathic cancer pain." | 9.11 | Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. ( Arcuri, E; Barbieri, M; Bonezzi, C; Caraceni, A; De Conno, F; Gorni, G; Maltoni, M; Martini, C; Tirelli, W; Visentin, M; Yaya Tur, R; Zecca, E, 2004) |
| "Gabapentin is effective in improving analgesia in patients with neuropathic cancer pain already treated with opioids." | 9.11 | Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. ( Arcuri, E; Barbieri, M; Bonezzi, C; Caraceni, A; De Conno, F; Gorni, G; Maltoni, M; Martini, C; Tirelli, W; Visentin, M; Yaya Tur, R; Zecca, E, 2004) |
| "Patients reported significant pain relief in favor of gabapentin in the first period." | 9.11 | Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. ( Kessels, AH; Stomp-van den Berg, SG; van de Vusse, AC; Weber, WE, 2004) |
| "Gabapentin had a mild effect on pain in CRPS I." | 9.11 | Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. ( Kessels, AH; Stomp-van den Berg, SG; van de Vusse, AC; Weber, WE, 2004) |
| "This multicenter, double-blind, 8-week, randomized clinical trial compared the effects of placebo with those of 150, 300, and 450 mg/day pregabalin on pain, sleep, fatigue, and health-related quality of life in 529 patients with FMS." | 9.11 | Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. ( Corbin, AE; Crofford, LJ; Dworkin, RH; LaMoreaux, LK; Martin, SA; Mease, PJ; Rowbotham, MC; Russell, IJ; Sharma, U; Young, JP, 2005) |
| "Pregabalin at 450 mg/day was efficacious for the treatment of FMS, reducing symptoms of pain, disturbed sleep, and fatigue compared with placebo." | 9.11 | Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. ( Corbin, AE; Crofford, LJ; Dworkin, RH; LaMoreaux, LK; Martin, SA; Mease, PJ; Rowbotham, MC; Russell, IJ; Sharma, U; Young, JP, 2005) |
| "Pregabalin at 450 mg/day significantly reduced the average severity of pain in the primary analysis compared with placebo (-0." | 9.11 | Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. ( Corbin, AE; Crofford, LJ; Dworkin, RH; LaMoreaux, LK; Martin, SA; Mease, PJ; Rowbotham, MC; Russell, IJ; Sharma, U; Young, JP, 2005) |
| "We evaluated the effects of gabapentin and carbamazepine for pain relief in 36 Guillain-Barré syndrome patients." | 9.11 | The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. ( Kumar, A; Navkar, DV; Pandey, CK; Raza, M; Singh, UK; Tripathi, M, 2005) |
| "Gabapentin has been evaluated in the treatment of nonmalignant neuropathic pain, however, there is little direct evidence evaluating its efficacy in cancer-related neuropathic pain." | 9.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "This study evaluated the effectiveness of gabapentin to treat cancer-related neuropathic pain." | 9.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "We conclude that gabapentin is an effective treatment for cancer-related neuropathic pain." | 9.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "A double-blind, randomised, placebo-controlled 8-week study was conducted to evaluate the efficacy and safety of gabapentin in the treatment of neuropathic pain, using doses up to 2400 mg/day." | 9.10 | Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. ( Serpell, MG, 2002) |
| "To assess the effects of gabapentin on sensory and motor symptoms in patients with restless legs syndrome (RLS)." | 9.10 | Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. ( de la Llave, Y; Garcia-Borreguero, D; Hernandez, G; Larrosa, O; Masramon, X; Verger, K, 2002) |
| "Gabapentin, an antiepileptic drug, has been used effectively for different types of pain management." | 9.10 | Gabapentin for the treatment of pain in guillain-barré syndrome: a double-blinded, placebo-controlled, crossover study. ( Agarwal, A; Baronia, A; Bose, N; Garg, G; Pandey, CK; Singh, N; Singh, PK; Singh, U, 2002) |
| "To assess the effectiveness and safety of the lidocaine patch 5%, a targeted peripheral analgesic, in the treatment of postherpetic neuralgia, painful diabetic neuropathy, and low back pain patients with incomplete responses to their current analgesic treatment regimen containing gabapentin." | 9.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Significant improvements in BPI measures of pain intensity and pain relief were reported for all groups of patients after 2 weeks of lidocaine patch 5% treatment." | 9.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "The aim of our study was to explore a potential analgesic effect of gabapentin in patients with neuropathic pain caused by anticancer treatment." | 9.10 | Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. ( Bosnjak, S; Jelic, S; Luki, V; Susnjar, S, 2002) |
| "Reports of gabapentin use in diabetic peripheral neuropathy pain stimulate a need for controlled trials to determine its comparative efficacy to the therapeutic standard of amitriptyline hydrochloride." | 9.09 | Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ( Leckband, SG; Moorhouse, DF; Morello, CM; Sahagian, GA; Stoner, CP, 1999) |
| "To determine the efficacy of gabapentin compared with amitriptyline in treating diabetic peripheral neuropathy pain." | 9.09 | Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ( Leckband, SG; Moorhouse, DF; Morello, CM; Sahagian, GA; Stoner, CP, 1999) |
| "Patients with stable glycemic control and neuropathic pain randomized to 6 weeks of therapy with gabapentin, 900 to 1800 mg/d, or amitriptyline hydrochloride, 25 to 75 mg/d, with a 1-week washout before crossover." | 9.09 | Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ( Leckband, SG; Moorhouse, DF; Morello, CM; Sahagian, GA; Stoner, CP, 1999) |
| "Although both drugs provide pain relief, mean pain score and global pain score data indicate no significant difference between gabapentin and amitriptyline." | 9.09 | Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ( Leckband, SG; Moorhouse, DF; Morello, CM; Sahagian, GA; Stoner, CP, 1999) |
| "The objective of this study was to compare the efficacy and tolerability of gabapentin and amitriptyline monotherapy in painful diabetic neuropathy." | 9.09 | Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. ( Buffa, C; Chiroli, S; Dallocchio, C; Mazzarello, P, 2000) |
| "Twenty-one patients referred with refractory genitourinary pain were treated with oral gabapentin." | 9.09 | Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. ( Chancellor, MB; Chuang, YC; Kim, JC; Lee, JY; Sasaki, K; Smith, CP, 2001) |
| "Although only 10 of 21 patients improved with gabapentin, this cohort included only patients with refractory genitourinary pain that failed a wide range of prior treatments." | 9.09 | Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. ( Chancellor, MB; Chuang, YC; Kim, JC; Lee, JY; Sasaki, K; Smith, CP, 2001) |
| "To evaluate the effects of gabapentin on pain scores and opiate use." | 9.08 | The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997) |
| " A significant decrease in pain scores with gabapentin was seen in the neuropathic pain group (paired t-test, p < ." | 9.08 | The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997) |
| "Gabapentin may be a useful adjunct for treating neuropathic pain with a minimum of side effects." | 9.08 | The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997) |
| "Having a differential sensitivity to morphine can distinguish migraine suffers from healthy people who are headache-exempt." | 9.08 | Painful and non-painful effects of low doses of morphine in migraine sufferers partly depend on excitatory amino acids and gamma-aminobutyric acid. ( Nicolodi, M, 1998) |
| "A large case series of patients with centrally mediated pain, peripherally mediated pain, migraine, and tremor were treated in an open-label study with gabapentin (maximum of 2,700 mg/day)." | 9.08 | Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998) |
| "Gabapentin offers an effective, safe alternative therapy or co-therapy for the listed painful conditions and tremor; it does not affect the metabolism of other medications and is well tolerated." | 9.08 | Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998) |
| "To evaluate the effect of gabapentin monotherapy on pain associated with diabetic peripheral neuropathy." | 9.08 | Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. ( Backonja, M; Beydoun, A; Edwards, KR; Fonseca, V; Garofalo, E; Hes, M; LaMoreaux, L; Schwartz, SL, 1998) |
| "Gabapentin monotherapy appears to be efficacious for the treatment of pain and sleep interference associated with diabetic peripheral neuropathy and exhibits positive effects on mood and quality of life." | 9.08 | Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. ( Backonja, M; Beydoun, A; Edwards, KR; Fonseca, V; Garofalo, E; Hes, M; LaMoreaux, L; Schwartz, SL, 1998) |
| "This article reviews the existing literature on the use of gabapentin (Neurontin®) as a co-analgesic in treating the neuropathic pain in OM." | 8.93 | Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016) |
| "No systematic reviews exist on the role of gabapentin for neuropathic pain in radiation-induced OM." | 8.93 | Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016) |
| "Gabapentin (GBP), originally an antiepileptic drug, is more commonly used in the treatment of neuropathic pain." | 8.90 | Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain. ( Butler, PM; Kurowski, D; Perloff, MD; Yan, PZ, 2014) |
| "We performed a meta-analysis of individual patient data from four large trials of pregabalin for fibromyalgia lasting 8-14 weeks." | 8.87 | Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. ( Derry, S; Hallier, E; McQuay, HJ; Moore, RA; Paine, J; Phillips, CJ; Straube, S, 2011) |
| "Significant benefit of pregabalin over placebo was seen for a variety of outcomes including mean pain and sleep scores, the proportion of patients achieving at least 50% pain relief and most of the individual domains of short-form 36." | 8.86 | Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S, 2010) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 8.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Recent studies showed effectiveness of gabapentin in improving the pain control in patients with neuropathic cancer pain, already treated with opiates." | 8.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Given the significant benefits of gabapentin and the combination of gabapentin with opioids for the treatment of neuropathic pain, randomized clinical trials are needed to establish the role of these analgesic regimens for the treatment of neuropathic cancer pain." | 8.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "To review the efficacy and safety of pregabalin, an alpha(2)-delta (alpha(2)-delta) ligand, for the management of fibromyalgia (FM)." | 8.86 | Pregabalin: an alpha2-delta (alpha2-delta) ligand for the management of fibromyalgia. ( Arnold, L; Mease, P; Silverman, S, 2010) |
| "What is the role of pregabalin (Lyrica) in the treatment of fibromyalgia? In this article the authors explore the putative pathophysiology of fibromyalgia, pregabalin's mechanism of action and evidence of efficacy, and its emerging role in treating this challenging disease." | 8.85 | Pregabalin for fibromyalgia: some relief but no cure. ( Deodhar, A; Kim, L; Lipton, S, 2009) |
| "Pregabalin has proven efficacy in neuropathic pain conditions and fibromyalgia." | 8.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "To assess analgesic efficacy and associated adverse events of pregabalin in acute and chronic pain." | 8.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "Randomised, double blind trials reporting on the analgesic effect of pregabalin, with subjective pain assessment by the patient as either the primary or a secondary outcome." | 8.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "There was no clear evidence of beneficial effects of pregabalin in established acute postoperative pain." | 8.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "Pregabalin is the first drug to receive approved labeling from the Food and Drug Administration (FDA) for the treatment of painful diabetic neuropathy and postherpetic neuralgia and is the first antiepileptic agent to receive FDA-approved labeling since 1999." | 8.84 | Pregabalin: an antiepileptic agent useful for neuropathic pain. ( Blommel, AL; Blommel, ML, 2007) |
| "Pregabalin may be beneficial for the treatment of neuropathic pain or partial-onset seizures in patients who do not respond to conventional treatments or cannot tolerate their adverse effects." | 8.84 | Pregabalin: an antiepileptic agent useful for neuropathic pain. ( Blommel, AL; Blommel, ML, 2007) |
| "Pregabalin is increasingly being used for the treatment ofneuropathic pain, often as the first-line choice." | 8.84 | [Pregabalin in the treatment of neuropathic pain]. ( Biegstraaten, M; van Schaik, IN, 2007) |
| "Multiple, large, high-quality trials have demonstrated the safety and efficacy of gabapentin and pregabalin in neuropathic pain." | 8.84 | Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. ( Gilron, I, 2007) |
| "Gabapentin and pregabalin are efficacious treatments for neuropathic and postsurgical pain." | 8.84 | Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. ( Gilron, I, 2007) |
| "Gabapentin is a drug that has been widely used in the treatment of chronic pain states." | 8.83 | alpha2delta and the mechanism of action of gabapentin in the treatment of pain. ( Lee, K; Luo, ZD; Maneuf, YP, 2006) |
| " Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Randomized controlled studies of gabapentin for neuropathic pain were identified through a search of PubMed and MEDLINE from 1966 to the present using the search terms gabapentin, randomized, placebo, and pain." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "At doses of 1800 to 3600 mg/d, gabapentin was effective and well tolerated in the treatment of adults with neuropathic pain." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Gabapentin is a very promising medication in the treatment of post-herpetic neuralgia and pain." | 8.82 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "This paper reviews the pharmacology and clinical effectiveness of gabapentin in the treatment of neuropathic pain." | 8.82 | Gabapentin in the treatment of neuropathic pain. ( Bennett, MI; Simpson, KH, 2004) |
| "To evaluate the analgesic effectiveness and adverse effects of gabapentin for pain management in clinical practice." | 8.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "Randomised trials of gabapentin in acute, chronic or cancer pain were identified by MEDLINE (1966-Nov 2004), EMBASE (1994-Nov 2004), SIGLE (1980-Jan 2004) and the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library Issue 4, 2004)." | 8.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "Randomised trials reporting the analgesic effects of gabapentin in patients, with subjective pain assessment as either the primary or a secondary outcome." | 8.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "There is evidence to show that gabapentin is effective in neuropathic pain." | 8.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| " The search terms included pregabalin, PD144723, CI-1008, gabapentin, and neuropathic pain." | 8.82 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "In preclinical studies, pregabalin, a structural congener of gabapentin, exhibited antinociceptive activity in animal models of neuropathic and inflammatory pain." | 8.82 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "This article reviews the available information on pregabalin, a new anticonvulsant for peripheral neuropathic pain." | 8.82 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "Gabapentin, which has been approved for add-on therapy of focal seizures, is increasingly used for treatment of neuropathic pain." | 8.81 | [Gabapentin therapy for pain]. ( Block, F, 2001) |
| "Although its exact mode of action is not known, gabapentin appears to have a unique effect on voltage-dependent calcium ion channels at the postsynaptic dorsal horns and may, therefore, interrupt the series of events that possibly leads to the experience of a neuropathic pain sensation." | 8.81 | Gabapentin: pharmacology and its use in pain management. ( Kam, PC; Rose, MA, 2002) |
| "There have been many proposed uses for gabapentin, including midscapular pain secondary to radiation myelopathy, RSD, neuropathic pain, postherpetic neuralgia, and migraine prophylaxis." | 8.79 | Use of gabapentin in pain management. ( Connelly, JF; Wetzel, CH, 1997) |
| "We assessed the efficacy and safety of extended-release gabapentin in a 15-week, open-label, single-arm, single-center study in patients with fibromyalgia (FM)." | 7.83 | The Effect of a Novel form of Extended-Release Gabapentin on Pain and Sleep in Fibromyalgia Subjects: An Open-Label Pilot Study. ( Hong, KS; North, JM; Rauck, RL, 2016) |
| "Extended-release gabapentin relieved FM pain symptoms and improved quality-of-life for the FM subjects studied." | 7.83 | The Effect of a Novel form of Extended-Release Gabapentin on Pain and Sleep in Fibromyalgia Subjects: An Open-Label Pilot Study. ( Hong, KS; North, JM; Rauck, RL, 2016) |
| "The study objective was to describe presenting pain behaviors, daily dose, and response to gabapentin for the management of frequent recurrent pain in this population." | 7.81 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| "A retrospective analysis was performed with data from 22 children with severe impairment of the CNS residing at a long-term care facility, treated with gabapentin for recurrent pain behaviors." | 7.81 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| "Gabapentin appears to be an effective treatment for children with severe impairment of the CNS and recurrent pain behaviors, including intermittent changes in muscle tone." | 7.81 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| "Although pregabalin has been shown to have preclinical and clinical efficacy in neuropathic pain, the mechanism of its antinociceptive action is still unknown in other pain states." | 7.80 | Inhibition of mitogen-activated protein kinases phosphorylation plays an important role in the anti-nociceptive effect of pregabalin in zymosan-induced inflammatory pain model. ( Jeong, YC; Kwon, YB; Pyun, K, 2014) |
| " We tested the ability of quantitative sensory testing to predict the analgesic effect of pregabalin and placebo in patients with chronic pancreatitis." | 7.79 | Quantitative sensory testing predicts pregabalin efficacy in painful chronic pancreatitis. ( Bouwense, SA; Drewes, AM; Graversen, C; Olesen, SS; van Goor, H; Wilder-Smith, OH, 2013) |
| "Sixty-four patients with painful chronic pancreatitis received pregabalin (150-300 mg BID) or matching placebo for three consecutive weeks." | 7.79 | Quantitative sensory testing predicts pregabalin efficacy in painful chronic pancreatitis. ( Bouwense, SA; Drewes, AM; Graversen, C; Olesen, SS; van Goor, H; Wilder-Smith, OH, 2013) |
| "The present study provides first evidence that quantitative sensory testing predicts the analgesic effect of pregabalin in patients with painful chronic pancreatitis." | 7.79 | Quantitative sensory testing predicts pregabalin efficacy in painful chronic pancreatitis. ( Bouwense, SA; Drewes, AM; Graversen, C; Olesen, SS; van Goor, H; Wilder-Smith, OH, 2013) |
| "The rostroventromedial medulla (RVM) is an important area of the endogenous pain-regulating system, in which 5-hydroxytryptamine (5-HT) and gamma-aminobutyric acid (GABA) are 2 main transmitters involved in pain modulation." | 7.79 | Neurokinin-1 receptor-expressing neurons that contain serotonin and gamma-aminobutyric acid in the rat rostroventromedial medulla are involved in pain processing. ( Chen, T; Li, YQ; Qu, J; Wang, W; Wang, XL; Wu, SX; Yanagawa, Y; Zhang, T, 2013) |
| "We report two cases of infants with NI, identified to have significant improvement in apnea following empiric treatment with gabapentin for presumed central pain and/or visceral hyperalgesia." | 7.79 | Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment. ( Hauer, J; Mackey, D, 2013) |
| " This secondary hypertonia may contribute to apnea as a result of alterations in airway tone and chest wall movement." | 7.79 | Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment. ( Hauer, J; Mackey, D, 2013) |
| "Infants with NI and apnea should have careful pain assessment and treatment, when considering other causes and interventions for apnea." | 7.79 | Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment. ( Hauer, J; Mackey, D, 2013) |
| "The involvement of voltage-dependent calcium channels and reactive oxygen species in the pathophysiology of neuropathic pain might justify the preventative administration of antioxidant enzymes, at low doses, in combination with gabapentin (GaP) to maximize its analgesic effect in an experimental model of neuropathic pain in rats." | 7.79 | Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model. ( Arcos, M; Barrios, C; Montes, F; Palanca, JM, 2013) |
| "The frequency of PHN after untreated zoster varies widely." | 7.79 | Postherpetic neuralgia: role of gabapentin and other treatment modalities. ( Beydoun, A, 1999) |
| "To characterize and compare healthcare resource utilization and costs among patients with painful diabetic peripheral neuropathy (pDPN) newly prescribed pregabalin or gabapentin in a real-world clinical setting." | 7.78 | Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. ( Harnett, J; Mardekian, J; Udall, M, 2012) |
| "The aim of present study was to investigate the antinociceptive effect of pregabalin and tramadol either alone and or in combination on acute model of pain." | 7.78 | Pregabalin antinociception and its interaction with tramadol in acute model of pain. ( Keyhanfar, F; Meymandi, MS, 2012) |
| "Pregabalin revealed a comparative antinociceptive effect as similar to tramadol in acute model of pain, but interaction between these two drugs depends highly on their proportion in the combination." | 7.78 | Pregabalin antinociception and its interaction with tramadol in acute model of pain. ( Keyhanfar, F; Meymandi, MS, 2012) |
| "The objective of the study was to conduct an analysis of pooled data from pregabalin fibromyalgia clinical trials to determine which fibromyalgia symptom and function domains drive patient perception of improvement." | 7.77 | Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin. ( Arnold, LM; Emir, B; Sadosky, A; Whalen, E; Zlateva, G, 2011) |
| "Data from three double-blind, placebo-controlled trials of pregabalin in fibromyalgia patients were pooled for this analysis." | 7.77 | Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin. ( Arnold, LM; Emir, B; Sadosky, A; Whalen, E; Zlateva, G, 2011) |
| "Numerous controlled clinical trials have demonstrated the safety and efficacy of pregabalin in the treatment of neuropathic pain." | 7.77 | Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. ( Anastassiou, E; Iatrou, CA; Lyras, L; Plesia, E; Stamatiou, G; Vadalouca, A; Vafiadou, M; Vlaikidis, N, 2011) |
| "This was a non-interventional, multicentre study in which pregabalin was administered for 8 weeks, at the therapeutic dosages of 150-600 mg/day, to patients with a diagnosis of neuropathic pain." | 7.77 | Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. ( Anastassiou, E; Iatrou, CA; Lyras, L; Plesia, E; Stamatiou, G; Vadalouca, A; Vafiadou, M; Vlaikidis, N, 2011) |
| "Significant reductions in pain and pain-related sleep interference, combined with reductions in feelings of anxiety and depression, suggest that pregabalin under real-world conditions improves the overall health and well-being of patients with neuropathic pain." | 7.77 | Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. ( Anastassiou, E; Iatrou, CA; Lyras, L; Plesia, E; Stamatiou, G; Vadalouca, A; Vafiadou, M; Vlaikidis, N, 2011) |
| "This retrospective study evaluates the efficacy of gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck tumors." | 7.76 | Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. ( Bar Ad, V; Both, S; Chalian, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "By using a median dose of 2700 mg/day of gabapentin, only 10% of patients required additional narcotic pain medications for adequate pain relief during the third and fourth week of treatment, despite grade 2 or higher mucositis present in 56% and 73% of the patients, respectively." | 7.76 | Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. ( Bar Ad, V; Both, S; Chalian, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "Gabapentin appears promising in reducing the need for narcotic pain medication for patients with head and neck malignancies treated with IMRT and should be further evaluated prospectively in controlled clinical trials." | 7.76 | Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. ( Bar Ad, V; Both, S; Chalian, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "Milnacipran and duloxetine, serotonin/noradrenalin reuptake inhibitors, and pregabalin, a alpha(2)-delta(1) Ca(2+) channel blocker, are efficacious against fibromyalgia, a condition characterized by diffuse chronic pain and associated with stress." | 7.76 | Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of stress-induced ultrasonic vocalizations in rats. ( Aliaga, M; Bardin, L; Depoortère, R; Gregoire, S; Ladure, P; Malfetes, N; Newman-Tancredi, A; Vitton, O, 2010) |
| "The aim of this study was to assess the role of adding gabapentin (Neurontin) to the prescription of patients with opiate resistant pain as a result of critical limb ischaemia (CLI)." | 7.76 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "The study has demonstrated that gabapentin is a useful adjuvant in the management of CLI and leads to significant reductions in pain scores and improves night pain for most patients." | 7.76 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "To determine the utility of substitution of pregabalin (PGB) for gabapentin (GBP) therapy in the relief of neuropathic pain (NeP) in patients with peripheral neuropathy (PN)." | 7.76 | Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. ( Toth, C, 2010) |
| "Gabapentin, an anticonvulsant, is widely accepted as an alternative therapeutic agent for neuropathic pain and has proved to produce analgesic effects in a mouse model of visceral pain." | 7.76 | Analgesic effects of gabapentin on mechanical hypersensitivity in a rat model of chronic pancreatitis. ( Chen, H; Liao, XZ; Mao, YF; Sun, JH; Xiong, YC; Xu, H; Zhou, MT, 2010) |
| "The objective of this study was to develop a pharmacokinetic-pharmacodynamic (PK-PD) model of the static allodynia response to pregabalin with and without sildenafil in a chronic constriction injury model of neuropathic pain." | 7.76 | Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain. ( Bender, G; Bies, RR; Bramwell, S; Danhof, M; DeJongh, J; Field, MJ; Florian, JA; Marshall, S; Tan, KK, 2010) |
| "Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy." | 7.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| "This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain." | 7.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| "This retrospective study evaluated the efficacy of gabapentin for the treatment of pain syndromes related to radiation-induced mucositis in patients with head and neck cancers treated with concurrent chemoradiation." | 7.76 | Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. ( Bar Ad, V; Both, S; Chalian, A; Dosoretz, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "At a median dose of 2700 mg/day of gabapentin, only 33% and 55% of patients required additional low-dose narcotic medications for pain control during the third and fourth week of treatment, respectively, despite exhibiting a grade 2 or higher mucositis in 71% and 86% of the patients, respectively." | 7.76 | Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. ( Bar Ad, V; Both, S; Chalian, A; Dosoretz, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "The inhibitory transmitters GABA and glycine play an important role in modulating pain transmission, both in normal and in pathological situations." | 7.76 | Differential distribution of activated spinal neurons containing glycine and/or GABA and expressing c-fos in acute and chronic pain models. ( Duraku, LS; Holstege, JC; Hossaini, M; Jongen, JLM; Saraç, Ç, 2010) |
| "To evaluate changes in healthcare resource use and costs after initiating pregabalin or duloxetine in employees with pain associated with diabetic peripheral neuropathy (pDPN)." | 7.76 | Evaluation of healthcare resource utilization and costs in employees with pain associated with diabetic peripheral neuropathy treated with pregabalin or duloxetine. ( Cao, Z; Fowler, R; Harnett, J; Mardekian, J; Margolis, J; Sanchez, RJ; Silverman, SL, 2010) |
| " Using pharmacological and transgenic approaches in mice, we evaluated adrenergic receptor (AR) implication in the action of the tricyclic antidepressant desipramine, the noradrenaline and serotonin reuptake inhibitor venlafaxine, and the noradrenaline reuptake inhibitor reboxetine." | 7.75 | Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain. ( Barrot, M; Doridot, S; Freund-Mercier, MJ; Hein, L; Petit-Demoulière, N; Tessier, LH; Yalcin, I, 2009) |
| "The GABA amides of the antidepressants nortriptyline and fluoxetine, 1 and 2, were compared to their respective parent compounds in rodent models of pain." | 7.75 | Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity. ( Aharoni, A; Geffen, Y; Gil-Ad, I; Halbfinger, E; Nisemblat, Y; Nudelman, A; Rephaeli, A; Tarasenko, I; Tarasenko, N; Weizman, A, 2009) |
| "In order to detect an anti-nociceptive interaction between morphine and gabapentin, the anti-allodynic and anti-hyperalgesic effects of these drugs, administered either separately or in combination, were determined using the von Frey and acetone tests in a rat model of neuropathic pain (Bennett model)." | 7.75 | Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury. ( Cortés-Arroyo, AR; De la O-Arciniega, M; Díaz-Reval, MI; Domínguez-Ramírez, AM; López-Muñoz, FJ, 2009) |
| "Gabapentin is a gamma-aminobutyric acid analog used for numerous neurologic conditions, including neuropathic pain and epilepsy." | 7.75 | Gabapentin therapy for pain and irritability in a neurologically impaired infant. ( Cox, TH; Garner, SS; Haney, AL, 2009) |
| "Evidence suggests an important role for supraspinal gamma-aminobutyric acid (GABA) in conditioned fear and pain." | 7.75 | Alterations in extracellular levels of gamma-aminobutyric acid in the rat basolateral amygdala and periaqueductal gray during conditioned fear, persistent pain and fear-conditioned analgesia. ( Finn, DP; Lang, Y; Rea, K, 2009) |
| "To observe the effects of gamma-aminobutyric acid (GABA) on the electric activities of pain-excited neurons (PEN) in nucleus accumbens (NAc) in central nervous system (CNS) of morphine-dependent rats." | 7.74 | Modulation of gamma-aminobutyric acid on painful sense in central nervous system of morphine-dependent rats. ( Li, X; Xu, MY; Xu, Y, 2008) |
| "After GABA or the GABA(A)-receptor antagonist, bicuculline (Bic), was injected into cerebral ventricles or NAc, right sciatic nerve was stimulated by electrical pulses, which was considered as traumatic pain stimulation." | 7.74 | Modulation of gamma-aminobutyric acid on painful sense in central nervous system of morphine-dependent rats. ( Li, X; Xu, MY; Xu, Y, 2008) |
| "During treatment and post-treatment phases, patients receiving Gp had cumulative morphine consumption and a mean daily pain score significantly lower than controls." | 7.74 | Effects of gabapentin on morphine consumption and pain in severely burned patients. ( Cuignet, O; Pirson, J; Soudon, O; Zizi, M, 2007) |
| "The effects of treatment with the anti-convulsant agents, lamotrigine and riluzole were compared with gabapentin in a rat experimental model of neuropathic pain." | 7.74 | A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2007) |
| "Pregabalin is used for treatment of neuropathic pain conditions." | 7.74 | Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats. ( Audette, KM; Maeda, Y; Sluka, KA; Yokoyama, T, 2007) |
| "This study shows that pregabalin reduces both cutaneous and muscle hyperalgesia in inflammatory and noninflammatory models of muscle pain." | 7.74 | Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats. ( Audette, KM; Maeda, Y; Sluka, KA; Yokoyama, T, 2007) |
| " The results showed that AVP elevated the concentrations of leucine-enkephalin (L-Ek), methionine-enkephalin (M-Ek) and beta-endorphin (beta-Ep), but did not change the concentrations of dynorphinA(1-13) (DynA(1-13)), OXT, classical neurotransmitters including achetylcholine (Ach), choline (Ch), serotonin (5-HT), gamma-aminobutyric acid (GABA), glutamate (Glu), dopamine (DA), norepinephrine (NE) and epinephrine (E), and their metabolic products in PAG perfusion liquid." | 7.74 | Arginine vasopressin induces periaqueductal gray release of enkephalin and endorphin relating to pain modulation in the rat. ( Chen, JM; Lin, BC; Liu, WY; Xu, HT; Yang, J; Yang, Y, 2007) |
| "Previous study has proven that microinjection of arginine vasopressin (AVP) into periaqueductal gray (PAG) raises the pain threshold, in which the antinociceptive effect of AVP can be reversed by PAG pretreatment with V2 rather than V1 or opiate receptor antagonist." | 7.74 | Arginine vasopressin induces periaqueductal gray release of enkephalin and endorphin relating to pain modulation in the rat. ( Chen, JM; Lin, BC; Liu, WY; Xu, HT; Yang, J; Yang, Y, 2007) |
| "Clinical studies investigating the use of pregabalin and duloxetine for the management of diabetic peripheral neuropathy and post-herpetic neuralgia are reviewed." | 7.74 | Pregabalin and duloxetine for the treatment of neuropathic pain disorders. ( Terneus, W, 2007) |
| "Although gabapentin may relieve neuropathic pain by actions at many sites, these results suggest that its actions in the brain to cause spinal cholinergic activation predominate after oral administration." | 7.74 | Oral gabapentin activates spinal cholinergic circuits to reduce hypersensitivity after peripheral nerve injury and interacts synergistically with oral donepezil. ( Eisenach, JC; Hayashida, K; Parker, R, 2007) |
| "These data demonstrated the comparable efficacy of gabapentin with morphine in visceral pain." | 7.74 | Gabapentin action and interaction on the antinociceptive effect of morphine on visceral pain in mice. ( Meymandi, MS; Sepehri, G, 2008) |
| "Pregabalin is often used for the treatment of chronic pain syndromes." | 7.74 | Pregabalin-induced generalized myoclonic status epilepticus in patients with chronic pain. ( Hamer, HM; Hattemer, K; Klein, KM; Knake, S; Oertel, WH; Rosenow, F; Wellek, A, 2007) |
| "To use gabapentin to relieve discomfort in a painful, blind glaucomatous eye of a patient unwilling to undergo further invasive treatment." | 7.74 | Gabapentin therapy for painful, blind glaucomatous eye: case report. ( Dimou, T; Kavalieratos, CS, 2008) |
| "Gabapentin may relieve pain in a painful, blind, glaucomatous eye." | 7.74 | Gabapentin therapy for painful, blind glaucomatous eye: case report. ( Dimou, T; Kavalieratos, CS, 2008) |
| "Gabapentin is an antiepileptic used for neuropathic pain treatment." | 7.74 | Gabapentin therapy for painful, blind glaucomatous eye: case report. ( Dimou, T; Kavalieratos, CS, 2008) |
| "Patient rated his pregabapentin and postgabapentin pain by a verbal descriptor scale and a numerical scale." | 7.74 | Gabapentin therapy for painful, blind glaucomatous eye: case report. ( Dimou, T; Kavalieratos, CS, 2008) |
| "Gabapentin provided significant pain relief (on a 0-10 scale, reduction from "8" to "0-2") at regular visits over 6 months." | 7.74 | Gabapentin therapy for painful, blind glaucomatous eye: case report. ( Dimou, T; Kavalieratos, CS, 2008) |
| "A rat model of cancer-induced bone pain using the MRMT-1 cell line injected into the tibia was established to investigate the efficacy of acute (10, 30, 100 mg/kg) and chronic (30 mg/kg) systemic gabapentin on electrophysiological superficial dorsal horn neuronal responses to natural and noxious electrical stimuli, as well as on pain-related behavior." | 7.73 | Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain. ( Dickenson, AH; Donovan-Rodriguez, T; Urch, CE, 2005) |
| "The anticonvulsant gabapentin (GBP) has been shown effective for the treatment of neuropathic pain, although its mechanism of action remains unclear." | 7.73 | Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. ( Aiyar, J; Anker, N; Belley, M; Bristow, L; Campbell, B; Cohen, C; Park, KT; Ren, K; Stearns, B; Urban, MO, 2005) |
| " In this study, we tested the hypothesis that removal of GABAergic and glycinergic inhibitory inputs attenuates the effect of morphine on dorsal horn projection neurons and the reduced spinal GABAergic tone contributes to attenuated morphine effect in neuropathic pain." | 7.73 | Effect of morphine on deep dorsal horn projection neurons depends on spinal GABAergic and glycinergic tone: implications for reduced opioid effect in neuropathic pain. ( Chen, SR; Chen, YP; Pan, HL, 2005) |
| "Here, we have examined the effect of the novel antinociceptive agent CHF3381 on the development of nocifensive behaviour as well as secondary mechanical allodynia and hyperalgesia induced by intraplantar injection of capsaicin in rats." | 7.73 | CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats. ( Bassani, F; Bergamaschi, M; Tonino Bolzoni, P; Villetti, G, 2005) |
| "Not all neuropathic pain patients gain relief from current therapies that include the anticonvulsant, gabapentin, thought to modulate calcium channel function." | 7.73 | Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin. ( Dickenson, AH; Hunt, SP; Rahman, W; Rygh, LJ; Suzuki, R; Webber, M, 2005) |
| "Hindpaw mechanical allodynia was dose-dependently reversed by gabapentin (50 and 100 mg/kg, s." | 7.73 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| "To systematically establish the pain relieving efficacies of venlafaxine and gabapentin alone and in combination." | 7.73 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| " In this study the co-administration of gabapentin with morphine is evaluated in acute model of pain." | 7.73 | Gabapentin enhances the analgesic response to morphine in acute model of pain in male rats. ( Meymandi, MS; Mobasher, M; Sepehri, G, 2006) |
| "We report two patients with refractory epilepsy who developed unilateral painful gynecomastia and lower extremity pain (one of them localized and the other one diffuse), shortly after receiving Pregabalin (PGB)." | 7.73 | Two cases of painful gynecomastia and lower extremity pain in association with pregabalin therapy. ( Málaga, I; Sanmarti, FX, 2006) |
| " In order to avoid drug interactions as well as adverse effects of carbamazepine in myasthenia gravis, gabapentin was chosen for the treatment of neuropathic pain." | 7.72 | Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin. ( Beuche, W; Scheschonka, A, 2003) |
| " When evaluated in the model of neuropathic pain caused by partial ligation of sciatic nerve, the hexanic extract inhibited the mechanical allodynia (77 +/- 7%), with a similar efficacy to the gabapentin (71 +/- 10%)." | 7.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| "This study investigated the anti-allodynic and anti-oedematogenic effects of the hexanic extract, lignan-rich fraction and purified lignans from a plant used in the traditional medicine, Phyllanthus amarus, in the inflammatory and neuropathic models of nociception." | 7.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| "Assessment of pain relief in type 2 diabetes mellitus patients with neuropathic pain treated with gabapentin at daily dose 2400 mg." | 7.72 | [Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003) |
| " After six weeks of gabapentin treatment in 2400 mg daily dose a significant pain reduction was observed, assessed by means of SF-MPQ, VAS and PPI questionnaires." | 7.72 | [Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003) |
| "We report and discuss a case of severe neuropathic orbital pain refractory to standard analgesics that responded well to treatment with the anticonvulsant gabapentin." | 7.72 | Treatment of neuropathic orbital pain with gabapentin. ( Kancharla, A; Sloan, PA, 2003) |
| "The antiepileptic drug, gabapentin, and another structurally related compound, pregabalin, are increasingly employed in the pharmacotherapy of chronic pain states, although their primary mechanism of action remains a topic of active study." | 7.72 | Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited. ( Chesler, EJ; Kokayeff, A; Lariviere, WR; Mogil, JS; Ritchie, J; Wilson, SG, 2003) |
| "We present 2 patients with severe and intractable central poststroke pain (CPSP) after right posterolateral thalamic infarcts who were successfully treated with zonisamide." | 7.72 | Successful use of zonisamide for central poststroke pain. ( Hashimoto, K; Takahashi, Y; Tsuji, S, 2004) |
| "Combined spinal administration of gabapentin and low doses of morphine significantly reduces pain-related behaviors in this acute rat pancreatitis model, whereas these agents were ineffective when used alone in this dose range." | 7.72 | Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model. ( Lu, Y; Smiley, MM; Vera-Portocarrero, LP; Westlund, KN; Zidan, A, 2004) |
| " In this study, intrathecal gabapentin, which by itself is ineffective when administered spinally, was combined with low-dose morphine and tested in an acute bradykinin-induced pancreatitis model in rats." | 7.72 | Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model. ( Lu, Y; Smiley, MM; Vera-Portocarrero, LP; Westlund, KN; Zidan, A, 2004) |
| "We report a case of neutropenia occurring in a patient receiving gabapentin for neuropathic pain." | 7.72 | Neutropenia occurring after starting gabapentin for neuropathic pain. ( Derbyshire, E; Martin, D, 2004) |
| "Although gabapentin was originally developed for treating partial seizures, it has been used mainly to treat various peripheral neuropathic pain conditions; however, there is very limited experience with gabapentin for the treatment of pain conditions of the central nervous system like central post-stroke pain syndrome." | 7.71 | Central post-stroke pain syndrome: yet another use for gabapentin? ( Chen, B; DeLisa, JA; Foye, PM; Nadler, SF; Stitik, TP, 2002) |
| "The present study examines the effect of combinations of gabapentin (Neurontin) and a selective neurokinin (NK)(1) receptor antagonist, 1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-benzofuranylmethyl ester (CI-1021), in two models of neuropathic pain." | 7.71 | Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. ( Field, MJ; Gonzalez, MI; Singh, L; Tallarida, RJ, 2002) |
| "The effects of systemic and local injections of gabapentin, a novel anticonvulsant agent, were tested on nociceptive behaviors in mice with acute herpetic pain." | 7.71 | Gabapentin antinociception in mice with acute herpetic pain induced by herpes simplex virus infection. ( Andoh, T; Kuraishi, Y; Nojima, H; Shiraki, K; Takasaki, I, 2001) |
| "The objective of this study was to assess the efficacy and safety of Gabapentin as the sole analgesic in patients with HIV-related painful neuropathy." | 7.71 | Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations. ( Bottura, P; La Spina, I; Maggiolo, F; Porazzi, D; Suter, F, 2001) |
| "A patient with mycosis fungoides illustrates the problem of pain management during wound care and suggests the utility of a novel treatment, gabapentin." | 7.71 | Gabapentin for pain control in cancer patients' wound dressing care. ( Devulder, J; Lambert, J; Naeyaert, JM, 2001) |
| "The new anticonvulsants, gabapentin and pregabalin, are effective in the treatment of neuropathic pain." | 7.71 | Stereospecific effect of pregabalin on ectopic afferent discharges and neuropathic pain induced by sciatic nerve ligation in rats. ( Chen, SR; Pan, HL; Xu, Z, 2001) |
| "These data strongly suggest that the analgesic effect of pregabalin on neuropathic pain is likely mediated, at least in part, by its peripheral inhibitory action on the impulse generation of ectopic discharges caused by nerve injury." | 7.71 | Stereospecific effect of pregabalin on ectopic afferent discharges and neuropathic pain induced by sciatic nerve ligation in rats. ( Chen, SR; Pan, HL; Xu, Z, 2001) |
| "To present two years of experience in the use of gabapentin for the alleviation of neuropathic pain in spinal cord injury patients." | 7.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "Data were retrieved from the medical records of all spinal cord injury patients prescribed gabapentin for neuropathic pain." | 7.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "Seventy-six per cent of patients receiving gabapentin reported a reduction in neuropathic pain." | 7.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "Our experience suggests that gabapentin offers an effective therapeutic alternative for the alleviation of neuropathic pain following spinal cord injury." | 7.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| ") gabapentin, administered before and after the injection of formalin into the rat hindpaw, on pain behavior and hemodynamics." | 7.70 | The effect of intrathecal gabapentin on pain behavior and hemodynamics on the formalin test in the rat. ( Yaksh, TL; Yoon, MH, 1999) |
| "Drug therapy for fibromyalgia is limited by incomplete efficacy and dose-limiting adverse effects (AEs)." | 7.30 | Combination analgesic development for enhanced clinical efficacy (the CADENCE trial): a double-blind, controlled trial of an alpha-lipoic acid-pregabalin combination for fibromyalgia pain. ( Gilron, I; Holden, RR; Milev, R; Robb, S; Towheed, T; Tu, D, 2023) |
| "The observation of similarly reached maximal tolerated drug doses of these 2 agents (which have differing side-effect profiles) during combination and monotherapy-without increased side effects-provides support for future development of potentially more beneficial combinations with complementary mechanisms and nonoverlapping side effects." | 7.30 | Combination analgesic development for enhanced clinical efficacy (the CADENCE trial): a double-blind, controlled trial of an alpha-lipoic acid-pregabalin combination for fibromyalgia pain. ( Gilron, I; Holden, RR; Milev, R; Robb, S; Towheed, T; Tu, D, 2023) |
| " Besides pregabalin (150 mg/day), the patients, upon their group assignment, received CoQ10 at a dosage of 100 mg every 8 h or matched placebo for 8 consecutive weeks." | 7.11 | Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial. ( Amini, P; Mehrpooya, M; Mirjalili, M; Mohammadi, Y; Sajedi, F, 2022) |
| "Gabapentin was maintained at 900mg/day for 4 weeks after CRT." | 6.82 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "Pregabalin has been used for the treatment of pain." | 6.82 | A Validated Fluorometric Method for the Rapid Determination of Pregabalin in Human Plasma Applied to Patients With Pain. ( Kawakami, J; Naito, T; Yagi, T; Yoshikawa, N, 2016) |
| " Dosing was set by the Dixon sequential up-down method; that is, a greater or less than 30% reduction in capsaicin pain decreased or increased the dose, respectively, by a fixed interval for the next subject." | 6.79 | Determination of the effective dose of pregabalin on human experimental pain using the sequential up-down method. ( Wallace, MS; Wong, W, 2014) |
| "Secondary outcome measures included secondary hyperalgesia and tactile and thermal allodynia, and their respective areas (cm(2))." | 6.79 | Determination of the effective dose of pregabalin on human experimental pain using the sequential up-down method. ( Wallace, MS; Wong, W, 2014) |
| "This pharmacostatistical model showed that: (1) pregabalin oral clearance (CL/F) was directly proportional to creatinine clearance (CLcr), but was independent of gender, race, age, female hormonal status, daily dose, and dosing regimen; (2) apparent volume of distribution was dependent on body weight and gender; (3) absorption rate was decreased when given with food; and (4) coadministration with marketed antiepileptic drugs (AEDs) had no significant effect on pregabalin CL/F." | 6.76 | Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. ( Bockbrader, HN; Burger, P; Corrigan, BW; Knapp, L, 2011) |
| " Adverse events were more frequent with pregabalin than with placebo and caused discontinuation in 9 (8." | 6.76 | Safety and efficacy of pregabalin in patients with central post-stroke pain. ( Bashford, G; Cheung, R; Dror, V; Kim, JS; Martin, A; Murphy, KT, 2011) |
| "Effects on allodynia and SF-MPQ were not significant." | 6.76 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| "Treatment with trazodone significantly improved global fibromyalgia severity, sleep quality, and depression, as well as pain interference with daily activities although without showing a direct effect on bodily pain." | 6.76 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| " Trazodone, flexibly dosed (50-300 mg/day), was administered to 66 fibromyalgia patients during 12 weeks; 41 patients who completed the treatment accepted to receive pregabalin, also flexibly dosed (75-450 mg/day), added to trazodone treatment for an additional 12-week period." | 6.76 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| "Gabapentin has demonstrated efficacy in clinical trials as a pre-emptive analgesic and in acute postoperative pain management." | 6.76 | Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia. ( Marashi, SH; Nadjafi, A; Panah Khahi, M; Yaghooti, AA, 2011) |
| "The postoperative pain was assessed using Visual Analogue Scale two, 12 and 24 hours after surgery." | 6.76 | Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia. ( Marashi, SH; Nadjafi, A; Panah Khahi, M; Yaghooti, AA, 2011) |
| " Patients were then started on open-label pregabalin (75, 150, 300 and 600 mg/day) according to a forced titration dosing regimen, while continuing the same dosage of oxycodone or placebo for 4 weeks." | 6.75 | A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. ( Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010) |
| "Peripheral neuropathic pain presents commonly in clinical practice, and 2 of its most prevalent types are PHN and PDN." | 6.75 | A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. ( Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010) |
| "Gabapentin was initiated in addition to the drugs currently being administered." | 6.75 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| "Neuropathic pain is regarded as one of the main causes of cancer pain refractory to standard opioid therapy in palliative care." | 6.75 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| " The aim of this study was to see whether low-dose gabapentin is effective in treating cancer-related neuropathic pain when combined with low-dose imipramine." | 6.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Low-dose gabapentin-antidepressant combination with opioids was effective in managing neuropathic cancer pain without severe adverse effects." | 6.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Painful neuropathic conditions of cancer pain often show little response to nonopioid and opioid analgesics but may be eased by antidepressants and anticonvulsants." | 6.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally." | 6.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| " Patients in group B who were receiving gabapentin continued this treatment up to a maximum daily dosage of 2400 mg during the observation period." | 6.74 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "Multimodal pain is comprised of nociceptive/inflammatory and neuropathic components." | 6.74 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| " Safety evaluation included adverse events (AEs), drug-related AEs (DRAEs), and withdrawal due to AEs." | 6.74 | Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "In patients with PHN and painful DPN failing to respond to monotherapy, combination therapy with 5% lidocaine medicated plaster and pregabalin provides additional clinically relevant pain relief and is safe and well-tolerated." | 6.74 | Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "Neuropathic pain is often difficult to treat due to a complex pathophysiology." | 6.74 | Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "Improvements were comparable between treatments in painful DPN." | 6.74 | 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| " We evaluated the efficacy of pregabalin 600 mg/d (300 mg dosed BID) versus placebo for relieving DPN-associated neuropathic pain, and assessed its safety using objective measures of nerve conduction (NC)." | 6.73 | Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. ( Arezzo, JC; Lamoreaux, L; Pauer, L; Rosenstock, J, 2008) |
| " After 1-weeks' dosage escalation, pregabalin-treated patients received 300 mg BID for 12 weeks." | 6.73 | Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. ( Arezzo, JC; Lamoreaux, L; Pauer, L; Rosenstock, J, 2008) |
| "Secondary hyperalgesia and allodynia are a reflection of central sensitization." | 6.73 | Effect of morphine and pregabalin compared with diphenhydramine hydrochloride and placebo on hyperalgesia and allodynia induced by intradermal capsaicin in healthy male subjects. ( Baxendale, J; Bolognese, J; Calder, N; Connell, J; Cummings, C; Herman, G; Kehler, A; Wang, H, 2008) |
| "Gabapentin-treated patients displayed a significantly greater improvement in the BPI average pain severity score (P=0." | 6.73 | Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. ( Arnold, LM; Bishop, F; Goldenberg, DL; Hess, EV; Hudson, JI; Keck, PE; Lalonde, JK; Sandhu, HS; Stanford, KE; Stanford, SB; Welge, JA, 2007) |
| "Gabapentin was generally well tolerated." | 6.73 | Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. ( Arnold, LM; Bishop, F; Goldenberg, DL; Hess, EV; Hudson, JI; Keck, PE; Lalonde, JK; Sandhu, HS; Stanford, KE; Stanford, SB; Welge, JA, 2007) |
| "The model assigned untreated pain scores over 84 days." | 6.73 | Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007) |
| "Pain was evaluated using a 0-10 scale." | 6.73 | Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007) |
| "Gabapentin was no more effective than diphenhydramine (P=." | 6.73 | Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. ( Courtade, D; Fiess, RN; Holmes, SA; Loubser, PG; Rintala, DH; Tastard, LV, 2007) |
| "The intensity of stump and phantom pain was recorded every day on a numeric rating scale (0-10) during the 30-day treatment period." | 6.72 | A randomized study of the effects of gabapentin on postamputation pain. ( Finnerup, NB; Jensen, TS; Keller, J; Kramp, S; Nikolajsen, L; Vimtrup, AS, 2006) |
| "The risk of phantom pain (gabapentin vs." | 6.72 | A randomized study of the effects of gabapentin on postamputation pain. ( Finnerup, NB; Jensen, TS; Keller, J; Kramp, S; Nikolajsen, L; Vimtrup, AS, 2006) |
| "The lidocaine patch 5% was found to be safe and well tolerated." | 6.71 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Patients with postherpetic neuralgia, painful diabetic neuropathy, or low back pain with partial responses (average daily pain intensity >4/10) to their current analgesic treatment regimen were included." | 6.71 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Gabapentin was titrated from 600 mg/d to 1,800 mg/d in addition to stable opioid dose." | 6.71 | Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. ( Arcuri, E; Barbieri, M; Bonezzi, C; Caraceni, A; De Conno, F; Gorni, G; Maltoni, M; Martini, C; Tirelli, W; Visentin, M; Yaya Tur, R; Zecca, E, 2004) |
| "Neuropathic pain is a prominent feature of CRPS I, and is often refractory to treatment." | 6.71 | Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. ( Kessels, AH; Stomp-van den Berg, SG; van de Vusse, AC; Weber, WE, 2004) |
| "Neuropathic pain is a syndrome that affects around 1% of population." | 6.71 | Treatment of diabetic neuropathic pain with gabapentin alone or combined with vitamin B complex. preliminary results. ( Espinoza-Raya, J; Granados-Soto, V; Medina-Santillán, R; Morales-Franco, G; Reyes-García, G, 2004) |
| "Fentanyl 2 microg/kg was used as a supplementary analgesic on patient demand." | 6.71 | The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. ( Kumar, A; Navkar, DV; Pandey, CK; Raza, M; Singh, UK; Tripathi, M, 2005) |
| "Gabapentin was dose-escalated from 300 mg/d to 1." | 6.71 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "Gabapentin has been evaluated in the treatment of nonmalignant neuropathic pain, however, there is little direct evidence evaluating its efficacy in cancer-related neuropathic pain." | 6.71 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "Gabapentin was given in three divided doses, initially titrated to 900 mg/day over 3 days, followed by two further increases, to a maximum of 2400 mg/day if required by the end of week 5." | 6.70 | Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. ( Serpell, MG, 2002) |
| " The mean effective dosage at the end of the 6-week treatment period was 1,855 mg, although therapeutic effects were already observed at the end of week 4 (1,391 mg)." | 6.70 | Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. ( de la Llave, Y; Garcia-Borreguero, D; Hernandez, G; Larrosa, O; Masramon, X; Verger, K, 2002) |
| "Gabapentin is an anticonvulsant with unclear but therapeutic effects on neurologic pain." | 6.70 | Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. ( Chancellor, MB; Chuang, YC; Kim, JC; Lee, JY; Sasaki, K; Smith, CP, 2001) |
| "Gabapentin was well tolerated; only 4 patients dropped out due to side effects." | 6.70 | Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. ( Chancellor, MB; Chuang, YC; Kim, JC; Lee, JY; Sasaki, K; Smith, CP, 2001) |
| "Five of 8 patients with interstitial cystitis reported improvement." | 6.70 | Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. ( Chancellor, MB; Chuang, YC; Kim, JC; Lee, JY; Sasaki, K; Smith, CP, 2001) |
| "Somnolence, mental clouding, and headache were the most frequently reported adverse events." | 6.70 | Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. ( Bosnjak, S; Jelic, S; Luki, V; Susnjar, S, 2002) |
| "Pain is the most disturbing symptom of diabetic peripheral neuropathy." | 6.69 | Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. ( Backonja, M; Beydoun, A; Edwards, KR; Fonseca, V; Garofalo, E; Hes, M; LaMoreaux, L; Schwartz, SL, 1998) |
| "Sixty-five percent of patients reached maximum dose with gabapentin and 54% with amitriptyline." | 6.69 | Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ( Leckband, SG; Moorhouse, DF; Morello, CM; Sahagian, GA; Stoner, CP, 1999) |
| "Decreases in paresthesia scores also were in favor of gabapentin (1." | 6.69 | Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. ( Buffa, C; Chiroli, S; Dallocchio, C; Mazzarello, P, 2000) |
| "Gabapentin (Neurontin) is a new generation antiepileptic drug which appears to be advantageous in treatment of intractable pain of reflex sympathetic dystrophy." | 6.68 | Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997) |
| "Pain is a frequent and distressing complaint in patients with multiple sclerosis (MS) and may present a difficult therapeutic problem." | 6.68 | Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997) |
| "His pain was scored as a five on a six-point visual analog scale, and it persisted despite routine supportive therapy." | 6.50 | [A case of Guillain-Barré syndrome with severe pain successfully controlled with acetaminophen, gabapentin, and parenterally infused fentanyl]. ( Anzai, S; Hashimoto, Y; Nagasawa, K; Suzuki, T, 2014) |
| " The proportions of patients with any adverse event, somnolence or dizziness were also significantly greater with pregabalin than with placebo." | 6.46 | Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S, 2010) |
| " A dose-response relationship was apparent for at least 50% pain relief and for adverse event outcomes." | 6.46 | Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S, 2010) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 6.46 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Gabapentin has been successfully used for the treatment of multiple neuropathic pain syndromes such as diabetic neuropathy and postherpetic neuralgia." | 6.46 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of pregabalin are reviewed." | 6.44 | Pregabalin: an antiepileptic agent useful for neuropathic pain. ( Blommel, AL; Blommel, ML, 2007) |
| " The starting dosage for patients with neuropathic pain associated with diabetic peripheral neuropathy is 50 mg three times daily and may be increased to 300 mg daily within one week based on efficacy and tolerability." | 6.44 | Pregabalin: an antiepileptic agent useful for neuropathic pain. ( Blommel, AL; Blommel, ML, 2007) |
| " Overall, pregabalin was well tolerated with no new adverse events emerging that have not been reported with its use in other indications." | 6.44 | Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome. ( Owen, RT, 2007) |
| " Peak plasma levels occur approximately 1 hour after oral doses and oral bioavailability is about 90%." | 6.43 | Pregabalin: a new agent for the treatment of neuropathic pain. ( Zareba, G, 2005) |
| "Gabapentin has become popular as a first-line treatment for neuropathic pain because of its efficacy as an antineuropathic agent and relatively benign side-effect profile." | 6.43 | The mechanism of action of gabapentin in neuropathic pain. ( Baillie, JK; Power, I, 2006) |
| "Neuropathic pain is a common and potentially treatable cause of considerable lifelong morbidity." | 6.43 | The mechanism of action of gabapentin in neuropathic pain. ( Baillie, JK; Power, I, 2006) |
| "Like gabapentin, pregabalin was predominantly excreted unchanged in the urine (> or = 98%)." | 6.43 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| " Unlike gabapentin, pregabalin was well absorbed (> 90%), and its absorption was dose independent." | 6.43 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| " Dosed at 50 to 200 mg TID, pregabalin was superior to placebo in relieving pain and improving sleep and health-related quality of life in patients with diabetic peripheral neuropathy and postherpetic neuralgia (P < 0." | 6.43 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| " The improved pharmacokinetic profile of pregabalin relative to gabapentin is manifested in linear and dose-independent absorption and a narrow therapeutic dosing range." | 6.43 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "Neuropathic pain is a condition affecting a significant proportion of the world's population." | 6.43 | [Pregabalin. A new treatment for neuropathic pain]. ( López-Trigo, J; Sancho Rieger, J, 2006) |
| "Gabapentin is a drug that has been widely used in the treatment of chronic pain states." | 6.43 | alpha2delta and the mechanism of action of gabapentin in the treatment of pain. ( Lee, K; Luo, ZD; Maneuf, YP, 2006) |
| "Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Pain is one of the most common reasons for seeking medical attention, and neuropathic pain is among the most common types of pain." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Despite its prevalence, neuropathic pain is often underrecognized and inadequately treated." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "It relieved symptoms of allodynia, burning pain, shooting pain, and hyperesthesia." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Gabapentin is a very promising medication in the treatment of post-herpetic neuralgia and pain." | 6.42 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "Gabapentin was first approved by the FDA in 1993 as an add-on treatment for partial epileptic seizures." | 6.42 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "Over 150 articles reviewed its use for neuropathic pain, neuritis or neuralgia of various sorts." | 6.42 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "Gabapentin has antihyperalgesic and antiallodynic properties but does not have significant actions as an anti-nociceptive agent." | 6.42 | Gabapentin in the treatment of neuropathic pain. ( Bennett, MI; Simpson, KH, 2004) |
| "Gabapentin is a novel anticonvulsant that may have a unique effect on voltage-dependent Ca2+ channel currents at postsynaptic dorsal horn neurons." | 6.41 | Gabapentin use in neuropathic pain syndromes. ( Nicholson, B, 2000) |
| "Gabapentin has been shown to be efficacious in numerous smaller clinical studies, case reports, and chart reviews in a variety of neuropathic pain syndromes." | 6.41 | Gabapentin use in neuropathic pain syndromes. ( Nicholson, B, 2000) |
| "Gabapentin, which has been approved for add-on therapy of focal seizures, is increasingly used for treatment of neuropathic pain." | 6.41 | [Gabapentin therapy for pain]. ( Block, F, 2001) |
| "Gabapentin has been clearly demonstrated to be effective for the treatment of neuropathic pain in diabetic neuropathy and postherpetic neuralgia." | 6.41 | Gabapentin: pharmacology and its use in pain management. ( Kam, PC; Rose, MA, 2002) |
| "We hypothesized that the addition of coenzyme Q10 (CoQ10) to pregabalin might be helpful in improving symptoms in patients suffering from painful diabetic neuropathy (PDN)." | 5.51 | Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial. ( Amini, P; Mehrpooya, M; Mirjalili, M; Mohammadi, Y; Sajedi, F, 2022) |
| "On the intent‑to‑treat population (ITT) analysis, the CoQ10 + pregabalin regimen resulted in significantly greater pain relief than the placebo + pregabalin regimen." | 5.51 | Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial. ( Amini, P; Mehrpooya, M; Mirjalili, M; Mohammadi, Y; Sajedi, F, 2022) |
| "Chronic pain is a multifactorial disease comprised of both inflammatory and neuropathic components that affect ∼20% of the world's population." | 5.46 | sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain. ( Bialer, M; Brennan, KC; Devor, M; Kaufmann, D; Smith, MD; West, PJ; White, HS; Yagen, B, 2017) |
| "Gabapentin appears to be an effective treatment for children with severe impairment of the CNS and recurrent pain behaviors, including intermittent changes in muscle tone." | 5.42 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| " Dosing information can guide treatment trials and future prospective studies." | 5.42 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent widely used to reduce blood loss during surgery." | 5.42 | Tranexamic acid evokes pain by modulating neuronal excitability in the spinal dorsal horn. ( Baba, H; Kamiya, Y; Kohno, T; Ohashi, M; Ohashi, N; Sasaki, M, 2015) |
| "Prophylactic gabapentin appears to be a promising treatment option for preventing pain, reducing opioids, and reducing weight loss in patients undergoing head and neck cancer therapy." | 5.41 | Prophylactic gabapentin during head and neck cancer therapy: a systematic review and meta-analysis. ( Murphy, BA; Smith, DK; Smith, LE, 2023) |
| "Gabapentin was found to reversibly decrease, but not suppress the flinching frequency of the second response peak only." | 5.40 | Semi-mechanistic modelling of the analgesic effect of gabapentin in the formalin-induced rat model of experimental pain. ( Danhof, M; Della Pasqua, O; Taneja, A; Troconiz, IF, 2014) |
| "The Fibromyalgia Impact Questionnaire (FIQ) is a patient-reported outcome that evaluates the impact of fibromyalgia (FM) on daily life." | 5.39 | Evaluation of the fibromyalgia impact questionnaire at baseline as a predictor for time to pain improvement in two clinical trials of pregabalin. ( Bushmakin, AG; Cappelleri, JC; Chandran, AB; Zlateva, G, 2013) |
| "Pain was ranked as the most important outcome explaining variability in PGIC, followed by fatigue and sleep." | 5.37 | Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin. ( Arnold, LM; Emir, B; Sadosky, A; Whalen, E; Zlateva, G, 2011) |
| "Gabapentin was commenced at 300 mg daily and titrated to 300 mg tds over 3 days." | 5.36 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "Pain was assessed by visual analogue scoring at baseline, 4, 7, 14 and 28 days." | 5.36 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "The static allodynia endpoint was modeled by using three population PD approaches: 1) the behavior of the injured paw using a three-category ordinal logistic regression model; 2) paw withdrawal threshold (PWT) (g) between the injured and uninjured paw using the Hill equation with a baseline function; and 3) the baseline normalized difference in PWT between the injured and uninjured paw." | 5.36 | Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain. ( Bender, G; Bies, RR; Bramwell, S; Danhof, M; DeJongh, J; Field, MJ; Florian, JA; Marshall, S; Tan, KK, 2010) |
| "Gabapentin was initiated in the second week of radiotherapy." | 5.36 | Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. ( Bar Ad, V; Both, S; Chalian, A; Dosoretz, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "Here, we tested the effect of FK1706 on painful diabetic neuropathy in rat model of diabetes induced by streptozotocin (STZ)." | 5.35 | FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy. ( Matsuoka, N; Murai, N; Mutoh, S; Price, RD; Yamaji, T; Yamamoto, H; Yamazaki, S, 2008) |
| "Pain is the result of an emotional and sensory experience and preclinical models of OA can thus be useful to better understand the underlying mechanisms of the disease and test new therapeutic options." | 5.35 | Differential analgesic effects of morphine and gabapentin on behavioural measures of pain and disability in a model of osteoarthritis pain in rats. ( Dickenson, AH; Ghandehari, J; Vonsy, JL, 2009) |
| "Neuropathic pain is a disease caused by a lesion or dysfunction of the nervous system." | 5.35 | Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain. ( Barrot, M; Doridot, S; Freund-Mercier, MJ; Hein, L; Petit-Demoulière, N; Tessier, LH; Yalcin, I, 2009) |
| "Morphine pretreatment produced an increase in GABA levels and a decrease in glutamate levels in the first few minutes." | 5.35 | [Effect of a simple morphine system injection in some aminoacids in the anterior cingulate cortex during acute pain]. ( Hernández, L; Páez, X; Quiñones, B; Silva, E, 2008) |
| "Pretreatment with morphine suppressed the glutamate increase." | 5.35 | [Effect of a simple morphine system injection in some aminoacids in the anterior cingulate cortex during acute pain]. ( Hernández, L; Páez, X; Quiñones, B; Silva, E, 2008) |
| "Gabapentin did not produce an anti-allodynic effect, whereas the morphine and gabapentin combination completely decreased allodynia behavior at 30 min post-injection, an effect that persisted until 120 min." | 5.35 | Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury. ( Cortés-Arroyo, AR; De la O-Arciniega, M; Díaz-Reval, MI; Domínguez-Ramírez, AM; López-Muñoz, FJ, 2009) |
| "Primary erythermalgia (erythromelalgia) is a rare autosomal dominant condition characterized by intermittent attacks of erythema, increased skin temperature and severe burning pain in the extremities, in a bilateral symmetrical distribution." | 5.35 | Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel. ( Atherton, D; Elmslie, F; Mansour, S; Mortimer, P; Natkunarajah, J, 2009) |
| "Gabapentin is a gamma-aminobutyric acid analog used for numerous neurologic conditions, including neuropathic pain and epilepsy." | 5.35 | Gabapentin therapy for pain and irritability in a neurologically impaired infant. ( Cox, TH; Garner, SS; Haney, AL, 2009) |
| " The infant continued to receive gabapentin; the dosage was increased to 10 mg/kg at bedtime after 6 days, then to 5 mg/kg in the morning and 10 mg/kg at bedtime 10 days later." | 5.35 | Gabapentin therapy for pain and irritability in a neurologically impaired infant. ( Cox, TH; Garner, SS; Haney, AL, 2009) |
| "Visceral pain is one of the most common forms of pain and for which new drugs would be welcome." | 5.35 | Gabapentin action and interaction on the antinociceptive effect of morphine on visceral pain in mice. ( Meymandi, MS; Sepehri, G, 2008) |
| "Gabapentin has established efficacy in the reduction of burn-induced hyperalgesia and allodynia in animal and human experimental burn models." | 5.35 | Successful use of gabapentin in acute pain management following burn injury: a case series. ( Cramond, T; Gray, P; Williams, B, 2008) |
| "Gabapentin is an antiepileptic used for neuropathic pain treatment." | 5.35 | Gabapentin therapy for painful, blind glaucomatous eye: case report. ( Dimou, T; Kavalieratos, CS, 2008) |
| "Gabapentin (Gp) is an antihyperalgesic drug that selectively affects central sensitization." | 5.34 | Effects of gabapentin on morphine consumption and pain in severely burned patients. ( Cuignet, O; Pirson, J; Soudon, O; Zizi, M, 2007) |
| "Muscle hyperalgesia (withdrawal threshold to compression of the muscle) and cutaneous hyperalgesia of the paw (withdrawal threshold to von Frey filaments) were measured before and after induction of hyperalgesia and after treatment with pregabalin (saline, 10 to 100 mg/kg i." | 5.34 | Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats. ( Audette, KM; Maeda, Y; Sluka, KA; Yokoyama, T, 2007) |
| "Chronic muscle pain is a problem with high prevalence in clinical practice and its pharmacological treatment is difficult." | 5.34 | Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF. ( Beyreuther, BK; Geis, C; Sommer, C; Stöhr, T, 2007) |
| "A complete reversal of hyperalgesia was seen with lacosamide at 30mg/kg." | 5.34 | Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF. ( Beyreuther, BK; Geis, C; Sommer, C; Stöhr, T, 2007) |
| "Cancer-induced bone pain is a major clinical problem for which current treatments lack full efficacy." | 5.33 | Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain. ( Dickenson, AH; Donovan-Rodriguez, T; Urch, CE, 2005) |
| "Secondary mechanical allodynia and hyperalgesia were measured at 5 and 15 min after capsaicin injection, respectively." | 5.33 | CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats. ( Bassani, F; Bergamaschi, M; Tonino Bolzoni, P; Villetti, G, 2005) |
| "Ambroxol's effects were compared with those of gabapentin." | 5.33 | Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. ( Arndt, K; Gaida, W; Klinder, K; Weiser, T, 2005) |
| "Neuropathic pain affects many patients, and treatment today is far from being perfect." | 5.33 | Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. ( Arndt, K; Gaida, W; Klinder, K; Weiser, T, 2005) |
| "Neuropathic pain is associated with a number of disease states of diverse aetiology that can share common pathophysiological mechanisms." | 5.33 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| "Hindpaw mechanical allodynia was dose-dependently reversed by gabapentin (50 and 100 mg/kg, s." | 5.33 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| "Neuropathic pain is a debilitating condition affecting millions of people around the world and is defined as pain that follows a lesion or dysfunction of the nervous system." | 5.33 | Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. ( Bramwell, S; Corradini, L; Cox, PJ; Dolphin, AC; England, S; Field, MJ; Hendrich, J; Kinloch, RA; Melrose, H; Offord, J; Stott, E; Su, TZ; Webb, T; Williams, D; Winks, J, 2006) |
| "Assessment of pain relief in type 2 diabetes mellitus patients with neuropathic pain treated with gabapentin at daily dose 2400 mg." | 5.32 | [Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003) |
| "26 patients with type 2 diabetes mellitus and painful neuropathy were included into the study." | 5.32 | [Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003) |
| " This dosage produced a substantial but non-significant decrease in the incidence of postherpetic pain-related responses." | 5.32 | Effects of the suppression of acute herpetic pain by gabapentin and amitriptyline on the incidence of delayed postherpetic pain in mice. ( Kuraishi, Y; Nojima, H; Shiraki, K; Takahata, H; Takasaki, I, 2004) |
| "Morphine sulfate has long been used for analgesia, but clinical applications can be limited by side effects, tolerance, and potential for addiction at therapeutic doses." | 5.32 | Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model. ( Lu, Y; Smiley, MM; Vera-Portocarrero, LP; Westlund, KN; Zidan, A, 2004) |
| "Gabapentin (GBP) is a new antiepileptic agent with an original spectrum of activity." | 5.32 | [Gabapentin (Neurontin) and cancer pain: a pilot study]. ( Body, JJ; Lossignol, DA; Plehiers, B, 2004) |
| "All were already treated for their pain syndrome." | 5.32 | [Gabapentin (Neurontin) and cancer pain: a pilot study]. ( Body, JJ; Lossignol, DA; Plehiers, B, 2004) |
| "We prospectively followed 20 cancer patients with advanced disease suffering from neuropathic pain." | 5.32 | [Gabapentin (Neurontin) and cancer pain: a pilot study]. ( Body, JJ; Lossignol, DA; Plehiers, B, 2004) |
| "Gabapentin treatment significantly and reversibly changed the responses, consistent with the attenuation of the abnormal sensory behavior, and the attenuated responses lasted for the duration of the drug effect (up to 6 h)." | 5.31 | Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin. ( Hulsebosch, CE; McAdoo, DJ; Perez-Polo, JR; Taylor, CP; Westlund, KN; Xu, GY, 2000) |
| "Pain was assessed prior to and during treatment at 1, 3 and 6 months with a 10 cm visual analogue scale which ranged from 0 ('no pain') to 10 ('worst pain imaginable'), or by the documentation of a verbal description of pain." | 5.31 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "A variety of treatments for the pain were ineffective." | 5.30 | Gabapentin for treatment of neuropathic pain in a 12-year-old girl. ( McGraw, T; Stacey, BR, 1998) |
| "05 mol/L GABA, 1% lidocaine) was investigated for the amelioration of pain and sensitivity induced by application of capsaicin (1%, 2 min) to the tongue of thirty healthy male and female subjects in this four-session, randomized, placebo-controlled, double-blinded, cross-over study." | 5.27 | γ-Aminobutyric acid (GABA) oral rinse reduces capsaicin-induced burning mouth pain sensation: An experimental quantitative sensory testing study in healthy subjects. ( Arendt-Nielsen, L; Cairns, BE; Wang, K; Zhang, Y, 2018) |
| "Capsaicin-induced burning tongue pain and decreases in WDT and HPT can be ameliorated by rinsing the mouth with lidocaine and GABA solutions." | 5.27 | γ-Aminobutyric acid (GABA) oral rinse reduces capsaicin-induced burning mouth pain sensation: An experimental quantitative sensory testing study in healthy subjects. ( Arendt-Nielsen, L; Cairns, BE; Wang, K; Zhang, Y, 2018) |
| "Capsaicin application on the tongue evoked burning pain with a peak of 4." | 5.27 | γ-Aminobutyric acid (GABA) oral rinse reduces capsaicin-induced burning mouth pain sensation: An experimental quantitative sensory testing study in healthy subjects. ( Arendt-Nielsen, L; Cairns, BE; Wang, K; Zhang, Y, 2018) |
| "Rinsing the mouth with an oral GABA containing solution ameliorated burning pain and increased heat sensitivity produced by application of capsaicin to the tongue." | 5.27 | γ-Aminobutyric acid (GABA) oral rinse reduces capsaicin-induced burning mouth pain sensation: An experimental quantitative sensory testing study in healthy subjects. ( Arendt-Nielsen, L; Cairns, BE; Wang, K; Zhang, Y, 2018) |
| "Treatment by progabide, a GABA-agonist, was successful in one case: a gradual improvement was observed during four weeks and the movements have now disappeared after six months of progabide therapy." | 5.27 | [Progabide treatment of a case of the syndrome of painful legs and moving toes]. ( Bovier, P; Hilleret, H; Tissot, R, 1985) |
| " Nonetheless, pain intensity reduction is achieved with 50% of the minimum required gabapentin dose alone (800 to 1600 mg/d) in classic NDD trials." | 5.22 | Clinical Trial Assessing the Efficacy of Gabapentin Plus B Complex (B1/B12) versus Pregabalin for Treating Painful Diabetic Neuropathy. ( Aguilar Navarro, S; Mimenza Alvarado, A, 2016) |
| "HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G)." | 5.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "This pilot study is the first prospective randomized trial of gabapentin for RIM-related pain." | 5.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "Pregabalin has been used for the treatment of pain." | 5.22 | A Validated Fluorometric Method for the Rapid Determination of Pregabalin in Human Plasma Applied to Patients With Pain. ( Kawakami, J; Naito, T; Yagi, T; Yoshikawa, N, 2016) |
| "No significant difference was found between pregabalin and active placebo for the time to first moderate pain symptom (difference in median Tfirst = -1." | 5.20 | Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication. ( Chowdhry, AK; Czerniecka, K; Dworkin, RH; Frazer, ME; Gewandter, JS; Markman, JD; McDermott, MP; Pilcher, WH; Rast, SA; Simon, LS, 2015) |
| "Pregabalin was not more effective than active placebo in reducing painful symptoms or functional limitations in patients with neurogenic claudication associated with lumbar spinal stenosis." | 5.20 | Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication. ( Chowdhry, AK; Czerniecka, K; Dworkin, RH; Frazer, ME; Gewandter, JS; Markman, JD; McDermott, MP; Pilcher, WH; Rast, SA; Simon, LS, 2015) |
| "This study provides Class I evidence that for patients with neurogenic claudication, compared with diphenhydramine, pregabalin does not increase the time to moderate pain during a treadmill test." | 5.20 | Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication. ( Chowdhry, AK; Czerniecka, K; Dworkin, RH; Frazer, ME; Gewandter, JS; Markman, JD; McDermott, MP; Pilcher, WH; Rast, SA; Simon, LS, 2015) |
| " According to a predefined scheme for 8 weeks, all patients in the intervention group received individual daily pain treatment with acetaminophen, extended release morphine, buprenorphine transdermal patch, and/or pregabaline." | 5.19 | The response of agitated behavior to pain management in persons with dementia. ( Aarsland, D; Ballard, C; Cohen-Mansfield, J; Husebo, BS; Seifert, R, 2014) |
| "To assess effects of pregabalin on colonic compliance, sensory and motor functions in patients with constipation-predominant irritable bowel syndrome." | 5.19 | Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome. ( Burton, D; Busciglio, I; Camilleri, M; Iturrino, J; Zinsmeister, AR, 2014) |
| "In a pilot, double-blind, placebo-controlled, parallel-group study, we tested oral pregabalin, 200mg, in 18 patients with constipation-predominant irritable bowel syndrome." | 5.19 | Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome. ( Burton, D; Busciglio, I; Camilleri, M; Iturrino, J; Zinsmeister, AR, 2014) |
| "Pregabalin, 200mg, might not reduce distension-related colonic pain in constipation-predominant irritable bowel syndrome patients." | 5.19 | Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome. ( Burton, D; Busciglio, I; Camilleri, M; Iturrino, J; Zinsmeister, AR, 2014) |
| "In prior studies, pregabalin reduced rectal or colonic pain in patients with irritable bowel syndrome and healthy adults, suggesting reduction of afferent function." | 5.19 | Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome. ( Burton, D; Busciglio, I; Camilleri, M; Iturrino, J; Zinsmeister, AR, 2014) |
| "The intradermal capsaicin pain model has been used to evaluate analgesic effects of a variety of drugs." | 5.19 | Determination of the effective dose of pregabalin on human experimental pain using the sequential up-down method. ( Wallace, MS; Wong, W, 2014) |
| "Using the Dixon sequential up-down method, the ED50 of pregabalin on intradermal capsaicin induced pain was successfully calculated (252 mg) using only 13 subjects." | 5.19 | Determination of the effective dose of pregabalin on human experimental pain using the sequential up-down method. ( Wallace, MS; Wong, W, 2014) |
| "Pain medication significantly improved pain in the intervention group, with indications that acetaminophen also improved ADL function." | 5.19 | Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: a cluster randomized trial. ( Aarsland, D; Ballard, C; Corbett, A; Husebo, BS; Sandvik, RK; Seifert, R; Selbaek, G, 2014) |
| "Based on the obtained data, prophylactic lornoxicam controlled postendodontic treatment pain more effectively than did the placebo drugs, and gabapentin was more effective in controlling the pain than either lornoxicam or the placebo." | 5.19 | Analgesic efficacy of prophylactic gabapentin and lornoxicam in preventing postendodontic pain. ( Aktuna, S; Işik, B; Turan, A; Yaman, S, 2014) |
| "This multicentre, double-blind, parallel-group study in diabetic peripheral neuropathic pain addressed whether, in patients not responding to standard doses of duloxetine or pregabalin, combining both medications is superior to increasing each drug to its maximum recommended dose." | 5.17 | Duloxetine and pregabalin: high-dose monotherapy or their combination? The "COMBO-DN study"--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. ( Bouhassira, D; Cruccu, G; Freynhagen, R; Lledo, A; Schacht, A; Skljarevski, V; Tesfaye, S; Tölle, T; Wilhelm, S, 2013) |
| "The aim of this study was to evaluate the opioid response in patients receiving morphine and pregabalin, independently from the presumed pain mechanisms, in comparison with patients receiving morphine treatment only." | 5.17 | The effects of low doses of pregabalin on morphine analgesia in advanced cancer patients. ( Aielli, F; Casuccio, A; Codipietro, L; Ferrera, P; Lo Presti, C; Mercadante, S; Porzio, G, 2013) |
| "Gabapentin is increasingly being used for the treatment of postoperative pain and a variety of psychiatric diseases, including chronic anxiety disorders." | 5.17 | Gabapentin reduces preoperative anxiety and pain catastrophizing in highly anxious patients prior to major surgery: a blinded randomized placebo-controlled trial. ( Clarke, H; Katz, J; Katznelson, R; Kirkham, KR; Ko, R; Ma, M; Mitsakakis, N; Orser, BA; Snyman, A, 2013) |
| " Following ethics approval and informed consent, 50 female patients with a 0-10 numeric rating scale (NRS) anxiety score of greater than or equal to 5/10 consented to receive either gabapentin 1,200 mg (n = 25) or placebo (n = 25) prior to surgery." | 5.17 | Gabapentin reduces preoperative anxiety and pain catastrophizing in highly anxious patients prior to major surgery: a blinded randomized placebo-controlled trial. ( Clarke, H; Katz, J; Katznelson, R; Kirkham, KR; Ko, R; Ma, M; Mitsakakis, N; Orser, BA; Snyman, A, 2013) |
| "Administration of gabapentin 1,200 mg prior to surgery reduces preoperative NRS anxiety scores and pain catastrophizing scores and increases sedation prior to entering the operating room." | 5.17 | Gabapentin reduces preoperative anxiety and pain catastrophizing in highly anxious patients prior to major surgery: a blinded randomized placebo-controlled trial. ( Clarke, H; Katz, J; Katznelson, R; Kirkham, KR; Ko, R; Ma, M; Mitsakakis, N; Orser, BA; Snyman, A, 2013) |
| "To study the effects of pregabalin on development of secondary oesophageal hypersensitivity in healthy humans." | 5.16 | Randomised clinical trial: pregabalin attenuates the development of acid-induced oesophageal hypersensitivity in healthy volunteers - a placebo-controlled study. ( Aziz, Q; Chua, YC; Jafari, J; Knowles, CH; Ng, KS; Sharma, A; Surguy, S; Yazaki, E, 2012) |
| "Pregabalin attenuates development of secondary hypersensitivity in the proximal oesophagus after distal oesophageal acidification; it may thus have a role in treatment of patients with proven oesophageal pain hypersensitivity." | 5.16 | Randomised clinical trial: pregabalin attenuates the development of acid-induced oesophageal hypersensitivity in healthy volunteers - a placebo-controlled study. ( Aziz, Q; Chua, YC; Jafari, J; Knowles, CH; Ng, KS; Sharma, A; Surguy, S; Yazaki, E, 2012) |
| "To assess the effect of pregabalin on polysomnographic (PSG) measures of sleep and patient-rated sleep, tiredness, and pain in fibromyalgia patients." | 5.16 | Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study. ( Bhadra, P; Lankford, DA; Resnick, EM; Roth, T; Whalen, E, 2012) |
| "Patients with fibromyalgia treated with pregabalin had statistically significant and meaningful improvements in sleep, as assessed by PSG." | 5.16 | Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study. ( Bhadra, P; Lankford, DA; Resnick, EM; Roth, T; Whalen, E, 2012) |
| "This study compared the effects of pregabalin (300 mg) and the tetracycline antibiotic and glial attenuator minocycline (400 mg) on capsaicin-induced spontaneous pain, flare, allodynia and hyperalgesia in patients with unilateral sciatica on both their affected and unaffected leg." | 5.16 | The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica. ( Briggs, N; Gentgall, M; Hutchinson, MR; Rolan, P; Sumracki, NM; Williams, DB, 2012) |
| "Patients with unilateral sciatica have heightened responses to intradermal capsaicin compared to pain-free volunteers." | 5.16 | The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica. ( Briggs, N; Gentgall, M; Hutchinson, MR; Rolan, P; Sumracki, NM; Williams, DB, 2012) |
| "It cannot be concluded that minocycline is unsuitable for further evaluation as an anti-neuropathic pain drug as pregabalin, our positive control, failed to reduce capsaicin-induced neuropathic pain." | 5.16 | The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica. ( Briggs, N; Gentgall, M; Hutchinson, MR; Rolan, P; Sumracki, NM; Williams, DB, 2012) |
| "Pregabalin, a high-affinity ligand for α2δ subunits of voltage-gated calcium channels, is a novel pharmacotherapy for chronic pain, partial seizures, and other disorders." | 5.15 | Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. ( Bockbrader, HN; Burger, P; Corrigan, BW; Knapp, L, 2011) |
| "Using nonlinear mixed-effect modeling, 5,583 plasma pregabalin concentration-time samples from 1,723 subjects were analyzed: 2,868 samples from healthy volunteers or subjects with renal impairment (n = 123), 1,513 from patients with partial seizures (n = 626), and 1,202 from patients with chronic pain (n = 974)." | 5.15 | Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. ( Bockbrader, HN; Burger, P; Corrigan, BW; Knapp, L, 2011) |
| "Pregabalin CL/F is related to CLcr, and this relationship is similar among healthy volunteers and patients with either partial seizures or chronic pain disorders." | 5.15 | Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. ( Bockbrader, HN; Burger, P; Corrigan, BW; Knapp, L, 2011) |
| "Pregabalin has demonstrated efficacy in several forms of neuropathic pain, but its long-term efficacy in central post-stroke pain (CPSP) is unproven." | 5.15 | Safety and efficacy of pregabalin in patients with central post-stroke pain. ( Bashford, G; Cheung, R; Dror, V; Kim, JS; Martin, A; Murphy, KT, 2011) |
| "In a randomized, double-blind, placebo-controlled, two-session crossover study the effect of a single oral dose of pregabalin (150 mg) on pain and allodynia was evaluated in 8 subjects with herpes zoster." | 5.15 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| "Compared to an earlier study of gabapentin 900 mg for acute zoster pain and allodynia that followed a nearly identical protocol, pregabalin had a similar effect on pain and was well tolerated, with no difference from placebo on sleepiness." | 5.15 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| "The effect of pregabalin on acute herpes zoster pain has not been previously evaluated." | 5.15 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| "Over 6 hours of observation, pain decreased by a mean of 33% with pregabalin and 14% with placebo (p < 0." | 5.15 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| "This randomised, double-blind, placebo-controlled trial assessed the efficacy and tolerability of pregabalin to alleviate the neuropathic component of moderate to severe burn pain." | 5.15 | Pregabalin in severe burn injury pain: a double-blind, randomised placebo-controlled trial. ( Cabot, PJ; Cramond, T; Doecke, J; Gray, P; Kirby, J; Smith, MT; Williams, B, 2011) |
| "Treatment with trazodone significantly improved global fibromyalgia severity, sleep quality, and depression, as well as pain interference with daily activities although without showing a direct effect on bodily pain." | 5.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| "Although trazodone is frequently used by fibromyalgia patients, its efficacy on this disease has not been adequately studied." | 5.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| " Trazodone, flexibly dosed (50-300 mg/day), was administered to 66 fibromyalgia patients during 12 weeks; 41 patients who completed the treatment accepted to receive pregabalin, also flexibly dosed (75-450 mg/day), added to trazodone treatment for an additional 12-week period." | 5.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| "Trazodone significantly improved fibromyalgia severity and associated symptomatology." | 5.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| " If effective, pregabalin, whose beneficial effects on pain and sleep quality in fibromyalgia have been demonstrated, could complement the antidepressant and anxiolytic effects of trazodone." | 5.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| "This study evaluates the efficacy and tolerability of long-term controlled-release (CR) oxycodone + pregabalin in patients with non-cancer pain, in a real-life setting." | 5.15 | Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study. ( Gatti, A; Longo, G; Sabato, AF; Sabato, E, 2011) |
| "Patients (n = 1,051) with chronic uncontrolled non-cancer pain received CR oxycodone + pregabalin for 1 year." | 5.15 | Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study. ( Gatti, A; Longo, G; Sabato, AF; Sabato, E, 2011) |
| "The combination of CR oxycodone + pregabalin could represent a valuable long-term therapeutic addition to existing pharmacological options for the treatment of non-cancer pain." | 5.15 | Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study. ( Gatti, A; Longo, G; Sabato, AF; Sabato, E, 2011) |
| "Gabapentin has demonstrated efficacy in clinical trials as a pre-emptive analgesic and in acute postoperative pain management." | 5.15 | Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia. ( Marashi, SH; Nadjafi, A; Panah Khahi, M; Yaghooti, AA, 2011) |
| "The pain score was significantly lower in the gabapentin group at two hours post surgery (p-value is 0." | 5.15 | Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia. ( Marashi, SH; Nadjafi, A; Panah Khahi, M; Yaghooti, AA, 2011) |
| "Pre-emptive use of gabapentin 300 mg orally significantly decreases postoperative pain two hours after surgery." | 5.15 | Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia. ( Marashi, SH; Nadjafi, A; Panah Khahi, M; Yaghooti, AA, 2011) |
| " Pharmacological therapy consists of the recommended pharmacological treatment for fibromyalgia: pregabalin (300-600 mg/day), with duloxetine (60-120 mg/day) added where there is a comorbid depression)." | 5.14 | Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial. ( Alda, M; Andrés, E; del Hoyo, YL; García-Campayo, J; Luciano, JV; Magallón, R; Rodero, B; Serrano-Blanco, A, 2009) |
| "To evaluate the adequacy of a low-dose combination of oxycodone and paracetamol (acetaminophen) in patients with multimodal, chronic, non-malignant pain using the Pain Management Index (PMI)." | 5.14 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "In patients with PHN and painful DPN failing to respond to monotherapy, combination therapy with 5% lidocaine medicated plaster and pregabalin provides additional clinically relevant pain relief and is safe and well-tolerated." | 5.14 | Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "To compare efficacy and safety of 5% lidocaine medicated plaster with pregabalin in patients with post-herpetic neuralgia (PHN) or painful diabetic polyneuropathy (DPN)." | 5.14 | 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| " Data are reported from the initial 4-week comparative phase, in which adults with PHN or painful DPN received either topical 5% lidocaine medicated plaster applied to the most painful skin area or twice-daily pregabalin capsules titrated to effect according to the Summary of Product Characteristics." | 5.14 | 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "Effects of pregabalin (PGB) on patient-reported health outcomes were assessed in 65 PGB-naive subjects with trigeminal neuralgia refractory to previous analgesic therapy in a prospective, multicentre observational study carried out in primary care." | 5.14 | Patient-reported outcomes in subjects with painful trigeminal neuralgia receiving pregabalin: evidence from medical practice in primary care settings. ( Martínez, S; Navarro, A; Pérez, C; Rejas, J; Saldaña, MT, 2009) |
| " Up to estimated 336 patients (interim analyses) with acute herpes zoster pain (VAS > 30 mm) will be randomised to one of three groups (a) semi-standardised acupuncture (168 patients); (b) gabapentine with individualised dosage between 900-3600 mg/d (84 patients); (c) sham laser acupuncture." | 5.14 | Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial. ( Fleckenstein, J; Hoffrogge, P; Irnich, D; Kramer, S; Lang, PM; Lehmeyer, L; Mansmann, U; Pfab, F; Ring, J; Schober, GM; Schotten, KJ; Thoma, S; Weisenseel, P, 2009) |
| "This study is the first large-scale randomised placebo controlled trial to evaluate the efficacy of acupuncture compared to gabapentine and sham treatment and will provide valuable new information about the clinical and physiological effects of acupuncture and gabapentine in the treatment of acute herpes zoster pain." | 5.14 | Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial. ( Fleckenstein, J; Hoffrogge, P; Irnich, D; Kramer, S; Lang, PM; Lehmeyer, L; Mansmann, U; Pfab, F; Ring, J; Schober, GM; Schotten, KJ; Thoma, S; Weisenseel, P, 2009) |
| "To compare the efficacy and safety of pregabalin and amitriptyline in alleviating pain associated with diabetic peripheral neuropathy." | 5.14 | Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. ( Bansal, D; Bhansali, A; Chakrabarti, A; Dutta, P; Hota, D, 2009) |
| "Good, moderate and mild pain relief were noted in 21 (48%), 6 (13%) and 7 (15%) patients on pregabalin and 15 (34%), 5 (11%) and 12 (27%) patients on amitriptyline, respectively, by patient's global assessment of efficacy and safety." | 5.14 | Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. ( Bansal, D; Bhansali, A; Chakrabarti, A; Dutta, P; Hota, D, 2009) |
| "The aim of this randomized double-blind, placebo-controlled, parallel-group study was to evaluate the efficacy, safety, and tolerability of pregabalin in combination with oxycodone or placebo, in patients with either postherpetic neuralgia (PHN) or painful diabetic neuropathy (PDN)." | 5.14 | A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. ( Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010) |
| "The clinical usefulness of gabapentin in combination with opioids for Japanese patients with neuropathic cancer pain was assessed in an open-label, single-center, prospective study." | 5.14 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| "Although gabapentin might be regarded as a promising new adjuvant analgesic for neuropathic cancer pain, our results indicated that the decrease in pain score was of minimal clinical benefit." | 5.14 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| "Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally." | 5.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Low-dose gabapentin-imipramine significantly decreased the total pain score and daily paroxysmal pain episodes." | 5.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Low-dose gabapentin-antidepressant combination with opioids was effective in managing neuropathic cancer pain without severe adverse effects." | 5.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "This study compared the efficacy and safety of tramadol/acetaminophen (T/A) and gabapentin in the management of painful diabetic neuropathy." | 5.14 | Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. ( Baik, SH; Cha, BY; Kim, CH; Kim, DS; Ko, KS; Ko, SH; Kwon, HS; Lee, JH; Mok, JO; Noh, JH; Park, IB; Park, TS; Son, HS; Yu, JM, 2010) |
| "This study suggests that the T/A combination treatment is as effective as gabapentin in the treatment of painful diabetic neuropathy in patients with Type 2 diabetes." | 5.14 | Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. ( Baik, SH; Cha, BY; Kim, CH; Kim, DS; Ko, KS; Ko, SH; Kwon, HS; Lee, JH; Mok, JO; Noh, JH; Park, IB; Park, TS; Son, HS; Yu, JM, 2010) |
| "The objective of this study was to evaluate the effect of patients' characteristics at baseline on the magnitude of pain response to pregabalin in patients with fibromyalgia." | 5.14 | Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics. ( Emir, B; Murphy, TK; Petersel, DL; Whalen, E, 2010) |
| "Data from four randomized, multicenter, placebo-controlled clinical studies of pregabalin in patients with fibromyalgia were used for the analysis." | 5.14 | Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics. ( Emir, B; Murphy, TK; Petersel, DL; Whalen, E, 2010) |
| "The magnitude of response to pregabalin in terms of changes in pain may depend on age, pain, and sleep levels at baseline in patients with fibromyalgia." | 5.14 | Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics. ( Emir, B; Murphy, TK; Petersel, DL; Whalen, E, 2010) |
| "Topical gabapentin seems to be well-tolerated and associated with significant pain relief in women with vulvodynia." | 5.13 | Topical gabapentin in the treatment of localized and generalized vulvodynia. ( Blais, LR; Boardman, LA; Cooper, AS; Raker, CA, 2008) |
| "Recent consensus guidelines recommend pregabalin as a first-tier treatment for painful diabetic peripheral neuropathy (DPN)." | 5.13 | Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. ( Arezzo, JC; Lamoreaux, L; Pauer, L; Rosenstock, J, 2008) |
| "Pregabalin 600 mg/d (300 mg BID) effectively reduced pain, was well tolerated, and had no statistically significant or clinically meaningful effect on NC in patients with painful DPN." | 5.13 | Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. ( Arezzo, JC; Lamoreaux, L; Pauer, L; Rosenstock, J, 2008) |
| "Intradermal (ID) capsaicin injection in humans induces spontaneous pain, flare, primary hyperalgesia, secondary hyperalgesia, and allodynia." | 5.13 | Effect of morphine and pregabalin compared with diphenhydramine hydrochloride and placebo on hyperalgesia and allodynia induced by intradermal capsaicin in healthy male subjects. ( Baxendale, J; Bolognese, J; Calder, N; Connell, J; Cummings, C; Herman, G; Kehler, A; Wang, H, 2008) |
| "To evaluate the efficacy and safety of pregabalin for symptomatic relief of pain associated with fibromyalgia (FM) and for management of FM." | 5.13 | A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. ( Arnold, LM; Florian, H; Martin, SA; Mease, PJ; Russell, IJ; Sharma, U; Young, JP, 2008) |
| "Patients in all pregabalin groups showed statistically significant improvement in endpoint mean pain score and in PGIC response compared with placebo." | 5.13 | A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. ( Arnold, LM; Florian, H; Martin, SA; Mease, PJ; Russell, IJ; Sharma, U; Young, JP, 2008) |
| "Pregabalin at 300, 450, and 600 mg/day was efficacious and safe for treatment of pain associated with FM." | 5.13 | A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. ( Arnold, LM; Florian, H; Martin, SA; Mease, PJ; Russell, IJ; Sharma, U; Young, JP, 2008) |
| " The analgesic activity of CHF3381 was investigated in the heat-capsaicin human pain model and compared with those of gabapentin." | 5.12 | CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model. ( Dahl, JB; Fabbri, L; Hilsted, KL; Imbimbo, BP; Mathiesen, O, 2006) |
| " The risk of phantom pain (gabapentin vs." | 5.12 | A randomized study of the effects of gabapentin on postamputation pain. ( Finnerup, NB; Jensen, TS; Keller, J; Kramp, S; Nikolajsen, L; Vimtrup, AS, 2006) |
| "Gabapentin administered in the first 30 postoperative days after amputation does not reduce the incidence or intensity of postamputation pain." | 5.12 | A randomized study of the effects of gabapentin on postamputation pain. ( Finnerup, NB; Jensen, TS; Keller, J; Kramp, S; Nikolajsen, L; Vimtrup, AS, 2006) |
| "Gabapentin, an oral non-opioid analgesic, has been used to decrease pain after a variety of surgical procedures." | 5.12 | Premedication with gabapentin: the effect on tourniquet pain and quality of intravenous regional anesthesia. ( Karamanlioglu, B; Pamukçu, Z; Turan, A; White, PF, 2007) |
| " However, tourniquet pain scores at 30, 40, 50, and 60 min after cuff inflation were lower in the gabapentin group (P < 0." | 5.12 | Premedication with gabapentin: the effect on tourniquet pain and quality of intravenous regional anesthesia. ( Karamanlioglu, B; Pamukçu, Z; Turan, A; White, PF, 2007) |
| "To assess the efficacy and safety of gabapentin in patients with fibromyalgia." | 5.12 | Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. ( Arnold, LM; Bishop, F; Goldenberg, DL; Hess, EV; Hudson, JI; Keck, PE; Lalonde, JK; Sandhu, HS; Stanford, KE; Stanford, SB; Welge, JA, 2007) |
| "A 12-week, randomized, double-blind study was designed to compare gabapentin (1,200-2,400 mg/day) (n=75 patients) with placebo (n=75 patients) for efficacy and safety in treating pain associated with fibromyalgia." | 5.12 | Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. ( Arnold, LM; Bishop, F; Goldenberg, DL; Hess, EV; Hudson, JI; Keck, PE; Lalonde, JK; Sandhu, HS; Stanford, KE; Stanford, SB; Welge, JA, 2007) |
| "Gabapentin (1,200-2,400 mg/day) is safe and efficacious for the treatment of pain and other symptoms associated with fibromyalgia." | 5.12 | Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. ( Arnold, LM; Bishop, F; Goldenberg, DL; Hess, EV; Hudson, JI; Keck, PE; Lalonde, JK; Sandhu, HS; Stanford, KE; Stanford, SB; Welge, JA, 2007) |
| "Gabapentin-treated patients displayed a significantly greater improvement in the BPI average pain severity score (P=0." | 5.12 | Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. ( Arnold, LM; Bishop, F; Goldenberg, DL; Hess, EV; Hudson, JI; Keck, PE; Lalonde, JK; Sandhu, HS; Stanford, KE; Stanford, SB; Welge, JA, 2007) |
| "To estimate the cost-effectiveness of branded pregabalin (PGB) versus generic gabapentin (GBP) in patients with neuropathic pain (NeP) due to painful diabetic polyneuropathy (DPN) or post-herpetic neuralgia (PHN) in Spain." | 5.12 | Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007) |
| "According with data used in this modeling in patients with NeP due to DPN and/or PHN, PGB was shown to be more cost-effective than generic gabapentin in Spain." | 5.12 | Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007) |
| "To test the hypotheses that both amitriptyline and gabapentin are more effective in relieving neuropathic pain than an active placebo, diphenhydramine." | 5.12 | Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. ( Courtade, D; Fiess, RN; Holmes, SA; Loubser, PG; Rintala, DH; Tastard, LV, 2007) |
| "Amitriptyline is more efficacious in relieving neuropathic pain than diphenhydramine at or below the level of spinal cord injury in people who have considerable depressive symptomatology." | 5.12 | Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. ( Courtade, D; Fiess, RN; Holmes, SA; Loubser, PG; Rintala, DH; Tastard, LV, 2007) |
| "To determine the analgesic effect of the addition of gabapentin to opioids in the management of neuropathic cancer pain." | 5.11 | Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. ( Arcuri, E; Barbieri, M; Bonezzi, C; Caraceni, A; De Conno, F; Gorni, G; Maltoni, M; Martini, C; Tirelli, W; Visentin, M; Yaya Tur, R; Zecca, E, 2004) |
| "Gabapentin is effective in improving analgesia in patients with neuropathic cancer pain already treated with opioids." | 5.11 | Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. ( Arcuri, E; Barbieri, M; Bonezzi, C; Caraceni, A; De Conno, F; Gorni, G; Maltoni, M; Martini, C; Tirelli, W; Visentin, M; Yaya Tur, R; Zecca, E, 2004) |
| "Patients reported significant pain relief in favor of gabapentin in the first period." | 5.11 | Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. ( Kessels, AH; Stomp-van den Berg, SG; van de Vusse, AC; Weber, WE, 2004) |
| "Gabapentin had a mild effect on pain in CRPS I." | 5.11 | Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. ( Kessels, AH; Stomp-van den Berg, SG; van de Vusse, AC; Weber, WE, 2004) |
| "This multicenter, double-blind, 8-week, randomized clinical trial compared the effects of placebo with those of 150, 300, and 450 mg/day pregabalin on pain, sleep, fatigue, and health-related quality of life in 529 patients with FMS." | 5.11 | Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. ( Corbin, AE; Crofford, LJ; Dworkin, RH; LaMoreaux, LK; Martin, SA; Mease, PJ; Rowbotham, MC; Russell, IJ; Sharma, U; Young, JP, 2005) |
| "Pregabalin at 450 mg/day was efficacious for the treatment of FMS, reducing symptoms of pain, disturbed sleep, and fatigue compared with placebo." | 5.11 | Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. ( Corbin, AE; Crofford, LJ; Dworkin, RH; LaMoreaux, LK; Martin, SA; Mease, PJ; Rowbotham, MC; Russell, IJ; Sharma, U; Young, JP, 2005) |
| "Pregabalin at 450 mg/day significantly reduced the average severity of pain in the primary analysis compared with placebo (-0." | 5.11 | Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. ( Corbin, AE; Crofford, LJ; Dworkin, RH; LaMoreaux, LK; Martin, SA; Mease, PJ; Rowbotham, MC; Russell, IJ; Sharma, U; Young, JP, 2005) |
| "We evaluated the effects of gabapentin and carbamazepine for pain relief in 36 Guillain-Barré syndrome patients." | 5.11 | The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. ( Kumar, A; Navkar, DV; Pandey, CK; Raza, M; Singh, UK; Tripathi, M, 2005) |
| "Gabapentin has been evaluated in the treatment of nonmalignant neuropathic pain, however, there is little direct evidence evaluating its efficacy in cancer-related neuropathic pain." | 5.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "This study evaluated the effectiveness of gabapentin to treat cancer-related neuropathic pain." | 5.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "We conclude that gabapentin is an effective treatment for cancer-related neuropathic pain." | 5.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "A double-blind, randomised, placebo-controlled 8-week study was conducted to evaluate the efficacy and safety of gabapentin in the treatment of neuropathic pain, using doses up to 2400 mg/day." | 5.10 | Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. ( Serpell, MG, 2002) |
| "To assess the effects of gabapentin on sensory and motor symptoms in patients with restless legs syndrome (RLS)." | 5.10 | Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. ( de la Llave, Y; Garcia-Borreguero, D; Hernandez, G; Larrosa, O; Masramon, X; Verger, K, 2002) |
| "Gabapentin, an antiepileptic drug, has been used effectively for different types of pain management." | 5.10 | Gabapentin for the treatment of pain in guillain-barré syndrome: a double-blinded, placebo-controlled, crossover study. ( Agarwal, A; Baronia, A; Bose, N; Garg, G; Pandey, CK; Singh, N; Singh, PK; Singh, U, 2002) |
| "To assess the effectiveness and safety of the lidocaine patch 5%, a targeted peripheral analgesic, in the treatment of postherpetic neuralgia, painful diabetic neuropathy, and low back pain patients with incomplete responses to their current analgesic treatment regimen containing gabapentin." | 5.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Significant improvements in BPI measures of pain intensity and pain relief were reported for all groups of patients after 2 weeks of lidocaine patch 5% treatment." | 5.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "The aim of our study was to explore a potential analgesic effect of gabapentin in patients with neuropathic pain caused by anticancer treatment." | 5.10 | Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. ( Bosnjak, S; Jelic, S; Luki, V; Susnjar, S, 2002) |
| "Reports of gabapentin use in diabetic peripheral neuropathy pain stimulate a need for controlled trials to determine its comparative efficacy to the therapeutic standard of amitriptyline hydrochloride." | 5.09 | Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ( Leckband, SG; Moorhouse, DF; Morello, CM; Sahagian, GA; Stoner, CP, 1999) |
| "To determine the efficacy of gabapentin compared with amitriptyline in treating diabetic peripheral neuropathy pain." | 5.09 | Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ( Leckband, SG; Moorhouse, DF; Morello, CM; Sahagian, GA; Stoner, CP, 1999) |
| "Patients with stable glycemic control and neuropathic pain randomized to 6 weeks of therapy with gabapentin, 900 to 1800 mg/d, or amitriptyline hydrochloride, 25 to 75 mg/d, with a 1-week washout before crossover." | 5.09 | Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ( Leckband, SG; Moorhouse, DF; Morello, CM; Sahagian, GA; Stoner, CP, 1999) |
| "Although both drugs provide pain relief, mean pain score and global pain score data indicate no significant difference between gabapentin and amitriptyline." | 5.09 | Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ( Leckband, SG; Moorhouse, DF; Morello, CM; Sahagian, GA; Stoner, CP, 1999) |
| "The objective of this study was to compare the efficacy and tolerability of gabapentin and amitriptyline monotherapy in painful diabetic neuropathy." | 5.09 | Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. ( Buffa, C; Chiroli, S; Dallocchio, C; Mazzarello, P, 2000) |
| "Twenty-one patients referred with refractory genitourinary pain were treated with oral gabapentin." | 5.09 | Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. ( Chancellor, MB; Chuang, YC; Kim, JC; Lee, JY; Sasaki, K; Smith, CP, 2001) |
| "Although only 10 of 21 patients improved with gabapentin, this cohort included only patients with refractory genitourinary pain that failed a wide range of prior treatments." | 5.09 | Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. ( Chancellor, MB; Chuang, YC; Kim, JC; Lee, JY; Sasaki, K; Smith, CP, 2001) |
| "To evaluate the effects of gabapentin on pain scores and opiate use." | 5.08 | The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997) |
| " A significant decrease in pain scores with gabapentin was seen in the neuropathic pain group (paired t-test, p < ." | 5.08 | The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997) |
| "Gabapentin may be a useful adjunct for treating neuropathic pain with a minimum of side effects." | 5.08 | The effect of gabapentin on neuropathic pain. ( de Rosayro, AM; Harrell, C; Ristic, H; Rosenberg, JM; Werner, RA, 1997) |
| "Having a differential sensitivity to morphine can distinguish migraine suffers from healthy people who are headache-exempt." | 5.08 | Painful and non-painful effects of low doses of morphine in migraine sufferers partly depend on excitatory amino acids and gamma-aminobutyric acid. ( Nicolodi, M, 1998) |
| "A large case series of patients with centrally mediated pain, peripherally mediated pain, migraine, and tremor were treated in an open-label study with gabapentin (maximum of 2,700 mg/day)." | 5.08 | Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998) |
| "Gabapentin offers an effective, safe alternative therapy or co-therapy for the listed painful conditions and tremor; it does not affect the metabolism of other medications and is well tolerated." | 5.08 | Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998) |
| "To evaluate the effect of gabapentin monotherapy on pain associated with diabetic peripheral neuropathy." | 5.08 | Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. ( Backonja, M; Beydoun, A; Edwards, KR; Fonseca, V; Garofalo, E; Hes, M; LaMoreaux, L; Schwartz, SL, 1998) |
| "Gabapentin monotherapy appears to be efficacious for the treatment of pain and sleep interference associated with diabetic peripheral neuropathy and exhibits positive effects on mood and quality of life." | 5.08 | Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. ( Backonja, M; Beydoun, A; Edwards, KR; Fonseca, V; Garofalo, E; Hes, M; LaMoreaux, L; Schwartz, SL, 1998) |
| "Studies investigating glutamate, GABA, Glx and/or glutamine in relation to experimental pain (e." | 5.05 | Excitatory and inhibitory responses in the brain to experimental pain: A systematic review of MR spectroscopy studies. ( Archibald, J; Enzler, A; Jutzeler, CR; Kramer, JLK; MacMillan, EL; Schweinhardt, P, 2020) |
| "MRS represents a promising tool to examine the brain in pain, functionally, and at rest with support for increased glutamate, glutamine and Glx levels in relation to pain." | 5.05 | Excitatory and inhibitory responses in the brain to experimental pain: A systematic review of MR spectroscopy studies. ( Archibald, J; Enzler, A; Jutzeler, CR; Kramer, JLK; MacMillan, EL; Schweinhardt, P, 2020) |
| " Overall, there was a low quality of evidence that gabapentin, pregabalin, amitriptyline, and venlafaxine were effective in reducing pain intensity in patients with cancer pain." | 4.95 | Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review. ( de Graeff, A; Dijkstra, D; Jongen, JL; Mostovaya, I; van den Beuken-van Everdingen, MH; Vissers, KC, 2017) |
| "This article reviews the existing literature on the use of gabapentin (Neurontin®) as a co-analgesic in treating the neuropathic pain in OM." | 4.93 | Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016) |
| "No systematic reviews exist on the role of gabapentin for neuropathic pain in radiation-induced OM." | 4.93 | Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016) |
| "Gabapentin (GBP), originally an antiepileptic drug, is more commonly used in the treatment of neuropathic pain." | 4.90 | Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain. ( Butler, PM; Kurowski, D; Perloff, MD; Yan, PZ, 2014) |
| "We performed a meta-analysis of individual patient data from four large trials of pregabalin for fibromyalgia lasting 8-14 weeks." | 4.87 | Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. ( Derry, S; Hallier, E; McQuay, HJ; Moore, RA; Paine, J; Phillips, CJ; Straube, S, 2011) |
| "Significant benefit of pregabalin over placebo was seen for a variety of outcomes including mean pain and sleep scores, the proportion of patients achieving at least 50% pain relief and most of the individual domains of short-form 36." | 4.86 | Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S, 2010) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 4.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Recent studies showed effectiveness of gabapentin in improving the pain control in patients with neuropathic cancer pain, already treated with opiates." | 4.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Given the significant benefits of gabapentin and the combination of gabapentin with opioids for the treatment of neuropathic pain, randomized clinical trials are needed to establish the role of these analgesic regimens for the treatment of neuropathic cancer pain." | 4.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "To review the efficacy and safety of pregabalin, an alpha(2)-delta (alpha(2)-delta) ligand, for the management of fibromyalgia (FM)." | 4.86 | Pregabalin: an alpha2-delta (alpha2-delta) ligand for the management of fibromyalgia. ( Arnold, L; Mease, P; Silverman, S, 2010) |
| "What is the role of pregabalin (Lyrica) in the treatment of fibromyalgia? In this article the authors explore the putative pathophysiology of fibromyalgia, pregabalin's mechanism of action and evidence of efficacy, and its emerging role in treating this challenging disease." | 4.85 | Pregabalin for fibromyalgia: some relief but no cure. ( Deodhar, A; Kim, L; Lipton, S, 2009) |
| "Pregabalin has proven efficacy in neuropathic pain conditions and fibromyalgia." | 4.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "To assess analgesic efficacy and associated adverse events of pregabalin in acute and chronic pain." | 4.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "Randomised, double blind trials reporting on the analgesic effect of pregabalin, with subjective pain assessment by the patient as either the primary or a secondary outcome." | 4.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "There was no clear evidence of beneficial effects of pregabalin in established acute postoperative pain." | 4.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "Pregabalin is the first drug to receive approved labeling from the Food and Drug Administration (FDA) for the treatment of painful diabetic neuropathy and postherpetic neuralgia and is the first antiepileptic agent to receive FDA-approved labeling since 1999." | 4.84 | Pregabalin: an antiepileptic agent useful for neuropathic pain. ( Blommel, AL; Blommel, ML, 2007) |
| "Pregabalin may be beneficial for the treatment of neuropathic pain or partial-onset seizures in patients who do not respond to conventional treatments or cannot tolerate their adverse effects." | 4.84 | Pregabalin: an antiepileptic agent useful for neuropathic pain. ( Blommel, AL; Blommel, ML, 2007) |
| "New treatment options for diabetic peripheral neuropathic pain (DPNP) have recently been developed, including two Food and Drug Administration (FDA) approved agents, duloxetine and pregabalin." | 4.84 | Safety profile of treatment in diabetic peripheral neuropathic pain. ( Robinson-Papp, J; Simpson, DM, 2007) |
| "Pregabalin is increasingly being used for the treatment ofneuropathic pain, often as the first-line choice." | 4.84 | [Pregabalin in the treatment of neuropathic pain]. ( Biegstraaten, M; van Schaik, IN, 2007) |
| "Depomed is developing an extended-release (ER) oral formulation of gabapentin, a GABA receptor agonist commonly used for the treatment of epilepsy and seizures, neuropathic pain and hot flushes." | 4.84 | Gabapentin Extended-Release - Depomed: Gabapentin ER, Gabapentin Gastric Retention, Gabapentin GR. ( , 2007) |
| "Multiple, large, high-quality trials have demonstrated the safety and efficacy of gabapentin and pregabalin in neuropathic pain." | 4.84 | Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. ( Gilron, I, 2007) |
| "Gabapentin and pregabalin are efficacious treatments for neuropathic and postsurgical pain." | 4.84 | Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. ( Gilron, I, 2007) |
| "Gabapentin, a gamma-aminobutyric acid (GABA) analogue anticonvulsant, is also an effective analgesic agent in neuropathic and inflammatory, but not acute, pain systemically and intrathecally." | 4.83 | Mechanisms of the antinociceptive action of gabapentin. ( Cheng, JK; Chiou, LC, 2006) |
| "Pregabalin, a compound with a novel mechanism of action (MOA), has demonstrated efficacy as an adjunctive treatment for epilepsy and in several neuropathic pain models." | 4.83 | Pregabalin: From molecule to medicine. ( Kavoussi, R, 2006) |
| "Gabapentin is a drug that has been widely used in the treatment of chronic pain states." | 4.83 | alpha2delta and the mechanism of action of gabapentin in the treatment of pain. ( Lee, K; Luo, ZD; Maneuf, YP, 2006) |
| " Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Randomized controlled studies of gabapentin for neuropathic pain were identified through a search of PubMed and MEDLINE from 1966 to the present using the search terms gabapentin, randomized, placebo, and pain." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "At doses of 1800 to 3600 mg/d, gabapentin was effective and well tolerated in the treatment of adults with neuropathic pain." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Gabapentin is a very promising medication in the treatment of post-herpetic neuralgia and pain." | 4.82 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "This paper reviews the pharmacology and clinical effectiveness of gabapentin in the treatment of neuropathic pain." | 4.82 | Gabapentin in the treatment of neuropathic pain. ( Bennett, MI; Simpson, KH, 2004) |
| "Pregabalin is a gamma-aminobutyric acid analog that is under development by Pfizer for the potential treatment of central nervous system disorders, including epilepsy, neuropathic pain, fibromyalgia and generalized anxiety disorder." | 4.82 | Pregabalin (Pfizer). ( Huckle, R, 2004) |
| "To evaluate the analgesic effectiveness and adverse effects of gabapentin for pain management in clinical practice." | 4.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "Randomised trials of gabapentin in acute, chronic or cancer pain were identified by MEDLINE (1966-Nov 2004), EMBASE (1994-Nov 2004), SIGLE (1980-Jan 2004) and the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library Issue 4, 2004)." | 4.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "Randomised trials reporting the analgesic effects of gabapentin in patients, with subjective pain assessment as either the primary or a secondary outcome." | 4.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "There is evidence to show that gabapentin is effective in neuropathic pain." | 4.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "To review pregabalin's pharmacology, pharmacokinetics, efficacy, and adverse effects in the treatment of neuropathic pain, epilepsy, and anxiety." | 4.82 | Pregabalin: a new neuromodulator with broad therapeutic indications. ( McAuley, JW; Shneker, BF, 2005) |
| " Key terms were anxiety, diabetic neuropathy, epilepsy, neuropathic pain, postherpetic neuralgia, pregabalin, and seizures." | 4.82 | Pregabalin: a new neuromodulator with broad therapeutic indications. ( McAuley, JW; Shneker, BF, 2005) |
| " The search terms included pregabalin, PD144723, CI-1008, gabapentin, and neuropathic pain." | 4.82 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "In preclinical studies, pregabalin, a structural congener of gabapentin, exhibited antinociceptive activity in animal models of neuropathic and inflammatory pain." | 4.82 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "This article reviews the available information on pregabalin, a new anticonvulsant for peripheral neuropathic pain." | 4.82 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "Gabapentin, which has been approved for add-on therapy of focal seizures, is increasingly used for treatment of neuropathic pain." | 4.81 | [Gabapentin therapy for pain]. ( Block, F, 2001) |
| "Pfizer is developing pregabalin, a follow-up compound to its GABA agonist gabapentin, for the potential treatment of several central nervous system (CNS) disorders including epilepsy, neuropathic pain, anxiety and social phobia [286425]." | 4.81 | Pregabalin (Pfizer). ( Selak, I, 2001) |
| "Although its exact mode of action is not known, gabapentin appears to have a unique effect on voltage-dependent calcium ion channels at the postsynaptic dorsal horns and may, therefore, interrupt the series of events that possibly leads to the experience of a neuropathic pain sensation." | 4.81 | Gabapentin: pharmacology and its use in pain management. ( Kam, PC; Rose, MA, 2002) |
| "Gabapentin has been approved for the treatment of neuropathic pain in six European countries, New Zealand and Australia, and numerous countries in Latin America." | 4.81 | Gabapentin. Pfizer. ( Wheeler, G, 2002) |
| "Gabapentin, an antiepileptic agent, is a safe and versatile medication also used in the adjunctive treatment of painful disorders." | 4.80 | Interstitial cystitis and the potential role of gabapentin. ( Hansen, HC, 2000) |
| "There have been many proposed uses for gabapentin, including midscapular pain secondary to radiation myelopathy, RSD, neuropathic pain, postherpetic neuralgia, and migraine prophylaxis." | 4.79 | Use of gabapentin in pain management. ( Connelly, JF; Wetzel, CH, 1997) |
| "In patients with diabetic neuropathy who were prescribed gabapentin and pregabalin, there is an increased risk for heart failure, myocardial infarction, peripheral vascular disease, stroke, deep venous thrombosis, and pulmonary embolism with long-term use." | 4.12 | Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy. ( Blankfield, RP; Davis, PB; Kaebler, DC; Pan, Y; Xu, R, 2022) |
| "Gabapentin and pregabalin are commonly prescribed medications to treat pain in patients with diabetic neuropathy." | 4.12 | Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy. ( Blankfield, RP; Davis, PB; Kaebler, DC; Pan, Y; Xu, R, 2022) |
| "Microinjection of bicuculline and muscimol into the NC decreased and increased pain responses, respectively, in a dose-dependent manner during both phases of the test." | 4.02 | Effects of GABAA receptors in nucleus cuneiformis on the cannabinoid antinociception using the formalin test. ( Chen, J; Hasanein, P; Komaki, A; Yari, S, 2021) |
| "Prior work applied hierarchical clustering, coarsened exact matching (CEM), time series regressions with lagged variables as inputs, and microsimulation to data from three randomized clinical trials (RCTs) and a large German observational study (OS) to predict pregabalin pain reduction outcomes for patients with painful diabetic peripheral neuropathy." | 3.88 | Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy. ( Alexander, J; Bonfanti, G; Brodsky, M; Edwards, RA; Emir, B; Grugni, R; Manca, L; Parsons, B; Savoldelli, A; Watt, S; Whalen, E, 2018) |
| " Daily gabapentin treatment attenuated mechanical allodynia and reduced face-grooming episodes in dIoN-CCI rats." | 3.85 | An Improved Rodent Model of Trigeminal Neuropathic Pain by Unilateral Chronic Constriction Injury of Distal Infraorbital Nerve. ( Chen, L; Ding, W; Doheny, JT; Lim, G; Mao, J; Shen, S; Yang, J; You, Z; Zhu, S, 2017) |
| "Gabapentinoids are effective adjunct drugs for reducing postoperative pain." | 3.83 | Comparison of the effects of gabapentin and pregabalin on wound healing in rats. ( Korkmaz, M; Sarıtaş, TB; Sarıtaş, ZK; Sevimli, A, 2016) |
| "We assessed the efficacy and safety of extended-release gabapentin in a 15-week, open-label, single-arm, single-center study in patients with fibromyalgia (FM)." | 3.83 | The Effect of a Novel form of Extended-Release Gabapentin on Pain and Sleep in Fibromyalgia Subjects: An Open-Label Pilot Study. ( Hong, KS; North, JM; Rauck, RL, 2016) |
| "Extended-release gabapentin relieved FM pain symptoms and improved quality-of-life for the FM subjects studied." | 3.83 | The Effect of a Novel form of Extended-Release Gabapentin on Pain and Sleep in Fibromyalgia Subjects: An Open-Label Pilot Study. ( Hong, KS; North, JM; Rauck, RL, 2016) |
| " Mechanical allodynia elicited by burn injury was partially reversed by meloxicam (5 mg/kg), gabapentin (100 mg/kg) and oxycodone (3 and 10 mg/kg), while thermal allodynia and gait abnormalities were only significantly improved by amitriptyline (3 mg/kg) and oxycodone (10 mg/kg)." | 3.83 | Transcriptomic and behavioural characterisation of a mouse model of burn pain identify the cholecystokinin 2 receptor as an analgesic target. ( Deuis, JR; Lewis, RJ; Vetter, I; Yin, K, 2016) |
| " Data pertaining to demographics, diagnosis, oral morphine dose equivalent of the opioid at the time of discharge, adjuvant analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and pain scores as reported by nurses and physicians were collected." | 3.81 | Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements? ( Davis, MP; Gordon, P; Gross, J; Sharma, P; Shinde, S, 2015) |
| " Sleep disruption-induced hypersensitivity was pharmacologically characterized with drugs relevant for pain treatment, including gabapentin (30 mg/kg and 50 mg/kg), Ica-6p (Kv7." | 3.81 | Development and pharmacological characterization of a model of sleep disruption-induced hypersensitivity in the rat. ( Gilmour, G; Kennedy, JD; Schuh-Hofer, S; Treede, RD; Wafford, KA; Wodarski, R; Yurek, DA, 2015) |
| "The study objective was to describe presenting pain behaviors, daily dose, and response to gabapentin for the management of frequent recurrent pain in this population." | 3.81 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| "A retrospective analysis was performed with data from 22 children with severe impairment of the CNS residing at a long-term care facility, treated with gabapentin for recurrent pain behaviors." | 3.81 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| "Gabapentin appears to be an effective treatment for children with severe impairment of the CNS and recurrent pain behaviors, including intermittent changes in muscle tone." | 3.81 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| " In particular, 14 and 15 were found to be more potent than morphine for both acute and inflammatory pain models and 100-fold more potent than gabapentin in a diabetic neuropathic pain model." | 3.81 | Antinociceptive Grayanoids from the Roots of Rhododendron molle. ( Li, Y; Liu, Y; Liu, YB; Lv, HN; Ma, SG; Qu, J; Yu, SS; Zhang, JJ, 2015) |
| "Synthetic approaches to gabapentin bioconjugates that overcome the tendency of gabapentin to cyclize into its γ-lactam are studied." | 3.80 | Gabapentin hybrid peptides and bioconjugates. ( Alamry, KA; Goncalves, K; Ibrahim, MA; Katritzky, AR; Lebedyeva, IO; Neubert, J; Ostrov, DA; Patel, K; Sileno, SM; Steel, PJ, 2014) |
| "This study investigated the effects of Phα1β, pregabalin and diclofenac using an animal model of fibromyalgia (FM)." | 3.80 | The effects of Phα1β, a spider toxin, calcium channel blocker, in a mouse fibromyalgia model. ( Castro, CJ; da Costa Lopes, AM; da Silva, CA; da Silva, JF; de Souza, AH; Ferreira, J; Gomez, MV; Klein, CP; Pereira, EM, 2014) |
| " In the writhing test, pain responses were scored every 5 min during a 30-min period after intraperitoneal injection of diluted acetic acid." | 3.80 | Synergic effects of pregabalin-acetaminophen combination in somatic and visceral nociceptive reactivity. ( Lupusoru, CE; Lupusoru, RV; Mititelu Tartau, L; Ochiuz, L; Popa, EG; Stoleriu, I, 2014) |
| "Although pregabalin has been shown to have preclinical and clinical efficacy in neuropathic pain, the mechanism of its antinociceptive action is still unknown in other pain states." | 3.80 | Inhibition of mitogen-activated protein kinases phosphorylation plays an important role in the anti-nociceptive effect of pregabalin in zymosan-induced inflammatory pain model. ( Jeong, YC; Kwon, YB; Pyun, K, 2014) |
| "The effect of new glutamic acid derivative on the cardiac ino- and chronotropic functions has been studied in experiments on rats exposed to 24-hour immobilization-and-pain stress." | 3.80 | [Cardioprotective properties of new glutamic acid derivative under stress conditions]. ( Berestovitskaia, VM; Perfilova, VN; Sadikova, NV; Vasil'eva, OS, 2014) |
| " We tested the ability of quantitative sensory testing to predict the analgesic effect of pregabalin and placebo in patients with chronic pancreatitis." | 3.79 | Quantitative sensory testing predicts pregabalin efficacy in painful chronic pancreatitis. ( Bouwense, SA; Drewes, AM; Graversen, C; Olesen, SS; van Goor, H; Wilder-Smith, OH, 2013) |
| "Sixty-four patients with painful chronic pancreatitis received pregabalin (150-300 mg BID) or matching placebo for three consecutive weeks." | 3.79 | Quantitative sensory testing predicts pregabalin efficacy in painful chronic pancreatitis. ( Bouwense, SA; Drewes, AM; Graversen, C; Olesen, SS; van Goor, H; Wilder-Smith, OH, 2013) |
| "The present study provides first evidence that quantitative sensory testing predicts the analgesic effect of pregabalin in patients with painful chronic pancreatitis." | 3.79 | Quantitative sensory testing predicts pregabalin efficacy in painful chronic pancreatitis. ( Bouwense, SA; Drewes, AM; Graversen, C; Olesen, SS; van Goor, H; Wilder-Smith, OH, 2013) |
| " Systemic administration of 1 reduced acetic acid-induced writhing, the inflammatory phase of formalin-induced pain, and capsaicin-induced mechanical allodynia." | 3.79 | Antiallodynic and analgesic effects of maslinic acid, a pentacyclic triterpenoid from Olea europaea. ( Baeyens, JM; Cobos, EJ; Entrena, JM; García-Granados, A; Nieto, FR; Parra, A, 2013) |
| "The rostroventromedial medulla (RVM) is an important area of the endogenous pain-regulating system, in which 5-hydroxytryptamine (5-HT) and gamma-aminobutyric acid (GABA) are 2 main transmitters involved in pain modulation." | 3.79 | Neurokinin-1 receptor-expressing neurons that contain serotonin and gamma-aminobutyric acid in the rat rostroventromedial medulla are involved in pain processing. ( Chen, T; Li, YQ; Qu, J; Wang, W; Wang, XL; Wu, SX; Yanagawa, Y; Zhang, T, 2013) |
| "We report two cases of infants with NI, identified to have significant improvement in apnea following empiric treatment with gabapentin for presumed central pain and/or visceral hyperalgesia." | 3.79 | Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment. ( Hauer, J; Mackey, D, 2013) |
| " This secondary hypertonia may contribute to apnea as a result of alterations in airway tone and chest wall movement." | 3.79 | Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment. ( Hauer, J; Mackey, D, 2013) |
| "Infants with NI and apnea should have careful pain assessment and treatment, when considering other causes and interventions for apnea." | 3.79 | Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment. ( Hauer, J; Mackey, D, 2013) |
| "The involvement of voltage-dependent calcium channels and reactive oxygen species in the pathophysiology of neuropathic pain might justify the preventative administration of antioxidant enzymes, at low doses, in combination with gabapentin (GaP) to maximize its analgesic effect in an experimental model of neuropathic pain in rats." | 3.79 | Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model. ( Arcos, M; Barrios, C; Montes, F; Palanca, JM, 2013) |
| "The frequency of PHN after untreated zoster varies widely." | 3.79 | Postherpetic neuralgia: role of gabapentin and other treatment modalities. ( Beydoun, A, 1999) |
| "To characterize and compare healthcare resource utilization and costs among patients with painful diabetic peripheral neuropathy (pDPN) newly prescribed pregabalin or gabapentin in a real-world clinical setting." | 3.78 | Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. ( Harnett, J; Mardekian, J; Udall, M, 2012) |
| "Prescription opioids and anticonvulsants such as gabapentin are often used as combination therapeutics for chronic as well as acute post-operative pain conditions although the effectiveness of such combinations may be dependent on the intensity of the pain state." | 3.78 | Temperature-dependent enhancement of the antinociceptive effects of opioids in combination with gabapentin in mice. ( Neelakantan, H; Walker, EA, 2012) |
| " A recent study from our laboratory revealed that gabapentin, a recommended first-line treatment for multiple neuropathic conditions, could also efficiently antagonize thermal hyperalgesia evoked by complete Freund's adjuvant (CFA)-induced monoarthritis (MA)." | 3.78 | Gabapentin reduces CX3CL1 signaling and blocks spinal microglial activation in monoarthritic rats. ( Deng, XM; Li, SS; Xu, B; Xu, H; Yang, JL; Zhang, WS; Zhang, YQ, 2012) |
| "The aim of present study was to investigate the antinociceptive effect of pregabalin and tramadol either alone and or in combination on acute model of pain." | 3.78 | Pregabalin antinociception and its interaction with tramadol in acute model of pain. ( Keyhanfar, F; Meymandi, MS, 2012) |
| "Pregabalin revealed a comparative antinociceptive effect as similar to tramadol in acute model of pain, but interaction between these two drugs depends highly on their proportion in the combination." | 3.78 | Pregabalin antinociception and its interaction with tramadol in acute model of pain. ( Keyhanfar, F; Meymandi, MS, 2012) |
| "The objective of the study was to conduct an analysis of pooled data from pregabalin fibromyalgia clinical trials to determine which fibromyalgia symptom and function domains drive patient perception of improvement." | 3.77 | Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin. ( Arnold, LM; Emir, B; Sadosky, A; Whalen, E; Zlateva, G, 2011) |
| "Data from three double-blind, placebo-controlled trials of pregabalin in fibromyalgia patients were pooled for this analysis." | 3.77 | Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin. ( Arnold, LM; Emir, B; Sadosky, A; Whalen, E; Zlateva, G, 2011) |
| "Numerous controlled clinical trials have demonstrated the safety and efficacy of pregabalin in the treatment of neuropathic pain." | 3.77 | Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. ( Anastassiou, E; Iatrou, CA; Lyras, L; Plesia, E; Stamatiou, G; Vadalouca, A; Vafiadou, M; Vlaikidis, N, 2011) |
| "This was a non-interventional, multicentre study in which pregabalin was administered for 8 weeks, at the therapeutic dosages of 150-600 mg/day, to patients with a diagnosis of neuropathic pain." | 3.77 | Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. ( Anastassiou, E; Iatrou, CA; Lyras, L; Plesia, E; Stamatiou, G; Vadalouca, A; Vafiadou, M; Vlaikidis, N, 2011) |
| "Significant reductions in pain and pain-related sleep interference, combined with reductions in feelings of anxiety and depression, suggest that pregabalin under real-world conditions improves the overall health and well-being of patients with neuropathic pain." | 3.77 | Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. ( Anastassiou, E; Iatrou, CA; Lyras, L; Plesia, E; Stamatiou, G; Vadalouca, A; Vafiadou, M; Vlaikidis, N, 2011) |
| " We investigated pregabalin, indicated for neuropathic pain, and ondansetron, a drug that disrupts descending serotonergic processing in the central nervous system, on spinal neuronal hyperexcitability and visceral hypersensitivity in a rat model of opioid-induced hyperalgesia." | 3.77 | Pregabalin suppresses spinal neuronal hyperexcitability and visceral hypersensitivity in the absence of peripheral pathophysiology. ( Bannister, K; Bauer, CS; Dickenson, AH; Dolphin, AC; Porreca, F; Sikandar, S, 2011) |
| "This retrospective study evaluates the efficacy of gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck tumors." | 3.76 | Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. ( Bar Ad, V; Both, S; Chalian, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "By using a median dose of 2700 mg/day of gabapentin, only 10% of patients required additional narcotic pain medications for adequate pain relief during the third and fourth week of treatment, despite grade 2 or higher mucositis present in 56% and 73% of the patients, respectively." | 3.76 | Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. ( Bar Ad, V; Both, S; Chalian, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "Gabapentin appears promising in reducing the need for narcotic pain medication for patients with head and neck malignancies treated with IMRT and should be further evaluated prospectively in controlled clinical trials." | 3.76 | Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. ( Bar Ad, V; Both, S; Chalian, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "Milnacipran and duloxetine, serotonin/noradrenalin reuptake inhibitors, and pregabalin, a alpha(2)-delta(1) Ca(2+) channel blocker, are efficacious against fibromyalgia, a condition characterized by diffuse chronic pain and associated with stress." | 3.76 | Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of stress-induced ultrasonic vocalizations in rats. ( Aliaga, M; Bardin, L; Depoortère, R; Gregoire, S; Ladure, P; Malfetes, N; Newman-Tancredi, A; Vitton, O, 2010) |
| "The aim of this study was to assess the role of adding gabapentin (Neurontin) to the prescription of patients with opiate resistant pain as a result of critical limb ischaemia (CLI)." | 3.76 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "The study has demonstrated that gabapentin is a useful adjuvant in the management of CLI and leads to significant reductions in pain scores and improves night pain for most patients." | 3.76 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "To determine the utility of substitution of pregabalin (PGB) for gabapentin (GBP) therapy in the relief of neuropathic pain (NeP) in patients with peripheral neuropathy (PN)." | 3.76 | Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. ( Toth, C, 2010) |
| "Gabapentin, an anticonvulsant, is widely accepted as an alternative therapeutic agent for neuropathic pain and has proved to produce analgesic effects in a mouse model of visceral pain." | 3.76 | Analgesic effects of gabapentin on mechanical hypersensitivity in a rat model of chronic pancreatitis. ( Chen, H; Liao, XZ; Mao, YF; Sun, JH; Xiong, YC; Xu, H; Zhou, MT, 2010) |
| "Peripherally administered pregabalin attenuates mechanical, cold, and heat allodynia in a rat model of neuropathic pain." | 3.76 | Attenuation of neuropathy-induced allodynia following intraplantar injection of pregabalin. ( Chang, HW; Hong, SH; Joo, HS; Lee, JY; Lee, Y; Moon, DE; Park, HJ, 2010) |
| "The objective of this study was to develop a pharmacokinetic-pharmacodynamic (PK-PD) model of the static allodynia response to pregabalin with and without sildenafil in a chronic constriction injury model of neuropathic pain." | 3.76 | Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain. ( Bender, G; Bies, RR; Bramwell, S; Danhof, M; DeJongh, J; Field, MJ; Florian, JA; Marshall, S; Tan, KK, 2010) |
| "Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy." | 3.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| "This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain." | 3.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| "This retrospective study evaluated the efficacy of gabapentin for the treatment of pain syndromes related to radiation-induced mucositis in patients with head and neck cancers treated with concurrent chemoradiation." | 3.76 | Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. ( Bar Ad, V; Both, S; Chalian, A; Dosoretz, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "At a median dose of 2700 mg/day of gabapentin, only 33% and 55% of patients required additional low-dose narcotic medications for pain control during the third and fourth week of treatment, respectively, despite exhibiting a grade 2 or higher mucositis in 71% and 86% of the patients, respectively." | 3.76 | Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. ( Bar Ad, V; Both, S; Chalian, A; Dosoretz, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "The inhibitory transmitters GABA and glycine play an important role in modulating pain transmission, both in normal and in pathological situations." | 3.76 | Differential distribution of activated spinal neurons containing glycine and/or GABA and expressing c-fos in acute and chronic pain models. ( Duraku, LS; Holstege, JC; Hossaini, M; Jongen, JLM; Saraç, Ç, 2010) |
| "Pregabalin, primarily used to manage neuropathic pain and fibromyalgia, is categorized as a Schedule V drug (ie, lowest potential for abuse) in the US Drug Enforcement Administration's Controlled Substances Act." | 3.76 | Potential for pregabalin abuse or diversion after past drug-seeking behavior. ( Coren, JS; Filipetto, FA; Zipp, CP, 2010) |
| "To evaluate changes in healthcare resource use and costs after initiating pregabalin or duloxetine in employees with pain associated with diabetic peripheral neuropathy (pDPN)." | 3.76 | Evaluation of healthcare resource utilization and costs in employees with pain associated with diabetic peripheral neuropathy treated with pregabalin or duloxetine. ( Cao, Z; Fowler, R; Harnett, J; Mardekian, J; Margolis, J; Sanchez, RJ; Silverman, SL, 2010) |
| "Gabapentin is widely used in the management of pain." | 3.75 | Gabapentin toxicity in renal failure: the importance of dose adjustment. ( Miller, A; Price, G, 2009) |
| "Gabapentin is used in analgesic treatment of neuropathic pain, and large interindividual variation has been observed in the pharmacokinetics (PK) of the drug." | 3.75 | A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling. ( Carlsson, KC; Eriksen, HO; Hoem, NO; Karlsson, MO; Moberg, ER; van de Schootbrugge, M, 2009) |
| " Using pharmacological and transgenic approaches in mice, we evaluated adrenergic receptor (AR) implication in the action of the tricyclic antidepressant desipramine, the noradrenaline and serotonin reuptake inhibitor venlafaxine, and the noradrenaline reuptake inhibitor reboxetine." | 3.75 | Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain. ( Barrot, M; Doridot, S; Freund-Mercier, MJ; Hein, L; Petit-Demoulière, N; Tessier, LH; Yalcin, I, 2009) |
| "Our data suggest that activation of spinal or dorsal root ganglion HCN channels or both is not involved in formalin-induced pain, and intrathecal gabapentin does not act as an HCN channel activator to achieve its antinociceptive effect in the formalin test." | 3.75 | Intrathecal gabapentin does not act as a hyperpolarization-activated cyclic nucleotide-gated channel activator in the rat formalin test. ( Chen, CC; Cheng, JK; Huang, YJ; Lin, CF; Lin, CS; Tsaur, ML, 2009) |
| "We compared the inhibitory action of gabapentin, which is used to treat neuropathic pain, on mechanical allodynia induced by chemotherapeutic agents, paclitaxel, oxaliplatin, and vincristine, in mice." | 3.75 | Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit. ( Andoh, T; Fujita, M; Gauchan, P; Ikeda, K; Kato, A; Kuraishi, Y; Sasaki, A, 2009) |
| "Neurotensin modulates pain via its actions within descending analgesic pathways which include brain regions such as the midbrain periaqueductal grey (PAG)." | 3.75 | Neurotensin inhibition of GABAergic transmission via mGluR-induced endocannabinoid signalling in rat periaqueductal grey. ( Kawahara, H; Mitchell, VA; Vaughan, CW, 2009) |
| "The GABA amides of the antidepressants nortriptyline and fluoxetine, 1 and 2, were compared to their respective parent compounds in rodent models of pain." | 3.75 | Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity. ( Aharoni, A; Geffen, Y; Gil-Ad, I; Halbfinger, E; Nisemblat, Y; Nudelman, A; Rephaeli, A; Tarasenko, I; Tarasenko, N; Weizman, A, 2009) |
| "In order to detect an anti-nociceptive interaction between morphine and gabapentin, the anti-allodynic and anti-hyperalgesic effects of these drugs, administered either separately or in combination, were determined using the von Frey and acetone tests in a rat model of neuropathic pain (Bennett model)." | 3.75 | Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury. ( Cortés-Arroyo, AR; De la O-Arciniega, M; Díaz-Reval, MI; Domínguez-Ramírez, AM; López-Muñoz, FJ, 2009) |
| " The results showed that (1) in the NRM perfuse liquid, pain stimulation could increase the concentrations of AVP, leucine-enkephalin (L-Ek), methionine-enkephalin (M-Ek), beta-endorphin (beta-Ep), serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA), but not change the concentrations of dynorphinA(1-13) (DynA(1-13)), oxytocin, achetylcholine, choline, gamma-aminobutyric acid, glutamate, dopamine, 3,4-dihydroxyphenylacetic acid, homovanilic acid, norepinephrine and epinephrine; (2) in the NRM perfuse liquid, AVP increased the concentrations of L-Ek, M-Ek, beta-Ep, DynA(1-13), 5-HT and 5-HIAA, but did not change the concentrations of oxytocin and the other studied neurotransmitters; (3) AVP antinociception in the NRM was attenuated by cypoheptadine (a 5-HT-receptor antagonist) or naloxone (an opiate receptor antagonist), but was not influenced by the other studied receptor antagonists." | 3.75 | Arginine vasopressin antinociception in the rat nucleus raphe magnus is involved in the endogenous opiate peptide and serotonin system. ( Chu, J; Lin, BC; Liu, WY; Wang, G; Xu, H; Yang, J; Yang, Y; Yuan, H, 2009) |
| "Gabapentin is a gamma-aminobutyric acid analog used for numerous neurologic conditions, including neuropathic pain and epilepsy." | 3.75 | Gabapentin therapy for pain and irritability in a neurologically impaired infant. ( Cox, TH; Garner, SS; Haney, AL, 2009) |
| "Evidence suggests an important role for supraspinal gamma-aminobutyric acid (GABA) in conditioned fear and pain." | 3.75 | Alterations in extracellular levels of gamma-aminobutyric acid in the rat basolateral amygdala and periaqueductal gray during conditioned fear, persistent pain and fear-conditioned analgesia. ( Finn, DP; Lang, Y; Rea, K, 2009) |
| "We examined reporting practices for trials of gabapentin funded by Pfizer and Warner-Lambert's subsidiary, Parke-Davis (hereafter referred to as Pfizer and Parke-Davis) for off-label indications (prophylaxis against migraine and treatment of bipolar disorders, neuropathic pain, and nociceptive pain), comparing internal company documents with published reports." | 3.75 | Outcome reporting in industry-sponsored trials of gabapentin for off-label use. ( Bero, L; Dickersin, K; Scherer, RW; Vedula, SS, 2009) |
| "To observe the effects of gamma-aminobutyric acid (GABA) on the electric activities of pain-excited neurons (PEN) in nucleus accumbens (NAc) in central nervous system (CNS) of morphine-dependent rats." | 3.74 | Modulation of gamma-aminobutyric acid on painful sense in central nervous system of morphine-dependent rats. ( Li, X; Xu, MY; Xu, Y, 2008) |
| "After GABA or the GABA(A)-receptor antagonist, bicuculline (Bic), was injected into cerebral ventricles or NAc, right sciatic nerve was stimulated by electrical pulses, which was considered as traumatic pain stimulation." | 3.74 | Modulation of gamma-aminobutyric acid on painful sense in central nervous system of morphine-dependent rats. ( Li, X; Xu, MY; Xu, Y, 2008) |
| "During treatment and post-treatment phases, patients receiving Gp had cumulative morphine consumption and a mean daily pain score significantly lower than controls." | 3.74 | Effects of gabapentin on morphine consumption and pain in severely burned patients. ( Cuignet, O; Pirson, J; Soudon, O; Zizi, M, 2007) |
| " To further establish the neurochemical basis for its supraspinally mediated analgesic action, concentrations of spinal noradrenaline, 4-hydroxy-3-methoxyphenylglycol (MHPG), serotonin (5-HT), 5-hydroxyindoleacetic acid (5-HIAA) and dopamine were measured using high-performance liquid chromatography in a murine neuropathic pain model that was prepared by partial ligation of the sciatic nerve (the Seltzer model)." | 3.74 | Neurochemical evidence that supraspinally administered gabapentin activates the descending noradrenergic system after peripheral nerve injury. ( Honda, M; Ono, H; Takasu, K; Takeuchi, Y; Tanabe, M, 2007) |
| "The effects of treatment with the anti-convulsant agents, lamotrigine and riluzole were compared with gabapentin in a rat experimental model of neuropathic pain." | 3.74 | A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2007) |
| "Pregabalin is used for treatment of neuropathic pain conditions." | 3.74 | Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats. ( Audette, KM; Maeda, Y; Sluka, KA; Yokoyama, T, 2007) |
| "This study shows that pregabalin reduces both cutaneous and muscle hyperalgesia in inflammatory and noninflammatory models of muscle pain." | 3.74 | Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats. ( Audette, KM; Maeda, Y; Sluka, KA; Yokoyama, T, 2007) |
| " The results showed that AVP elevated the concentrations of leucine-enkephalin (L-Ek), methionine-enkephalin (M-Ek) and beta-endorphin (beta-Ep), but did not change the concentrations of dynorphinA(1-13) (DynA(1-13)), OXT, classical neurotransmitters including achetylcholine (Ach), choline (Ch), serotonin (5-HT), gamma-aminobutyric acid (GABA), glutamate (Glu), dopamine (DA), norepinephrine (NE) and epinephrine (E), and their metabolic products in PAG perfusion liquid." | 3.74 | Arginine vasopressin induces periaqueductal gray release of enkephalin and endorphin relating to pain modulation in the rat. ( Chen, JM; Lin, BC; Liu, WY; Xu, HT; Yang, J; Yang, Y, 2007) |
| "Previous study has proven that microinjection of arginine vasopressin (AVP) into periaqueductal gray (PAG) raises the pain threshold, in which the antinociceptive effect of AVP can be reversed by PAG pretreatment with V2 rather than V1 or opiate receptor antagonist." | 3.74 | Arginine vasopressin induces periaqueductal gray release of enkephalin and endorphin relating to pain modulation in the rat. ( Chen, JM; Lin, BC; Liu, WY; Xu, HT; Yang, J; Yang, Y, 2007) |
| "Clinical studies investigating the use of pregabalin and duloxetine for the management of diabetic peripheral neuropathy and post-herpetic neuralgia are reviewed." | 3.74 | Pregabalin and duloxetine for the treatment of neuropathic pain disorders. ( Terneus, W, 2007) |
| " For example, previous evidence of colocalization of EM2 with substance P (SP), calcitonin gene-related peptide (CGRP), and MOR in primary afferent neurons suggested an interaction of these peptides in pain modulation." | 3.74 | Colocalization and shared distribution of endomorphins with substance P, calcitonin gene-related peptide, gamma-aminobutyric acid, and the mu opioid receptor. ( Greenwell, TN; Inglis, FM; Martin-Schild, S; Zadina, JE, 2007) |
| "Although gabapentin may relieve neuropathic pain by actions at many sites, these results suggest that its actions in the brain to cause spinal cholinergic activation predominate after oral administration." | 3.74 | Oral gabapentin activates spinal cholinergic circuits to reduce hypersensitivity after peripheral nerve injury and interacts synergistically with oral donepezil. ( Eisenach, JC; Hayashida, K; Parker, R, 2007) |
| "Although this is a small study, it appears that gabapentin and nortriptyline are effective in the treatment of idiopathic chronic orchialgia but not post-vasectomy pain." | 3.74 | Chronic orchialgia: consider gabapentin or nortriptyline before considering surgery. ( Lee, LK; Miller, B; Sinclair, AM, 2007) |
| "6% of patients commenced on nortriptyline had a greater than 50% improvement in pain." | 3.74 | Chronic orchialgia: consider gabapentin or nortriptyline before considering surgery. ( Lee, LK; Miller, B; Sinclair, AM, 2007) |
| "These data demonstrated the comparable efficacy of gabapentin with morphine in visceral pain." | 3.74 | Gabapentin action and interaction on the antinociceptive effect of morphine on visceral pain in mice. ( Meymandi, MS; Sepehri, G, 2008) |
| " The three models were benchmarked using compounds known to be active in neuropathic pain patients and nerve injury animal models, including gabapentin, amitriptyline and clonidine." | 3.74 | Transient allodynia pain models in mice for early assessment of analgesic activity. ( Cheevers, CV; Donello, JE; Gil, DW, 2008) |
| "A comparison of total body doses that cause allodynia following spinal or systemic administration indicated that NMDA induces allodynia in the spinal cord while sulprostone and phenylephrine act through a peripheral mechanism." | 3.74 | Transient allodynia pain models in mice for early assessment of analgesic activity. ( Cheevers, CV; Donello, JE; Gil, DW, 2008) |
| " The case presentation illustrates the role of pregabalin in successful medical management of this chronic pain disorder, as well as the management of common psychiatric morbidities associated with this condition." | 3.74 | Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia. ( Jerome, L, 2007) |
| "Pregabalin is often used for the treatment of chronic pain syndromes." | 3.74 | Pregabalin-induced generalized myoclonic status epilepticus in patients with chronic pain. ( Hamer, HM; Hattemer, K; Klein, KM; Knake, S; Oertel, WH; Rosenow, F; Wellek, A, 2007) |
| " Intra-VL-PAG injection of capsaicin increased the threshold of thermal pain sensitivity, whereas the selective TRPV1 antagonist 5'-iodo-resiniferatoxin (I-RTX) facilitated nociceptive responses, and blocked capsaicin analgesic effect at a dose inactive per se." | 3.74 | Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. ( Cristino, L; de Novellis, V; Di Marzo, V; Maione, S; Marabese, I; Palazzo, E; Rossi, F; Starowicz, K, 2007) |
| "We have previously demonstrated that gabapentin supraspinally activates the descending noradrenergic system to ameliorate pain hypersensitivity in mice with partial nerve ligation." | 3.74 | Gabapentin produces PKA-dependent pre-synaptic inhibition of GABAergic synaptic transmission in LC neurons following partial nerve injury in mice. ( Ono, H; Takasu, K; Tanabe, M, 2008) |
| "We determined if cutaneous hyperalgesia and pain-induced c-Fos overexpression in the spinal cord produced by repeated forced swimming (FS) stress in the rat were related to changes in GABA neurotransmission by studying spinal release of GABA and the effect of positive modulation of GABA-A receptors with diazepam." | 3.74 | Reduced GABA neurotransmission underlies hyperalgesia induced by repeated forced swimming stress. ( Leal, L; Pinerua-Shuhaibar, L; Quintero, L; Silva, JA; Suarez-Roca, H, 2008) |
| "Gabapentin (GBP; 1-(aminomethyl)cyclohexane acetic acid) is used clinically in the treatment of pain." | 3.74 | Gabapentin evoked changes in functional activity in nociceptive regions in the brain of the anaesthetized rat: an fMRI study. ( Chapman, V; Governo, RJ; Marsden, CA; Morris, PG, 2008) |
| "Data were obtained from a cohort of 603 patients with neuropathic pain undergoing analgesic treatment with gabapentin who completed four health scales: Medical Outcomes Study Sleep Scale, Sheehan Disability Scale, Covi Anxiety Scale, and Raskin Depression scale." | 3.74 | Standard error of measurement as a valid alternative to minimally important difference for evaluating the magnitude of changes in patient-reported outcomes measures. ( Pardo, A; Rejas, J; Ruiz, MA, 2008) |
| "To use gabapentin to relieve discomfort in a painful, blind glaucomatous eye of a patient unwilling to undergo further invasive treatment." | 3.74 | Gabapentin therapy for painful, blind glaucomatous eye: case report. ( Dimou, T; Kavalieratos, CS, 2008) |
| "Gabapentin may relieve pain in a painful, blind, glaucomatous eye." | 3.74 | Gabapentin therapy for painful, blind glaucomatous eye: case report. ( Dimou, T; Kavalieratos, CS, 2008) |
| "Gabapentin is an antiepileptic used for neuropathic pain treatment." | 3.74 | Gabapentin therapy for painful, blind glaucomatous eye: case report. ( Dimou, T; Kavalieratos, CS, 2008) |
| "Patient rated his pregabapentin and postgabapentin pain by a verbal descriptor scale and a numerical scale." | 3.74 | Gabapentin therapy for painful, blind glaucomatous eye: case report. ( Dimou, T; Kavalieratos, CS, 2008) |
| "Gabapentin provided significant pain relief (on a 0-10 scale, reduction from "8" to "0-2") at regular visits over 6 months." | 3.74 | Gabapentin therapy for painful, blind glaucomatous eye: case report. ( Dimou, T; Kavalieratos, CS, 2008) |
| "There is evidence supporting the antinociceptive effects of carbamazepine, oxcarbazepine, gabapentin, and topiramate in various models of neuropathic pain as well as inflammatory somatic pain." | 3.74 | The antinociceptive effects of anticonvulsants in a mouse visceral pain model. ( Boskovic, B; Milovanovic, S; Paranos, S; Prostran, MS; Stepanovic-Petrovic, RM; Tomic, MA; Ugresic, ND; Vuckovic, SM, 2008) |
| "Duloxetine, a selective but balanced serotonergic and noradrenergic reuptake inhibitor, was evaluated in the acute nociceptive pain models of tail flick and hot plate in mice and in the persistent and/or inflammatory pain models of acetic acid-induced writhing in mice, carrageenan-induced thermal hyperalgesia and mechanical allodynia in rats, and capsaicin-induced mechanical allodynia in rats." | 3.73 | Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. ( Jones, CK; Peters, SC; Shannon, HE, 2005) |
| "A rat model of cancer-induced bone pain using the MRMT-1 cell line injected into the tibia was established to investigate the efficacy of acute (10, 30, 100 mg/kg) and chronic (30 mg/kg) systemic gabapentin on electrophysiological superficial dorsal horn neuronal responses to natural and noxious electrical stimuli, as well as on pain-related behavior." | 3.73 | Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain. ( Dickenson, AH; Donovan-Rodriguez, T; Urch, CE, 2005) |
| "The anticonvulsant gabapentin (GBP) has been shown effective for the treatment of neuropathic pain, although its mechanism of action remains unclear." | 3.73 | Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. ( Aiyar, J; Anker, N; Belley, M; Bristow, L; Campbell, B; Cohen, C; Park, KT; Ren, K; Stearns, B; Urban, MO, 2005) |
| " Here, we show that in the spinal sensory circuit progesterone conversion into 5alpha-DHP and 3alpha,5alpha-THP is inhibited dose-dependently by substance P (SP), a major mediator of painful signals." | 3.73 | Substance P inhibits progesterone conversion to neuroactive metabolites in spinal sensory circuit: a potential component of nociception. ( Kibaly, C; Mensah-Nyagan, AG; Patte-Mensah, C, 2005) |
| " In the current study, we evaluated the behavioral effects of two standard drugs used clinically for neuropathic pain, the anticonvulsant gabapentin and antidepressant imipramine, in rats at different times after peripheral nerve injury." | 3.73 | The effect of antinociceptive drugs tested at different times after nerve injury in rats. ( Borsook, D; Hama, AT, 2005) |
| " In this study, we tested the hypothesis that removal of GABAergic and glycinergic inhibitory inputs attenuates the effect of morphine on dorsal horn projection neurons and the reduced spinal GABAergic tone contributes to attenuated morphine effect in neuropathic pain." | 3.73 | Effect of morphine on deep dorsal horn projection neurons depends on spinal GABAergic and glycinergic tone: implications for reduced opioid effect in neuropathic pain. ( Chen, SR; Chen, YP; Pan, HL, 2005) |
| "Here, we have examined the effect of the novel antinociceptive agent CHF3381 on the development of nocifensive behaviour as well as secondary mechanical allodynia and hyperalgesia induced by intraplantar injection of capsaicin in rats." | 3.73 | CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats. ( Bassani, F; Bergamaschi, M; Tonino Bolzoni, P; Villetti, G, 2005) |
| "The 5-HT re-uptake inhibitor fluoxetine (3-30 mg/kg), the NA re-uptake inhibitor reboxetine (3-30 mg/kg), the dual 5-HT and NA re-uptake inhibitor venlafaxine (3-100 mg/kg) and the dual DA and NA re-uptake inhibitor bupropion (3-30 mg/kg) were tested after intraperitoneal administration in rat models of acute, persistent and neuropathic pain." | 3.73 | Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. ( Blackburn-Munro, G; Nielsen, AN; Pedersen, LH, 2005) |
| "Not all neuropathic pain patients gain relief from current therapies that include the anticonvulsant, gabapentin, thought to modulate calcium channel function." | 3.73 | Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin. ( Dickenson, AH; Hunt, SP; Rahman, W; Rygh, LJ; Suzuki, R; Webber, M, 2005) |
| " The effects of diacerhein were compared with those of gabapentin, a drug used clinically for the management of neuropathic pain." | 3.73 | The effects of diacerhein on mechanical allodynia in inflammatory and neuropathic models of nociception in mice. ( Calixto, JB; Campos, MM; Medeiros, R; Quintão, NLM; Santos, ARS, 2005) |
| "Hindpaw mechanical allodynia was dose-dependently reversed by gabapentin (50 and 100 mg/kg, s." | 3.73 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| "To systematically establish the pain relieving efficacies of venlafaxine and gabapentin alone and in combination." | 3.73 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| " In this study the co-administration of gabapentin with morphine is evaluated in acute model of pain." | 3.73 | Gabapentin enhances the analgesic response to morphine in acute model of pain in male rats. ( Meymandi, MS; Mobasher, M; Sepehri, G, 2006) |
| "We report two patients with refractory epilepsy who developed unilateral painful gynecomastia and lower extremity pain (one of them localized and the other one diffuse), shortly after receiving Pregabalin (PGB)." | 3.73 | Two cases of painful gynecomastia and lower extremity pain in association with pregabalin therapy. ( Málaga, I; Sanmarti, FX, 2006) |
| "Gabapentin has recently been used clinically as an antihyperalgesic agent to treat certain neuropathic pain states." | 3.72 | Gabapentin markedly reduces acetic acid-induced visceral nociception. ( Cui, M; Feng, Y; Willis, WD, 2003) |
| "Case report on a patient with SUNCT-syndrome (short lasting, unilateral neuralgiform headache attacks with conjunctival injection, sweating, and rhinorrhoea) who was successfully treated with gabapentin." | 3.72 | [Case report on a patient with SUNCT-syndrome]. ( Brinkschmidt, T; Jensen, U; Neumeier, S, 2003) |
| " In order to avoid drug interactions as well as adverse effects of carbamazepine in myasthenia gravis, gabapentin was chosen for the treatment of neuropathic pain." | 3.72 | Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin. ( Beuche, W; Scheschonka, A, 2003) |
| "To test whether gabapentin, an anticonvulsant, is able to inhibit responses to peritoneal irritation-induced visceral pain and to examine the effect of gabapentin on spinal cord amino acid release." | 3.72 | [Effect of anticonvulsant gabapentin on visceral nociception and its relationship with amino acid neurotransmitters released from spinal cord]. ( Cui, M; Feng, Y; Willis, WD, 2003) |
| " When evaluated in the model of neuropathic pain caused by partial ligation of sciatic nerve, the hexanic extract inhibited the mechanical allodynia (77 +/- 7%), with a similar efficacy to the gabapentin (71 +/- 10%)." | 3.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| "This study investigated the anti-allodynic and anti-oedematogenic effects of the hexanic extract, lignan-rich fraction and purified lignans from a plant used in the traditional medicine, Phyllanthus amarus, in the inflammatory and neuropathic models of nociception." | 3.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| "Assessment of pain relief in type 2 diabetes mellitus patients with neuropathic pain treated with gabapentin at daily dose 2400 mg." | 3.72 | [Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003) |
| " After six weeks of gabapentin treatment in 2400 mg daily dose a significant pain reduction was observed, assessed by means of SF-MPQ, VAS and PPI questionnaires." | 3.72 | [Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003) |
| "Little is known about current practice in using the anticonvulsant gabapentin in the management of cancer-related neuropathic pain." | 3.72 | The pattern of gabapentin use in a tertiary palliative care unit. ( al-Shahri, MZ; Oneschuk, D, 2003) |
| "The main objective of this study was to describe the pattern of gabapentin use as an adjuvant analgesic for cancer-related neuropathic pain in patients admitted to a tertiary palliative care unit." | 3.72 | The pattern of gabapentin use in a tertiary palliative care unit. ( al-Shahri, MZ; Oneschuk, D, 2003) |
| "We report and discuss a case of severe neuropathic orbital pain refractory to standard analgesics that responded well to treatment with the anticonvulsant gabapentin." | 3.72 | Treatment of neuropathic orbital pain with gabapentin. ( Kancharla, A; Sloan, PA, 2003) |
| "The antiepileptic drug, gabapentin, and another structurally related compound, pregabalin, are increasingly employed in the pharmacotherapy of chronic pain states, although their primary mechanism of action remains a topic of active study." | 3.72 | Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited. ( Chesler, EJ; Kokayeff, A; Lariviere, WR; Mogil, JS; Ritchie, J; Wilson, SG, 2003) |
| "A pharmacokinetic-pharmacodynamic (PK/PD) model relating pain relief to gabapentin plasma concentrations was derived from a phase 3 study." | 3.72 | The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain. ( Cook, JA; Ewy, WE; Lockwood, PA; Mandema, JW, 2003) |
| "We present 2 patients with severe and intractable central poststroke pain (CPSP) after right posterolateral thalamic infarcts who were successfully treated with zonisamide." | 3.72 | Successful use of zonisamide for central poststroke pain. ( Hashimoto, K; Takahashi, Y; Tsuji, S, 2004) |
| "A series of mutual prodrugs derived from gabapentin, pregabalin, memantine, venlafaxine were synthesized and their pharmacological properties to treat neuropathic pain were investigated in a rat model of chronic sciatic nerve constriction injury (CCI)." | 3.72 | Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury. ( Bo-Hua, Z; He, L; Hong-Ju, Y; Jun-Wei, W; Nan, Z; Wei-Guo, S; Wei-Xiu, Y; Zhe-Hui, G; Zheng-Hua, G; Zhi-Pu, L; Zhong-Wei, J, 2004) |
| "The present study investigated whether mechanical allodynia following contusive spinal cord injury (SCI) of the thoracic segments 12 and 13 of the rat was associated with a reduction in gamma-aminobutyric acid (GABA)ergic inhibition adjacent to the site of injury." | 3.72 | Mechanical allodynia following contusion injury of the rat spinal cord is associated with loss of GABAergic inhibition in the dorsal horn. ( Drew, GM; Duggan, AW; Siddall, PJ, 2004) |
| "Combined spinal administration of gabapentin and low doses of morphine significantly reduces pain-related behaviors in this acute rat pancreatitis model, whereas these agents were ineffective when used alone in this dose range." | 3.72 | Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model. ( Lu, Y; Smiley, MM; Vera-Portocarrero, LP; Westlund, KN; Zidan, A, 2004) |
| " In this study, intrathecal gabapentin, which by itself is ineffective when administered spinally, was combined with low-dose morphine and tested in an acute bradykinin-induced pancreatitis model in rats." | 3.72 | Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model. ( Lu, Y; Smiley, MM; Vera-Portocarrero, LP; Westlund, KN; Zidan, A, 2004) |
| "We report a case of neutropenia occurring in a patient receiving gabapentin for neuropathic pain." | 3.72 | Neutropenia occurring after starting gabapentin for neuropathic pain. ( Derbyshire, E; Martin, D, 2004) |
| "To clarify molecular substrates involved in the development of radicular pain, and to investigate the responsiveness of radicular pain to gabapentin." | 3.71 | Changes in expression of voltage-dependent ion channel subunits in dorsal root ganglia of rats with radicular injury and pain. ( Abe, M; Han, W; Kurihara, T; Shinomiya, K; Tanabe, T, 2002) |
| "Although gabapentin was originally developed for treating partial seizures, it has been used mainly to treat various peripheral neuropathic pain conditions; however, there is very limited experience with gabapentin for the treatment of pain conditions of the central nervous system like central post-stroke pain syndrome." | 3.71 | Central post-stroke pain syndrome: yet another use for gabapentin? ( Chen, B; DeLisa, JA; Foye, PM; Nadler, SF; Stitik, TP, 2002) |
| "Topical application of brain-derived neurotrophic factor (BDNF) to the adult rat isolated dorsal horn with dorsal root attached preparation inhibited the electrically evoked release of substance P (SP) from sensory neurons." | 3.71 | BDNF modulates sensory neuron synaptic activity by a facilitation of GABA transmission in the dorsal horn. ( Cunningham, J; Gavazzi, I; Grist, J; Lever, IJ; Malcangio, M; Patel, J; Pezet, S, 2002) |
| "The present study examines the effect of combinations of gabapentin (Neurontin) and a selective neurokinin (NK)(1) receptor antagonist, 1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-benzofuranylmethyl ester (CI-1021), in two models of neuropathic pain." | 3.71 | Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. ( Field, MJ; Gonzalez, MI; Singh, L; Tallarida, RJ, 2002) |
| "The effects of systemic and local injections of gabapentin, a novel anticonvulsant agent, were tested on nociceptive behaviors in mice with acute herpetic pain." | 3.71 | Gabapentin antinociception in mice with acute herpetic pain induced by herpes simplex virus infection. ( Andoh, T; Kuraishi, Y; Nojima, H; Shiraki, K; Takasaki, I, 2001) |
| "Changes in the inhibitory activity mediated by gamma-aminobutyric acid (GABA) and glycine, acting at spinal GABAA receptors and strychnine-sensitive glycine receptors, are of interest in the development of neuropathic pain." | 3.71 | Electrophysiologic evidence for increased endogenous gabaergic but not glycinergic inhibitory tone in the rat spinal nerve ligation model of neuropathy. ( Basu, A; Dickenson, AH; Kontinen, VK; Stanfa, LC, 2001) |
| "In this study, the possible changes in GABAergic and glycinergic inhibitory activity in the spinal nerve ligation model of neuropathic pain were studied by comparing the effects of the GABAA-receptor antagonist bicuculline and the glycine-receptor antagonist strychnine in neuropathic rats to their effects in sham-operated and nonoperated control rats." | 3.71 | Electrophysiologic evidence for increased endogenous gabaergic but not glycinergic inhibitory tone in the rat spinal nerve ligation model of neuropathy. ( Basu, A; Dickenson, AH; Kontinen, VK; Stanfa, LC, 2001) |
| "The objective of this study was to assess the efficacy and safety of Gabapentin as the sole analgesic in patients with HIV-related painful neuropathy." | 3.71 | Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations. ( Bottura, P; La Spina, I; Maggiolo, F; Porazzi, D; Suter, F, 2001) |
| "A patient with mycosis fungoides illustrates the problem of pain management during wound care and suggests the utility of a novel treatment, gabapentin." | 3.71 | Gabapentin for pain control in cancer patients' wound dressing care. ( Devulder, J; Lambert, J; Naeyaert, JM, 2001) |
| " We show that the conjugate of arachidonic acid and glycine (N-arachidonylglycine (NAGly)) is present in bovine and rat brain as well as other tissues and that it suppresses tonic inflammatory pain." | 3.71 | Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. ( Bisogno, T; Burstein, S; Chang, SY; Coop, A; De Petrocellis, L; Di Marzo, V; Huang, SM; Maeda, DY; Petros, TJ; Sivakumar, R; Walker, JM; Zavitsanos, PA; Zipkin, RE, 2001) |
| " Recent electrophysiological studies by our group have suggested that increased excitation of spinal GABAergic neurons by activation of N-methyl-D-aspartate (NMDA) and non-NMDA receptors following intradermal injection of capsaicin results in the generation of DRRs that contribute to neurogenic inflammation." | 3.71 | NMDA or non-NMDA receptor antagonists attenuate increased Fos expression in spinal dorsal horn GABAergic neurons after intradermal injection of capsaicin in rats. ( Lin, Q; Willis, WD; Zou, X, 2001) |
| "The new anticonvulsants, gabapentin and pregabalin, are effective in the treatment of neuropathic pain." | 3.71 | Stereospecific effect of pregabalin on ectopic afferent discharges and neuropathic pain induced by sciatic nerve ligation in rats. ( Chen, SR; Pan, HL; Xu, Z, 2001) |
| "These data strongly suggest that the analgesic effect of pregabalin on neuropathic pain is likely mediated, at least in part, by its peripheral inhibitory action on the impulse generation of ectopic discharges caused by nerve injury." | 3.71 | Stereospecific effect of pregabalin on ectopic afferent discharges and neuropathic pain induced by sciatic nerve ligation in rats. ( Chen, SR; Pan, HL; Xu, Z, 2001) |
| "By use of the rat formalin test, a model of persistent pain, we examined the effect of a combination of amitriptyline and gabapentin, which are used to treat chronic pain in humans." | 3.71 | The interaction between gabapentin and amitriptyline in the rat formalin test after systemic administration. ( Heughan, CE; Sawynok, J, 2002) |
| "This study tests the hypothesis that loss of spinal activity of gamma-aminobutyric acid (GABA) contributes to the allodynia and hyperalgesia observed after peripheral nerve injury." | 3.71 | Spinal GABA(A) and GABA(B) receptor pharmacology in a rat model of neuropathic pain. ( Malan, TP; Mata, HP; Porreca, F, 2002) |
| " To resolve this issue, we combined immunocytochemical and patch recording techniques to study the actions of GBP on NMDA receptors in dorsal horn cells isolated from rats with inflammation and to determine the gamma-aminobutyric acid (GABA) content in the recorded cells." | 3.71 | Gabapentin potentiates N-methyl-D-aspartate receptor mediated currents in rat GABAergic dorsal horn neurons. ( Gu, Y; Huang, LY, 2002) |
| "To present two years of experience in the use of gabapentin for the alleviation of neuropathic pain in spinal cord injury patients." | 3.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "Data were retrieved from the medical records of all spinal cord injury patients prescribed gabapentin for neuropathic pain." | 3.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "Seventy-six per cent of patients receiving gabapentin reported a reduction in neuropathic pain." | 3.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "Our experience suggests that gabapentin offers an effective therapeutic alternative for the alleviation of neuropathic pain following spinal cord injury." | 3.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "Gabapentin is an effective option for the treatment of neuropathic pain syndromes because of its efficacy and favorable side-effect profile." | 3.70 | Gabapentin induced polyneuropathy. ( Gould, HJ, 1998) |
| " In vivo microdialysis was performed in parallel in awake, freely moving rats in order to evaluate possible alterations in extracellular gamma-aminobutyric acid (GABA) levels in a pain-modulating region, the medial thalamus." | 3.70 | Tiagabine antinociception in rodents depends on GABA(B) receptor activation: parallel antinociception testing and medial thalamus GABA microdialysis. ( Bartolini, A; Ipponi, A; Lamberti, C; Malmberg-Aiello, P; Medica, A, 1999) |
| ") gabapentin, administered before and after the injection of formalin into the rat hindpaw, on pain behavior and hemodynamics." | 3.70 | The effect of intrathecal gabapentin on pain behavior and hemodynamics on the formalin test in the rat. ( Yaksh, TL; Yoon, MH, 1999) |
| "The anticonvulsant gabapentin is effective against neuropathic pain, but the primary site(s) and mechanism(s) of action are unknown." | 3.70 | Antinociceptive effect of systemic gabapentin in mononeuropathic rats, depends on stimulus characteristics and level of test integration. ( Christensen, D; Kayser, V, 2000) |
| "Gabapentin is a novel anticonvulsant that may be of value for the relief of clinical pain." | 3.69 | Spinal gabapentin is antinociceptive in the rat formalin test. ( Davis, AM; Elliott, KJ; Inturrisi, CE; Shimoyama, M; Shimoyama, N, 1997) |
| "The novel anti-epileptic drugs lamotrigine, felbamate and gabapentin were compared in rat experimental models of acute (tail flick) and chronic pain: the chronic constriction injury and spinal nerve ligation models." | 3.69 | The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. ( Fontana, DJ; Gogas, KR; Hedley, LR; Hunter, JC; Jacobson, LO; Kassotakis, L; Thompson, J, 1997) |
| "Experimental studies indicate that the effects of spinal cord stimulation (SCS) on 'hypersymptoms' in neuropathic pain conditions may at least partly be mediated via GABAergic and adenosine-dependent mechanisms." | 3.69 | Modulation of spinal pain mechanisms by spinal cord stimulation and the potential role of adjuvant pharmacotherapy. ( Cui, JG; Linderoth, B; Meyerson, BA; O'Connor, WT; Segerdahl, M; Sollevi, A; Stiller, CO; Yakhnitsa, V, 1997) |
| "Drug therapy for fibromyalgia is limited by incomplete efficacy and dose-limiting adverse effects (AEs)." | 3.30 | Combination analgesic development for enhanced clinical efficacy (the CADENCE trial): a double-blind, controlled trial of an alpha-lipoic acid-pregabalin combination for fibromyalgia pain. ( Gilron, I; Holden, RR; Milev, R; Robb, S; Towheed, T; Tu, D, 2023) |
| "The observation of similarly reached maximal tolerated drug doses of these 2 agents (which have differing side-effect profiles) during combination and monotherapy-without increased side effects-provides support for future development of potentially more beneficial combinations with complementary mechanisms and nonoverlapping side effects." | 3.30 | Combination analgesic development for enhanced clinical efficacy (the CADENCE trial): a double-blind, controlled trial of an alpha-lipoic acid-pregabalin combination for fibromyalgia pain. ( Gilron, I; Holden, RR; Milev, R; Robb, S; Towheed, T; Tu, D, 2023) |
| " Besides pregabalin (150 mg/day), the patients, upon their group assignment, received CoQ10 at a dosage of 100 mg every 8 h or matched placebo for 8 consecutive weeks." | 3.11 | Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial. ( Amini, P; Mehrpooya, M; Mirjalili, M; Mohammadi, Y; Sajedi, F, 2022) |
| "Dental pain is a common complaint in patients undergoing endodontic treatment." | 2.82 | GABAergic signalling in modulation of dental pain. ( Ramli, R; Sivakumar, D, 2022) |
| "Gabapentin was maintained at 900mg/day for 4 weeks after CRT." | 2.82 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "Pregabalin has been used for the treatment of pain." | 2.82 | A Validated Fluorometric Method for the Rapid Determination of Pregabalin in Human Plasma Applied to Patients With Pain. ( Kawakami, J; Naito, T; Yagi, T; Yoshikawa, N, 2016) |
| "In addition, restlessness and pacing were sensible to analgesics." | 2.79 | The response of agitated behavior to pain management in persons with dementia. ( Aarsland, D; Ballard, C; Cohen-Mansfield, J; Husebo, BS; Seifert, R, 2014) |
| " Dosing was set by the Dixon sequential up-down method; that is, a greater or less than 30% reduction in capsaicin pain decreased or increased the dose, respectively, by a fixed interval for the next subject." | 2.79 | Determination of the effective dose of pregabalin on human experimental pain using the sequential up-down method. ( Wallace, MS; Wong, W, 2014) |
| "Secondary outcome measures included secondary hyperalgesia and tactile and thermal allodynia, and their respective areas (cm(2))." | 2.79 | Determination of the effective dose of pregabalin on human experimental pain using the sequential up-down method. ( Wallace, MS; Wong, W, 2014) |
| "Pain is frequent and distressing in people with dementia, but no randomized controlled trials have evaluated the effect of analgesic treatment on pain intensity as a key outcome." | 2.79 | Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: a cluster randomized trial. ( Aarsland, D; Ballard, C; Corbett, A; Husebo, BS; Sandvik, RK; Seifert, R; Selbaek, G, 2014) |
| "This pharmacostatistical model showed that: (1) pregabalin oral clearance (CL/F) was directly proportional to creatinine clearance (CLcr), but was independent of gender, race, age, female hormonal status, daily dose, and dosing regimen; (2) apparent volume of distribution was dependent on body weight and gender; (3) absorption rate was decreased when given with food; and (4) coadministration with marketed antiepileptic drugs (AEDs) had no significant effect on pregabalin CL/F." | 2.76 | Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. ( Bockbrader, HN; Burger, P; Corrigan, BW; Knapp, L, 2011) |
| " Adverse events were more frequent with pregabalin than with placebo and caused discontinuation in 9 (8." | 2.76 | Safety and efficacy of pregabalin in patients with central post-stroke pain. ( Bashford, G; Cheung, R; Dror, V; Kim, JS; Martin, A; Murphy, KT, 2011) |
| "Effects on allodynia and SF-MPQ were not significant." | 2.76 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| "Treatment with trazodone significantly improved global fibromyalgia severity, sleep quality, and depression, as well as pain interference with daily activities although without showing a direct effect on bodily pain." | 2.76 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| " Trazodone, flexibly dosed (50-300 mg/day), was administered to 66 fibromyalgia patients during 12 weeks; 41 patients who completed the treatment accepted to receive pregabalin, also flexibly dosed (75-450 mg/day), added to trazodone treatment for an additional 12-week period." | 2.76 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| "Patients with diabetic polyneuropathy were examined to study their biological age, rate of aging and pain syndrome." | 2.76 | [Biological age and the pain syndrome at diabetic polyneuropathy]. ( Emel'ianov, VV; Galkin, VV; Nesterova, MV, 2011) |
| "Gabapentin has demonstrated efficacy in clinical trials as a pre-emptive analgesic and in acute postoperative pain management." | 2.76 | Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia. ( Marashi, SH; Nadjafi, A; Panah Khahi, M; Yaghooti, AA, 2011) |
| "The postoperative pain was assessed using Visual Analogue Scale two, 12 and 24 hours after surgery." | 2.76 | Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia. ( Marashi, SH; Nadjafi, A; Panah Khahi, M; Yaghooti, AA, 2011) |
| " Patients were then started on open-label pregabalin (75, 150, 300 and 600 mg/day) according to a forced titration dosing regimen, while continuing the same dosage of oxycodone or placebo for 4 weeks." | 2.75 | A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. ( Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010) |
| "Peripheral neuropathic pain presents commonly in clinical practice, and 2 of its most prevalent types are PHN and PDN." | 2.75 | A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. ( Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010) |
| "Gabapentin was initiated in addition to the drugs currently being administered." | 2.75 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| "Neuropathic pain is regarded as one of the main causes of cancer pain refractory to standard opioid therapy in palliative care." | 2.75 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| " The aim of this study was to see whether low-dose gabapentin is effective in treating cancer-related neuropathic pain when combined with low-dose imipramine." | 2.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Low-dose gabapentin-antidepressant combination with opioids was effective in managing neuropathic cancer pain without severe adverse effects." | 2.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Painful neuropathic conditions of cancer pain often show little response to nonopioid and opioid analgesics but may be eased by antidepressants and anticonvulsants." | 2.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally." | 2.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Fibromyalgia is a prevalent and disabling disorder characterized by widespread pain and other symptoms such as insomnia, fatigue or depression." | 2.74 | Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial. ( Alda, M; Andrés, E; del Hoyo, YL; García-Campayo, J; Luciano, JV; Magallón, R; Rodero, B; Serrano-Blanco, A, 2009) |
| " Patients in group B who were receiving gabapentin continued this treatment up to a maximum daily dosage of 2400 mg during the observation period." | 2.74 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "Multimodal pain is comprised of nociceptive/inflammatory and neuropathic components." | 2.74 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| " Safety evaluation included adverse events (AEs), drug-related AEs (DRAEs), and withdrawal due to AEs." | 2.74 | Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "In patients with PHN and painful DPN failing to respond to monotherapy, combination therapy with 5% lidocaine medicated plaster and pregabalin provides additional clinically relevant pain relief and is safe and well-tolerated." | 2.74 | Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "Neuropathic pain is often difficult to treat due to a complex pathophysiology." | 2.74 | Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| "Improvements were comparable between treatments in painful DPN." | 2.74 | 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. ( Baron, R; Binder, A; Leijon, G; Mayoral, V; Serpell, M; Steigerwald, I, 2009) |
| " Up to estimated 336 patients (interim analyses) with acute herpes zoster pain (VAS > 30 mm) will be randomised to one of three groups (a) semi-standardised acupuncture (168 patients); (b) gabapentine with individualised dosage between 900-3600 mg/d (84 patients); (c) sham laser acupuncture." | 2.74 | Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial. ( Fleckenstein, J; Hoffrogge, P; Irnich, D; Kramer, S; Lang, PM; Lehmeyer, L; Mansmann, U; Pfab, F; Ring, J; Schober, GM; Schotten, KJ; Thoma, S; Weisenseel, P, 2009) |
| "Acute herpes zoster is a prevalent condition." | 2.74 | Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial. ( Fleckenstein, J; Hoffrogge, P; Irnich, D; Kramer, S; Lang, PM; Lehmeyer, L; Mansmann, U; Pfab, F; Ring, J; Schober, GM; Schotten, KJ; Thoma, S; Weisenseel, P, 2009) |
| " We evaluated the efficacy of pregabalin 600 mg/d (300 mg dosed BID) versus placebo for relieving DPN-associated neuropathic pain, and assessed its safety using objective measures of nerve conduction (NC)." | 2.73 | Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. ( Arezzo, JC; Lamoreaux, L; Pauer, L; Rosenstock, J, 2008) |
| " After 1-weeks' dosage escalation, pregabalin-treated patients received 300 mg BID for 12 weeks." | 2.73 | Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. ( Arezzo, JC; Lamoreaux, L; Pauer, L; Rosenstock, J, 2008) |
| "Secondary hyperalgesia and allodynia are a reflection of central sensitization." | 2.73 | Effect of morphine and pregabalin compared with diphenhydramine hydrochloride and placebo on hyperalgesia and allodynia induced by intradermal capsaicin in healthy male subjects. ( Baxendale, J; Bolognese, J; Calder, N; Connell, J; Cummings, C; Herman, G; Kehler, A; Wang, H, 2008) |
| "Gabapentin-treated patients displayed a significantly greater improvement in the BPI average pain severity score (P=0." | 2.73 | Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. ( Arnold, LM; Bishop, F; Goldenberg, DL; Hess, EV; Hudson, JI; Keck, PE; Lalonde, JK; Sandhu, HS; Stanford, KE; Stanford, SB; Welge, JA, 2007) |
| "Gabapentin was generally well tolerated." | 2.73 | Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. ( Arnold, LM; Bishop, F; Goldenberg, DL; Hess, EV; Hudson, JI; Keck, PE; Lalonde, JK; Sandhu, HS; Stanford, KE; Stanford, SB; Welge, JA, 2007) |
| "The model assigned untreated pain scores over 84 days." | 2.73 | Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007) |
| "Pain was evaluated using a 0-10 scale." | 2.73 | Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007) |
| "Gabapentin was no more effective than diphenhydramine (P=." | 2.73 | Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. ( Courtade, D; Fiess, RN; Holmes, SA; Loubser, PG; Rintala, DH; Tastard, LV, 2007) |
| "The intensity of stump and phantom pain was recorded every day on a numeric rating scale (0-10) during the 30-day treatment period." | 2.72 | A randomized study of the effects of gabapentin on postamputation pain. ( Finnerup, NB; Jensen, TS; Keller, J; Kramp, S; Nikolajsen, L; Vimtrup, AS, 2006) |
| "The risk of phantom pain (gabapentin vs." | 2.72 | A randomized study of the effects of gabapentin on postamputation pain. ( Finnerup, NB; Jensen, TS; Keller, J; Kramp, S; Nikolajsen, L; Vimtrup, AS, 2006) |
| "Gabapentin is an important adjuvant to the management of opiate dependence both in acute detoxification as well as stabilisation phase." | 2.71 | Gabapentin in the management of pentazocine dependence: a potent analgesic--anticraving agent. ( Jain, MK; Kumar, P, 2003) |
| "Gabapentin (1200 mg/day) was additionally added in group B." | 2.71 | Gabapentin in the management of pentazocine dependence: a potent analgesic--anticraving agent. ( Jain, MK; Kumar, P, 2003) |
| "The lidocaine patch 5% was found to be safe and well tolerated." | 2.71 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Patients with postherpetic neuralgia, painful diabetic neuropathy, or low back pain with partial responses (average daily pain intensity >4/10) to their current analgesic treatment regimen were included." | 2.71 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Gabapentin was titrated from 600 mg/d to 1,800 mg/d in addition to stable opioid dose." | 2.71 | Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. ( Arcuri, E; Barbieri, M; Bonezzi, C; Caraceni, A; De Conno, F; Gorni, G; Maltoni, M; Martini, C; Tirelli, W; Visentin, M; Yaya Tur, R; Zecca, E, 2004) |
| "Gabapentin 2400 mg/day was given in case of treatment failure or if imipramine treatment was not possible." | 2.71 | Therapeutic outcome in neuropathic pain: relationship to evidence of nervous system lesion. ( Bach, FW; Jensen, TS; Rasmussen, PV; Sindrup, SH, 2004) |
| "Neuropathic pain is a prominent feature of CRPS I, and is often refractory to treatment." | 2.71 | Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. ( Kessels, AH; Stomp-van den Berg, SG; van de Vusse, AC; Weber, WE, 2004) |
| "Neuropathic pain is a syndrome that affects around 1% of population." | 2.71 | Treatment of diabetic neuropathic pain with gabapentin alone or combined with vitamin B complex. preliminary results. ( Espinoza-Raya, J; Granados-Soto, V; Medina-Santillán, R; Morales-Franco, G; Reyes-García, G, 2004) |
| "Oxcarbazepine appears to be a promising alternative monotherapeutic approach for patients affected by PHN." | 2.71 | Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin. ( Auletta, C; Brogi, A; Brogi, F; Criscuolo, S; Lippi, S, 2005) |
| "Oxcarbazepine was effective from the first week of treatment." | 2.71 | Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin. ( Auletta, C; Brogi, A; Brogi, F; Criscuolo, S; Lippi, S, 2005) |
| "Pain was assessed using a visual analog scale (VAS)." | 2.71 | Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin. ( Auletta, C; Brogi, A; Brogi, F; Criscuolo, S; Lippi, S, 2005) |
| "Fentanyl 2 microg/kg was used as a supplementary analgesic on patient demand." | 2.71 | The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. ( Kumar, A; Navkar, DV; Pandey, CK; Raza, M; Singh, UK; Tripathi, M, 2005) |
| "Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain." | 2.71 | Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans. ( Buchanan, TJ; Huggins, JP; Iannetti, GD; Smart, TS; Tracey, I; Vennart, W; Wise, RG; Zambreanu, L, 2005) |
| "Gabapentin was dose-escalated from 300 mg/d to 1." | 2.71 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "Gabapentin has been evaluated in the treatment of nonmalignant neuropathic pain, however, there is little direct evidence evaluating its efficacy in cancer-related neuropathic pain." | 2.71 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "Gabapentin was given in three divided doses, initially titrated to 900 mg/day over 3 days, followed by two further increases, to a maximum of 2400 mg/day if required by the end of week 5." | 2.70 | Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. ( Serpell, MG, 2002) |
| " The mean effective dosage at the end of the 6-week treatment period was 1,855 mg, although therapeutic effects were already observed at the end of week 4 (1,391 mg)." | 2.70 | Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. ( de la Llave, Y; Garcia-Borreguero, D; Hernandez, G; Larrosa, O; Masramon, X; Verger, K, 2002) |
| "Gabapentin is an anticonvulsant with unclear but therapeutic effects on neurologic pain." | 2.70 | Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. ( Chancellor, MB; Chuang, YC; Kim, JC; Lee, JY; Sasaki, K; Smith, CP, 2001) |
| "Gabapentin was well tolerated; only 4 patients dropped out due to side effects." | 2.70 | Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. ( Chancellor, MB; Chuang, YC; Kim, JC; Lee, JY; Sasaki, K; Smith, CP, 2001) |
| "Five of 8 patients with interstitial cystitis reported improvement." | 2.70 | Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. ( Chancellor, MB; Chuang, YC; Kim, JC; Lee, JY; Sasaki, K; Smith, CP, 2001) |
| "Somnolence, mental clouding, and headache were the most frequently reported adverse events." | 2.70 | Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. ( Bosnjak, S; Jelic, S; Luki, V; Susnjar, S, 2002) |
| "Pain is the most disturbing symptom of diabetic peripheral neuropathy." | 2.69 | Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. ( Backonja, M; Beydoun, A; Edwards, KR; Fonseca, V; Garofalo, E; Hes, M; LaMoreaux, L; Schwartz, SL, 1998) |
| "Sixty-five percent of patients reached maximum dose with gabapentin and 54% with amitriptyline." | 2.69 | Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ( Leckband, SG; Moorhouse, DF; Morello, CM; Sahagian, GA; Stoner, CP, 1999) |
| "Decreases in paresthesia scores also were in favor of gabapentin (1." | 2.69 | Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. ( Buffa, C; Chiroli, S; Dallocchio, C; Mazzarello, P, 2000) |
| "Gabapentin (Neurontin) is a new generation antiepileptic drug which appears to be advantageous in treatment of intractable pain of reflex sympathetic dystrophy." | 2.68 | Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997) |
| "Pain is a frequent and distressing complaint in patients with multiple sclerosis (MS) and may present a difficult therapeutic problem." | 2.68 | Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997) |
| "To update our guidelines for the treatment of pain in patients with cancer, we performed a systematic review on the use of adjuvant analgesics in pain in cancer." | 2.55 | Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review. ( de Graeff, A; Dijkstra, D; Jongen, JL; Mostovaya, I; van den Beuken-van Everdingen, MH; Vissers, KC, 2017) |
| "In patients with cancer, pain is one of the most feared and burdensome symptoms." | 2.55 | Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review. ( de Graeff, A; Dijkstra, D; Jongen, JL; Mostovaya, I; van den Beuken-van Everdingen, MH; Vissers, KC, 2017) |
| "The treatment of pain associated with cancer should be tailored to the patient's personal preferences." | 2.55 | Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review. ( de Graeff, A; Dijkstra, D; Jongen, JL; Mostovaya, I; van den Beuken-van Everdingen, MH; Vissers, KC, 2017) |
| "Mechanistic approaches and multimodal analgesic techniques have been clearly demonstrated to be the most effective pain management strategy to improve outcomes." | 2.55 | Analgesia in the surgical intensive care unit. ( Brudney, CS; Ehieli, E; Pyati, S; Yalamuri, S, 2017) |
| "Chronic pain is treated most commonly with opioid analgesics, anti-inflammatory steroids and nonsteroidal anti-inflammatory drugs." | 2.55 | GABA ( Fischer, BD, 2017) |
| " Rodent models of CIPN have been developed using a range of dosing regimens to reproduce pain-like behaviours akin to patient-reported symptoms." | 2.53 | Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics. ( Duggett, NA; Flatters, SJL; Hopkins, HL, 2016) |
| " We present an overview of dosing regimens to produce CIPN models and their phenotype of pain-like behaviours." | 2.53 | Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics. ( Duggett, NA; Flatters, SJL; Hopkins, HL, 2016) |
| "The review outlines the latest description of the most-relevant rodent models of CIPN enabling comparison between chemotherapeutics, dosing regimen, rodent strain, and sex." | 2.53 | Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics. ( Duggett, NA; Flatters, SJL; Hopkins, HL, 2016) |
| "Pain was rated on a scale from 0 (no pain) to 10 (maximum pain)." | 2.52 | Pharmacological treatment for pain in Guillain-Barré syndrome. ( Liu, J; McNicol, ED; Wang, LN, 2015) |
| "Pain is a hallmark of almost all bodily ailments and can be modulated by agents, including analgesics and anesthetics that suppress pain signals in the central nervous system." | 2.52 | Therapeutic Basis of Clinical Pain Modulation. ( Agrawal, DK; Hambsch, ZJ; Kerfeld, MJ; Kirkpatrick, DR; McEntire, DM; Reisbig, MD; Smith, TA; Youngblood, CF, 2015) |
| "Gabapentin is a reasonable first-line choice, and opioid medications can be added for more severe pain but there are few clinical trials to inform specific recommendations." | 2.52 | Headache and Pain in Guillain-Barré Syndrome. ( Farmakidis, C; Herskovitz, S; Inan, S; Milstein, M, 2015) |
| "Most of the reports of headache in GBS place it in the context of the posterior reversible encephalopathy syndrome (PRES) which is increasingly recognized as a likely dysautonomia-related GBS complication." | 2.52 | Headache and Pain in Guillain-Barré Syndrome. ( Farmakidis, C; Herskovitz, S; Inan, S; Milstein, M, 2015) |
| "His pain was scored as a five on a six-point visual analog scale, and it persisted despite routine supportive therapy." | 2.50 | [A case of Guillain-Barré syndrome with severe pain successfully controlled with acetaminophen, gabapentin, and parenterally infused fentanyl]. ( Anzai, S; Hashimoto, Y; Nagasawa, K; Suzuki, T, 2014) |
| "Pain is a multidimensional response involving several levels of expression ranging from somatosensory to emotional." | 2.50 | Restless legs syndrome and pain disorders: what's in common? ( Delgado Rodrigues, RN; Goulart, LI; Prieto Peres, MF, 2014) |
| " Range of dosage may fluctuate considerably, from 75 mg to 600 mg per day." | 2.49 | The potential of pregabalin in neurology, psychiatry and addiction: a qualitative overview. ( Aguglia, E; Cavuto, M; De Berardis, D; Di Giannantonio, M; Iasevoli, F; Lupi, M; Martinotti, G; Salone, A; Santacroce, R; Sarchione, F; Serroni, N; Signorelli, M; Valchera, A, 2013) |
| "Pain was rated on a scale from 0 (no pain) to 10 (maximum pain)." | 2.49 | Pharmacological treatment for pain in Guillain-Barré syndrome. ( Liu, J; McNicol, ED; Wang, LN, 2013) |
| "Once established, postherpetic neuralgia is particularly difficult to treat, and is often resistant to conventional analgesics." | 2.47 | [Development of animal models of herpetic pain and postherpetic neuralgia and elucidation of the mechanisms of the onset and inhibition of allodynia]. ( Takasaki, I, 2011) |
| " The proportions of patients with any adverse event, somnolence or dizziness were also significantly greater with pregabalin than with placebo." | 2.46 | Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S, 2010) |
| " A dose-response relationship was apparent for at least 50% pain relief and for adverse event outcomes." | 2.46 | Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S, 2010) |
| "Migraine and headache studies are excluded in this revision." | 2.46 | WITHDRAWN. Anticonvulsant drugs for acute and chronic pain. ( Carroll, D; Collins, S; Jadad, A; McQuay, HJ; Moore, RA; Wiffen, PJ, 2010) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 2.46 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Gabapentin has been successfully used for the treatment of multiple neuropathic pain syndromes such as diabetic neuropathy and postherpetic neuralgia." | 2.46 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Chronic pain is now viewed as a biopsychosocial phenomenon, in which biological, psychological, and social factors are at work." | 2.44 | Practical management strategies for the chronic pain patient. ( Forde, G; Stanos, S, 2007) |
| "neuropathic pain) is not very satisfactorily managed." | 2.44 | [Central and peripheral mechanisms in antinociception: current and future perspectives]. ( Fürst, Z, 2008) |
| "The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of pregabalin are reviewed." | 2.44 | Pregabalin: an antiepileptic agent useful for neuropathic pain. ( Blommel, AL; Blommel, ML, 2007) |
| " The starting dosage for patients with neuropathic pain associated with diabetic peripheral neuropathy is 50 mg three times daily and may be increased to 300 mg daily within one week based on efficacy and tolerability." | 2.44 | Pregabalin: an antiepileptic agent useful for neuropathic pain. ( Blommel, AL; Blommel, ML, 2007) |
| " As clinicians face a broader spectrum of efficacious treatments, side-effect profiles play an increasingly important role in the development of a pain management regimen." | 2.44 | Safety profile of treatment in diabetic peripheral neuropathic pain. ( Robinson-Papp, J; Simpson, DM, 2007) |
| "Gabapentin ER was originally developed by DDL, a joint venture between Depomed and Elan established in January 2000 to design products using the GR family of technologies." | 2.44 | Gabapentin Extended-Release - Depomed: Gabapentin ER, Gabapentin Gastric Retention, Gabapentin GR. ( , 2007) |
| " Gabapentin ER is based on the company's proprietary AcuForm drug delivery technology, which is part of the Gastric Retention (GR) family of technologies; this offers improved drug absorption and bioavailability compared with the existing immediate-release formulation of gabapentin (Neurontin), making gabapentin ER suitable for twice-daily dosing." | 2.44 | Gabapentin Extended-Release - Depomed: Gabapentin ER, Gabapentin Gastric Retention, Gabapentin GR. ( , 2007) |
| " Overall, pregabalin was well tolerated with no new adverse events emerging that have not been reported with its use in other indications." | 2.44 | Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome. ( Owen, RT, 2007) |
| "Migraine and headache studies are excluded in this revision." | 2.43 | Anticonvulsant drugs for acute and chronic pain. ( Carroll, D; Collins, S; Jadad, A; McQuay, H; Moore, A; Wiffen, P, 2005) |
| " Peak plasma levels occur approximately 1 hour after oral doses and oral bioavailability is about 90%." | 2.43 | Pregabalin: a new agent for the treatment of neuropathic pain. ( Zareba, G, 2005) |
| "Gabapentin has become popular as a first-line treatment for neuropathic pain because of its efficacy as an antineuropathic agent and relatively benign side-effect profile." | 2.43 | The mechanism of action of gabapentin in neuropathic pain. ( Baillie, JK; Power, I, 2006) |
| "Neuropathic pain is a common and potentially treatable cause of considerable lifelong morbidity." | 2.43 | The mechanism of action of gabapentin in neuropathic pain. ( Baillie, JK; Power, I, 2006) |
| "Like gabapentin, pregabalin was predominantly excreted unchanged in the urine (> or = 98%)." | 2.43 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| " Unlike gabapentin, pregabalin was well absorbed (> 90%), and its absorption was dose independent." | 2.43 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| " Dosed at 50 to 200 mg TID, pregabalin was superior to placebo in relieving pain and improving sleep and health-related quality of life in patients with diabetic peripheral neuropathy and postherpetic neuralgia (P < 0." | 2.43 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| " The improved pharmacokinetic profile of pregabalin relative to gabapentin is manifested in linear and dose-independent absorption and a narrow therapeutic dosing range." | 2.43 | Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? ( Guay, DR, 2005) |
| "Neuropathic pain is a condition affecting a significant proportion of the world's population." | 2.43 | [Pregabalin. A new treatment for neuropathic pain]. ( López-Trigo, J; Sancho Rieger, J, 2006) |
| "Gabapentin is a drug that has been widely used in the treatment of chronic pain states." | 2.43 | alpha2delta and the mechanism of action of gabapentin in the treatment of pain. ( Lee, K; Luo, ZD; Maneuf, YP, 2006) |
| "Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Pain is one of the most common reasons for seeking medical attention, and neuropathic pain is among the most common types of pain." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Despite its prevalence, neuropathic pain is often underrecognized and inadequately treated." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "It relieved symptoms of allodynia, burning pain, shooting pain, and hyperesthesia." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Gabapentin was originally designed as an anti-convulsant gamma-aminobutyric acid (GABA) mimetic capable of crossing the blood-brain barrier." | 2.42 | Cellular and molecular action of the putative GABA-mimetic, gabapentin. ( Chung, FZ; Gonzalez, MI; Lee, K; Maneuf, YP; Pinnock, RD; Sutton, KS, 2003) |
| "Gabapentin is a very promising medication in the treatment of post-herpetic neuralgia and pain." | 2.42 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "Gabapentin was first approved by the FDA in 1993 as an add-on treatment for partial epileptic seizures." | 2.42 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "Over 150 articles reviewed its use for neuropathic pain, neuritis or neuralgia of various sorts." | 2.42 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "Gabapentin has antihyperalgesic and antiallodynic properties but does not have significant actions as an anti-nociceptive agent." | 2.42 | Gabapentin in the treatment of neuropathic pain. ( Bennett, MI; Simpson, KH, 2004) |
| "The most common risk factor for shingles and its potential sequela, PHN, is advanced age." | 2.42 | Post-herpetic neuralgia case study: optimizing pain control. ( Baron, R, 2004) |
| "Gabapentin has demonstrated efficacy, specifically in painful diabetic neuropathy and postherpetic neuralgia." | 2.41 | Use of anticonvulsants for treatment of neuropathic pain. ( Backonja, MM, 2002) |
| "Lamotrigine has been reported to be effective in relieving pain from trigeminal neuralgia refractory to other treatments, HIV neuropathy, and central post-stroke pain." | 2.41 | Use of anticonvulsants for treatment of neuropathic pain. ( Backonja, MM, 2002) |
| "Two patients with interstitial cystitis improved functional capacity within their activities of daily living and received adequate pain control with the addition of gabapentin to their medication regimen." | 2.41 | Interstitial cystitis and the potential role of gabapentin. ( Hansen, HC, 2000) |
| "Gabapentin is a novel anticonvulsant that may have a unique effect on voltage-dependent Ca2+ channel currents at postsynaptic dorsal horn neurons." | 2.41 | Gabapentin use in neuropathic pain syndromes. ( Nicholson, B, 2000) |
| "Gabapentin has been shown to be efficacious in numerous smaller clinical studies, case reports, and chart reviews in a variety of neuropathic pain syndromes." | 2.41 | Gabapentin use in neuropathic pain syndromes. ( Nicholson, B, 2000) |
| "Gabapentin, which has been approved for add-on therapy of focal seizures, is increasingly used for treatment of neuropathic pain." | 2.41 | [Gabapentin therapy for pain]. ( Block, F, 2001) |
| "Among the more common symptoms is spasticity." | 2.41 | Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. ( Schapiro, RT, 2001) |
| "Gabapentin has been clearly demonstrated to be effective for the treatment of neuropathic pain in diabetic neuropathy and postherpetic neuralgia." | 2.41 | Gabapentin: pharmacology and its use in pain management. ( Kam, PC; Rose, MA, 2002) |
| "Gabapentin has been approved for the treatment of neuropathic pain in six European countries, New Zealand and Australia, and numerous countries in Latin America." | 2.41 | Gabapentin. Pfizer. ( Wheeler, G, 2002) |
| "Gabapentin is an amino acid, with a mechanism that differs from those of other anticonvulsant drugs such as phenytoin, carbamazepine or valproate." | 2.40 | A summary of mechanistic hypotheses of gabapentin pharmacology. ( Boden, P; Brown, JP; Dooley, DJ; Gee, NS; Kocsis, JD; Singh, L; Su, TZ; Taylor, CP; Welty, DF, 1998) |
| "Pain is a phenomenon experienced by all forms of life." | 2.37 | Neurophysiological and nutritional considerations of pain control. ( Nickles, SL; Pressman, AH, 1984) |
| " However, whether long-term use of gabapentin and pregabalin is associated with adverse cardiovascular diseases remains unknown." | 1.72 | Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy. ( Blankfield, RP; Davis, PB; Kaebler, DC; Pan, Y; Xu, R, 2022) |
| " In the dose-response analysis, moderate-dose (OR 2." | 1.46 | Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. ( Antoniou, T; Gomes, T; Juurlink, DN; Mamdani, MM; Paterson, JM; van den Brink, W, 2017) |
| "Chronic pain is a multifactorial disease comprised of both inflammatory and neuropathic components that affect ∼20% of the world's population." | 1.46 | sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain. ( Bialer, M; Brennan, KC; Devor, M; Kaufmann, D; Smith, MD; West, PJ; White, HS; Yagen, B, 2017) |
| "Daily gabapentin treatment attenuated mechanical allodynia and reduced face-grooming episodes in dIoN-CCI rats." | 1.46 | An Improved Rodent Model of Trigeminal Neuropathic Pain by Unilateral Chronic Constriction Injury of Distal Infraorbital Nerve. ( Chen, L; Ding, W; Doheny, JT; Lim, G; Mao, J; Shen, S; Yang, J; You, Z; Zhu, S, 2017) |
| "A rodent model of trigeminal neuropathic pain was first developed in 1994, in which chronic constriction injury (CCI) is induced by ligation of the infraorbital nerve (IoN)." | 1.46 | An Improved Rodent Model of Trigeminal Neuropathic Pain by Unilateral Chronic Constriction Injury of Distal Infraorbital Nerve. ( Chen, L; Ding, W; Doheny, JT; Lim, G; Mao, J; Shen, S; Yang, J; You, Z; Zhu, S, 2017) |
| "However, studies on trigeminal neuropathic pain remain limited." | 1.46 | An Improved Rodent Model of Trigeminal Neuropathic Pain by Unilateral Chronic Constriction Injury of Distal Infraorbital Nerve. ( Chen, L; Ding, W; Doheny, JT; Lim, G; Mao, J; Shen, S; Yang, J; You, Z; Zhu, S, 2017) |
| "Adults with moderate-to-severe primary restless legs syndrome (RLS) often experience painful dysesthesias, which may lead to impaired quality of life." | 1.43 | The Effect of Gabapentin Enacarbil on Pain Associated with Moderate-to-Severe Primary Restless Legs Syndrome in Adults: Pooled Analyses from Three Randomized Controlled Trials. ( Buchfuhrer, M; Ellenbogen, A; Hermanowicz, N; Irving, G; Jaros, MJ; Kim, R; Shang, G, 2016) |
| "One way to better understand migraine is to examine its clinical characteristics and potential biomarkers such as gamma-aminobutyric acid (GABA)." | 1.43 | The Association Between Clinical Characteristics of Migraine and Brain GABA Levels: An Exploratory Study. ( Aguila, MR; Brennan, PC; Hübscher, M; Lagopoulos, J; Leaver, AM; Rebbeck, T; Refshauge, KM, 2016) |
| "Migraine is prevalent and disabling yet is poorly understood." | 1.43 | The Association Between Clinical Characteristics of Migraine and Brain GABA Levels: An Exploratory Study. ( Aguila, MR; Brennan, PC; Hübscher, M; Lagopoulos, J; Leaver, AM; Rebbeck, T; Refshauge, KM, 2016) |
| "Mechanical allodynia elicited by burn injury was partially reversed by meloxicam (5 mg/kg), gabapentin (100 mg/kg) and oxycodone (3 and 10 mg/kg), while thermal allodynia and gait abnormalities were only significantly improved by amitriptyline (3 mg/kg) and oxycodone (10 mg/kg)." | 1.43 | Transcriptomic and behavioural characterisation of a mouse model of burn pain identify the cholecystokinin 2 receptor as an analgesic target. ( Deuis, JR; Lewis, RJ; Vetter, I; Yin, K, 2016) |
| "Cancer pain is complex, and despite the introduction of the WHO cancer pain ladder, few studies have looked at the prevalence of adjuvant medication use in an inpatient palliative medicine unit." | 1.42 | Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements? ( Davis, MP; Gordon, P; Gross, J; Sharma, P; Shinde, S, 2015) |
| "Gabapentin appears to be an effective treatment for children with severe impairment of the CNS and recurrent pain behaviors, including intermittent changes in muscle tone." | 1.42 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| " Dosing information can guide treatment trials and future prospective studies." | 1.42 | Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis. ( Hauer, JM; Solodiuk, JC, 2015) |
| "Diclofenac treatment produced dose-related reversal of CRANE at 0." | 1.42 | Complete Freund's adjuvant-induced reduction of exploratory activity in a novel environment as an objective nociceptive endpoint for sub-acute inflammatory pain model in rats. ( Bannon, AW; Joshi, SK; Zhu, CZ, 2015) |
| " Effects of orally dosed standard analgesics on CRANE were examined 48 h following bilateral CFA injection." | 1.42 | Complete Freund's adjuvant-induced reduction of exploratory activity in a novel environment as an objective nociceptive endpoint for sub-acute inflammatory pain model in rats. ( Bannon, AW; Joshi, SK; Zhu, CZ, 2015) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent widely used to reduce blood loss during surgery." | 1.42 | Tranexamic acid evokes pain by modulating neuronal excitability in the spinal dorsal horn. ( Baba, H; Kamiya, Y; Kohno, T; Ohashi, M; Ohashi, N; Sasaki, M, 2015) |
| "Gabapentin was found to reversibly decrease, but not suppress the flinching frequency of the second response peak only." | 1.40 | Semi-mechanistic modelling of the analgesic effect of gabapentin in the formalin-induced rat model of experimental pain. ( Danhof, M; Della Pasqua, O; Taneja, A; Troconiz, IF, 2014) |
| "Gabapentin was converted by N-acylation at its N-terminus into di-, tri-, and tetrapeptides (L-Ala-Gbp, L-Val-Gbp, L-Ala-L-Phe-Gbp, Gly-L-Ala-β-Ala-Gbp)." | 1.40 | Gabapentin hybrid peptides and bioconjugates. ( Alamry, KA; Goncalves, K; Ibrahim, MA; Katritzky, AR; Lebedyeva, IO; Neubert, J; Ostrov, DA; Patel, K; Sileno, SM; Steel, PJ, 2014) |
| "Synthetic approaches to gabapentin bioconjugates that overcome the tendency of gabapentin to cyclize into its γ-lactam are studied." | 1.40 | Gabapentin hybrid peptides and bioconjugates. ( Alamry, KA; Goncalves, K; Ibrahim, MA; Katritzky, AR; Lebedyeva, IO; Neubert, J; Ostrov, DA; Patel, K; Sileno, SM; Steel, PJ, 2014) |
| "Reserpine treatment significantly increased the immobility time in the forced swim test, which is indicative of depression in the animals." | 1.40 | The effects of Phα1β, a spider toxin, calcium channel blocker, in a mouse fibromyalgia model. ( Castro, CJ; da Costa Lopes, AM; da Silva, CA; da Silva, JF; de Souza, AH; Ferreira, J; Gomez, MV; Klein, CP; Pereira, EM, 2014) |
| "Chronic pain is often associated with sexual dysfunction, suggesting that pain can reduce libido." | 1.40 | Pain reduces sexual motivation in female but not male mice. ( Binik, YM; Chan, L; Chen, M; Farmer, MA; Foxen-Craft, E; Leja, A; MacIntyre, LC; Mapplebeck, JC; Mogil, JS; Niaki, T; Pfaus, JG; Sukosd, M; Tabry, V; Topham, L, 2014) |
| "Pain was produced by injection of inflammogens zymosan A (0." | 1.40 | Pain reduces sexual motivation in female but not male mice. ( Binik, YM; Chan, L; Chen, M; Farmer, MA; Foxen-Craft, E; Leja, A; MacIntyre, LC; Mapplebeck, JC; Mogil, JS; Niaki, T; Pfaus, JG; Sukosd, M; Tabry, V; Topham, L, 2014) |
| "Gabapentin, commonly used to treat neuropathic pain, produced increased NAc DA in rats with SNL but not in animals with incisional, injury." | 1.40 | Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain: a potential biomarker of efficacy. ( Becerra, L; Borsook, D; Navratilova, E; Ossipov, MH; Patwardhan, A; Porreca, F; Qu, C; Xie, JY, 2014) |
| " Below we describe the preliminary evaluation of support vector machine in the regression mode (SVR) application for the prediction of maximal antiallodynic effect of a new derivative of dihydrofuran-2-one (LPP1) used in combination with pregabalin (PGB) in the streptozocin-induced neuropathic pain model in mice." | 1.39 | The application of support vector regression for prediction of the antiallodynic effect of drug combinations in the mouse model of streptozocin-induced diabetic neuropathy. ( Sałat, K; Sałat, R, 2013) |
| "Chronic pain is thought to be partly caused by a loss of GABAergic inhibition and resultant neuronal hyperactivation in the central pain-modulating system, but the underlying mechanisms for pain-modulating neurons in the brain are unclear." | 1.39 | Brain-derived neurotrophic factor-mediated downregulation of brainstem K+-Cl- cotransporter and cell-type-specific GABA impairment for activation of descending pain facilitation. ( Lu, YG; Pan, ZZ; Wang, W; Wang, X; Zhang, Z, 2013) |
| "The Fibromyalgia Impact Questionnaire (FIQ) is a patient-reported outcome that evaluates the impact of fibromyalgia (FM) on daily life." | 1.39 | Evaluation of the fibromyalgia impact questionnaire at baseline as a predictor for time to pain improvement in two clinical trials of pregabalin. ( Bushmakin, AG; Cappelleri, JC; Chandran, AB; Zlateva, G, 2013) |
| "Using behavioral approaches in vivo, we found that D3KO animals exhibit reduced paw withdrawal latencies to thermal pain stimulation (Hargreaves' test) over wild type (WT) controls." | 1.38 | Increased excitability of spinal pain reflexes and altered frequency-dependent modulation in the dopamine D3-receptor knockout mouse. ( Baran, CA; Brewer, KL; Clemens, S; Keeler, BE, 2012) |
| "Pain was ranked as the most important outcome explaining variability in PGIC, followed by fatigue and sleep." | 1.37 | Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin. ( Arnold, LM; Emir, B; Sadosky, A; Whalen, E; Zlateva, G, 2011) |
| "In morphine-treated animals, evoked spinal neuronal responses were enhanced to a subset of thermal and mechanical stimuli." | 1.37 | Pregabalin suppresses spinal neuronal hyperexcitability and visceral hypersensitivity in the absence of peripheral pathophysiology. ( Bannister, K; Bauer, CS; Dickenson, AH; Dolphin, AC; Porreca, F; Sikandar, S, 2011) |
| "Opioid-induced hyperalgesia is recognized in the laboratory and the clinic, generating central hyperexcitability in the absence of peripheral pathology." | 1.37 | Pregabalin suppresses spinal neuronal hyperexcitability and visceral hypersensitivity in the absence of peripheral pathophysiology. ( Bannister, K; Bauer, CS; Dickenson, AH; Dolphin, AC; Porreca, F; Sikandar, S, 2011) |
| "In opioid-induced hyperalgesia, which extends to colonic distension, a serotonergic facilitatory system may be up-regulated, creating an environment that is permissive for pregabalin-mediated analgesia without peripheral pathology." | 1.37 | Pregabalin suppresses spinal neuronal hyperexcitability and visceral hypersensitivity in the absence of peripheral pathophysiology. ( Bannister, K; Bauer, CS; Dickenson, AH; Dolphin, AC; Porreca, F; Sikandar, S, 2011) |
| "Chronic pain is a common neurological disease involving lasting, multifaceted maladaptations ranging from gene modulation to synaptic dysfunction and emotional disorders." | 1.37 | Epigenetic suppression of GAD65 expression mediates persistent pain. ( Bie, B; Cai, YQ; Pan, ZZ; Zhang, Z; Zou, F, 2011) |
| "Fibromyalgia is a chronic pain disorder characterized by widespread pain, stiffness, insomnia, fatigue and distress." | 1.36 | Pharmacological treatment of fibromyalgia syndrome: new developments. ( Staud, R, 2010) |
| "However, new pharmacological approaches for the treatment of fibromyalgia pain and insomnia using sodium oxybate appear to be promising." | 1.36 | Pharmacological treatment of fibromyalgia syndrome: new developments. ( Staud, R, 2010) |
| "Gabapentin was commenced at 300 mg daily and titrated to 300 mg tds over 3 days." | 1.36 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "Pain was assessed by visual analogue scoring at baseline, 4, 7, 14 and 28 days." | 1.36 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "The static allodynia endpoint was modeled by using three population PD approaches: 1) the behavior of the injured paw using a three-category ordinal logistic regression model; 2) paw withdrawal threshold (PWT) (g) between the injured and uninjured paw using the Hill equation with a baseline function; and 3) the baseline normalized difference in PWT between the injured and uninjured paw." | 1.36 | Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain. ( Bender, G; Bies, RR; Bramwell, S; Danhof, M; DeJongh, J; Field, MJ; Florian, JA; Marshall, S; Tan, KK, 2010) |
| "Neuropathic pain is a common problem following spinal cord injury (SCI)." | 1.36 | Role of NKCC1 and KCC2 in the development of chronic neuropathic pain following spinal cord injury. ( Ahmed, MM; Hasbargen, T; Kahle, KT; Li, L; Miranpuri, G; Resnick, D; Sun, D, 2010) |
| "Neuropathic pain is a major health issue and is frequently accompanied by allodynia (painful sensations in response to normally non-painful stimulations), and unpleasant paresthesia/dysesthesia, pointing to alterations in sensory pathways normally dedicated to the processing of non-nociceptive information." | 1.36 | Upregulation of the GABA transporter GAT-1 in the gracile nucleus in the spared nerve injury model of neuropathic pain. ( Bebber, D; Decosterd, I; Gosselin, RD, 2010) |
| "Gabapentin was initiated in the second week of radiotherapy." | 1.36 | Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. ( Bar Ad, V; Both, S; Chalian, A; Dosoretz, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "Gabapentin and R-PIA were administered to obtain the dose-response curve and the 50% effective dose (ED(50))." | 1.35 | The interaction of gabapentin and N6-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA) on mechanical allodynia in rats with a spinal nerve ligation. ( Jun, IG; Park, JY, 2008) |
| " Gabapentin and R-PIA were administered to obtain the dose-response curve and the 50% effective dose (ED(50))." | 1.35 | The interaction of gabapentin and N6-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA) on mechanical allodynia in rats with a spinal nerve ligation. ( Jun, IG; Park, JY, 2008) |
| "Here, we tested the effect of FK1706 on painful diabetic neuropathy in rat model of diabetes induced by streptozotocin (STZ)." | 1.35 | FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy. ( Matsuoka, N; Murai, N; Mutoh, S; Price, RD; Yamaji, T; Yamamoto, H; Yamazaki, S, 2008) |
| "Spinal sagittal slices with attached dorsal roots (DR) were prepared from L(4) to L(6) level." | 1.35 | Spinal cord injury-induced attenuation of GABAergic inhibition in spinal dorsal horn circuits is associated with down-regulation of the chloride transporter KCC2 in rat. ( Lu, Y; Xiong, L; Yang, J; Zheng, J; Zimmermann, M, 2008) |
| "Pain is the result of an emotional and sensory experience and preclinical models of OA can thus be useful to better understand the underlying mechanisms of the disease and test new therapeutic options." | 1.35 | Differential analgesic effects of morphine and gabapentin on behavioural measures of pain and disability in a model of osteoarthritis pain in rats. ( Dickenson, AH; Ghandehari, J; Vonsy, JL, 2009) |
| " Bioavailability was included in the models as a function of dose by using a hyperbolic function derived from data previously reported in the literature." | 1.35 | A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling. ( Carlsson, KC; Eriksen, HO; Hoem, NO; Karlsson, MO; Moberg, ER; van de Schootbrugge, M, 2009) |
| " Steady-state serum concentrations of gabapentin, distributed over a dosage interval, were obtained from 16 adult patients." | 1.35 | A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling. ( Carlsson, KC; Eriksen, HO; Hoem, NO; Karlsson, MO; Moberg, ER; van de Schootbrugge, M, 2009) |
| "Neuropathic pain is a disease caused by a lesion or dysfunction of the nervous system." | 1.35 | Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain. ( Barrot, M; Doridot, S; Freund-Mercier, MJ; Hein, L; Petit-Demoulière, N; Tessier, LH; Yalcin, I, 2009) |
| "Morphine pretreatment produced an increase in GABA levels and a decrease in glutamate levels in the first few minutes." | 1.35 | [Effect of a simple morphine system injection in some aminoacids in the anterior cingulate cortex during acute pain]. ( Hernández, L; Páez, X; Quiñones, B; Silva, E, 2008) |
| "Pretreatment with morphine suppressed the glutamate increase." | 1.35 | [Effect of a simple morphine system injection in some aminoacids in the anterior cingulate cortex during acute pain]. ( Hernández, L; Páez, X; Quiñones, B; Silva, E, 2008) |
| "The Fibromyalgia Impact Questionnaire (FIQ) is a disease-specific composite instrument that measures the effect of problems experienced by patients with fibromyalgia (FM)." | 1.35 | Minimal clinically important difference in the fibromyalgia impact questionnaire. ( Bennett, RM; Bushmakin, AG; Cappelleri, JC; Sadosky, AB; Zlateva, G, 2009) |
| " Here we determined the antinociceptive effect of chronic administration of neramexane and compared its effect with that of memantine and gabapentin in a rat model of diabetic neuropathic pain." | 1.35 | Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain. ( Chen, SR; Pan, HL; Samoriski, G, 2009) |
| "Gabapentin did not produce an anti-allodynic effect, whereas the morphine and gabapentin combination completely decreased allodynia behavior at 30 min post-injection, an effect that persisted until 120 min." | 1.35 | Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury. ( Cortés-Arroyo, AR; De la O-Arciniega, M; Díaz-Reval, MI; Domínguez-Ramírez, AM; López-Muñoz, FJ, 2009) |
| "Primary erythermalgia (erythromelalgia) is a rare autosomal dominant condition characterized by intermittent attacks of erythema, increased skin temperature and severe burning pain in the extremities, in a bilateral symmetrical distribution." | 1.35 | Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel. ( Atherton, D; Elmslie, F; Mansour, S; Mortimer, P; Natkunarajah, J, 2009) |
| "Gabapentin is a gamma-aminobutyric acid analog used for numerous neurologic conditions, including neuropathic pain and epilepsy." | 1.35 | Gabapentin therapy for pain and irritability in a neurologically impaired infant. ( Cox, TH; Garner, SS; Haney, AL, 2009) |
| " The infant continued to receive gabapentin; the dosage was increased to 10 mg/kg at bedtime after 6 days, then to 5 mg/kg in the morning and 10 mg/kg at bedtime 10 days later." | 1.35 | Gabapentin therapy for pain and irritability in a neurologically impaired infant. ( Cox, TH; Garner, SS; Haney, AL, 2009) |
| "Both indomethacin and morphine were able to block or reverse thermal hyperalgesia and normalize gait in the CARR model." | 1.35 | Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models. ( Cummons, TA; Harrison, JE; Leventhal, L; Lu, P; Piesla, MJ; Strassle, BW; Whiteside, GT, 2009) |
| "Gabapentin and duloxetine reversed mechanical hyperalgesia but did not normalize gait in any nerve injury model." | 1.35 | Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models. ( Cummons, TA; Harrison, JE; Leventhal, L; Lu, P; Piesla, MJ; Strassle, BW; Whiteside, GT, 2009) |
| "Cilnidipine is a 1,4-dihydropyridine-derived voltage-dependent calcium channel (VDCC) blocker and suppresses N-type VDCC currents in addition to L-type VDCC currents." | 1.35 | Suppression of formalin-induced nociception by cilnidipine, a voltage-dependent calcium channel blocker. ( Iwata, S; Koganei, H; Shoji, M, 2009) |
| "Visceral pain is one of the most common forms of pain and for which new drugs would be welcome." | 1.35 | Gabapentin action and interaction on the antinociceptive effect of morphine on visceral pain in mice. ( Meymandi, MS; Sepehri, G, 2008) |
| "Inhibition of the allodynia with receptor antagonists indicated that each agent induces allodynia by a distinct mechanism." | 1.35 | Transient allodynia pain models in mice for early assessment of analgesic activity. ( Cheevers, CV; Donello, JE; Gil, DW, 2008) |
| "These transient allodynia models are a useful addition to the toolbox of preclinical pain models." | 1.35 | Transient allodynia pain models in mice for early assessment of analgesic activity. ( Cheevers, CV; Donello, JE; Gil, DW, 2008) |
| "When diazepam was given only 1h before the formalin test, it slightly but significantly reduced pain scores during late phase in FS rats but not in SS rats." | 1.35 | Reduced GABA neurotransmission underlies hyperalgesia induced by repeated forced swimming stress. ( Leal, L; Pinerua-Shuhaibar, L; Quintero, L; Silva, JA; Suarez-Roca, H, 2008) |
| "We determined if cutaneous hyperalgesia and pain-induced c-Fos overexpression in the spinal cord produced by repeated forced swimming (FS) stress in the rat were related to changes in GABA neurotransmission by studying spinal release of GABA and the effect of positive modulation of GABA-A receptors with diazepam." | 1.35 | Reduced GABA neurotransmission underlies hyperalgesia induced by repeated forced swimming stress. ( Leal, L; Pinerua-Shuhaibar, L; Quintero, L; Silva, JA; Suarez-Roca, H, 2008) |
| "Gabapentin has established efficacy in the reduction of burn-induced hyperalgesia and allodynia in animal and human experimental burn models." | 1.35 | Successful use of gabapentin in acute pain management following burn injury: a case series. ( Cramond, T; Gray, P; Williams, B, 2008) |
| "Gabapentin is an antiepileptic used for neuropathic pain treatment." | 1.35 | Gabapentin therapy for painful, blind glaucomatous eye: case report. ( Dimou, T; Kavalieratos, CS, 2008) |
| "Gabapentin (Gp) is an antihyperalgesic drug that selectively affects central sensitization." | 1.34 | Effects of gabapentin on morphine consumption and pain in severely burned patients. ( Cuignet, O; Pirson, J; Soudon, O; Zizi, M, 2007) |
| "Muscle hyperalgesia (withdrawal threshold to compression of the muscle) and cutaneous hyperalgesia of the paw (withdrawal threshold to von Frey filaments) were measured before and after induction of hyperalgesia and after treatment with pregabalin (saline, 10 to 100 mg/kg i." | 1.34 | Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats. ( Audette, KM; Maeda, Y; Sluka, KA; Yokoyama, T, 2007) |
| "Chronic muscle pain is a problem with high prevalence in clinical practice and its pharmacological treatment is difficult." | 1.34 | Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF. ( Beyreuther, BK; Geis, C; Sommer, C; Stöhr, T, 2007) |
| "A complete reversal of hyperalgesia was seen with lacosamide at 30mg/kg." | 1.34 | Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF. ( Beyreuther, BK; Geis, C; Sommer, C; Stöhr, T, 2007) |
| "Cancer-induced bone pain is a major clinical problem for which current treatments lack full efficacy." | 1.33 | Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain. ( Dickenson, AH; Donovan-Rodriguez, T; Urch, CE, 2005) |
| "GBP increases the risk of myoclonus in ESRD." | 1.33 | Gabapentin-induced myoclonus in end-stage renal disease. ( Bell, WL; Glenn, DG; O'Donovan, CA; Zhang, C, 2005) |
| "Three of 71 patients had myoclonus with GBP doses ranging from 9 mg/kg to 20 mg/kg and within 4 months of treatment onset." | 1.33 | Gabapentin-induced myoclonus in end-stage renal disease. ( Bell, WL; Glenn, DG; O'Donovan, CA; Zhang, C, 2005) |
| "Myoclonus was characterized as multifocal, involving all extremities in the three patients." | 1.33 | Gabapentin-induced myoclonus in end-stage renal disease. ( Bell, WL; Glenn, DG; O'Donovan, CA; Zhang, C, 2005) |
| "In contrast, analgesia, sedation and catalepsy were not observed in this dose range, but were apparent at 100 mg/kg." | 1.33 | Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. ( Boulet, JM; Chaffer, SM; Elsemore, DA; Gottshall, SL; Harrison, JE; Koetzner, L; Lee, G; Mark, L; Miller, W; Pearson, MS; Rabadi, L; Rotshteyn, Y; Shan, S; Tafesse, L; Toth, M; Turchin, PI; Valenzano, KJ; Whiteside, GT, 2005) |
| "Secondary mechanical allodynia and hyperalgesia were measured at 5 and 15 min after capsaicin injection, respectively." | 1.33 | CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats. ( Bassani, F; Bergamaschi, M; Tonino Bolzoni, P; Villetti, G, 2005) |
| "Neuropathic pain is characterised by hyperexcitability within nociceptive pathways that manifests behaviourally as allodynia and hyperalgesia and remains difficult to treat with standard analgesics." | 1.33 | Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. ( Blackburn-Munro, G; Nielsen, AN; Pedersen, LH, 2005) |
| "Neuropathic pain is a clinical manifestation characterized by the presence of spontaneous pain, allodynia and hyperalgesia." | 1.33 | Development and expression of neuropathic pain in CB1 knockout mice. ( Castañé, A; Célérier, E; Ledent, C; Maldonado, R; Martín, M; Parmentier, M; Valverde, O, 2006) |
| "The development of mechanical and thermal allodynia, and thermal hyperalgesia was evaluated by using the von Frey filaments, cold-plate and plantar tests, respectively." | 1.33 | Development and expression of neuropathic pain in CB1 knockout mice. ( Castañé, A; Célérier, E; Ledent, C; Maldonado, R; Martín, M; Parmentier, M; Valverde, O, 2006) |
| "Ambroxol's effects were compared with those of gabapentin." | 1.33 | Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. ( Arndt, K; Gaida, W; Klinder, K; Weiser, T, 2005) |
| "Neuropathic pain affects many patients, and treatment today is far from being perfect." | 1.33 | Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. ( Arndt, K; Gaida, W; Klinder, K; Weiser, T, 2005) |
| "Pinacidil activity was not blocked by L-NAME, D-NAME, 7-nitroindazole, ODQ, KT-5823 or okadaic acid." | 1.33 | The nitric oxide-cyclic GMP-protein kinase G-K+ channel pathway participates in the antiallodynic effect of spinal gabapentin. ( Flores-Murrieta, FJ; Granados-Soto, V; Mixcoatl-Zecuatl, T, 2006) |
| "The severe burning pain, deep pressure-like pain, and deep mechanical allodynia, which presented over the contralateral side to the TBI, were successfully relieved with motor cortex stimulation (MCS)." | 1.33 | Motor cortex stimulation for central pain following a traumatic brain injury. ( Choi, ES; Hong, JT; Lee, SW; Son, BC; Sung, JH, 2006) |
| "Paclitaxel (Taxol) is a widely used chemotherapeutic agent in the treatment of several tumors." | 1.33 | Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin. ( Hald, A; Inoue, M; Matsumoto, M; Ueda, H; Xie, W, 2006) |
| "Neuropathic pain is associated with a number of disease states of diverse aetiology that can share common pathophysiological mechanisms." | 1.33 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| "Hindpaw mechanical allodynia was dose-dependently reversed by gabapentin (50 and 100 mg/kg, s." | 1.33 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| "Neuropathic pain is a debilitating condition affecting millions of people around the world and is defined as pain that follows a lesion or dysfunction of the nervous system." | 1.33 | Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. ( Bramwell, S; Corradini, L; Cox, PJ; Dolphin, AC; England, S; Field, MJ; Hendrich, J; Kinloch, RA; Melrose, H; Offord, J; Stott, E; Su, TZ; Webb, T; Williams, D; Winks, J, 2006) |
| "Gabapentin has recently been used clinically as an antihyperalgesic agent to treat certain neuropathic pain states." | 1.32 | Gabapentin markedly reduces acetic acid-induced visceral nociception. ( Cui, M; Feng, Y; Willis, WD, 2003) |
| "SUNCT, a still relatively unknown headache syndrome, is characterized by attacks of periorbital pain with accompanying ipsilateral autonomic symptoms." | 1.32 | [Case report on a patient with SUNCT-syndrome]. ( Brinkschmidt, T; Jensen, U; Neumeier, S, 2003) |
| "Assessment of pain relief in type 2 diabetes mellitus patients with neuropathic pain treated with gabapentin at daily dose 2400 mg." | 1.32 | [Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003) |
| "26 patients with type 2 diabetes mellitus and painful neuropathy were included into the study." | 1.32 | [Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003) |
| "Gabapentin was discontinued in 10 patients (46%)." | 1.32 | The pattern of gabapentin use in a tertiary palliative care unit. ( al-Shahri, MZ; Oneschuk, D, 2003) |
| "Of the 147 patients with a cancer diagnosis, 45 (31%) had neuropathic pain." | 1.32 | The pattern of gabapentin use in a tertiary palliative care unit. ( al-Shahri, MZ; Oneschuk, D, 2003) |
| " This dosage produced a substantial but non-significant decrease in the incidence of postherpetic pain-related responses." | 1.32 | Effects of the suppression of acute herpetic pain by gabapentin and amitriptyline on the incidence of delayed postherpetic pain in mice. ( Kuraishi, Y; Nojima, H; Shiraki, K; Takahata, H; Takasaki, I, 2004) |
| "The present study investigated whether mechanical allodynia following contusive spinal cord injury (SCI) of the thoracic segments 12 and 13 of the rat was associated with a reduction in gamma-aminobutyric acid (GABA)ergic inhibition adjacent to the site of injury." | 1.32 | Mechanical allodynia following contusion injury of the rat spinal cord is associated with loss of GABAergic inhibition in the dorsal horn. ( Drew, GM; Duggan, AW; Siddall, PJ, 2004) |
| "Morphine sulfate has long been used for analgesia, but clinical applications can be limited by side effects, tolerance, and potential for addiction at therapeutic doses." | 1.32 | Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model. ( Lu, Y; Smiley, MM; Vera-Portocarrero, LP; Westlund, KN; Zidan, A, 2004) |
| "Gabapentin (GBP) is a new antiepileptic agent with an original spectrum of activity." | 1.32 | [Gabapentin (Neurontin) and cancer pain: a pilot study]. ( Body, JJ; Lossignol, DA; Plehiers, B, 2004) |
| "All were already treated for their pain syndrome." | 1.32 | [Gabapentin (Neurontin) and cancer pain: a pilot study]. ( Body, JJ; Lossignol, DA; Plehiers, B, 2004) |
| "We prospectively followed 20 cancer patients with advanced disease suffering from neuropathic pain." | 1.32 | [Gabapentin (Neurontin) and cancer pain: a pilot study]. ( Body, JJ; Lossignol, DA; Plehiers, B, 2004) |
| "The substance P effect was also blocked by a bilateral microinjection of bicuculline, at a dose that was without effect on basal baroreceptor reflex gain." | 1.31 | Somatic nociception activates NK1 receptors in the nucleus tractus solitarii to attenuate the baroreceptor cardiac reflex. ( Boscan, P; Kasparov, S; Paton, JF, 2002) |
| "The initial hyperalgesia induced by 0." | 1.31 | Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia. ( Assié, MB; Bardin, L; Carilla-Durand, E; Colpaert, FC; Cosi, C; Koek, W; Pauwels, PJ; Tarayre, JP; Vacher, B; Wiesenfeld-Hallin, Z; Xu, XJ, 2002) |
| "Allodynia and hyperalgesia appeared on day 5 post-inoculation." | 1.31 | Pharmacological and immunohistochemical characterization of a mouse model of acute herpetic pain. ( Andoh, T; Kuraishi, Y; Nemoto, H; Nitta, M; Nojima, H; Shiraki, K; Takahata, H; Takasaki, I, 2000) |
| "Gabapentin treatment significantly and reversibly changed the responses, consistent with the attenuation of the abnormal sensory behavior, and the attenuated responses lasted for the duration of the drug effect (up to 6 h)." | 1.31 | Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin. ( Hulsebosch, CE; McAdoo, DJ; Perez-Polo, JR; Taylor, CP; Westlund, KN; Xu, GY, 2000) |
| "SCI gabapentin-treated rats did not display differences in total rearing time until PSD 28 and a significant difference in total activity of all measured parameters was not seen until PSD 60." | 1.31 | Changes in exploratory behavior as a measure of chronic central pain following spinal cord injury. ( Grady, JJ; Hulsebosch, CE; Mills, CD, 2001) |
| "A well known drug in the treatment of spasticity is the GABA(B) agonist Baclofen." | 1.31 | Baclofen inhibits ANP-mediated cyclic GMP synthesis in the rat cervical spinal cord. ( de Louw, AJ; de Vente, J; Steinbusch, HP; Steinbusch, HW; Troost, J; Vles, JS, 2002) |
| "Acyclovir treatment healed all skin lesions by day 15 after inoculation." | 1.31 | Effects of analgesics on delayed postherpetic pain in mice. ( Andoh, T; Kuraishi, Y; Nojima, H; Sasaki, A; Shiraki, K; Takasaki, I, 2002) |
| "Tactile allodynia was quantitated using the threshold to withdrawal of the hind paw on probing with von Frey filaments." | 1.31 | Spinal GABA(A) and GABA(B) receptor pharmacology in a rat model of neuropathic pain. ( Malan, TP; Mata, HP; Porreca, F, 2002) |
| "Isoguvacine and baclofen each reversed tactile allodynia and thermal hyperalgesia produced by spinal nerve ligation." | 1.31 | Spinal GABA(A) and GABA(B) receptor pharmacology in a rat model of neuropathic pain. ( Malan, TP; Mata, HP; Porreca, F, 2002) |
| "Pain was assessed prior to and during treatment at 1, 3 and 6 months with a 10 cm visual analogue scale which ranged from 0 ('no pain') to 10 ('worst pain imaginable'), or by the documentation of a verbal description of pain." | 1.31 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "Gabapentin is a novel anticonvulsant that may be of value for the relief of clinical pain." | 1.30 | Spinal gabapentin is antinociceptive in the rat formalin test. ( Davis, AM; Elliott, KJ; Inturrisi, CE; Shimoyama, M; Shimoyama, N, 1997) |
| "Gabapentin (GBP) is a gamma-aminobutyric acid analog originally synthesized for its anticonvulsant actions." | 1.30 | Gabapentin reverses the allodynia produced by the administration of anti-GD2 ganglioside, an immunotherapeutic drug. ( Gillin, S; Sorkin, LS, 1998) |
| "Gabapentin is an anticonvulsant that may represent a novel class of drugs, which has novel spinal antihyperalgesic activity." | 1.30 | The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat. ( Jun, JH; Yaksh, TL, 1998) |
| "Gabapentin is an effective option for the treatment of neuropathic pain syndromes because of its efficacy and favorable side-effect profile." | 1.30 | Gabapentin induced polyneuropathy. ( Gould, HJ, 1998) |
| "Gabapentin (GP) has been shown to have antihyperalgesic properties and the site of drug action is reported to be the central nervous system." | 1.30 | Attenuation of formalin-induced nociceptive behaviors following local peripheral injection of gabapentin. ( Carlton, SM; Zhou, S, 1998) |
| "A variety of treatments for the pain were ineffective." | 1.30 | Gabapentin for treatment of neuropathic pain in a 12-year-old girl. ( McGraw, T; Stacey, BR, 1998) |
| "Laudanosine was almost ineffective at [3H]muscimol binding to high-affinity GABA receptors (IC50 = 100 microM)." | 1.29 | Interactions between laudanosine, GABA, and opioid subtype receptors: implication for laudanosine seizure activity. ( Fonia, O; Gavish, M; Katz, Y; Liu, L; Pasternak, GW; Pick, CG; Weizman, A, 1994) |
| "Gamma-aminobutyric acid (GABA) is a putative inhibitory neurotransmitter in the vertebrate nervous system." | 1.28 | GABA-immunoreactive terminals synapse on primate spinothalamic tract cells. ( Carlton, SM; Westlund, KN; Willis, WD; Zhang, D, 1992) |
| "D-Baclofen is an antagonist at spinal baclofen receptors." | 1.27 | GABAergic mechanisms in antinociception. ( Sawynok, J, 1984) |
| "Treatment by progabide, a GABA-agonist, was successful in one case: a gradual improvement was observed during four weeks and the movements have now disappeared after six months of progabide therapy." | 1.27 | [Progabide treatment of a case of the syndrome of painful legs and moving toes]. ( Bovier, P; Hilleret, H; Tissot, R, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 48 (6.46) | 18.7374 |
| 1990's | 75 (10.09) | 18.2507 |
| 2000's | 381 (51.28) | 29.6817 |
| 2010's | 214 (28.80) | 24.3611 |
| 2020's | 25 (3.36) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, H | 1 |
| Altenbach, RJ | 1 |
| Carr, TL | 1 |
| Chandran, P | 1 |
| Hsieh, GC | 1 |
| Lewis, LG | 1 |
| Manelli, AM | 1 |
| Milicic, I | 1 |
| Marsh, KC | 1 |
| Miller, TR | 1 |
| Strakhova, MI | 1 |
| Vortherms, TA | 1 |
| Wakefield, BD | 1 |
| Wetter, JM | 1 |
| Witte, DG | 1 |
| Honore, P | 1 |
| Esbenshade, TA | 1 |
| Brioni, JD | 1 |
| Cowart, MD | 1 |
| Polychronopoulou, E | 1 |
| Kuo, YF | 1 |
| Wilkes, D | 1 |
| Raji, MA | 1 |
| Sivakumar, D | 1 |
| Ramli, R | 2 |
| Pan, Y | 1 |
| Davis, PB | 1 |
| Kaebler, DC | 1 |
| Blankfield, RP | 1 |
| Xu, R | 1 |
| Amini, P | 1 |
| Sajedi, F | 1 |
| Mirjalili, M | 1 |
| Mohammadi, Y | 1 |
| Mehrpooya, M | 1 |
| Jia, T | 2 |
| Wang, YD | 2 |
| Chen, J | 3 |
| Zhang, X | 2 |
| Cao, JL | 2 |
| Xiao, C | 3 |
| Zhou, C | 3 |
| Xie, L | 2 |
| Wu, H | 2 |
| Chen, Q | 3 |
| Xu, F | 2 |
| Li, H | 2 |
| Xu, Q | 3 |
| Jiao, C | 2 |
| Sun, L | 3 |
| Ullah, R | 2 |
| Chen, X | 2 |
| Hao, H | 1 |
| Wang, C | 1 |
| Liu, C | 1 |
| Shah, S | 1 |
| Mullen, P | 1 |
| Lall, V | 1 |
| Jones, F | 1 |
| Shao, J | 1 |
| Zhang, H | 2 |
| Jaffe, DB | 1 |
| Gamper, N | 2 |
| Du, X | 2 |
| Gilron, I | 6 |
| Robb, S | 1 |
| Tu, D | 1 |
| Holden, RR | 1 |
| Milev, R | 1 |
| Towheed, T | 1 |
| Smith, LE | 1 |
| Murphy, BA | 1 |
| Smith, DK | 1 |
| Cao, P | 1 |
| Zhang, M | 1 |
| Ni, Z | 1 |
| Song, XJ | 1 |
| Yang, CL | 1 |
| Mao, Y | 1 |
| Zhou, W | 2 |
| Dong, WY | 1 |
| Peng, X | 1 |
| Zheng, C | 1 |
| Zhang, Z | 4 |
| Jin, Y | 1 |
| Tao, W | 2 |
| Bouchet, CA | 1 |
| McPherson, KB | 1 |
| Coutens, B | 1 |
| Janowsky, A | 1 |
| Ingram, SL | 2 |
| Qian, X | 1 |
| Zhao, X | 1 |
| Yu, L | 1 |
| Yin, Y | 1 |
| Zhang, XD | 1 |
| Wang, L | 2 |
| Li, JX | 1 |
| Zhu, Q | 1 |
| Luo, JL | 1 |
| Bohic, M | 1 |
| Marics, I | 1 |
| Santos, C | 1 |
| Malapert, P | 1 |
| Ben-Arie, N | 1 |
| Salio, C | 3 |
| Reynders, A | 1 |
| Le Feuvre, Y | 1 |
| Saurin, AJ | 1 |
| Moqrich, A | 1 |
| Archibald, J | 1 |
| MacMillan, EL | 1 |
| Enzler, A | 1 |
| Jutzeler, CR | 1 |
| Schweinhardt, P | 1 |
| Kramer, JLK | 1 |
| Lapane, KL | 1 |
| Hume, AL | 1 |
| Morrison, RA | 1 |
| Jesdale, BM | 1 |
| Zhang, W | 1 |
| Yang, X | 1 |
| Wang, R | 1 |
| Wang, H | 3 |
| Benke, D | 1 |
| Cruz-Almeida, Y | 1 |
| Porges, E | 1 |
| Alderman, C | 1 |
| Lepski, G | 1 |
| Comitato, A | 1 |
| Bardoni, R | 2 |
| Hasanein, P | 2 |
| Komaki, A | 1 |
| Yari, S | 1 |
| Fanton, S | 1 |
| Sandström, A | 1 |
| Tour, J | 1 |
| Kadetoff, D | 1 |
| Schalling, M | 1 |
| Jensen, KB | 1 |
| Sitnikov, R | 1 |
| Ellerbrock, I | 1 |
| Kosek, E | 1 |
| Luo, Y | 1 |
| Kusay, AS | 1 |
| Jiang, T | 1 |
| Chebib, M | 1 |
| Balle, T | 1 |
| Jiang, YM | 1 |
| Sun, DD | 1 |
| Wang, ZG | 1 |
| Li, T | 1 |
| Zhao, XL | 1 |
| Jiao, Y | 1 |
| Liu, Y | 2 |
| Li, YJ | 1 |
| Ouyang, JF | 1 |
| Wang, DQ | 1 |
| Gomes, T | 1 |
| Juurlink, DN | 1 |
| Antoniou, T | 1 |
| Mamdani, MM | 1 |
| Paterson, JM | 1 |
| van den Brink, W | 1 |
| Zhang, Y | 1 |
| Wang, K | 1 |
| Arendt-Nielsen, L | 2 |
| Cairns, BE | 1 |
| Johansen, ME | 1 |
| Grau, JW | 2 |
| Huang, YJ | 3 |
| Alexander, J | 1 |
| Edwards, RA | 1 |
| Brodsky, M | 1 |
| Manca, L | 1 |
| Grugni, R | 1 |
| Savoldelli, A | 1 |
| Bonfanti, G | 1 |
| Emir, B | 3 |
| Whalen, E | 5 |
| Watt, S | 1 |
| Parsons, B | 1 |
| Koetsier, E | 1 |
| Franken, G | 1 |
| Debets, J | 1 |
| Heijmans, L | 1 |
| van Kuijk, SMJ | 1 |
| Linderoth, B | 4 |
| Joosten, EA | 1 |
| Maino, P | 1 |
| Gradinger, T | 1 |
| Sack, M | 1 |
| Cardinale, V | 1 |
| Thiacourt, M | 1 |
| Baumgärtner, U | 1 |
| Schmahl, C | 1 |
| Ende, G | 1 |
| Fraccaro, E | 1 |
| Coetzee, JF | 2 |
| Odore, R | 1 |
| Edwards-Callaway, LN | 1 |
| Kukanich, B | 1 |
| Badino, P | 1 |
| Bertolotti, L | 1 |
| Glynn, H | 1 |
| Dockweiler, J | 1 |
| Allen, K | 1 |
| Bergamasco, L | 1 |
| Olesen, SS | 1 |
| Graversen, C | 1 |
| Bouwense, SA | 1 |
| van Goor, H | 1 |
| Wilder-Smith, OH | 1 |
| Drewes, AM | 1 |
| Guerrini, G | 1 |
| Ciciani, G | 1 |
| Nieto, FR | 1 |
| Cobos, EJ | 1 |
| Entrena, JM | 1 |
| Parra, A | 1 |
| García-Granados, A | 1 |
| Baeyens, JM | 1 |
| Sarifakioglu, E | 1 |
| Onur, O | 1 |
| García-Hernández, L | 1 |
| Navarrete-Vázquez, G | 1 |
| González-Trujano, ME | 1 |
| López-Muñoz, FJ | 2 |
| Déciga-Campos, M | 1 |
| Husebo, BS | 2 |
| Ballard, C | 2 |
| Cohen-Mansfield, J | 1 |
| Seifert, R | 2 |
| Aarsland, D | 2 |
| Ramirez-Fort, MK | 1 |
| Doan, HQ | 1 |
| Nguyen, HP | 1 |
| Khan, F | 1 |
| Kauffman, J | 1 |
| Campbell, LS | 1 |
| Chen, T | 4 |
| Wang, XL | 1 |
| Qu, J | 2 |
| Wang, W | 6 |
| Zhang, T | 2 |
| Yanagawa, Y | 2 |
| Wu, SX | 3 |
| Li, YQ | 7 |
| Sałat, R | 1 |
| Sałat, K | 1 |
| Suehs, BT | 1 |
| Louder, A | 1 |
| Udall, M | 2 |
| Cappelleri, JC | 4 |
| Joshi, AV | 1 |
| Patel, NC | 1 |
| Tesfaye, S | 2 |
| Wilhelm, S | 1 |
| Lledo, A | 1 |
| Schacht, A | 1 |
| Tölle, T | 1 |
| Bouhassira, D | 1 |
| Cruccu, G | 1 |
| Skljarevski, V | 1 |
| Freynhagen, R | 1 |
| Martinotti, G | 1 |
| Lupi, M | 1 |
| Sarchione, F | 1 |
| Santacroce, R | 1 |
| Salone, A | 1 |
| De Berardis, D | 1 |
| Serroni, N | 1 |
| Cavuto, M | 1 |
| Signorelli, M | 1 |
| Aguglia, E | 1 |
| Valchera, A | 1 |
| Iasevoli, F | 1 |
| Di Giannantonio, M | 1 |
| Finnerup, NB | 2 |
| Wang, X | 1 |
| Lu, YG | 1 |
| Pan, ZZ | 2 |
| Boulton, AJ | 1 |
| Dickenson, AH | 9 |
| Bicknell, M | 1 |
| Iturrino, J | 1 |
| Camilleri, M | 1 |
| Busciglio, I | 1 |
| Burton, D | 1 |
| Zinsmeister, AR | 1 |
| Taneja, A | 1 |
| Troconiz, IF | 1 |
| Danhof, M | 2 |
| Della Pasqua, O | 1 |
| Liu, J | 3 |
| Wang, LN | 2 |
| McNicol, ED | 2 |
| Wong, W | 1 |
| Wallace, MS | 1 |
| Yan, PZ | 1 |
| Butler, PM | 1 |
| Kurowski, D | 1 |
| Perloff, MD | 1 |
| Scheinfeld, N | 2 |
| Zugaib, J | 1 |
| Coutinho, MR | 2 |
| Ferreira, MD | 1 |
| Menescal-de-Oliveira, L | 3 |
| Luz, LL | 1 |
| Szucs, P | 1 |
| Safronov, BV | 1 |
| Lebedyeva, IO | 1 |
| Ostrov, DA | 1 |
| Neubert, J | 1 |
| Steel, PJ | 1 |
| Patel, K | 1 |
| Sileno, SM | 1 |
| Goncalves, K | 1 |
| Ibrahim, MA | 1 |
| Alamry, KA | 1 |
| Katritzky, AR | 1 |
| Haviv, Y | 1 |
| Zadik, Y | 1 |
| Sharav, Y | 1 |
| Benoliel, R | 1 |
| de Souza, AH | 1 |
| da Costa Lopes, AM | 1 |
| Castro, CJ | 1 |
| Pereira, EM | 1 |
| Klein, CP | 1 |
| da Silva, CA | 1 |
| da Silva, JF | 1 |
| Ferreira, J | 2 |
| Gomez, MV | 1 |
| Fujishiro, H | 1 |
| McCarson, KE | 2 |
| Enna, SJ | 4 |
| Mandal, S | 1 |
| Biswas, A | 1 |
| Starmer, HM | 1 |
| Yang, W | 2 |
| Raval, R | 1 |
| Gourin, CG | 1 |
| Richardson, M | 1 |
| Kumar, R | 1 |
| Jones, B | 1 |
| McNutt, T | 1 |
| Cheng, Z | 1 |
| Cheng, S | 1 |
| Quon, H | 3 |
| Farmer, MA | 1 |
| Leja, A | 1 |
| Foxen-Craft, E | 1 |
| Chan, L | 1 |
| MacIntyre, LC | 1 |
| Niaki, T | 1 |
| Chen, M | 1 |
| Mapplebeck, JC | 1 |
| Tabry, V | 1 |
| Topham, L | 1 |
| Sukosd, M | 1 |
| Binik, YM | 1 |
| Pfaus, JG | 1 |
| Mogil, JS | 2 |
| Zhang, TC | 1 |
| Janik, JJ | 1 |
| Grill, WM | 1 |
| Sandvik, RK | 1 |
| Selbaek, G | 1 |
| Corbett, A | 1 |
| Devigili, G | 1 |
| Eleopra, R | 1 |
| Pierro, T | 1 |
| Lombardi, R | 1 |
| Rinaldo, S | 1 |
| Lettieri, C | 1 |
| Faber, CG | 1 |
| Merkies, ISJ | 1 |
| Waxman, SG | 1 |
| Lauria, G | 1 |
| Xie, JY | 1 |
| Qu, C | 1 |
| Patwardhan, A | 1 |
| Ossipov, MH | 1 |
| Navratilova, E | 1 |
| Becerra, L | 2 |
| Borsook, D | 3 |
| Porreca, F | 3 |
| Zhang, MM | 1 |
| Liu, SB | 1 |
| Koga, K | 1 |
| Zhuo, M | 1 |
| Mititelu Tartau, L | 1 |
| Popa, EG | 1 |
| Lupusoru, RV | 1 |
| Lupusoru, CE | 1 |
| Stoleriu, I | 1 |
| Ochiuz, L | 1 |
| Lau, BK | 1 |
| Vaughan, CW | 2 |
| Jeong, YC | 1 |
| Pyun, K | 1 |
| Kwon, YB | 1 |
| Işik, B | 1 |
| Yaman, S | 1 |
| Aktuna, S | 1 |
| Turan, A | 2 |
| Suzuki, T | 3 |
| Hashimoto, Y | 1 |
| Anzai, S | 1 |
| Nagasawa, K | 1 |
| Shinde, S | 1 |
| Gordon, P | 1 |
| Sharma, P | 1 |
| Gross, J | 1 |
| Davis, MP | 1 |
| Wodarski, R | 2 |
| Schuh-Hofer, S | 1 |
| Yurek, DA | 1 |
| Wafford, KA | 1 |
| Gilmour, G | 1 |
| Treede, RD | 1 |
| Kennedy, JD | 1 |
| Boyle, Y | 1 |
| Fernando, D | 1 |
| Kurz, H | 1 |
| Miller, SR | 1 |
| Zucchetto, M | 1 |
| Storey, J | 1 |
| Goulart, LI | 1 |
| Delgado Rodrigues, RN | 1 |
| Prieto Peres, MF | 1 |
| Breivik, H | 1 |
| Sarıtaş, TB | 1 |
| Korkmaz, M | 1 |
| Sevimli, A | 1 |
| Sarıtaş, ZK | 1 |
| Perfilova, VN | 1 |
| Sadikova, NV | 1 |
| Berestovitskaia, VM | 1 |
| Vasil'eva, OS | 1 |
| Scholl, JH | 1 |
| van Eekeren, R | 1 |
| van Puijenbroek, EP | 1 |
| Dai, S | 1 |
| Ma, Z | 1 |
| Markman, JD | 1 |
| Frazer, ME | 1 |
| Rast, SA | 1 |
| McDermott, MP | 2 |
| Gewandter, JS | 1 |
| Chowdhry, AK | 1 |
| Czerniecka, K | 1 |
| Pilcher, WH | 1 |
| Simon, LS | 1 |
| Dworkin, RH | 4 |
| Takasu, K | 5 |
| Ogawa, K | 1 |
| Nakamura, A | 2 |
| Kanbara, T | 1 |
| Ono, H | 5 |
| Tomii, T | 1 |
| Morioka, Y | 1 |
| Hasegawa, M | 1 |
| Shibasaki, M | 1 |
| Mori, T | 1 |
| Sakaguchi, G | 1 |
| Marseglia, L | 1 |
| D'Angelo, G | 1 |
| Manti, S | 1 |
| Aversa, S | 1 |
| Arrigo, T | 1 |
| Reiter, RJ | 1 |
| Gitto, E | 1 |
| Matsumura, S | 1 |
| Taniguchi, W | 1 |
| Nishida, K | 2 |
| Nakatsuka, T | 1 |
| Ito, S | 3 |
| Hauer, JM | 1 |
| Solodiuk, JC | 1 |
| Hanack, C | 1 |
| Moroni, M | 1 |
| Lima, WC | 1 |
| Wende, H | 1 |
| Kirchner, M | 1 |
| Adelfinger, L | 1 |
| Schrenk-Siemens, K | 1 |
| Tappe-Theodor, A | 1 |
| Wetzel, C | 1 |
| Kuich, PH | 1 |
| Gassmann, M | 1 |
| Roggenkamp, D | 1 |
| Bettler, B | 1 |
| Lewin, GR | 1 |
| Selbach, M | 1 |
| Siemens, J | 1 |
| Price, TJ | 2 |
| Prescott, SA | 1 |
| Zhu, CZ | 1 |
| Bannon, AW | 1 |
| Joshi, SK | 1 |
| Bray, N | 1 |
| Wise, J | 1 |
| Todd, AJ | 3 |
| Neugebauer, V | 3 |
| Wang, Y | 2 |
| Bogan, RK | 1 |
| Lee, DO | 1 |
| Buchfuhrer, MJ | 1 |
| Jaros, MJ | 2 |
| Kim, R | 2 |
| Shang, G | 2 |
| Martins, I | 1 |
| Carvalho, P | 1 |
| de Vries, MG | 1 |
| Teixeira-Pinto, A | 1 |
| Wilson, SP | 2 |
| Westerink, BHC | 1 |
| Tavares, I | 3 |
| Kirkpatrick, DR | 1 |
| McEntire, DM | 1 |
| Hambsch, ZJ | 1 |
| Kerfeld, MJ | 1 |
| Smith, TA | 1 |
| Reisbig, MD | 1 |
| Youngblood, CF | 1 |
| Agrawal, DK | 1 |
| McCartney, M | 1 |
| Inkpen, H | 1 |
| Bagmetova, VV | 1 |
| Krivitskaya, AN | 1 |
| Tyurenkov, IN | 1 |
| North, JM | 1 |
| Hong, KS | 1 |
| Rauck, RL | 1 |
| Farmakidis, C | 1 |
| Inan, S | 1 |
| Milstein, M | 1 |
| Herskovitz, S | 1 |
| Huang, D | 1 |
| Huang, S | 2 |
| Peers, C | 1 |
| Ohashi, N | 1 |
| Sasaki, M | 1 |
| Ohashi, M | 1 |
| Kamiya, Y | 1 |
| Baba, H | 1 |
| Kohno, T | 1 |
| Bassani, AS | 1 |
| Banov, D | 1 |
| Li, Y | 3 |
| Liu, YB | 1 |
| Zhang, JJ | 1 |
| Ma, SG | 1 |
| Lv, HN | 1 |
| Yu, SS | 1 |
| Szabo, AZ | 1 |
| Bocsan, IC | 1 |
| Suciu, S | 1 |
| Buzoianu, AD | 1 |
| Gould, SA | 1 |
| Doods, H | 1 |
| Lamla, T | 1 |
| Pekcec, A | 1 |
| Lee-Kubli, CA | 1 |
| Ingves, M | 1 |
| Henry, KW | 1 |
| Shiao, R | 1 |
| Collyer, E | 1 |
| Tuszynski, MH | 1 |
| Campana, WM | 1 |
| Mimenza Alvarado, A | 1 |
| Aguilar Navarro, S | 1 |
| Alrawashdeh, O | 1 |
| Kataoka, T | 1 |
| Kiyota, N | 1 |
| Shimada, T | 1 |
| Funakoshi, Y | 1 |
| Chayahara, N | 1 |
| Toyoda, M | 1 |
| Fujiwara, Y | 1 |
| Nibu, K | 1 |
| Komori, T | 1 |
| Sasaki, R | 1 |
| Mukohara, T | 1 |
| Minami, H | 1 |
| Hopkins, HL | 1 |
| Duggett, NA | 1 |
| Flatters, SJL | 1 |
| Hermanowicz, N | 1 |
| Ellenbogen, A | 1 |
| Irving, G | 1 |
| Buchfuhrer, M | 1 |
| Todorovic, SM | 1 |
| Reckziegel, D | 1 |
| Raschke, F | 1 |
| Cottam, WJ | 1 |
| Auer, DP | 1 |
| van den Beuken-van Everdingen, MH | 1 |
| de Graeff, A | 1 |
| Jongen, JL | 1 |
| Dijkstra, D | 1 |
| Mostovaya, I | 1 |
| Vissers, KC | 1 |
| Aguila, MR | 1 |
| Rebbeck, T | 1 |
| Leaver, AM | 1 |
| Lagopoulos, J | 1 |
| Brennan, PC | 1 |
| Hübscher, M | 1 |
| Refshauge, KM | 1 |
| Yoshikawa, N | 1 |
| Naito, T | 1 |
| Yagi, T | 1 |
| Kawakami, J | 1 |
| Yin, K | 1 |
| Deuis, JR | 1 |
| Lewis, RJ | 1 |
| Vetter, I | 1 |
| Zunhammer, M | 1 |
| Schweizer, LM | 1 |
| Witte, V | 1 |
| Harris, RE | 1 |
| Bingel, U | 1 |
| Schmidt-Wilcke, T | 1 |
| Ehieli, E | 1 |
| Yalamuri, S | 1 |
| Brudney, CS | 1 |
| Pyati, S | 1 |
| Balázs, A | 1 |
| Mészár, Z | 1 |
| Hegedűs, K | 1 |
| Kenyeres, A | 1 |
| Hegyi, Z | 1 |
| Dócs, K | 1 |
| Antal, M | 1 |
| Matias, M | 1 |
| Silvestre, S | 1 |
| Falcao, A | 1 |
| Alves, G | 1 |
| Milazzo-Kiedaisch, CA | 1 |
| Itano, J | 1 |
| Dutta, PR | 3 |
| Kaufmann, D | 1 |
| West, PJ | 1 |
| Smith, MD | 1 |
| Yagen, B | 1 |
| Bialer, M | 1 |
| Devor, M | 2 |
| White, HS | 1 |
| Brennan, KC | 1 |
| Li, MH | 1 |
| Suchland, KL | 1 |
| Fischer, BD | 1 |
| Ding, W | 1 |
| You, Z | 1 |
| Shen, S | 1 |
| Yang, J | 6 |
| Lim, G | 1 |
| Doheny, JT | 1 |
| Chen, L | 1 |
| Zhu, S | 1 |
| Mao, J | 2 |
| Breton, JD | 1 |
| Veinante, P | 1 |
| Uhl-Bronner, S | 1 |
| Vergnano, AM | 1 |
| Freund-Mercier, MJ | 2 |
| Schlichter, R | 1 |
| Poisbeau, P | 1 |
| Caraceni, A | 2 |
| Zecca, E | 2 |
| Martini, C | 2 |
| Pigni, A | 1 |
| Bracchi, P | 1 |
| Young, T | 1 |
| Wittenauer, S | 1 |
| Parker, R | 2 |
| Vincler, M | 1 |
| Huo, FQ | 2 |
| Qu, CL | 1 |
| Tang, JS | 3 |
| Jia, H | 2 |
| Wood, PL | 1 |
| Mahmood, SA | 1 |
| Moskal, JR | 1 |
| Forde, G | 2 |
| Stanos, S | 1 |
| Miller, A | 1 |
| Price, G | 1 |
| Pinto, M | 1 |
| Castro, AR | 1 |
| Tshudy, F | 1 |
| Lima, D | 1 |
| Park, JY | 1 |
| Jun, IG | 1 |
| Boardman, LA | 1 |
| Cooper, AS | 1 |
| Blais, LR | 1 |
| Raker, CA | 1 |
| Yamazaki, S | 1 |
| Yamaji, T | 1 |
| Murai, N | 1 |
| Yamamoto, H | 2 |
| Price, RD | 1 |
| Matsuoka, N | 1 |
| Mutoh, S | 1 |
| Huang, J | 3 |
| Wei, Y | 1 |
| Wu, S | 1 |
| Arezzo, JC | 1 |
| Rosenstock, J | 1 |
| Lamoreaux, L | 2 |
| Pauer, L | 1 |
| Hayashida, K | 4 |
| Eisenach, JC | 6 |
| Bannwarth, B | 1 |
| Chen, TC | 1 |
| Cheng, YY | 1 |
| Sun, WZ | 1 |
| Shyu, BC | 2 |
| Smith, SM | 1 |
| Mirazi, N | 1 |
| Javanmardi, K | 1 |
| Xu, Y | 1 |
| Xu, MY | 1 |
| Li, X | 1 |
| Lu, Y | 2 |
| Zheng, J | 1 |
| Xiong, L | 1 |
| Zimmermann, M | 2 |
| Favaroni Mendes, LA | 1 |
| Kang, JS | 1 |
| Krakow, K | 1 |
| Roggendorf, J | 1 |
| Steinmetz, H | 1 |
| Hilker, R | 1 |
| Vonsy, JL | 1 |
| Ghandehari, J | 1 |
| Fürst, Z | 1 |
| Clark, AK | 1 |
| Grist, J | 2 |
| Marchand, F | 1 |
| Malcangio, M | 3 |
| Condés-Lara, M | 1 |
| Rojas-Piloni, G | 1 |
| Martínez-Lorenzana, G | 1 |
| López-Hidalgo, M | 1 |
| Rodríguez-Jiménez, J | 1 |
| Somers, DL | 1 |
| Clemente, FR | 1 |
| Bolognese, J | 1 |
| Calder, N | 1 |
| Baxendale, J | 1 |
| Kehler, A | 1 |
| Cummings, C | 1 |
| Connell, J | 1 |
| Herman, G | 1 |
| Pigatto, PD | 1 |
| Guzzi, G | 1 |
| Carlsson, KC | 1 |
| van de Schootbrugge, M | 1 |
| Eriksen, HO | 1 |
| Moberg, ER | 1 |
| Karlsson, MO | 1 |
| Hoem, NO | 1 |
| Yalcin, I | 1 |
| Tessier, LH | 1 |
| Petit-Demoulière, N | 1 |
| Doridot, S | 1 |
| Hein, L | 1 |
| Barrot, M | 1 |
| Kupers, R | 1 |
| Danielsen, ER | 1 |
| Kehlet, H | 1 |
| Christensen, R | 1 |
| Thomsen, C | 1 |
| Robbins, MS | 1 |
| Barbano, RL | 1 |
| Tyring, SK | 1 |
| Betts, RF | 1 |
| Pennella-Vaughan, J | 1 |
| Bennett, GJ | 1 |
| Berber, E | 1 |
| Gnann, JW | 1 |
| Irvine, C | 1 |
| Kamp, C | 1 |
| Kieburtz, K | 1 |
| Max, MB | 2 |
| Schmader, KE | 1 |
| Quilici, S | 1 |
| Chancellor, J | 1 |
| Löthgren, M | 1 |
| Simon, D | 1 |
| Said, G | 1 |
| Le, TK | 1 |
| Garcia-Cebrian, A | 1 |
| Monz, B | 1 |
| Takazawa, T | 2 |
| Furue, H | 1 |
| Nishikawa, K | 1 |
| Uta, D | 1 |
| Takeshima, K | 1 |
| Goto, F | 1 |
| Yoshimura, M | 1 |
| Kim, H | 1 |
| Cui, L | 1 |
| Kim, J | 1 |
| Kim, SJ | 1 |
| Chiechio, S | 1 |
| Zammataro, M | 1 |
| Caraci, F | 1 |
| Rampello, L | 1 |
| Copani, A | 1 |
| Sabato, AF | 3 |
| Nicoletti, F | 1 |
| Silva, E | 1 |
| Quiñones, B | 1 |
| Páez, X | 1 |
| Hernández, L | 2 |
| Gustafsson, H | 1 |
| Sandin, J | 1 |
| Lin, CF | 1 |
| Tsaur, ML | 1 |
| Lin, CS | 1 |
| Chen, CC | 1 |
| Cheng, JK | 2 |
| Gauchan, P | 1 |
| Andoh, T | 5 |
| Ikeda, K | 1 |
| Fujita, M | 1 |
| Sasaki, A | 3 |
| Kato, A | 1 |
| Kuraishi, Y | 7 |
| Kim, L | 1 |
| Lipton, S | 1 |
| Deodhar, A | 1 |
| Omori, Y | 1 |
| Kagaya, K | 1 |
| Enomoto, R | 1 |
| Nojima, H | 6 |
| Takahata, H | 4 |
| Inoue, N | 1 |
| Tajima, K | 1 |
| Nogawa, M | 1 |
| Takahashi, Y | 2 |
| Sasagawa, T | 1 |
| Kyoi, T | 1 |
| Landry, M | 1 |
| Nagy, F | 1 |
| Mitchell, VA | 1 |
| Kawahara, H | 1 |
| Recla, JM | 1 |
| Sarantopoulos, CD | 1 |
| Bennett, RM | 1 |
| Bushmakin, AG | 3 |
| Zlateva, G | 3 |
| Sadosky, AB | 1 |
| Rephaeli, A | 1 |
| Gil-Ad, I | 1 |
| Aharoni, A | 1 |
| Tarasenko, I | 1 |
| Tarasenko, N | 1 |
| Geffen, Y | 1 |
| Halbfinger, E | 1 |
| Nisemblat, Y | 1 |
| Weizman, A | 2 |
| Nudelman, A | 1 |
| García-Campayo, J | 1 |
| Serrano-Blanco, A | 1 |
| Rodero, B | 1 |
| Magallón, R | 1 |
| Alda, M | 1 |
| Andrés, E | 1 |
| Luciano, JV | 1 |
| del Hoyo, YL | 1 |
| Wang, YY | 1 |
| Wei, YY | 1 |
| Tamamaki, N | 1 |
| Russell, IJ | 3 |
| Crofford, LJ | 2 |
| Leon, T | 1 |
| Barrett, JA | 2 |
| Sadosky, A | 2 |
| Chen, SR | 6 |
| Samoriski, G | 1 |
| Pan, HL | 6 |
| Gatti, A | 2 |
| Carucci, A | 1 |
| Bertini, L | 1 |
| Mammucari, M | 1 |
| Occhioni, R | 1 |
| De la O-Arciniega, M | 1 |
| Díaz-Reval, MI | 1 |
| Cortés-Arroyo, AR | 1 |
| Domínguez-Ramírez, AM | 1 |
| Baron, R | 4 |
| Mayoral, V | 2 |
| Leijon, G | 2 |
| Binder, A | 2 |
| Steigerwald, I | 2 |
| Serpell, M | 2 |
| Marino, F | 1 |
| Kinoshita, Y | 1 |
| Tanabe, M | 4 |
| Pérez, C | 1 |
| Navarro, A | 1 |
| Saldaña, MT | 1 |
| Martínez, S | 1 |
| Rejas, J | 3 |
| Yuan, H | 1 |
| Chu, J | 1 |
| Yang, Y | 2 |
| Xu, H | 3 |
| Wang, G | 1 |
| Liu, WY | 2 |
| Lin, BC | 2 |
| Davis, AM | 2 |
| Bruce, AS | 1 |
| Mangiaracina, C | 1 |
| Schulz, T | 1 |
| Hyman, P | 1 |
| Natkunarajah, J | 1 |
| Atherton, D | 1 |
| Elmslie, F | 1 |
| Mansour, S | 1 |
| Mortimer, P | 1 |
| Bar Ad, V | 3 |
| Weinstein, G | 2 |
| Chalian, A | 2 |
| Both, S | 2 |
| Moore, RA | 6 |
| Straube, S | 3 |
| Wiffen, PJ | 4 |
| Derry, S | 3 |
| McQuay, HJ | 6 |
| Kostopanagiotou, G | 1 |
| Arvaniti, C | 1 |
| Kitsiou, MC | 1 |
| Apostolaki, S | 1 |
| Chatzimichael, K | 1 |
| Matsota, P | 1 |
| Haney, AL | 1 |
| Garner, SS | 1 |
| Cox, TH | 1 |
| Piesla, MJ | 1 |
| Leventhal, L | 1 |
| Strassle, BW | 1 |
| Harrison, JE | 2 |
| Cummons, TA | 1 |
| Lu, P | 1 |
| Whiteside, GT | 3 |
| Fleckenstein, J | 1 |
| Kramer, S | 1 |
| Hoffrogge, P | 1 |
| Thoma, S | 1 |
| Lang, PM | 1 |
| Lehmeyer, L | 1 |
| Schober, GM | 1 |
| Pfab, F | 1 |
| Ring, J | 1 |
| Weisenseel, P | 1 |
| Schotten, KJ | 1 |
| Mansmann, U | 1 |
| Irnich, D | 1 |
| Takatani, J | 1 |
| Takeshima, N | 1 |
| Okuda, K | 1 |
| Miyakawa, H | 1 |
| Noguchi, T | 1 |
| Rea, K | 2 |
| Lang, Y | 1 |
| Finn, DP | 2 |
| You, HJ | 1 |
| Lei, J | 1 |
| Koganei, H | 1 |
| Shoji, M | 1 |
| Iwata, S | 1 |
| Bardin, L | 2 |
| Gregoire, S | 1 |
| Aliaga, M | 1 |
| Malfetes, N | 1 |
| Vitton, O | 1 |
| Ladure, P | 1 |
| Newman-Tancredi, A | 1 |
| Depoortère, R | 1 |
| Bansal, D | 1 |
| Bhansali, A | 1 |
| Hota, D | 1 |
| Chakrabarti, A | 1 |
| Dutta, P | 1 |
| Vedula, SS | 1 |
| Bero, L | 1 |
| Scherer, RW | 1 |
| Dickersin, K | 1 |
| Möhler, H | 1 |
| Tsuda, M | 1 |
| Inoue, K | 1 |
| Zin, CS | 1 |
| Nissen, LM | 1 |
| O'Callaghan, JP | 1 |
| Duffull, SB | 1 |
| Smith, MT | 2 |
| Moore, BJ | 1 |
| Staud, R | 1 |
| Morris-Stiff, G | 1 |
| Lewis, MH | 1 |
| Takahashi, H | 1 |
| Shimoyama, N | 2 |
| Filler, AG | 1 |
| Bacon, M | 1 |
| Frederickson, M | 1 |
| Howe, FA | 1 |
| Rabinowitz, MD | 1 |
| Sokoloff, AJ | 1 |
| Deacon, TW | 1 |
| Abell, C | 1 |
| Munglani, R | 1 |
| Griffiths, JR | 1 |
| Bell, BA | 1 |
| Lever, AM | 1 |
| Collins, S | 2 |
| Carroll, D | 2 |
| Jadad, A | 2 |
| Toth, C | 1 |
| Kopsky, DJ | 1 |
| Keppel Hesselink, JM | 1 |
| Arai, YC | 1 |
| Matsubara, T | 1 |
| Shimo, K | 1 |
| Suetomi, K | 1 |
| Nishihara, M | 1 |
| Ushida, T | 1 |
| Kobayashi, K | 1 |
| Suzuki, C | 1 |
| Kinoshita, A | 1 |
| Kondo, M | 1 |
| Matsubara, S | 1 |
| Hayashi, R | 1 |
| Tohyama, Y | 1 |
| Arakawa, M | 1 |
| Farrar, JT | 1 |
| Wolfe, KC | 1 |
| Poma, R | 1 |
| da Silva, LF | 1 |
| Ji, G | 2 |
| Sun, H | 1 |
| Fu, Y | 1 |
| Li, Z | 2 |
| Pais-Vieira, M | 1 |
| Galhardo, V | 1 |
| Liao, XZ | 1 |
| Zhou, MT | 1 |
| Mao, YF | 1 |
| Chen, H | 1 |
| Sun, JH | 1 |
| Xiong, YC | 1 |
| Rashiq, S | 1 |
| Tran, DQ | 1 |
| Duong, S | 1 |
| Finlayson, RJ | 1 |
| Park, HJ | 1 |
| Joo, HS | 1 |
| Chang, HW | 1 |
| Lee, JY | 2 |
| Hong, SH | 1 |
| Lee, Y | 1 |
| Moon, DE | 1 |
| Bender, G | 1 |
| Florian, JA | 1 |
| Bramwell, S | 2 |
| Field, MJ | 5 |
| Tan, KK | 1 |
| Marshall, S | 1 |
| DeJongh, J | 1 |
| Bies, RR | 1 |
| Kolosov, A | 1 |
| Goodchild, CS | 1 |
| Cooke, I | 1 |
| Tuchman, M | 1 |
| Donevan, S | 1 |
| Hedberg, TG | 1 |
| Taylor, CP | 3 |
| Chao, CL | 1 |
| Lu, XF | 1 |
| Zhang, LC | 1 |
| Scrivani, S | 1 |
| Wallin, D | 1 |
| Moulton, EA | 1 |
| Cole, S | 1 |
| Wasan, AD | 1 |
| Lockerman, L | 1 |
| Bajwa, Z | 1 |
| Upadhyay, J | 1 |
| MacDermott, AB | 3 |
| Hasbargen, T | 1 |
| Ahmed, MM | 1 |
| Miranpuri, G | 1 |
| Li, L | 1 |
| Kahle, KT | 1 |
| Resnick, D | 1 |
| Sun, D | 1 |
| Gosselin, RD | 1 |
| Bebber, D | 1 |
| Decosterd, I | 2 |
| Heidelbaugh, JJ | 1 |
| Llanes, M | 1 |
| Weadock, WJ | 1 |
| Munro, G | 3 |
| Dyhr, H | 2 |
| Grunnet, M | 1 |
| Dosoretz, A | 1 |
| Raffa, RB | 1 |
| Pergolizzi, JV | 1 |
| Segarnick, DJ | 1 |
| Tallarida, RJ | 2 |
| Arnold, L | 1 |
| Mease, P | 1 |
| Silverman, S | 1 |
| Peters, CM | 1 |
| Ewan, EE | 1 |
| Nakajima, K | 1 |
| Obata, H | 3 |
| Yaksh, TL | 7 |
| Lindsay, TJ | 1 |
| Rodgers, BC | 1 |
| Savath, V | 1 |
| Hettinger, K | 1 |
| Huo, XL | 1 |
| Song, T | 1 |
| Ko, SH | 1 |
| Kwon, HS | 1 |
| Yu, JM | 1 |
| Baik, SH | 1 |
| Park, IB | 1 |
| Lee, JH | 1 |
| Ko, KS | 1 |
| Noh, JH | 1 |
| Kim, DS | 1 |
| Kim, CH | 1 |
| Mok, JO | 1 |
| Park, TS | 1 |
| Son, HS | 1 |
| Cha, BY | 1 |
| Hossaini, M | 1 |
| Duraku, LS | 1 |
| Saraç, Ç | 1 |
| Jongen, JLM | 1 |
| Holstege, JC | 1 |
| Christianson, CA | 1 |
| Corr, M | 1 |
| Firestein, GS | 1 |
| Mobargha, A | 1 |
| Svensson, CI | 2 |
| Rutten, K | 1 |
| De Vry, J | 1 |
| Robens, A | 1 |
| Tzschentke, TM | 1 |
| van der Kam, EL | 1 |
| Murphy, TK | 1 |
| Petersel, DL | 1 |
| Charavel, M | 1 |
| Veyrat, E | 1 |
| Ripart, J | 1 |
| Tzellos, TG | 1 |
| Toulis, KA | 1 |
| Goulis, DG | 1 |
| Papazisis, G | 1 |
| Zampeli, VA | 1 |
| Vakfari, A | 1 |
| Kouvelas, D | 1 |
| Filipetto, FA | 1 |
| Zipp, CP | 1 |
| Coren, JS | 1 |
| Margolis, J | 1 |
| Cao, Z | 1 |
| Fowler, R | 1 |
| Harnett, J | 2 |
| Sanchez, RJ | 1 |
| Mardekian, J | 2 |
| Silverman, SL | 1 |
| Pal'tsev, AI | 1 |
| Torgashov, MN | 1 |
| Vorontsova, IuS | 1 |
| Baiandina, EV | 1 |
| Luniakina, SB | 1 |
| Arnold, LM | 3 |
| Bockbrader, HN | 1 |
| Burger, P | 1 |
| Knapp, L | 1 |
| Corrigan, BW | 1 |
| Takasaki, I | 5 |
| Kim, JS | 1 |
| Bashford, G | 1 |
| Murphy, KT | 1 |
| Martin, A | 1 |
| Dror, V | 1 |
| Cheung, R | 1 |
| Böhm, J | 1 |
| Visser, LH | 1 |
| Lehmann, TN | 1 |
| Attal, N | 1 |
| Jensen-Dahm, C | 1 |
| Rowbotham, MC | 2 |
| Reda, H | 1 |
| Petersen, KL | 1 |
| Gray, P | 2 |
| Kirby, J | 1 |
| Cabot, PJ | 1 |
| Williams, B | 2 |
| Doecke, J | 1 |
| Cramond, T | 2 |
| Edwards, J | 1 |
| Palazzo, E | 2 |
| Marabese, I | 2 |
| Soukupova, M | 1 |
| Luongo, L | 1 |
| Boccella, S | 1 |
| Giordano, C | 1 |
| de Novellis, V | 2 |
| Rossi, F | 2 |
| Maione, S | 2 |
| Nowak, A | 1 |
| Mathieson, HR | 1 |
| Chapman, RJ | 1 |
| Janzsó, G | 1 |
| Obata, K | 1 |
| Szabo, G | 1 |
| King, AE | 1 |
| Anastassiou, E | 1 |
| Iatrou, CA | 1 |
| Vlaikidis, N | 1 |
| Vafiadou, M | 1 |
| Stamatiou, G | 1 |
| Plesia, E | 1 |
| Lyras, L | 1 |
| Vadalouca, A | 1 |
| Schleich, A | 1 |
| Baumann, H | 1 |
| Touchette, D | 1 |
| Gessler, EM | 1 |
| Calandre, EP | 1 |
| Morillas-Arques, P | 1 |
| Molina-Barea, R | 1 |
| Rodriguez-Lopez, CM | 1 |
| Rico-Villademoros, F | 1 |
| Longo, G | 1 |
| Sabato, E | 1 |
| Bannister, K | 1 |
| Sikandar, S | 1 |
| Bauer, CS | 1 |
| Dolphin, AC | 2 |
| Paine, J | 1 |
| Phillips, CJ | 1 |
| Hallier, E | 1 |
| Ogino, Y | 1 |
| Chaitoff, KA | 1 |
| Toner, F | 1 |
| Tedesco, A | 1 |
| Maher, TJ | 1 |
| Ally, A | 1 |
| Lantos, PM | 1 |
| Vettorato, E | 1 |
| Corletto, F | 1 |
| Jamshidian, F | 1 |
| Hubbard, AE | 1 |
| Jewell, NP | 1 |
| Oshita, K | 1 |
| Saeki, N | 1 |
| Niinai, H | 1 |
| Hamada, H | 1 |
| Kawamoto, M | 1 |
| Galkin, VV | 1 |
| Nesterova, MV | 1 |
| Emel'ianov, VV | 1 |
| Cai, YQ | 1 |
| Zou, F | 1 |
| Bie, B | 1 |
| Ho, YC | 1 |
| Lee, HJ | 1 |
| Tung, LW | 1 |
| Liao, YY | 1 |
| Fu, SY | 1 |
| Teng, SF | 1 |
| Liao, HT | 1 |
| Mackie, K | 1 |
| Chiou, LC | 2 |
| Howard, P | 1 |
| Twycross, R | 1 |
| Shuster, J | 1 |
| Mihalyo, M | 1 |
| Rémi, J | 1 |
| Wilcock, A | 1 |
| Panah Khahi, M | 1 |
| Yaghooti, AA | 1 |
| Marashi, SH | 1 |
| Nadjafi, A | 1 |
| Chua, YC | 1 |
| Ng, KS | 1 |
| Sharma, A | 1 |
| Jafari, J | 1 |
| Surguy, S | 1 |
| Yazaki, E | 1 |
| Knowles, CH | 1 |
| Aziz, Q | 1 |
| Roth, T | 1 |
| Lankford, DA | 1 |
| Bhadra, P | 1 |
| Resnick, EM | 1 |
| Zeilhofer, HU | 3 |
| Wildner, H | 1 |
| Yévenes, GE | 1 |
| Storm, A | 1 |
| Hansen, MK | 1 |
| Marcher, L | 1 |
| Erichsen, HK | 2 |
| Sheykhzade, M | 1 |
| Andrews, N | 1 |
| Legg, E | 1 |
| Lisak, D | 1 |
| Issop, Y | 1 |
| Richardson, D | 1 |
| Harper, S | 1 |
| Pheby, T | 2 |
| Huang, W | 1 |
| Burgess, G | 1 |
| Machin, I | 1 |
| Rice, AS | 2 |
| Oh, TH | 1 |
| Fass, R | 1 |
| Mercadante, S | 2 |
| Porzio, G | 1 |
| Aielli, F | 1 |
| Ferrera, P | 1 |
| Codipietro, L | 1 |
| Lo Presti, C | 1 |
| Casuccio, A | 1 |
| Neelakantan, H | 1 |
| Walker, EA | 1 |
| Yang, JL | 1 |
| Xu, B | 1 |
| Li, SS | 1 |
| Zhang, WS | 1 |
| Deng, XM | 1 |
| Zhang, YQ | 2 |
| Ben Achour, S | 1 |
| Pascual, O | 1 |
| Sumracki, NM | 1 |
| Hutchinson, MR | 1 |
| Gentgall, M | 1 |
| Briggs, N | 1 |
| Williams, DB | 1 |
| Rolan, P | 1 |
| Kimura, M | 1 |
| Yoshizumi, M | 1 |
| Hobo, S | 1 |
| Inceoglu, B | 1 |
| Wagner, KM | 1 |
| Bettaieb, A | 1 |
| Schebb, NH | 1 |
| Hwang, SH | 1 |
| Morisseau, C | 1 |
| Haj, FG | 1 |
| Hammock, BD | 1 |
| Kawasaki, M | 1 |
| Hatashima, S | 1 |
| Matsuda, T | 1 |
| Kilic, FS | 1 |
| Sirmagul, B | 1 |
| Yildirim, E | 1 |
| Oner, S | 1 |
| Erol, K | 1 |
| Meymandi, MS | 3 |
| Keyhanfar, F | 1 |
| Hauer, J | 1 |
| Mackey, D | 1 |
| Hansen, RR | 1 |
| Brown, DT | 1 |
| Mirza, NR | 1 |
| Boyle, J | 1 |
| Eriksson, ME | 1 |
| Gribble, L | 1 |
| Gouni, R | 1 |
| Johnsen, S | 1 |
| Coppini, DV | 1 |
| Kerr, D | 1 |
| Keeler, BE | 1 |
| Baran, CA | 1 |
| Brewer, KL | 1 |
| Clemens, S | 1 |
| Thiagarajan, VR | 1 |
| Shanmugam, P | 1 |
| Krishnan, UM | 1 |
| Muthuraman, A | 1 |
| Chandran, AB | 1 |
| Arcos, M | 1 |
| Palanca, JM | 1 |
| Montes, F | 1 |
| Barrios, C | 1 |
| Oya, H | 1 |
| Matoba, M | 1 |
| Murakami, S | 1 |
| Ohshiro, T | 1 |
| Kishino, T | 1 |
| Satoh, Y | 1 |
| Tsukahara, T | 1 |
| Hori, S | 1 |
| Maeda, M | 1 |
| Makino, T | 1 |
| Maeda, T | 1 |
| Clarke, H | 1 |
| Kirkham, KR | 1 |
| Orser, BA | 1 |
| Katznelson, R | 1 |
| Mitsakakis, N | 1 |
| Ko, R | 1 |
| Snyman, A | 1 |
| Ma, M | 1 |
| Katz, J | 1 |
| Zhang, XY | 1 |
| Zhang, JW | 1 |
| Chen, B | 2 |
| Bai, ZT | 1 |
| Shen, J | 1 |
| Ji, YH | 1 |
| Abe, M | 1 |
| Kurihara, T | 1 |
| Han, W | 1 |
| Shinomiya, K | 1 |
| Tanabe, T | 1 |
| Pelham, A | 1 |
| Lee, MA | 1 |
| Regnard, CB | 1 |
| Wallin, J | 1 |
| Cui, JG | 3 |
| Yakhnitsa, V | 2 |
| Schechtmann, G | 1 |
| Meyerson, BA | 3 |
| Hunt, CH | 1 |
| Dodick, DW | 1 |
| Bosch, EP | 1 |
| Stitik, TP | 1 |
| Foye, PM | 1 |
| Nadler, SF | 1 |
| DeLisa, JA | 1 |
| Diop, L | 1 |
| Raymond, F | 1 |
| Fargeau, H | 1 |
| Petoux, F | 1 |
| Chovet, M | 1 |
| Doherty, AM | 1 |
| Laughlin, TM | 1 |
| Tram, KV | 1 |
| Wilcox, GL | 1 |
| Birnbaum, AK | 1 |
| Ding, YQ | 1 |
| Lu, CR | 2 |
| Su, CJ | 1 |
| Chen, LW | 1 |
| Ju, G | 1 |
| Backonja, MM | 1 |
| Pezet, S | 1 |
| Cunningham, J | 1 |
| Patel, J | 1 |
| Gavazzi, I | 1 |
| Lever, IJ | 1 |
| Boscan, P | 1 |
| Kasparov, S | 1 |
| Paton, JF | 1 |
| Gonzalez, MI | 2 |
| Singh, L | 3 |
| Bortalanza, LB | 1 |
| Hess, SC | 1 |
| Delle Monache, F | 1 |
| Yunes, RA | 1 |
| Calixto, JB | 3 |
| Serpell, MG | 1 |
| Vitek, L | 1 |
| Tettenborn, B | 1 |
| Colpaert, FC | 2 |
| Tarayre, JP | 2 |
| Koek, W | 2 |
| Pauwels, PJ | 1 |
| Xu, XJ | 3 |
| Wiesenfeld-Hallin, Z | 3 |
| Cosi, C | 1 |
| Carilla-Durand, E | 1 |
| Assié, MB | 1 |
| Vacher, B | 1 |
| Luo, ZD | 2 |
| Calcutt, NA | 1 |
| Higuera, ES | 2 |
| Valder, CR | 1 |
| Song, YH | 1 |
| Myers, RR | 1 |
| Wu, DC | 1 |
| Chen, YH | 1 |
| He, W | 1 |
| Yu, LC | 2 |
| Garcia-Borreguero, D | 1 |
| Larrosa, O | 1 |
| de la Llave, Y | 1 |
| Verger, K | 1 |
| Masramon, X | 1 |
| Hernandez, G | 1 |
| Pandey, CK | 2 |
| Bose, N | 1 |
| Garg, G | 1 |
| Singh, N | 1 |
| Baronia, A | 1 |
| Agarwal, A | 1 |
| Singh, PK | 1 |
| Singh, U | 1 |
| Eisenberg, E | 1 |
| Brecker, C | 1 |
| Marder, E | 1 |
| Feng, Y | 2 |
| Cui, M | 2 |
| Willis, WD | 6 |
| Nicolas, X | 1 |
| Vaillant, PY | 1 |
| Bellard, S | 1 |
| Backonja, M | 2 |
| Glanzman, RL | 1 |
| Iida, Y | 1 |
| Zhang, HW | 1 |
| Uehara, S | 1 |
| Murata, J | 1 |
| Saiki, I | 1 |
| Ouchi, H | 1 |
| Morgan, MM | 2 |
| Clayton, CC | 1 |
| Lane, DA | 1 |
| Neumeier, S | 1 |
| Brinkschmidt, T | 1 |
| Jensen, U | 1 |
| Degtyarenko, AM | 1 |
| Kaufman, MP | 1 |
| Boyce, JR | 1 |
| Peters, GE | 1 |
| Biederman, J | 1 |
| Jhamandas, K | 1 |
| Hong, M | 2 |
| Yen, HL | 1 |
| Chan, W | 1 |
| Sarantopoulos, C | 2 |
| McCallum, B | 1 |
| Sapunar, D | 1 |
| Kwok, WM | 1 |
| Hogan, Q | 2 |
| Maneuf, YP | 3 |
| Sutton, KS | 1 |
| Chung, FZ | 1 |
| Pinnock, RD | 1 |
| Lee, K | 2 |
| Twaddle, ML | 1 |
| Scheschonka, A | 1 |
| Beuche, W | 1 |
| Staley, K | 1 |
| Kassuya, CA | 1 |
| Silvestre, AA | 1 |
| Rehder, VL | 1 |
| Paradowski, B | 1 |
| Bilinska, M | 1 |
| Oneschuk, D | 1 |
| al-Shahri, MZ | 1 |
| Kumar, P | 1 |
| Jain, MK | 1 |
| Sloan, PA | 1 |
| Kancharla, A | 1 |
| Chesler, EJ | 1 |
| Ritchie, J | 1 |
| Kokayeff, A | 1 |
| Lariviere, WR | 1 |
| Wilson, SG | 1 |
| Lockwood, PA | 1 |
| Cook, JA | 1 |
| Ewy, WE | 1 |
| Mandema, JW | 1 |
| Wu, WP | 1 |
| Hao, JX | 2 |
| Ongini, E | 1 |
| Impagnatiello, F | 1 |
| Presotto, C | 1 |
| Kirouac, GJ | 1 |
| Li, S | 1 |
| Mabrouk, G | 1 |
| von Orelli, F | 1 |
| Scullin, P | 1 |
| Sheahan, P | 1 |
| Sheila, K | 1 |
| Reyes-García, G | 2 |
| Medina-Santillán, R | 2 |
| Rocha-González, HI | 2 |
| Granados-Soto, V | 4 |
| Ohara, PT | 2 |
| Granato, A | 1 |
| Moallem, TM | 1 |
| Wang, BR | 1 |
| Tillet, Y | 1 |
| Jasmin, L | 2 |
| Blake, R | 1 |
| Andrews, NA | 1 |
| McKnight, AT | 1 |
| White, WT | 1 |
| Patel, N | 1 |
| Drass, M | 1 |
| Nalamachu, S | 1 |
| Bennett, MI | 1 |
| Simpson, KH | 1 |
| Huckle, R | 1 |
| Kanai, A | 1 |
| McCallum, JB | 1 |
| Shiraki, K | 4 |
| Lotery, HE | 1 |
| McClure, N | 1 |
| Galask, RP | 1 |
| Villarejo, A | 1 |
| Porta-Etessam, J | 3 |
| Camacho, A | 1 |
| González De La Aleja, J | 1 |
| Martínez-Salio, A | 3 |
| Penas, M | 1 |
| Keskinbora, K | 1 |
| Pekel, AF | 1 |
| Aydinli, I | 1 |
| Hashimoto, K | 1 |
| Tsuji, S | 1 |
| Hong-Ju, Y | 1 |
| He, L | 1 |
| Wei-Guo, S | 1 |
| Nan, Z | 1 |
| Wei-Xiu, Y | 1 |
| Zhong-Wei, J | 1 |
| Jun-Wei, W | 1 |
| Zheng-Hua, G | 1 |
| Bo-Hua, Z | 1 |
| Zhi-Pu, L | 1 |
| Zhe-Hui, G | 1 |
| Dmitrieva, N | 1 |
| Rodríguez-Malaver, AJ | 1 |
| Pérez, J | 1 |
| Rotella, DP | 1 |
| Cordero-Erausquin, M | 1 |
| Pons, S | 1 |
| Faure, P | 1 |
| Changeux, JP | 1 |
| Drew, GM | 1 |
| Siddall, PJ | 1 |
| Duggan, AW | 3 |
| Stahl, SM | 1 |
| Yang, K | 1 |
| Fujita, T | 1 |
| Kumamoto, E | 1 |
| Hobgood, C | 1 |
| Hevia, A | 1 |
| Hinchey, P | 1 |
| Wolfe, D | 1 |
| Hao, S | 1 |
| Glorioso, JC | 1 |
| Mata, M | 1 |
| Fink, DJ | 1 |
| Bonezzi, C | 1 |
| Arcuri, E | 1 |
| Yaya Tur, R | 1 |
| Maltoni, M | 1 |
| Visentin, M | 1 |
| Gorni, G | 1 |
| Tirelli, W | 1 |
| Barbieri, M | 1 |
| De Conno, F | 1 |
| Iyengar, S | 1 |
| Webster, AA | 1 |
| Hemrick-Luecke, SK | 1 |
| Xu, JY | 1 |
| Simmons, RM | 1 |
| Ilag, VL | 1 |
| Allchorne, A | 1 |
| Woolf, CJ | 1 |
| Rasmussen, PV | 1 |
| Sindrup, SH | 1 |
| Jensen, TS | 3 |
| Bach, FW | 2 |
| Viggiano, A | 2 |
| Monda, M | 1 |
| Chiefari, M | 1 |
| Aurilio, C | 1 |
| De Luca, B | 1 |
| Lim, LS | 1 |
| Takahashi, PY | 1 |
| Zamiri, M | 1 |
| Bilsland, D | 1 |
| Smiley, MM | 1 |
| Vera-Portocarrero, LP | 1 |
| Zidan, A | 1 |
| Westlund, KN | 4 |
| van de Vusse, AC | 1 |
| Stomp-van den Berg, SG | 1 |
| Kessels, AH | 1 |
| Weber, WE | 1 |
| Jones, CK | 1 |
| Peters, SC | 1 |
| Shannon, HE | 1 |
| Wu, MV | 1 |
| Lossignol, DA | 1 |
| Plehiers, B | 1 |
| Body, JJ | 1 |
| Donovan-Rodriguez, T | 1 |
| Urch, CE | 1 |
| Yoon, MH | 2 |
| Choi, JI | 1 |
| Park, HC | 1 |
| Bae, HB | 1 |
| Jeong, SW | 1 |
| Jeong, CY | 1 |
| Derbyshire, E | 1 |
| Martin, D | 1 |
| Morales-Franco, G | 1 |
| Espinoza-Raya, J | 1 |
| Braune, S | 1 |
| Zhang, C | 1 |
| Glenn, DG | 1 |
| Bell, WL | 1 |
| O'Donovan, CA | 1 |
| Urban, MO | 1 |
| Ren, K | 1 |
| Park, KT | 1 |
| Campbell, B | 1 |
| Anker, N | 1 |
| Stearns, B | 1 |
| Aiyar, J | 1 |
| Belley, M | 1 |
| Cohen, C | 1 |
| Bristow, L | 1 |
| Bartoshuk, LM | 1 |
| Snyder, DJ | 1 |
| Grushka, M | 1 |
| Berger, AM | 1 |
| Duffy, VB | 1 |
| Kveton, JF | 1 |
| Criscuolo, S | 1 |
| Auletta, C | 1 |
| Lippi, S | 1 |
| Brogi, F | 1 |
| Brogi, A | 1 |
| Jensen, NH | 1 |
| Hansen, RW | 1 |
| Hedal, BS | 1 |
| Korsgaard, AG | 1 |
| Jonsson, T | 1 |
| Jeppesen, S | 1 |
| Valenzano, KJ | 1 |
| Tafesse, L | 1 |
| Lee, G | 1 |
| Boulet, JM | 1 |
| Gottshall, SL | 1 |
| Mark, L | 1 |
| Pearson, MS | 1 |
| Miller, W | 1 |
| Shan, S | 1 |
| Rabadi, L | 1 |
| Rotshteyn, Y | 1 |
| Chaffer, SM | 1 |
| Turchin, PI | 1 |
| Elsemore, DA | 1 |
| Toth, M | 1 |
| Koetzner, L | 1 |
| Garber, K | 1 |
| Mease, PJ | 2 |
| Corbin, AE | 1 |
| Young, JP | 2 |
| LaMoreaux, LK | 1 |
| Martin, SA | 2 |
| Sharma, U | 2 |
| Willcockson, HH | 1 |
| Phend, KD | 1 |
| Lucifora, S | 1 |
| Darstein, M | 1 |
| Valtschanoff, JG | 1 |
| Rustioni, A | 1 |
| Hong, HB | 1 |
| Xu, RJ | 1 |
| Persson, F | 1 |
| Mogensen, CE | 1 |
| Mandrup-Poulsen, T | 1 |
| Wang, J | 1 |
| Han, F | 1 |
| Patte-Mensah, C | 1 |
| Kibaly, C | 1 |
| Mensah-Nyagan, AG | 1 |
| Kirkpatrick, P | 1 |
| Hama, AT | 2 |
| Raza, M | 1 |
| Tripathi, M | 1 |
| Navkar, DV | 1 |
| Kumar, A | 2 |
| Singh, UK | 1 |
| Nordmann, GR | 1 |
| Lauder, GR | 1 |
| Grier, DJ | 1 |
| Cervero, F | 1 |
| de Koninck, Y | 1 |
| Chen, YP | 1 |
| Wiffen, P | 1 |
| McQuay, H | 1 |
| Moore, A | 1 |
| Edwards, JE | 1 |
| Feng, YP | 1 |
| Shigemoto, R | 1 |
| Mizuno, N | 1 |
| Kroin, JS | 1 |
| Buvanendran, A | 1 |
| Cochran, E | 1 |
| Tuman, KJ | 1 |
| Bassani, F | 1 |
| Bergamaschi, M | 1 |
| Tonino Bolzoni, P | 1 |
| Villetti, G | 1 |
| Pedersen, LH | 1 |
| Nielsen, AN | 1 |
| Blackburn-Munro, G | 2 |
| Suzuki, R | 1 |
| Rahman, W | 1 |
| Rygh, LJ | 1 |
| Webber, M | 1 |
| Hunt, SP | 1 |
| Castañé, A | 1 |
| Célérier, E | 1 |
| Martín, M | 1 |
| Ledent, C | 1 |
| Parmentier, M | 1 |
| Maldonado, R | 1 |
| Valverde, O | 1 |
| Gaida, W | 1 |
| Klinder, K | 1 |
| Arndt, K | 1 |
| Weiser, T | 1 |
| Zareba, G | 1 |
| Shneker, BF | 1 |
| McAuley, JW | 1 |
| Quintão, NLM | 1 |
| Medeiros, R | 1 |
| Santos, ARS | 1 |
| Campos, MM | 1 |
| Fang, M | 1 |
| Lorke, DE | 1 |
| Li, J | 1 |
| Gong, X | 1 |
| Yew, JC | 1 |
| Yew, DT | 1 |
| Iannetti, GD | 2 |
| Zambreanu, L | 1 |
| Wise, RG | 2 |
| Buchanan, TJ | 1 |
| Huggins, JP | 1 |
| Smart, TS | 2 |
| Vennart, W | 1 |
| Tracey, I | 2 |
| Ross, JR | 1 |
| Goller, K | 1 |
| Hardy, J | 1 |
| Riley, J | 1 |
| Broadley, K | 1 |
| A'hern, R | 1 |
| Williams, J | 1 |
| Torsney, C | 1 |
| Baillie, JK | 1 |
| Power, I | 1 |
| Mixcoatl-Zecuatl, T | 1 |
| Flores-Murrieta, FJ | 1 |
| Morato, M | 1 |
| Pinho, D | 1 |
| Sousa, T | 1 |
| Albino-Teixeira, A | 1 |
| Ebell, M | 1 |
| Kripke, C | 1 |
| Guay, DR | 1 |
| Lu, VB | 1 |
| Moran, TD | 1 |
| Balasubramanyan, S | 1 |
| Alier, KA | 1 |
| Dryden, WF | 1 |
| Colmers, WF | 1 |
| Smith, PA | 1 |
| López-Trigo, J | 1 |
| Sancho Rieger, J | 1 |
| Son, BC | 1 |
| Lee, SW | 1 |
| Choi, ES | 1 |
| Sung, JH | 1 |
| Hong, JT | 1 |
| Matsumoto, M | 1 |
| Inoue, M | 1 |
| Hald, A | 1 |
| Xie, W | 1 |
| Ueda, H | 2 |
| Kulkarni, SK | 2 |
| Bekkelund, SI | 1 |
| Lilleng, H | 1 |
| Tønseth, S | 1 |
| Kavoussi, R | 1 |
| Rode, F | 1 |
| Broløs, T | 1 |
| Bjerrum, OJ | 1 |
| Mathiesen, O | 1 |
| Imbimbo, BP | 1 |
| Hilsted, KL | 1 |
| Fabbri, L | 1 |
| Dahl, JB | 1 |
| Moulin, D | 1 |
| Potes, CS | 1 |
| Neto, FL | 1 |
| Castro-Lopes, JM | 1 |
| Sepehri, G | 2 |
| Mobasher, M | 1 |
| Málaga, I | 1 |
| Sanmarti, FX | 1 |
| Nikolajsen, L | 1 |
| Kramp, S | 1 |
| Vimtrup, AS | 1 |
| Keller, J | 1 |
| Cuignet, O | 1 |
| Pirson, J | 1 |
| Soudon, O | 1 |
| Zizi, M | 1 |
| Felicio, AC | 1 |
| Godeiro, Cde O | 1 |
| Borges, V | 1 |
| Silva, SM | 1 |
| Ferraz, HB | 1 |
| Cox, PJ | 1 |
| Stott, E | 1 |
| Melrose, H | 1 |
| Offord, J | 1 |
| Su, TZ | 2 |
| Corradini, L | 1 |
| England, S | 1 |
| Winks, J | 1 |
| Kinloch, RA | 1 |
| Hendrich, J | 1 |
| Webb, T | 1 |
| Williams, D | 1 |
| Zhou, HY | 1 |
| Zhang, HM | 1 |
| Rios, MY | 1 |
| Aguilar-Guadarrama, AB | 1 |
| Gutiérrez, Mdel C | 1 |
| Takeuchi, Y | 2 |
| Honda, M | 1 |
| LaGraize, SC | 1 |
| Fuchs, PN | 1 |
| White, PF | 1 |
| Karamanlioglu, B | 1 |
| Pamukçu, Z | 1 |
| Rashid, RM | 1 |
| Ibrahim, S | 1 |
| Patel, V | 1 |
| Eaton, MJ | 1 |
| Wolfe, SQ | 1 |
| Martinez, M | 2 |
| Hernandez, M | 1 |
| Furst, C | 1 |
| Frydel, BR | 1 |
| Gómez-Marín, O | 1 |
| Barsukov, IN | 1 |
| Kashin, AV | 1 |
| Kostiuk, GP | 1 |
| Coderre, TJ | 2 |
| Kumar, N | 1 |
| Lefebvre, CD | 1 |
| Yu, JS | 1 |
| Norman, P | 1 |
| Yokoyama, T | 2 |
| Maeda, Y | 1 |
| Audette, KM | 1 |
| Sluka, KA | 1 |
| Takahashi, A | 1 |
| Mikami, M | 1 |
| Xu, HT | 1 |
| Chen, JM | 1 |
| Beyreuther, BK | 1 |
| Geis, C | 1 |
| Stöhr, T | 1 |
| Sommer, C | 1 |
| Ortega-Varela, LF | 1 |
| Herrera, JE | 1 |
| Caram-Salas, NL | 1 |
| Goldenberg, DL | 2 |
| Stanford, SB | 1 |
| Lalonde, JK | 1 |
| Sandhu, HS | 1 |
| Keck, PE | 1 |
| Welge, JA | 1 |
| Bishop, F | 1 |
| Stanford, KE | 1 |
| Hess, EV | 1 |
| Hudson, JI | 1 |
| Harris, G | 1 |
| Horowitz, B | 1 |
| Borgida, A | 1 |
| Baccei, ML | 1 |
| Terneus, W | 1 |
| Houghton, LA | 1 |
| Fell, C | 1 |
| Whorwell, PJ | 1 |
| Jones, I | 1 |
| Sudworth, DP | 1 |
| Gale, JD | 1 |
| Yogeeswari, P | 1 |
| Ragavendran, JV | 1 |
| Sriram, D | 1 |
| Nageswari, Y | 1 |
| Kavya, R | 1 |
| Sreevatsan, N | 1 |
| Vanitha, K | 1 |
| Stables, J | 1 |
| Schwarz, JB | 1 |
| Greenwell, TN | 1 |
| Martin-Schild, S | 1 |
| Inglis, FM | 1 |
| Zadina, JE | 1 |
| Wallace, JM | 1 |
| Ghirri, A | 1 |
| Prandini, M | 1 |
| Merighi, A | 1 |
| Wallace, VC | 1 |
| Segerdahl, AR | 1 |
| Lambert, DM | 1 |
| Vandevoorde, S | 1 |
| Blackbeard, J | 1 |
| Hasnie, F | 1 |
| Kruszewski, SP | 1 |
| Shane, JA | 1 |
| Blommel, ML | 1 |
| Blommel, AL | 1 |
| Sinclair, AM | 1 |
| Miller, B | 1 |
| Lee, LK | 1 |
| Fusumada, K | 1 |
| Miki, T | 1 |
| Wang, ZY | 1 |
| Lee, NS | 1 |
| Endo, Y | 1 |
| Gil, DW | 1 |
| Cheevers, CV | 1 |
| Donello, JE | 1 |
| Mukhida, K | 1 |
| Mendez, I | 1 |
| McLeod, M | 1 |
| Kobayashi, N | 1 |
| Haughn, C | 1 |
| Milne, B | 1 |
| Baghbaderani, B | 1 |
| Sen, A | 1 |
| Behie, LA | 1 |
| Vranken, JH | 1 |
| Dijkgraaf, MG | 1 |
| Kruis, MR | 1 |
| van der Vegt, MH | 1 |
| Hollmann, MW | 1 |
| Heesen, M | 1 |
| Wu, SC | 1 |
| Wrobel, JS | 1 |
| Armstrong, DG | 1 |
| Robinson-Papp, J | 1 |
| Simpson, DM | 1 |
| Biegstraaten, M | 1 |
| van Schaik, IN | 1 |
| Jerome, L | 1 |
| Roche, M | 1 |
| Harnack, D | 1 |
| Scheel, M | 1 |
| Mundt, A | 1 |
| Kupsch, A | 1 |
| Heinz, A | 1 |
| Ströhle, A | 1 |
| Rodríguez, MJ | 1 |
| Díaz, S | 1 |
| Vera-Llonch, M | 1 |
| Dukes, E | 1 |
| Knake, S | 1 |
| Klein, KM | 1 |
| Hattemer, K | 1 |
| Wellek, A | 1 |
| Oertel, WH | 1 |
| Hamer, HM | 1 |
| Rosenow, F | 1 |
| Savica, R | 1 |
| Beghi, E | 1 |
| Mazzaglia, G | 1 |
| Innocenti, F | 1 |
| Brignoli, O | 1 |
| Cricelli, C | 1 |
| Caputi, AP | 1 |
| Musolino, R | 1 |
| Spina, E | 1 |
| Trifirò, G | 1 |
| Spiller, J | 1 |
| Niscola, P | 1 |
| Perrotti, AP | 1 |
| del Poeta, G | 1 |
| Romani, C | 1 |
| Palombi, M | 1 |
| Piccioni, D | 1 |
| Scaramucci, L | 1 |
| Tolu, B | 1 |
| Tendas, A | 1 |
| Cupelli, L | 1 |
| Abruzzese, E | 1 |
| D'Elia, GM | 1 |
| Brunetti, GA | 1 |
| Maurillo, L | 1 |
| Giovannini, M | 1 |
| Cartoni, C | 1 |
| de Fabritiis, P | 1 |
| Vecht, CJ | 1 |
| Biavatti, MW | 1 |
| Westerlon, R | 1 |
| Burger, C | 1 |
| Mora, TC | 1 |
| De Souza, MM | 1 |
| Christie, J | 1 |
| Pinto, LG | 1 |
| Jesse, CR | 1 |
| Nogueira, CW | 1 |
| Savegnago, L | 1 |
| Gajraj, NM | 1 |
| Rintala, DH | 1 |
| Holmes, SA | 1 |
| Courtade, D | 1 |
| Fiess, RN | 1 |
| Tastard, LV | 1 |
| Loubser, PG | 1 |
| Aizawa, H | 1 |
| Nymdelger, S | 1 |
| Nieber, K | 1 |
| Starowicz, K | 1 |
| Cristino, L | 1 |
| Di Marzo, V | 2 |
| Owen, RT | 1 |
| Tanimoto-Mori, S | 1 |
| Nakazato-Imasato, E | 1 |
| Toide, K | 1 |
| Kita, Y | 1 |
| Mitsis, GD | 1 |
| Suarez-Roca, H | 1 |
| Leal, L | 1 |
| Silva, JA | 1 |
| Pinerua-Shuhaibar, L | 1 |
| Quintero, L | 1 |
| Atlas, G | 1 |
| Delphin, E | 1 |
| Ye, JH | 1 |
| Governo, RJ | 1 |
| Morris, PG | 1 |
| Marsden, CA | 1 |
| Chapman, V | 3 |
| Millecamps, M | 1 |
| Florian, H | 1 |
| Celebi, N | 1 |
| Canbay, O | 1 |
| Aycan, IO | 1 |
| Sahin, A | 1 |
| Aypar, U | 1 |
| Pardo, A | 1 |
| Ruiz, MA | 1 |
| Gwak, YS | 1 |
| Crown, ED | 1 |
| Unabia, GC | 1 |
| Hulsebosch, CE | 3 |
| Kavalieratos, CS | 1 |
| Dimou, T | 1 |
| Bras, M | 1 |
| Haugen, RN | 1 |
| Tharp, MD | 1 |
| Haslam, C | 1 |
| Nurmikko, T | 1 |
| Iyer, R | 1 |
| Egloff, L | 1 |
| Fraas, J | 1 |
| Harris, JD | 1 |
| Coste, O | 1 |
| Pierre, S | 1 |
| Marian, C | 1 |
| Brenneis, C | 1 |
| Angioni, C | 1 |
| Schmidt, H | 1 |
| Popp, L | 1 |
| Geisslinger, G | 1 |
| Scholich, K | 1 |
| Stepanovic-Petrovic, RM | 1 |
| Tomic, MA | 1 |
| Vuckovic, SM | 1 |
| Paranos, S | 1 |
| Ugresic, ND | 1 |
| Prostran, MS | 1 |
| Milovanovic, S | 1 |
| Boskovic, B | 1 |
| Quintero Wolfe, SC | 1 |
| Cumberbatch, N | 1 |
| Menendez, I | 1 |
| Eaton, M | 1 |
| Sawynok, J | 2 |
| Buckett, WR | 2 |
| King, RB | 1 |
| Zakusov, VV | 2 |
| Ostrovskaia, RU | 1 |
| Bulaev, VM | 1 |
| DeFeudis, FV | 1 |
| Ostrovskaya, RU | 1 |
| Bulayev, VM | 1 |
| Oliverio, A | 1 |
| Castellano, C | 1 |
| Puglisi-Allegra, S | 1 |
| Pressman, AH | 1 |
| Nickles, SL | 1 |
| Wilson, PR | 1 |
| Jessell, TM | 1 |
| Snell, D | 1 |
| Feller, D | 1 |
| Bylund, D | 1 |
| Harris, RA | 1 |
| Marlinskiĭ, VV | 1 |
| Soja, PJ | 1 |
| Sinclair, JG | 1 |
| Izumi, K | 1 |
| Munekata, E | 1 |
| Nakanishi, T | 1 |
| Barbeau, A | 1 |
| Menon, MK | 1 |
| Clark, WG | 1 |
| Vivonia, C | 1 |
| Mantegazza, P | 1 |
| Tammiso, R | 1 |
| Vicentini, L | 1 |
| Zambotti, F | 1 |
| Zonta, N | 1 |
| Thiébot, MH | 1 |
| Jobert, A | 1 |
| Soubrié, P | 1 |
| Kryzhanovskiĭ, GN | 1 |
| Danilova, EI | 1 |
| Grafova, VN | 1 |
| Reshetniak, VK | 1 |
| Olausson, B | 1 |
| Xu, ZQ | 1 |
| Wang, QP | 1 |
| Nakai, Y | 1 |
| Lin, Q | 2 |
| Peng, Y | 1 |
| Katz, Y | 1 |
| Pick, CG | 1 |
| Pasternak, GW | 1 |
| Liu, L | 1 |
| Fonia, O | 1 |
| Gavish, M | 1 |
| Yamamoto, T | 1 |
| Zapp, JJ | 1 |
| Minami, T | 1 |
| Okuda-Ashitaka, E | 1 |
| Mori, H | 1 |
| Hayaishi, O | 1 |
| Bowery, NG | 1 |
| Zhang, S | 1 |
| Yuan, B | 2 |
| McGraw, T | 2 |
| Kosek, P | 1 |
| Shimoyama, M | 1 |
| Inturrisi, CE | 1 |
| Elliott, KJ | 1 |
| Ibuki, T | 1 |
| Wang, XT | 1 |
| Pappas, GD | 1 |
| Sagen, J | 1 |
| Cesaro, P | 1 |
| Albe-Fessard, D | 2 |
| Hunter, JC | 2 |
| Gogas, KR | 1 |
| Hedley, LR | 2 |
| Jacobson, LO | 1 |
| Kassotakis, L | 1 |
| Thompson, J | 1 |
| Fontana, DJ | 1 |
| Sist, T | 1 |
| Filadora, V | 1 |
| Miner, M | 1 |
| Lema, M | 1 |
| Green, GM | 1 |
| Samkoff, LM | 1 |
| Daras, M | 1 |
| Tuchman, AJ | 1 |
| Koppel, BS | 1 |
| Wetzel, CH | 1 |
| Connelly, JF | 1 |
| Rosenberg, JM | 1 |
| Harrell, C | 1 |
| Ristic, H | 1 |
| Werner, RA | 1 |
| de Rosayro, AM | 1 |
| Nguyen, TT | 1 |
| Matsumoto, K | 1 |
| Watanabe, H | 1 |
| Khatri, A | 1 |
| Pearlstein, L | 1 |
| Houtchens, MK | 1 |
| Richert, JR | 1 |
| Sami, A | 1 |
| Rose, JW | 1 |
| Gillin, S | 1 |
| Sorkin, LS | 1 |
| Jun, JH | 1 |
| Li, HS | 1 |
| Monhemius, R | 3 |
| Simpson, BA | 1 |
| Roberts, MH | 3 |
| Goto, T | 1 |
| Canavero, S | 1 |
| Bonicalzi, V | 1 |
| Gould, HJ | 1 |
| Gee, NS | 1 |
| Kocsis, JD | 1 |
| Welty, DF | 1 |
| Brown, JP | 1 |
| Dooley, DJ | 1 |
| Boden, P | 1 |
| McCaffery, M | 1 |
| Nicolodi, M | 1 |
| Carlton, SM | 3 |
| Zhou, S | 1 |
| Sollevi, A | 1 |
| Segerdahl, M | 1 |
| Stiller, CO | 1 |
| O'Connor, WT | 1 |
| Yamashiro, K | 1 |
| Tomiyama, N | 1 |
| Ishida, A | 1 |
| Terada, Y | 1 |
| Mukawa, J | 1 |
| Yoshii, Y | 1 |
| Tasker, RR | 1 |
| Merren, MD | 1 |
| Ness, TJ | 1 |
| San Pedro, EC | 1 |
| Richards, SJ | 1 |
| Kezar, L | 1 |
| Liu, HG | 1 |
| Mountz, JM | 1 |
| Beydoun, A | 2 |
| Edwards, KR | 1 |
| Schwartz, SL | 1 |
| Fonseca, V | 1 |
| Hes, M | 1 |
| Garofalo, E | 1 |
| Low, PA | 1 |
| Dotson, RM | 1 |
| Stacey, BR | 1 |
| Gorson, KC | 1 |
| Schott, C | 1 |
| Herman, R | 1 |
| Ropper, AH | 1 |
| Rand, WM | 1 |
| Rezayat, M | 1 |
| Tabarrai, E | 1 |
| Parvini, S | 1 |
| Zarrindast, MR | 1 |
| Pirali, M | 1 |
| Seidl, JJ | 1 |
| Slawson, JG | 1 |
| Berkley, KJ | 1 |
| Ipponi, A | 1 |
| Lamberti, C | 1 |
| Medica, A | 1 |
| Bartolini, A | 1 |
| Malmberg-Aiello, P | 1 |
| McCleary, S | 1 |
| Hughes, J | 1 |
| Schiebel, NE | 1 |
| Ebbert, J | 1 |
| Margolis, K | 1 |
| Hansen, HC | 2 |
| Jett, MF | 1 |
| Dillon, MP | 1 |
| Eglen, RM | 1 |
| van Deventer, H | 1 |
| Bernard, S | 1 |
| Chizh, BA | 1 |
| Wnendt, S | 1 |
| Morello, CM | 1 |
| Leckband, SG | 1 |
| Stoner, CP | 1 |
| Moorhouse, DF | 1 |
| Sahagian, GA | 1 |
| Maurer, I | 1 |
| Volz, HP | 1 |
| Sauer, H | 1 |
| Hawkins, MF | 1 |
| Baumeister, AA | 2 |
| Larue, RH | 1 |
| Fountain, LT | 1 |
| Highsmith, RW | 1 |
| Jeffries, SK | 1 |
| Duke, MA | 1 |
| Meldrum, BS | 1 |
| Chapman, AG | 1 |
| Urban, L | 1 |
| McCaslin, PP | 1 |
| McLeod, AL | 1 |
| Krause, JE | 1 |
| Ribeiro-Da-Silva, A | 1 |
| Davis, JB | 1 |
| Gray, J | 1 |
| Gunthorpe, MJ | 1 |
| Hatcher, JP | 1 |
| Davey, PT | 1 |
| Overend, P | 1 |
| Harries, MH | 1 |
| Latcham, J | 1 |
| Clapham, C | 1 |
| Atkinson, K | 1 |
| Hughes, SA | 1 |
| Rance, K | 1 |
| Grau, E | 1 |
| Harper, AJ | 1 |
| Pugh, PL | 1 |
| Rogers, DC | 1 |
| Bingham, S | 1 |
| Randall, A | 1 |
| Sheardown, SA | 1 |
| Holtom, N | 1 |
| Solaro, C | 1 |
| Uccelli, MM | 1 |
| Guglieri, P | 1 |
| Uccelli, A | 1 |
| Mancardi, GL | 1 |
| Nicholson, B | 1 |
| García-Morales, I | 1 |
| Berbel, A | 2 |
| Benito-León, J | 2 |
| Pérez, HE | 1 |
| Sánchez, GF | 1 |
| Chen, LL | 1 |
| Nitta, M | 1 |
| Nemoto, H | 1 |
| Zylicz, Z | 1 |
| Dallocchio, C | 1 |
| Buffa, C | 1 |
| Mazzarello, P | 1 |
| Chiroli, S | 1 |
| Kapadia, NP | 1 |
| Harden, N | 1 |
| Chandler, A | 1 |
| Williams, JE | 1 |
| Kayser, V | 1 |
| Christensen, D | 1 |
| Derk, CT | 1 |
| Cynwyd, B | 1 |
| Green, DL | 2 |
| Azami, J | 2 |
| Kontinen, VK | 1 |
| Stanfa, LC | 1 |
| Basu, A | 1 |
| Xu, GY | 1 |
| Perez-Polo, JR | 1 |
| McAdoo, DJ | 1 |
| Puskár, Z | 1 |
| Polgár, E | 1 |
| Block, F | 1 |
| Sasaki, K | 1 |
| Smith, CP | 1 |
| Chuang, YC | 1 |
| Kim, JC | 1 |
| Chancellor, MB | 1 |
| Li, AH | 1 |
| Wang, HL | 1 |
| Rovetta, G | 1 |
| Baratto, L | 1 |
| Farinelli, G | 1 |
| Monteforte, P | 1 |
| Villari, P | 1 |
| Fulfaro, F | 1 |
| Nozaki-Taguchi, N | 1 |
| Chaplan, SR | 1 |
| Ajakwe, RC | 1 |
| Dolezal, T | 1 |
| Behm, MO | 1 |
| Kearns, GL | 1 |
| La Spina, I | 1 |
| Porazzi, D | 1 |
| Maggiolo, F | 1 |
| Bottura, P | 1 |
| Suter, F | 1 |
| Devulder, J | 1 |
| Lambert, J | 1 |
| Naeyaert, JM | 1 |
| Huang, SM | 1 |
| Bisogno, T | 1 |
| Petros, TJ | 1 |
| Chang, SY | 1 |
| Zavitsanos, PA | 1 |
| Zipkin, RE | 1 |
| Sivakumar, R | 1 |
| Coop, A | 1 |
| Maeda, DY | 1 |
| De Petrocellis, L | 1 |
| Burstein, S | 1 |
| Walker, JM | 2 |
| Zou, X | 1 |
| Selak, I | 1 |
| Mills, CD | 1 |
| Grady, JJ | 1 |
| Fisenko, VP | 1 |
| Brooks-Rock, K | 1 |
| Sokal, DM | 1 |
| Wang, D | 1 |
| Wu, JH | 1 |
| Dong, YX | 1 |
| Ahmadi, S | 1 |
| Lippross, S | 1 |
| Neuhuber, WL | 1 |
| Xu, Z | 1 |
| Azulay, JP | 1 |
| Pouget, J | 1 |
| Alam, M | 1 |
| Rabinowitz, AD | 1 |
| Engler, DE | 1 |
| de Louw, AJ | 1 |
| de Vente, J | 1 |
| Steinbusch, HP | 1 |
| Steinbusch, HW | 1 |
| Troost, J | 1 |
| Vles, JS | 1 |
| Matthews, EA | 1 |
| Schapiro, RT | 1 |
| Heughan, CE | 1 |
| Fischer, J | 1 |
| Franzoni, MF | 1 |
| Conrath, M | 1 |
| Rose, MA | 1 |
| Kam, PC | 1 |
| Malan, TP | 1 |
| Mata, HP | 1 |
| Gu, Y | 1 |
| Huang, LY | 1 |
| Bosnjak, S | 1 |
| Jelic, S | 1 |
| Susnjar, S | 1 |
| Luki, V | 1 |
| Sussman, N | 1 |
| To, TP | 1 |
| Lim, TC | 1 |
| Hill, ST | 1 |
| Frauman, AG | 1 |
| Cooper, N | 1 |
| Kirsa, SW | 1 |
| Brown, DJ | 1 |
| Wheeler, G | 1 |
| Bruins Slot, LA | 1 |
| Ribet, JP | 1 |
| Dismukes, RK | 1 |
| Meerson, FZ | 2 |
| Pavlova, VI | 2 |
| Iakushev, VS | 2 |
| Kamilov, FKh | 2 |
| Lifshits, RI | 1 |
| Sherman, AD | 1 |
| Gebhart, GF | 1 |
| Roberts, WA | 1 |
| Eaton, SA | 1 |
| Salt, TE | 1 |
| Wang, XM | 1 |
| Hou, ZL | 1 |
| Zhang, D | 2 |
| Serrano, I | 1 |
| Ruiz, RM | 1 |
| Serrano, JS | 1 |
| Fernández, A | 1 |
| Powell, JJ | 1 |
| Matsumoto, RR | 1 |
| Otsuka, M | 2 |
| Yanagisawa, M | 1 |
| Aston-Jones, G | 1 |
| Chiang, C | 1 |
| Alexinsky, T | 1 |
| Dutta, AS | 1 |
| Chaudhuri, AK | 1 |
| Cho, HJ | 1 |
| Basbaum, AI | 3 |
| Han, JS | 1 |
| Reichling, DB | 2 |
| Day, TA | 1 |
| Sibbald, JR | 1 |
| Aley, KO | 1 |
| Li, YR | 1 |
| Yang, YZ | 1 |
| Sun, MZ | 1 |
| Hill, RG | 1 |
| Andreev, BV | 1 |
| Ignatov, IuD | 1 |
| Matthews, MA | 1 |
| McDonald, GK | 1 |
| Hernandez, TV | 1 |
| Ge, M | 1 |
| Satoh, M | 1 |
| Bovier, P | 1 |
| Hilleret, H | 1 |
| Tissot, R | 1 |
| Frye, GD | 1 |
| Reyes-Vazquez, C | 1 |
| Dafny, N | 1 |
| Roberts, LA | 1 |
| Beyer, C | 1 |
| Komisaruk, BR | 1 |
| Baraldi, M | 1 |
| Zanoli, P | 1 |
| Benelli, A | 1 |
| Sandrini, M | 1 |
| Giberti, A | 1 |
| Caselgrandi, E | 1 |
| Tosi, G | 1 |
| Preti, C | 1 |
| Stein, C | 1 |
| Liebeskind, JC | 1 |
| Laviola, G | 1 |
| Drower, EJ | 1 |
| Hammond, DL | 1 |
| Ye, WL | 1 |
| Feng, XC | 1 |
| Pelley, KA | 1 |
| Vaught, JL | 1 |
| Carstens, E | 1 |
| Gilly, H | 1 |
| Schreiber, H | 1 |
| Moreau, JL | 1 |
| Fields, HL | 1 |
| Morris, R | 1 |
| Whitehouse, WG | 1 |
| Blustein, JE | 1 |
| Walker, J | 1 |
| Bersh, PJ | 1 |
| Margules, DL | 1 |
| Xu, W | 1 |
| Lin, Y | 1 |
| Chen, ZQ | 1 |
| Zhang, YF | 1 |
| Zorn, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Vurdering af Perifere GABAA-receptorer Med Henblik på Lokal Smertelindring[NCT02928328] | 90 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | |||
| GABA-WHY Study: Deprescription of Gabapentinoids in Medical Inpatients[NCT04855578] | 160 participants (Actual) | Interventional | 2021-05-28 | Completed | |||
| A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy[NCT00159679] | Phase 4 | 167 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy[NCT00143156] | Phase 3 | 450 participants | Interventional | 2005-03-31 | Completed | ||
| A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN).[NCT00156078] | Phase 4 | 450 participants | Interventional | 2005-01-31 | Completed | ||
| Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin (CI-1008) In The Treatment For Pain Associated With Diabetic Peripheral Neuropathy[NCT00553475] | Phase 3 | 314 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| The Impact of Pain on Behavioural Disturbances in Patients With Moderate and Severe Dementia. A Cluster Randomized Trial[NCT01021696] | Phase 2/Phase 3 | 352 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD[NCT02884908] | Phase 3 | 252 participants (Anticipated) | Interventional | 2016-09-30 | Active, not recruiting | ||
| The Benefits of Vitamin B Combination as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient: Randomized Clinical Trial[NCT04689971] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2020-11-03 | Recruiting | ||
| Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial[NCT03080493] | Phase 4 | 121 participants (Actual) | Interventional | 2017-03-20 | Completed | ||
| Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain[NCT02339662] | Phase 4 | 50 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
| A Randomized, Double Blind, Placebo Controlled Study to Investigate the Effect of Donepezil and Gabapentin Combination on an Experimental Pain Model in Healthy Subjects[NCT01485185] | Phase 1 | 48 participants (Actual) | Interventional | 2011-10-11 | Completed | ||
| Comparison of Oral Lamotrigine Versus Pregabalin for Control of Acute and Chronic Pain Following Modified Radical Mastectomy: Controlled Double-blind Study[NCT03419949] | 0 participants | Expanded Access | Available | ||||
| Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain[NCT01364298] | Phase 4 | 353 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management: A Randomized Controlled Trial of Efficacy and Safety[NCT05427058] | 36 participants (Anticipated) | Interventional | 2022-08-01 | Not yet recruiting | |||
| Analgesic Effect of Oxytocin Receptor Modulation in Healthy Volunteers[NCT01918475] | 25 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Persistent Postoperative Pain Incidence With Long Term Perioperative Gabapentin Used[NCT02693821] | Phase 4 | 122 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Effects of Percutaneous Neuromodulation on Plasticity in the Somatosensory System[NCT04475133] | 29 participants (Actual) | Interventional | 2020-08-13 | Completed | |||
| Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia[NCT03120962] | 140 participants (Anticipated) | Interventional | 2017-05-31 | Not yet recruiting | |||
| Efficacy of Duloxetine in Conjunction With Tramadol for Chronic Cancer Pain[NCT05311774] | 400 participants (Anticipated) | Interventional | 2022-04-30 | Not yet recruiting | |||
| Development of a Mobile Application to Promote Self-care in Patients With Fibromyalgia[NCT03004911] | 40 participants (Actual) | Interventional | 2017-02-14 | Completed | |||
| The Effects of Mindfulness Meditation on Fibromyalgia-Related Pain[NCT02581332] | 0 participants (Actual) | Interventional | 2017-01-31 | Withdrawn (stopped due to Due to insufficient interest in the study and enrollment has been closed) | |||
| Evaluation of Spa Therapy in the Treatment of Fibromyalgia : a Randomized, Controlled, Open Multicenter Study[NCT02265029] | 220 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia[NCT03487211] | Phase 2/Phase 3 | 200 participants (Actual) | Interventional | 2018-04-09 | Completed | ||
| The Efficacy of Mindfulness- Based Intervention for Fibromyalgia Patients: a Randomized Control Trial[NCT04304664] | 95 participants (Actual) | Interventional | 2017-01-23 | Completed | |||
| Evaluation of the Efficiency of a Therapeutic Education Program in Standardized Thermal Cure for Fibromyalgia Patients[NCT02406313] | 152 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | |||
| Efficacy of Extremely Low Magnetic Field (ELF) in Fibromyalgic Patients: Effect on Symptoms Severity, Sleep and Quality of Life.[NCT03503760] | 48 participants (Actual) | Interventional | 2016-07-31 | Completed | |||
| Efficacy of Acceptance and Commitment Therapy (ACT) in Group in Fibromyalgia: a Randomized, Controlled Study.[NCT01611831] | 80 participants (Anticipated) | Interventional | 2012-01-31 | Active, not recruiting | |||
| Safety and Efficacy of Lidocaine 5% Medicated Plaster in Comparison to Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain.[NCT00414349] | Phase 3 | 431 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Use of Single Dose Pre-Operative Pregabalin for Post-Operative Analgesia in Bilateral Head and Neck Cancer Surgery: A Randomized, Double-Blinded, Placebo-Controlled Trial[NCT03714867] | Phase 4 | 0 participants (Actual) | Interventional | 2019-03-22 | Withdrawn (stopped due to Inability to recruit patients) | ||
| Cannabidiol for Fibromyalgia -The CANNFIB Trial Protocol for a Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial[NCT04729179] | Phase 3 | 200 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Analgetic Effectiveness of Acupuncture When Compared to a Standardised Analgesic Regimen in the Treatment of Herpes Zoster Neuralgia[NCT00885586] | Phase 4 | 68 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| The Efficacy and Safety of Intradermal Acupuncture for Acute Herpes Zoster: Study Protocol for a Randomized Controlled Trial[NCT05348382] | 72 participants (Anticipated) | Interventional | 2022-07-04 | Recruiting | |||
| Double Blind Trial Investigating the Role of Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients[NCT03847311] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-05-03 | Recruiting | ||
| Self-Management to Improve Walking Ability in Degenerative Lumbar Spinal Stenosis: the Evaluation of Four Novel Strategies.[NCT02592642] | 104 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI[NCT00243152] | 6 participants (Actual) | Interventional | 2005-10-31 | Completed | |||
| Efficacy of Pregabalin and Duloxetine in Patients With Painful Diabetic Peripheral Neuropathy (PDPN): the Effect of Pain on Cognitive Function, Sleep and Quality of Life (BLOSSOM)[NCT04246619] | Phase 4 | 254 participants (Actual) | Interventional | 2019-11-12 | Terminated (stopped due to The statistical analysis will still provide relevant results with the same statistical power as initially planned.COVID-19 pandemic prolonged the recruiting period and consequently affected the costs of the clinical trial.) | ||
| Placebo-Controlled Study of Pregabalin for the Pain of Acute Herpes Zoster[NCT00352651] | Phase 2 | 34 participants (Anticipated) | Interventional | 2006-06-30 | Terminated (stopped due to "This study should be terminated as the study has been closed for years and the investigator has since retired. No records are available.~Thank you, Marlene") | ||
| Effect of Preoperative Pregabalin on Pain Intensity and Interleukin-6 Levels in Living Donor Kidney[NCT01529190] | Phase 2 | 40 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Open Label Trial Concerning the Effectiveness of Trazodone in the Treatment of Fibromyalgia (Phase I) and Its Augmentation With Pregabalin in Trazodone Partial Responders (Phase II)[NCT00791739] | Phase 4 | 66 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| A 14-Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia[NCT00230776] | Phase 3 | 740 participants | Interventional | 2005-10-31 | Completed | ||
| A 13-week, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Trial of Pregabalin (BID) in Patients With Fibromyalgia[NCT00645398] | Phase 3 | 751 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| A 14 Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia.[NCT00333866] | Phase 3 | 747 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Regional Anesthesia and Valproate Sodium for the Prevention of Chronic Post-Amputation Pain[NCT01928849] | Phase 2 | 128 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients[NCT02160301] | Phase 4 | 0 participants (Actual) | Interventional | 2017-11-30 | Withdrawn (stopped due to Insufficient infrastructure/funding for enrollment) | ||
| Effects Of Pregabalin On Sleep Maintenance In Subjects With Fibromyalgia Syndrome And Sleep Maintenance Disturbance: A Randomized Placebo-Controlled 2-Way Crossover Polysomnography Study[NCT00883740] | Phase 3 | 119 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Effect of Minocycline on Neuropathic Pain[NCT01869907] | Phase 4 | 60 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| The Effect of Foot and Ankle Exercise on Pain and Quality of Life in Patients With Diabetic Neuropathy[NCT05670600] | 100 participants (Actual) | Interventional | 2021-07-19 | Completed | |||
| A Double-blind, Randomised, Parallel Groups Investigation Into the Effects of Pregabalin, Duloxetine and Amitriptyline on Aspects of Pain, Sleep, and Next Day Performance in Patients Suffering From Diabetic Peripheral Neuropathy[NCT00370656] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2007-02-28 | Completed | ||
| The Effect of Preoperative Anxiety Level to Postoperative Pain and Analgesic Consumption in Patients Who Had Laparoscopic Sleeve Gastrectomy[NCT04432558] | 42 participants (Actual) | Observational [Patient Registry] | 2017-04-12 | Completed | |||
| Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures[NCT02957097] | Phase 4 | 0 participants (Actual) | Interventional | 2019-09-30 | Withdrawn (stopped due to Original PI left institution and the PI who took over was not able to initiate the study so it was never started.) | ||
| Randomized Phase II Trial Evaluating Activity and Tolerability of Fixed Dose of Oxycodone and Increasing Dose of Pregabalin Versus Increasing Dose of Oxycodone and Fixed Dose of Pregabalin for the Treatment of Oncological Neuropathic Pain[NCT00637975] | Phase 2 | 80 participants (Anticipated) | Interventional | 2007-09-30 | Completed | ||
| Pregabalin for Pain Reduction in Critical Limb Ischemia - A Double Blind, Randomized Controlled Study[NCT00403780] | Phase 4 | 18 participants (Actual) | Interventional | 2006-06-30 | Terminated (stopped due to low inclusion rate) | ||
| Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)[NCT01623271] | 5 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to Due to limited population of research participants.) | |||
| Burning Mouth Disorder (BMD) - a Neuropathic Pain Disorder? An Investigation Using Qualitative and Quantitative Sensory Testing (QST)[NCT00504387] | 12 participants (Anticipated) | Observational | 2007-04-30 | Recruiting | |||
| Fibromyalgia of Less Than One Year Duration in Primary Care: Treatment Response in a Double Blind, Placebo Controlled Study of Pregabalin[NCT01397006] | Phase 4 | 0 participants (Actual) | Interventional | 2011-09-30 | Withdrawn | ||
| Randomized Controlled Pilot Trial of Adjunct Group Acupuncture vs Usual Care Among Patients With Painful Diabetic Neuropathy[NCT02104466] | 40 participants (Actual) | Interventional | 2015-03-31 | Completed | |||
| Effect of Ambroxol on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy[NCT05558878] | 80 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | |||
| Pharmacokinetic Non-interaction Study Between Pregabalin 150 mg and Tramadol 50 mg, Administered Individually or in Combination, Single Dose in Healthy Subjects of Both Genders Under Fasting Conditions[NCT05389150] | Phase 1 | 30 participants (Actual) | Interventional | 2019-01-17 | Completed | ||
| Effect of Two Different Doses of Oral Pregabalin Premedication for Postoperative Pain Relief After Gynecological Surgeries[NCT04708353] | 90 participants (Anticipated) | Interventional | 2020-08-20 | Recruiting | |||
| Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187] | 8 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to PI left institution) | |||
| Effect of Preoperative Pregabalin on Propofol Induction Dose[NCT01158859] | Phase 4 | 50 participants (Anticipated) | Interventional | 2010-04-30 | Completed | ||
| The Effect of Neurontin on Pain Management in the Acutely Burned Patient[NCT01265056] | 53 participants (Actual) | Interventional | 2010-02-28 | Completed | |||
| Open Labeled, Non-randomized, Study of Efficacy and Safety of Gralise in Fibromyalgia Patients.[NCT02052414] | 34 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Phase III Study of the Use of Gabapentin and Osteopathic Manipulative Medicine to Treat Fibromyalgia[NCT01107574] | Phase 3 | 41 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Analgesic Effect of Pregabalin in Patients Undergoing Total Abdominal Hysterectomy[NCT01466101] | 0 participants (Actual) | Interventional | 2011-01-31 | Withdrawn (stopped due to PI left the institution. No subjects screened or enrolled.) | |||
| Perioperative Administration of Pregabalin in Laparoscopic Living Donor Nephrectomy (L-LDN) - an Adjuvance to Peroral Analgetic Treatment - a Randomized Controlled Study[NCT01059331] | Phase 4 | 80 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia[NCT02024568] | Phase 2 | 38 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| Preoperative Use of Pregabalin and Analgesia Levels After Laparoscopic Cholecystectomy[NCT01321801] | 50 participants (Actual) | Interventional | 2009-11-30 | Completed | |||
| A Phase III, Double Blind, Randomized, Placebo-controlled Study to Assess the Efficacy of Adjunct Monochromatic Near-infrared Photoenergy (MIRE) in Patients With Painful Axonal Peripheral Neuropathy[NCT00125268] | Phase 3 | 30 participants (Actual) | Interventional | 2005-07-31 | Terminated (stopped due to Unable to enroll enough patients) | ||
| Use of Functional Magnetic Resonance Imaging (fMRI) to Study Brain Activation Following Rectal Stimulation in Children With Irritable Bowel Syndrome[NCT00677976] | 17 participants (Actual) | Observational | 2007-06-30 | Completed | |||
| Influence of Patient Sex on Pain Control and Multimodal Analgesia in Total Knee Arthroplasty[NCT04471233] | Phase 4 | 250 participants (Actual) | Interventional | 2020-12-09 | Completed | ||
| The Neural Immune Mechanisms and Genetic Influences on Chronic Pelvic Pain in Women With Endometriosis[NCT00073801] | 78 participants (Actual) | Observational | 2004-04-22 | Completed | |||
| Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297] | 301 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 1.~Change from baseline: Score at Week 1 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 1
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.39 |
| Pregabalin 300 mg/Day | -0.82 |
| Pregabalin 600 mg/Day | -1.14 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 10.~Change from baseline: Score at Week 10 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 10
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.23 |
| Pregabalin 300 mg/Day | -1.93 |
| Pregabalin 600 mg/Day | -2.10 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 11.~Change from baseline: Score at Week 11 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 11
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.32 |
| Pregabalin 300 mg/Day | -1.95 |
| Pregabalin 600 mg/Day | -2.09 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 12.~Change from baseline: Score at Week 12 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 12
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.36 |
| Pregabalin 300 mg/Day | -2.01 |
| Pregabalin 600 mg/Day | -2.13 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 13.~Change from baseline: Score at Week 13 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 13
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.38 |
| Pregabalin 300 mg/Day | -2.04 |
| Pregabalin 600 mg/Day | -2.12 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 2.~Change from baseline: Score at Week 2 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 2
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.57 |
| Pregabalin 300 mg/Day | -1.17 |
| Pregabalin 600 mg/Day | -1.80 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 3.~Change from baseline: Score at Week 3 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 3
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.80 |
| Pregabalin 300 mg/Day | -1.40 |
| Pregabalin 600 mg/Day | -1.93 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 4.~Change from baseline: Score at Week 4 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 4
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.89 |
| Pregabalin 300 mg/Day | -1.53 |
| Pregabalin 600 mg/Day | -2.00 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 5.~Change from baseline: Score at Week 5 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 5
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.91 |
| Pregabalin 300 mg/Day | -1.57 |
| Pregabalin 600 mg/Day | -2.07 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 6.~Change from baseline: Score at Week 6 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 6
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.94 |
| Pregabalin 300 mg/Day | -1.72 |
| Pregabalin 600 mg/Day | -2.06 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 7.~Change from baseline: Score at Week 7 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 7
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.04 |
| Pregabalin 300 mg/Day | -1.76 |
| Pregabalin 600 mg/Day | -2.13 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 8.~Change from baseline: Score at Week 8 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 8
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.18 |
| Pregabalin 300 mg/Day | -1.85 |
| Pregabalin 600 mg/Day | -2.12 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 9.~Change from baseline: Score at Week 9 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 9
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.20 |
| Pregabalin 300 mg/Day | -1.93 |
| Pregabalin 600 mg/Day | -2.06 |
The mean change from baseline in the weekly mean sleep interference score at study endpoint. Score range is from 0-10. Higher scores indicate more severe interference with sleep. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.74 |
| Pregabalin 300 mg/Day | -1.59 |
| Pregabalin 600 mg/Day | -1.36 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for overall sleep problems index ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -7.91 |
| Pregabalin 300 mg/Day | -11.45 |
| Pregabalin 600 mg/Day | -9.73 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for quantity of sleep ranges from 0-24. Higher scores indicate more of the attribute named in the subscale. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 0.37 |
| Pregabalin 300 mg/Day | 0.69 |
| Pregabalin 600 mg/Day | 0.54 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep adequacy ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 12.08 |
| Pregabalin 300 mg/Day | 17.69 |
| Pregabalin 600 mg/Day | 21.73 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep disturbance ranges from 0-100. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -9.03 |
| Pregabalin 300 mg/Day | -15.40 |
| Pregabalin 600 mg/Day | -12.81 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep shortness of breath or headache ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.63 |
| Pregabalin 300 mg/Day | -3.02 |
| Pregabalin 600 mg/Day | -4.47 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for snoring ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -6.00 |
| Pregabalin 300 mg/Day | -5.96 |
| Pregabalin 600 mg/Day | -1.56 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for somnolence ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -2.96 |
| Pregabalin 300 mg/Day | 0.83 |
| Pregabalin 600 mg/Day | 4.83 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 10.34 |
| Pregabalin 300 mg/Day | 11.84 |
| Pregabalin 600 mg/Day | 12.89 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 2.31 |
| Pregabalin 300 mg/Day | 3.29 |
| Pregabalin 600 mg/Day | 4.40 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 3.84 |
| Pregabalin 300 mg/Day | 5.33 |
| Pregabalin 600 mg/Day | 7.81 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 2.70 |
| Pregabalin 300 mg/Day | 2.43 |
| Pregabalin 600 mg/Day | 3.86 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 4.13 |
| Pregabalin 300 mg/Day | 5.05 |
| Pregabalin 600 mg/Day | 6.35 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 4.38 |
| Pregabalin 300 mg/Day | 2.28 |
| Pregabalin 600 mg/Day | 3.97 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 3.00 |
| Pregabalin 300 mg/Day | 8.06 |
| Pregabalin 600 mg/Day | 11.16 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 5.28 |
| Pregabalin 300 mg/Day | 4.20 |
| Pregabalin 600 mg/Day | 12.87 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Affective score ranges from 0-12. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.83 |
| Pregabalin 300 mg/Day | -1.43 |
| Pregabalin 600 mg/Day | -1.39 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Present pain intensity score ranges from 0-5. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.59 |
| Pregabalin 300 mg/Day | -0.80 |
| Pregabalin 600 mg/Day | -0.96 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Sensory score ranges from 0-33. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -2.82 |
| Pregabalin 300 mg/Day | -4.60 |
| Pregabalin 600 mg/Day | -4.95 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Total score ranges from 0-45. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -3.68 |
| Pregabalin 300 mg/Day | -6.03 |
| Pregabalin 600 mg/Day | -6.36 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Visual Analogue Scale Score ranges from 0-100 mm. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | mm (Least Squares Mean) |
|---|---|
| Placebo | -16.92 |
| Pregabalin 300 mg/Day | -24.19 |
| Pregabalin 600 mg/Day | -24.41 |
Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.20 |
| Pregabalin 300 mg/Day | -1.82 |
| Pregabalin 600 mg/Day | -1.94 |
Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. Subjects are classified by exposure to pregabalin, which is estimated by creatinine clearance (CLcr). (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.27 |
| Expected Exposure Pregabalin 300 mg/Day | -1.93 |
| Expected Exposure Pregabalin 600 mg/Day | -1.90 |
Clinical Global Impression of Change is a clinician-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00553475)
Timeframe: Week 13 or up to discontinuation
| Intervention | score on scale (Mean) |
|---|---|
| Placebo | 3.3 |
| Pregabalin 300 mg/Day | 2.9 |
| Pregabalin 600 mg/Day | 2.7 |
A responder is defined as a subject with a 50% reduction in weekly mean pain score from baseline to study endpoint. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | participants (Number) |
|---|---|
| Placebo | 29 |
| Pregabalin 300 mg/Day | 39 |
| Pregabalin 600 mg/Day | 16 |
The Patient Global Impression of Change is a patient-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00553475)
Timeframe: Week 13 or up to discontinuation
| Intervention | score on scale (Mean) |
|---|---|
| Placebo | 3.4 |
| Pregabalin 300 mg/Day | 3.2 |
| Pregabalin 600 mg/Day | 2.8 |
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message. (NCT03080493)
Timeframe: 2 hours after insertion of last osmotic dilator
| Intervention | Numeric rating scale pain score change (Median) |
|---|---|
| Gabapentin | 3.5 |
| Placebo Oral Capsule | 4 |
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message. (NCT03080493)
Timeframe: 4 hours after insertion of last osmotic dilator
| Intervention | Numeric rating scale pain score change (Mean) |
|---|---|
| Gabapentin | 3 |
| Placebo Oral Capsule | 3.5 |
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained in person before subject leaves clinic appointment. (NCT03080493)
Timeframe: 5 minutes after insertion of last osmotic dilator
| Intervention | Numeric rating scale pain score change (Median) |
|---|---|
| Gabapentin | 1 |
| Placebo Oral Capsule | 2 |
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message. (NCT03080493)
Timeframe: 8 hours after insertion of last osmotic dilator
| Intervention | Numeric rating scale pain score change (Median) |
|---|---|
| Gabapentin | 2 |
| Placebo Oral Capsule | 2.5 |
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained in person upon presentation for D&E procedure. (NCT03080493)
Timeframe: Time of presentation for D&E (day after dilator insertion)
| Intervention | Numeric rating scale pain score change (Median) |
|---|---|
| Gabapentin | 0.5 |
| Placebo Oral Capsule | 1 |
Subject account of how many used acetaminophen/codeine (standard medications given for supplement NSAID as needed after dilator insertion) (NCT03080493)
Timeframe: Collected between each subject contact (2 hours, 4 hours, 8 hours after dilator insertion and at time of presentation for D&E procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 35 |
| Placebo Oral Capsule | 40 |
An adverse event (AE) is defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to Baseline during a clinical study with an investigational medicinal product (IMP), regardless of causal relationship and even if no IMP has been administered. (NCT01364298)
Timeframe: Day 7 up to Day 84 (+7 days)
| Intervention | participants (Number) |
|---|---|
| Gabapentin/B-complex | 80 |
| Pregabalin | 93 |
"POMS is a rating scale, which comprises of 65 items that are evaluated in a 0-4 scale, where 0 means not at all and 4 extremely. The scores for the 65 items are added in various combinations to throw six validated factors which are used to calculate total POMS score: (tension-anxiety) + (depression-dejection) + (anger-hostility)+ (fatigue-Inertia) + (confusion-bewilderment) - (vigor-activity). Score range (-40 to 192). Score -40 denotes the best score and score 192 denotes the worst score." (NCT01364298)
Timeframe: Day 84 (Week 12)
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin/B-complex | 1.3 |
| Pregabalin | 3.4 |
An average NPIS pain score (daily average records of the past seven days) was evaluated. Numeric pain intensity scale (NPIS) is a 11-point scale, with 0 representing no pain and 10 representing the worst possible pain. The participants were asked to mark the number that best represents the current level of pain they have experienced during the previous 24 hours. Change from baseline data has been calculated as value at baseline minus value at Day 84. (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (n=147, 123) | Change at Day 84 (n=146, 122) | |
| Gabapentin/B-complex | 6.7 | 3.905 |
| Pregabalin | 6.8 | 4.260 |
The LANSS scale score is 7-item pain scale that consists of grouped sensory description and sensory examination with simple scoring system. Evaluations in two main areas: pain and sensorial exploration. The first 5 questions asks for presence of unpleasant skin sensations (pricking, tingling, pins and needles), appearance of skin (mottled, red, or pink), increased sensitivity of skin to touch, sudden bursts of electric shock sensations, and hot or burning skin sensations. Last 2 questions involve sensory testing for the presence of allodynia and altered pinprick threshold. Different numbers of points, relative to their significance to neuropathic pain, are given to positive answers for maximum of 24 points. A score less than 12 makes unlikely that participant's symptoms are neuropathic in nature, whereas score more than 12 make neuropathic mechanisms likely to be contributing to participant's pain. Change from baseline data has been calculated as value at baseline minus value at Day 84. (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (n=147, 123) | Change at Day 84 (n=146, 122) | |
| Gabapentin/B-complex | 16.2 | 8.082 |
| Pregabalin | 15.8 | 6.967 |
VAS is used to rate the pain as per 10 centimeter (cm) line. The pain intensity score ranges from '0=no pain' to '10=worst possible pain'. Change from baseline data has been calculated as value at baseline minus value at Day 84. (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)
| Intervention | centimeter (Mean) | |
|---|---|---|
| Baseline (n=147, 123) | Change at Day 84 (n=146, 122) | |
| Gabapentin/B-complex | 7.0 | 4.182 |
| Pregabalin | 7.1 | 4.529 |
CGIC is an assessment that the physician performs to assess the participant's global change in health condition from start of the study on a 7-point scale (1 = extremely improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse 6 = much worse, 7 = extremely worse). (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Health: extremely improved | Health: much improved | Health: minimally improved | |
| Gabapentin/B-complex | 55 | 79 | 11 |
| Pregabalin | 47 | 69 | 6 |
GIPC is an assessment that the participant's global change in health condition from start of the study on a 7-point scale (1 = extremely improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse 6 = much worse, 7 = extremely worse). (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Health: extremely improved | Health: much improved | Health: minimally improved | |
| Gabapentin/B-complex | 62 | 73 | 10 |
| Pregabalin | 47 | 65 | 10 |
NPIS is a 11-point scale, with 0 representing no pain and 10 representing the worst possible pain. The participants were asked to mark the number that best represents the current level of pain they have experienced during the previous 24 hours. (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| At least 30% improvement | At least 50% improvement | |
| Gabapentin/B-complex | 76.9 | 66.0 |
| Pregabalin | 85.4 | 72.4 |
Sleep evaluation was performed by assessing number of participants who fell asleep in a particular pre-specified range of time duration, that is, 0-15 minutes, 16-30 minutes, 31-45 minutes, 46-60 minutes and greater than 60 minutes at Day 84 (Week 12). (NCT01364298)
Timeframe: Day 84 (Week 12)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| 0 to 15 minutes | 16 to 30 minutes | 31 to 45 minutes | 46 to 60 minutes | Greater than 60 minutes | |
| Gabapentin/B-complex | 85 | 33 | 13 | 8 | 8 |
| Pregabalin | 72 | 33 | 12 | 4 | 2 |
Number of clicks on the app functions (NCT03004911)
Timeframe: 6 weeks
| Intervention | Clicks on app functions (Median) |
|---|---|
| Mobile Application | 106 |
Minimum value: 0. Maximum value: 100. Higher scores mean worse outcome. (NCT03004911)
Timeframe: 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Mobile Application | 53.7 |
| Paper Booklet | 55.5 |
Minimum value: 0. Maximum value: 19. (NCT03004911)
Timeframe: 6 weeks
| Intervention | number of painful areas (Mean) |
|---|---|
| Mobile Application | 12.5 |
| Paper Booklet | 12.3 |
Minimum value: 0. Maximum value: 10. Higher scores mean worse outcome. (NCT03004911)
Timeframe: 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Mobile Application | 5.1 |
| Paper Booklet | 5.3 |
Minimum value: 15. Maximum value: 75. Higher scores mean better outcome. (NCT03004911)
Timeframe: 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Mobile Application | 56.8 |
| Paper Booklet | 54.3 |
Minimum value: 0. Maximum value: 12. Higher scores mean worse outcome. (NCT03004911)
Timeframe: 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Mobile Application | 7.6 |
| Paper Booklet | 7.6 |
fMRI scans acquired Stimuli Type: Brush Stimulation Regions: Face (V2) Right and Left Sides Rating: Pain/ unpleasantness fMRI scans acquired Stimuli Type: Cold, threshold -1°C Stimulation Regions: Face (V2) Right and Left Sides Rating: Pain/ unpleasantness **Extra time allotted for probe repositioning** fMRI scans acquired Stimuli Type: Heat, threshold +1°C Stimulation Regions: Face (V2) Right and Left Sides Rating: Pain/ unpleasantness **Extra time allotted for probe repositioning** Cortical, subcortical, and brain stem sensory regions Z-scores Increase or decrease in activation as affected by the drug (NCT00243152)
Timeframe: Week 10 during scanning session
| Intervention | Z-statistic (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Heat Affected Thalamus (10,-14,8) | Heat Affected Post-Central (-56,-12,28) | Cold Affected Post-Central (68, -8, 32) | Cold Affected Thalamus (-4, -8, 0) | Brush Affected Post-Central (66,-16,14) | Brush Affected Thalamus (-14,-22, 4) | Brush Affected Spinal Trigeminal Nucles(2,-48,-68) | |
| Lamotrigine vs Placebo | -2.9294 | -2.7323 | -2.5114 | -3.033 | 3.905 | -3.791 | 2.9058 |
"Quantitative Sensory Testing (QST)~Stimuli Type: Heat, Cold, Brush Stimulation Regions: Face Affected and contralateral Unaffected mirror area Rating: Pain/ unpleasantness Stimuli Type: Cold, threshold -1°C Stimulation Regions: Face Affected and contralateral Unaffected mirror area Rating: Pain/ unpleasantness Stimuli Type: Heat, threshold +1°C Stimulation Regions: Face Affected and contralateral Unaffected mirror area Rating: Pain/ unpleasantness~Ratings on a likert scale of 0-10 with 0 being defined as no pain and 10 being defined as worst possible pain" (NCT00243152)
Timeframe: week 10 (during the scan)
| Intervention | scores on a pain scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Heat Affected | Heat Unaffected | Cold Affected | Cold Unaffected | Brush Affected | Brush Unaffected | |
| Lamotrigine | 3.2 | 3 | 2.1 | 2.2 | 2.8 | 1.2 |
| Placebo | 5.5 | 4 | 2.5 | 1.1 | 3.9 | .4 |
FIQ: 20-item self-administered questionnaire designed to assess areas such as health status, progress, and outcomes in participants with fibromyalgia. 11 items related to physical functioning, other items assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. FIQ contains 10 sub-scales scored from 0 to 10, with higher scores indicating more impairment in the subscale attribute. Total score range from 0 to 100 with higher scores indicating more impairment. (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -6.94 |
| Pregabalin 300 mg | -8.11 |
| Pregabalin 450 mg | -12.79 |
| Pregabalin 600 mg | -8.38 |
Daily pain diary consists of 11-point NRS ranging from 0(no pain) to 10(worst possible pain). Participants rated their pain during past 24 hours, self-assessment done daily at awakening. Baseline=Last 7 available pain scores before taking study medication up to and including Day 1. Final weekly (endpoint) mean pain score is defined as the mean pain score from the last 7 pain diary entries in the study while the participant was on study medication. (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.73 |
| Pregabalin 300 mg | -1.06 |
| Pregabalin 450 mg | -1.29 |
| Pregabalin 600 mg | -0.96 |
Daily quality of sleep diary consists of 11-point NRS ranging from 0(best possible sleep) to 10(worst possible sleep). Participants rated their quality of sleep during past 24 hours, self-assessment done daily upon awakening. Baseline=Last 7 available scores before taking study medication up to and including Day 1. The endpoint (up to week 14) mean quality of sleep score was based on Least Squares (LS) Means using ANCOVA, with treatment group and center in the model and the baseline mean sleep score used as the covariate. Final weekly (endpoint) mean sleep quality score is defined as the mean sleep quality score from the last 7 sleep diary entries in the study while the participant was on study medication. (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.94 |
| Pregabalin 300 mg | -1.42 |
| Pregabalin 450 mg | -1.72 |
| Pregabalin 600 mg | -1.95 |
MAF is a 16-item self-administered questionnaire that yields a Global Fatigue Index (GFI), measures 4 dimensions of fatigue: degree and severity, amount of distress it causes, its timing and degree to which fatigue interferes with activities of daily living. Only 15 items are used to calculate the GFI. GFI score range from 1 (no fatigue) to 50 (severe fatigue). (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.91 |
| Pregabalin 300 mg | -2.78 |
| Pregabalin 450 mg | -3.32 |
| Pregabalin 600 mg | -2.19 |
Pain visual analog scale (VAS): Participants assessed the severity of their pain using a 100 mm visual analog scale (VAS). The scale ranged from 0 (no pain) to 100 (worst possible pain), measurement on a scale corresponds to the magnitude of their pain. (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | mm (Least Squares Mean) |
|---|---|
| Placebo | -10.30 |
| Pregabalin 300 mg | -12.86 |
| Pregabalin 450 mg | -17.75 |
| Pregabalin 600 mg | -11.74 |
Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no), as well as a 9-item overall sleep problems index. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range*100);total score range:0-100,higher score=more disturbance. (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 30.8 |
| Pregabalin 300 mg | 33.5 |
| Pregabalin 450 mg | 44.0 |
| Pregabalin 600 mg | 32.4 |
Acetaminophen (up to 4 gram/day as needed for pain relief) was an allowable concomitant medication as a rescue therapy. The total daily acetaminophen dose taken during double-blind treatment was calculated for each participant as: (total acetaminophen dose during the study) divided by (total number of study days). (NCT00333866)
Timeframe: Week 14
| Intervention | mg/day (Least Squares Mean) |
|---|---|
| Placebo | 460.65 |
| Pregabalin 300 mg | 449.14 |
| Pregabalin 450 mg | 508.53 |
| Pregabalin 600 mg | 724.42 |
FIQ: 20-item self-administered questionnaire designed to assess areas such as health status, progress, and outcomes in participants with fibromyalgia. 11 items related to physical functioning, other items assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. FIQ contains 10 sub-scales scored from 0 to 10, with higher scores indicating more impairment in the subscale attribute. Total score range from 0 to 100 with higher scores indicating more impairment. (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | Units on a scale (Least Squares Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| FIQ Physical Impairment (n=183,184,179,186) | FIQ Feel Good (n=182,184,178,183) | FIQ Work Missed (n=182,181,178,184) | FIQ Do Work (n=182,183,179,185) | FIQ Pain (n=183,184,179,185) | FIQ Fatigue (n=183,184,179,184) | FIQ Rested (n=183,184,179,185) | FIQ Stiffness (n=183,184,179,185) | FIQ Anxiety (n=183,184,179,185) | FIQ Depression (n=181,184,179,184) | |
| Placebo | -0.09 | -1.15 | -0.13 | -0.90 | -0.97 | -0.81 | -0.94 | -1.06 | -0.48 | -0.22 |
| Pregabalin 300 mg | -0.26 | -1.11 | -0.29 | -1.04 | -1.18 | -0.86 | -1.17 | -1.02 | -0.66 | -0.56 |
| Pregabalin 450 mg | -0.35 | -1.77 | -0.75 | -1.60 | -1.72 | -1.36 | -1.47 | -1.28 | -1.12 | -1.19 |
| Pregabalin 600 mg | -0.26 | -1.26 | -0.27 | -0.98 | -1.10 | -1.05 | -1.40 | -0.94 | -0.68 | -0.43 |
HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms. (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | Units on a scale (Least Squares Mean) | |
|---|---|---|
| HADS Anxiety (HADS-A) Total | HADS Depression (HADS-D) Total | |
| Placebo | -0.31 | -0.11 |
| Pregabalin 300 mg | -0.42 | -0.33 |
| Pregabalin 450 mg | -0.81 | -0.70 |
| Pregabalin 600 mg | -0.90 | 0.04 |
Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no), as well as a 9-item overall sleep problems index. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range*100);total score range:0-100,higher score=more intensity of attribute. (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | Units on a scale (Least Squares Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Sleep Disturbance (n=183,183,177,185) | Snoring (n=172,174,174,177) | Shortness of Breath, Headache (n=182,182,177,184) | Quantity of Sleep (n=182,182,175,182) | Sleep Adequacy (n=183,183,179,185) | Somnolence (n=182,182,177,184) | Overall Sleep Problem Index (n=181,181,174,184) | |
| Placebo | -5.99 | -0.03 | -0.67 | 0.41 | 7.62 | -0.10 | -4.83 |
| Pregabalin 300 mg | -13.18 | 1.17 | -9.62 | 0.61 | 10.19 | 0.67 | -9.19 |
| Pregabalin 450 mg | -19.26 | 4.89 | -12.59 | 0.91 | 16.76 | 0.61 | -13.07 |
| Pregabalin 600 mg | -18.70 | 5.87 | -9.91 | 0.76 | 11.97 | 1.92 | -11.72 |
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0- 100, where higher score represents higher level of functioning. (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | Units on a scale (Least Squares Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Physical Functioning (n=184,184,177,186) | Physical Role Limitations (n=183,183,177,185) | Emotional Role Limitations (n=183,183,177,185) | Social Functioning (n=183,184,178,186) | Mental Health (n=183,184,178,186) | Bodily Pain (n=183,184,178,186) | Vitality (n=183,184,178,186) | General Health Perception (n=183,184,177,186) | Mental Component Score (n=182,183,176,184) | Physical Component Score (n=182,183,176,184) | |
| Placebo | 4.64 | 4.01 | -2.31 | 0.75 | -1.67 | 4.95 | 4.15 | 0.94 | -1.27 | 2.47 |
| Pregabalin 300 mg | 5.22 | 4.40 | 1.44 | 4.10 | 1.65 | 7.77 | 4.89 | 2.76 | 0.87 | 2.60 |
| Pregabalin 450 mg | 6.63 | 5.50 | 3.93 | 5.76 | 4.25 | 10.32 | 9.25 | 3.67 | 2.39 | 3.01 |
| Pregabalin 600 mg | 4.13 | 5.03 | 1.56 | 3.60 | 2.41 | 7.53 | 7.29 | 2.21 | 1.35 | 2.34 |
Daily quality of sleep diary consists of 11-point NRS ranging from 0(best possible sleep) to 10(worst possible sleep). Participants rated their quality of sleep during past 24 hours, self-assessment done daily upon awakening. Baseline=Last 7 available scores before taking study medication up to and including Day 1. The weekly mean quality of sleep score was based on LS Means using mixed model repeated measures ANCOVA, with treatment, center, week, and treatment-by-week interaction in the model and the baseline mean sleep score used as the covariate. Weekly mean sleep quality score is defined as the mean of the last 7 daily sleep diary entries. (NCT00333866)
Timeframe: Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
| Intervention | Units on a scale (Least Squares Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 (n=183,179,174,178) | Week 2 (n=180,172,168,174) | Week 3 (n=174, 164, 159,163) | Week 4 (n=165,157,155,156) | Week 5 (n=163, 150, 152,148) | Week 6 (n=159,145,148,144) | Week 7 (n=155,140,144,133) | Week 8 (n=149,133,142,127) | Week 9 (n=146,128,141,126) | Week 10 (n=144,125,139,126) | Week 11 (n=143,123,137,121) | Week 12 (n=141,121,135,119) | Week 13 (n=140,120,133,118) | Week 14 (n=134,115,128,111) | Overall (n=183,179,174,178) | |
| Placebo | -0.38 | -0.62 | -0.75 | -0.73 | -0.82 | -0.84 | -0.91 | -0.99 | -1.11 | -1.14 | -1.09 | -1.22 | -1.05 | -1.08 | -0.91 |
| Pregabalin 300 mg | -1.20 | -1.48 | -1.42 | -1.52 | -1.67 | -1.56 | -1.50 | -1.60 | -1.64 | -1.75 | -1.65 | -1.62 | -1.66 | -1.73 | -1.57 |
| Pregabalin 450 mg | -1.08 | -1.43 | -1.56 | -1.67 | -1.69 | -1.76 | -1.83 | -1.95 | -1.94 | -2.03 | -1.92 | -1.95 | -1.93 | -1.95 | -1.76 |
| Pregabalin 600 mg | -1.23 | -1.59 | -1.90 | -2.01 | -1.99 | -2.15 | -2.20 | -2.25 | -2.24 | -2.34 | -2.24 | -2.29 | -2.26 | -2.29 | -2.07 |
Number of participants with categorical change in overall status. PGIC: a participant-rated instrument assessing change in participant's overall status from baseline, on a scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00333866)
Timeframe: Week 14
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
| Placebo | 7 | 43 | 45 | 43 | 11 | 17 | 3 |
| Pregabalin 300 mg | 13 | 45 | 50 | 28 | 9 | 14 | 5 |
| Pregabalin 450 mg | 16 | 50 | 55 | 27 | 7 | 8 | 2 |
| Pregabalin 600 mg | 20 | 46 | 41 | 25 | 10 | 10 | 3 |
The S-LANSS is a self-reported version of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale. It aims to differentiate neuropathic pain from somatic or nociceptive pain. We will analyze the change in numeric average pain score during the past week (range from 0-10) from baseline. Higher scores indicate greater pain. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
| Intervention | score on a scale (Median) |
|---|---|
| Cherry Syrup | -2 |
| Valproic Acid | -2 |
The primary endpoint is the incidence of chronic pain after surgery. The study team will use the average pain score over the past week as noted on the Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS) for the assessment of pain, and define chronic pain as a score greater than or equal to 3. (NCT01928849)
Timeframe: 3 months or time of final adjudication assessment, up to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Cherry Syrup | 37 |
| Valproic Acid | 36 |
The BPI short form is a multidimensional patient-completed measure that assesses the sensory component of pain intensity. We will analyze the change in average pain score question (ranges 0-10) and the sum of the 7 interference questions (total range 0-70) from baseline. Higher score indicates greater pain and interference. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
| Intervention | score on a scale (Median) | |
|---|---|---|
| BPI Average Pain Score | BPI interference question sum | |
| Cherry Syrup | -2 | -15 |
| Valproic Acid | -1 | -7 |
The DVPRS is a pain assessment tool developed by the military in an effort to improve reliability and interpretability of pain assessment in the military population. It has been found to be an effective and valid tool in this population. We will analyze the change in numeric pain response (range 0-10) and the sum of the four supplemental questions (range 0-40) from baseline. Higher scores indicate greater pain and functional limitations. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
| Intervention | score on a scale (Median) | |
|---|---|---|
| DVPRS numeric pain | DVPRS Supplemental Question Sum | |
| Cherry Syrup | -2 | -9 |
| Valproic Acid | 0 | -4.5 |
The effect of study drug on perioperative analgesic consumption and corresponding analysis of pain/sedation scales. Outcome defined as total opioid consumption (mg) during each 24-hour periods following surgery. (NCT01928849)
Timeframe: Assessments during hospitalization (0-24 hours and 24-48 hours post-surgery)
| Intervention | morphine milligram equivalents (Median) | |
|---|---|---|
| Postoperative hours 0-24 | Postoperative hours 24-48 | |
| Cherry Syrup | 59 | 49 |
| Valproic Acid | 33 | 45 |
The incidence of neuropathic limb or post-amputation pain sub-types as defined by adjudication classification at each assessment time point. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Residual limb pain | Phantom limb | |
| Cherry Syrup | 29 | 22 |
| Valproic Acid | 31 | 26 |
The RASS is a commonly used, valid and reliable assessment tool for use in hospitalized patients. Validity testing reveals good inter-rater reliability among medical, surgical, and intensive care units. We will analyze the numeric score at each assessment (range -5 (unarousable) to 4 (combative)). (NCT01928849)
Timeframe: during hospitalization (0-24 hours and 24-48 hours post-surgery)
| Intervention | score on a scale (Median) | |
|---|---|---|
| Post-op hours 0-24 | Post-op hours 24-48 | |
| Cherry Syrup | 0 | 0 |
| Valproic Acid | 0 | 0 |
LPS, as determined by PSG, was the total number of epochs recorded on 2 consecutive nights divided by 2 at the end of each intervention period, from the beginning of the recording to the start of the first 20 consecutive non-wake epochs. (NCT00883740)
Timeframe: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
| Intervention | Minutes (Least Squares Mean) |
|---|---|
| Placebo | 41.63 |
| Pregabalin | 34.45 |
NAASO 1, as determined by PSG, was the number of times there was a wake period of at least one epoch in duration. Each entry counted was separated by a Stage 2 epoch, Stage 3 and 4 epoch, or Stage rapid eye movement (REM) epoch. The sum of 2 consecutive nights of recording was divided by 2 at the end of each intervention period. (NCT00883740)
Timeframe: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
| Intervention | Awakenings (Least Squares Mean) |
|---|---|
| Placebo | 26.92 |
| Pregabalin | 24.51 |
NAASO 2, as determined by PSG, was the number of times that there was a wake period of at least two epochs in duration. Each entry counted was separated by a Stage 2 epoch, Stage 3 and 4 epoch, or Stage REM epoch. The sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period. (NCT00883740)
Timeframe: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
| Intervention | Awakenings (Least Squares Mean) |
|---|---|
| Placebo | 10.16 |
| Pregabalin | 8.63 |
SE, as determined by PSG, was the TST divided by the time in bed, multiplied by 100. The sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period. (NCT00883740)
Timeframe: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
| Intervention | Percentage of time asleep (Least Squares Mean) |
|---|---|
| Placebo | 77.21 |
| Pregabalin | 82.64 |
SWS, as determined by PSG, Stage 3 plus 4 sleep divided by TST times 100 was the percentage of TST. The sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period. (NCT00883740)
Timeframe: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
| Intervention | Percentage of total sleep time (Least Squares Mean) |
|---|---|
| Placebo | 15.04 |
| Pregabalin | 17.18 |
TST, as determined by PSG, was the number of non-wake epochs from the beginning of recording to the end of the recording. TST was the sum of 2 consecutive nights of recording divided by 2 at the end of each intervention period. (NCT00883740)
Timeframe: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
| Intervention | Minutes (Least Squares Mean) |
|---|---|
| Placebo | 370.6 |
| Pregabalin | 396.2 |
WASO was the sum of wake time during sleep measured in epochs (30 seconds of polysomnography [PSG]) recording) after the onset of persistent sleep and prior to final awakening and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording [i.e. awake epoch immediately prior to the end of the recording]) on 2 consecutive nights divided by 2 at the end of each intervention period. (NCT00883740)
Timeframe: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or Early Termination (ET)
| Intervention | Minutes (Least Squares Mean) |
|---|---|
| Placebo | 70.69 |
| Pregabalin | 51.54 |
WTAS, as determined by PSG, was the total amount of time awake after the final awakening until the end of the 8 hours. WTAS was the sum of 2 consecutive nights of recordings divided by 2 at the end of each intervention period. (NCT00883740)
Timeframe: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
| Intervention | Minutes (Least Squares Mean) |
|---|---|
| Placebo | 9.19 |
| Pregabalin | 7.38 |
WTDS, as determined by PSG, was the total amount of time awake the participant experienced after the onset of persistent sleep and prior to the final awakening, or at the end of 8 hours of recording. WTDS was the sum of 2 consecutive nights of recordings divided by 2 at the end of each intervention period. (NCT00883740)
Timeframe: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
| Intervention | Minutes (Least Squares Mean) |
|---|---|
| Placebo | 63.38 |
| Pregabalin | 45.83 |
MOS-SS, a participant rated instrument used to assess sleep quantity and quality over the previous week, was comprised of 12 items yielding 7 subscale scores and 2 index composite index scores. Sleep Disturbance subscale score (4 items): individual scores were transformed (actual raw score minus lowest possible score divided by possible raw score range times 100) and ranged from 0 to 100; higher score indicated greater disturbance. Total score ranged=0 to 100; higher score indicates greater intensity of attribute. Change was score at week x minus score at baseline. (NCT00883740)
Timeframe: Week 1 (Baseline Intervention Period 1), Week 5 (End of Intervention Period 1), Week 7 (Baseline Intervention Period 2) and Week 11 (End of Intervention Period 2) or ET
| Intervention | Units on a scale (Least Squares Mean) | |
|---|---|---|
| Change Week 1 to Week 5 (n=59, 56) | Change Week 7 to Week 11 (n=50, 52) | |
| Placebo | -19.0 | -2.23 |
| Pregabalin | -27.1 | -21.0 |
MOS-SS, a participant rated instrument used to assess sleep quantity and quality over the previous week, was compromised of 12 items yielding 7 subscale scores and 2 index composite index scores. Composite index included Sleep Problems Index II (9 items), scores ranged from 0 to 100; higher scores indicated greater sleep problems. Change was score at week x minus score at baseline. (NCT00883740)
Timeframe: Week 1 (Baseline Intervention Period 1), Week 5 (End of Intervention Period 1), Week 7 (Baseline Intervention Period 2) and Week 11 (End of Intervention Period 2) or ET
| Intervention | Units on a scale (Least Squares Mean) | |
|---|---|---|
| Change Week 1 to Week 5 (n=59, 56) | Change Week 7 to Week 11 (50, 52) | |
| Placebo | -16.4 | -0.98 |
| Pregabalin | -21.9 | -14.4 |
Pain intensity as measured by NRS; a participant rated scale 0 to 10 (0 = no pain to 10 = worst pain possible). Weekly values were calculated as the average of the participants daily pain scores. (NCT00883740)
Timeframe: Daily up to Day 73 or ET
| Intervention | Units on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | |
| Placebo | 6.12 | 5.81 | 5.73 | 5.44 |
| Pregabalin | 5.42 | 5.10 | 5.14 | 4.92 |
LSO as reported on daily Subjective Sleep Questionnaire (SSQ), a participant reported subjective estimate of the amount of time to fall asleep after lights out. Weekly values were calculated as the average minutes reported on the participant's daily SSQ. (NCT00883740)
Timeframe: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
| Intervention | Minutes (Least Squares Mean) | |||
|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | |
| Placebo | 51.23 | 49.94 | 48.92 | 46.70 |
| Pregabalin | 43.56 | 42.27 | 43.24 | 40.51 |
Sleep Quality as meassured by numeric rating scale (NRS), a participant rated scale 0 to 10, (0 = very poor sleep, 10 = excellent sleep). Weekly values were calculated as the average of the participants daily diary scores. (NCT00883740)
Timeframe: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
| Intervention | Unit on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | |
| Placebo | 4.79 | 4.95 | 5.09 | 5.17 |
| Pregabalin | 5.70 | 6.09 | 5.96 | 6.06 |
sTST as reported on daily SSQ, a participant reported subjective estimate of the total amount of time the participant was asleep after lights out until final awakening. Weekly values were calculated as the average of the participants daily SSQ values. (NCT00883740)
Timeframe: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
| Intervention | Minutes (Least Squares Mean) | |||
|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | |
| Placebo | 336.8 | 341.9 | 344.1 | 352.5 |
| Pregabalin | 361.7 | 371.3 | 370.9 | 377.9 |
sWASO as reported on daily SSQ, a participant reported subjective estimate of the total amount of time the participant was awake after initial sleep onset until final awakening. Weekly values were calculated as the average of the participant's daily SSQ values. (NCT00883740)
Timeframe: Weeks 1, 2, 3 and 4 of Each Intervention Period or ET
| Intervention | Minutes (Least Squares Mean) | |||
|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | |
| Placebo | 80.86 | 75.48 | 74.97 | 69.65 |
| Pregabalin | 62.59 | 59.43 | 61.73 | 59.40 |
WASO, as determined by PSG, was the sum of wake time during sleep (number of wake epochs after the onset of persistent sleep and prior to final awakening) and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording) on 2 consecutive nights divided by 2 at the end of each intervention period by each individual quarter of the night (eight hours in 2 hour increments). (NCT00883740)
Timeframe: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
| Intervention | Minutes (Least Squares Mean) | |||
|---|---|---|---|---|
| Quarter 1 | Quarter 2 | Quarter 3 | Quarter 4 | |
| Placebo | 7.23 | 16.04 | 21.73 | 28.04 |
| Pregabalin | 5.98 | 10.04 | 14.90 | 22.60 |
WASO, as determined by PSG, was the wake time during sleep (number of wake epochs after the onset of persistent sleep and prior to final awakening) and wake time after sleep (the number of epochs after the final awakening until the end of PSG recording) on 2 consecutive nights divided by 2 at the end of each intervention period by each individual hour (8 hours total). (NCT00883740)
Timeframe: Week 5 (End of Intervention Period 1) and Week 11 (End of Intervention Period 2) or ET
| Intervention | Minutes (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Hour 1 | Hour 2 | Hour 3 | Hour 4 | Hour 5 | Hour 6 | Hour 7 | Hour 8 | |
| Placebo | 1.96 | 5.66 | 7.09 | 8.95 | 10.55 | 11.26 | 10.96 | 17.08 |
| Pregabalin | 1.62 | 4.56 | 4.65 | 5.43 | 7.54 | 7.38 | 8.38 | 14.23 |
Subjects rated their pain using the VAS at visit 3, which was the last day of their maintenance phase. After this visit, subjects begin to taper the gralise. The VAS is subject reported on a scale of 0-10 with 0 being no pain and 10 being the worst pain they can imagine. Results reported are an average of the 3 subjects who completed visit 3. (NCT01623271)
Timeframe: At visit 3
| Intervention | units on the VAS (Mean) |
|---|---|
| CRPS I Pain Subjects | 3.67 |
The sickness inventory profile (SIP) is a behaviorally based measure of health status. Scores range from 0-68 with higher numbers indicating worse outcomes. The study report total SIP score. The higher the score the worse the function. (NCT01265056)
Timeframe: First Clinic Follow Up After Discharge
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 34.9 |
| Gabapentin | 36.0 |
(NCT01265056)
Timeframe: From time of enrollment to 2 weeks after being discharged
| Intervention | morphine equivalents (Mean) |
|---|---|
| Placebo | 7.0 |
| Gabapentin | 6.7 |
The Brief Symptom Inventory 18 (BSI 18) is designed with reliability in mind. The BSI 18 assessment gathers patient-reported data to help measure psychological distress and psychiatric disorders in medical and community populations. As the latest in an integrated series of test instruments that include the SCL-90-R®, BSI® (53 questions), and DPRS® instruments, the BSI 18 test offers a more effective, easy-to-administer tool to help support clinical decision-making and monitor progress throughout treatment. BSI-18 measures three dimensions with 6 questions a piece (somatization , depression , anxiety) and overall psychological distress scores (Global severity index, GSI). Each of the 18 items range from a score of 0-4; total score ranges from 0-72 with higher scores indicating worse function. The GSI score is calculated as the mean of the three subscales. The study reported the GSI score. Higher score is worse. (NCT01265056)
Timeframe: First Clinic Follow Up After Discharge
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 9 |
| Gabapentin | 7.3 |
The Fibromyalgia Impact Questionnaire (FIQ) is an instrument designed to quantitate the overall impact of fibromyalgia over many dimensions (e.g. function, pain level, fatigue, sleep disturbance, psychological distress etc.). It is scored from 0 to 100 with the latter number being the worst case. The average score for patients seen in tertiary care settings is about 50. The FIQ is widely used to assess change in fibromyalgia status. (NCT02052414)
Timeframe: 15 weeks.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| FIQ Baseline | FIQ Week 4 | FIQ Week 8 | FIQ Week 12 | FIQ Week 15 | |
| Gralise (Gabapentin ER) | 71.04 | 41.82 | 40.79 | 39.27 | 61.86 |
"Medical Outcomes Study (MOS) sleep questionnaires to assess how Fibromyalgia impacts patients' sleep in various areas.~Specifically, Data reported below measured number of hours subjects spent per night sleeping. MOS sleep questionnaires were assessed at each follow up visits. (visits 1, 2, 3, 4, and 5)." (NCT02052414)
Timeframe: 15 weeks
| Intervention | Hours (Mean) | ||||
|---|---|---|---|---|---|
| Sleep Quantity Baseline | Sleep Quantity week 4 | Sleep quantity week 8 | Sleep quantity week 12 | Sleep quantity week 15 | |
| Gralise (Gabapentin ER) | 5.86 | 7.17 | 6.81 | 7.04 | 6.23 |
Fibromyalgia pain experienced by study subjects will be captured using NPRS at baseline visit, at each follow visits that are scheduled to occur every 4 weeks over 12 weeks of treatment period, and at the end of treatment visit that will occur 3 weeks after treatment period (12 weeks treatment period + 3 weeks = 15 weeks). Any difference in NPRS scores between baseline and any subsequent visits will indicate the magnitude of pain relief as reflected in digital scale of 0-10 (0=no pain, 10=worst pain imaginable). (NCT02052414)
Timeframe: 15 weeks
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| NPRS Baseline (Visit 1) | NPRS on Week 4 (Visit 2) | NPRS on week 8 (Visit 3) | NPRS on Week 12 (Visit 4) | NPRS on week 15 (Visit 5) | |
| Gralise (Gabapentin ER) | 7.29 | 4.72 | 3.95 | 3.83 | 6.94 |
Patient Global impression of Change (PGIC) is an outcome commonly used measure of the efficacy of treatments. PGIC is a 7 point scale that requires the subjects to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. (NCT02052414)
Timeframe: 15 Weeks.
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| PGIC After 4 weeks | PGIC After 8 weeks | PGIC After 12 weeks | PGIC After 15 weeks | |
| Gralise (Gabapentin ER) | 4.96 | 5.40 | 5.37 | 4.44 |
Side / adverse effects were assessed at each follow up visits and resulted are as follows. (NCT02052414)
Timeframe: 15 Weeks
| Intervention | participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Extremity Swelling | Weight Gain | Drowsy | Dizzy | Irritability | Dry Eyes | Pain | Mood Changes | Difficulty Concentrating | Dry Mouth | Suspected Drug interaction | Acute Delerium | Adhesion | None | |
| Gralise (Gabapentin ER) | 2 | 2 | 8 | 3 | 3 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 12 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
132 reviews available for gamma-aminobutyric acid and Pain
| Article | Year |
|---|---|
GABAergic signalling in modulation of dental pain.
Topics: gamma-Aminobutyric Acid; Humans; Pain; Signal Transduction; Spinal Cord | 2022 |
Prophylactic gabapentin during head and neck cancer therapy: a systematic review and meta-analysis.
Topics: Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric | 2023 |
Current status of GABA receptor subtypes in analgesia.
Topics: Analgesia; Animals; Chloride Channels; gamma-Aminobutyric Acid; Glutamic Acid; Mammals; Neurotransmi | 2023 |
Excitatory and inhibitory responses in the brain to experimental pain: A systematic review of MR spectroscopy studies.
Topics: Brain; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Magnetic Resonance Spectroscopy; P | 2020 |
GABA
Topics: Analgesics; gamma-Aminobutyric Acid; Humans; Pain; Receptors, GABA-B | 2022 |
Presynaptic Inhibition of Pain and Touch in the Spinal Cord: From Receptors to Circuits.
Topics: Animals; Astrocytes; GABA Antagonists; GABAergic Neurons; gamma-Aminobutyric Acid; Nerve Fibers; Neu | 2021 |
Delta-containing GABA
Topics: Analgesics; Animals; gamma-Aminobutyric Acid; Humans; Pain; Pain Management; Receptors, GABA-A | 2021 |
A review of analgesic compounds used in food animals in the United States.
Topics: Adrenergic alpha-Agonists; Amines; Analgesia; Analgesics; Analgesics, Opioid; Anesthetics, Local; An | 2013 |
Benzodiazepine receptor ligands: a patent review (2006-2012).
Topics: Animals; Binding Sites; Cognition Disorders; Drug Design; gamma-Aminobutyric Acid; Humans; Ligands; | 2013 |
The potential of pregabalin in neurology, psychiatry and addiction: a qualitative overview.
Topics: Analgesics; Animals; Anticonvulsants; Calcium Channel Blockers; Calcium Channels; Central Nervous Sy | 2013 |
Mechanisms and management of diabetic painful distal symmetrical polyneuropathy.
Topics: Diabetic Neuropathies; Duloxetine Hydrochloride; gamma-Aminobutyric Acid; Humans; Pain; Peripheral N | 2013 |
Pharmacological treatment for pain in Guillain-Barré syndrome.
Topics: Amines; Analgesics; Carbamazepine; Constipation; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Amin | 2013 |
Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neopla | 2014 |
Treatment of hidradenitis supprurativa associated pain with nonsteroidal anti-inflammatory drugs, acetaminophen, celecoxib, gabapentin, pegabalin, duloxetine, and venlafaxine.
Topics: Acetaminophen; Amines; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclohexaneca | 2013 |
GABA pharmacology: the search for analgesics.
Topics: Analgesics; gamma-Aminobutyric Acid; Humans; Pain; Receptors, GABA | 2014 |
Descending modulation of pain: the GABA disinhibition hypothesis of analgesia.
Topics: Analgesics; Animals; Efferent Pathways; gamma-Aminobutyric Acid; Humans; Pain | 2014 |
[A case of Guillain-Barré syndrome with severe pain successfully controlled with acetaminophen, gabapentin, and parenterally infused fentanyl].
Topics: Acetaminophen; Amines; Child; Cyclohexanecarboxylic Acids; Drug Combinations; Fentanyl; Gabapentin; | 2014 |
Restless legs syndrome and pain disorders: what's in common?
Topics: Calcium Channel Blockers; Diagnosis, Differential; Dopamine Agonists; Fibromyalgia; gamma-Aminobutyr | 2014 |
Analgesic, anxiolytic and anaesthetic effects of melatonin: new potential uses in pediatrics.
Topics: Analgesics; Anesthetics, General; Anti-Anxiety Agents; Anxiety Disorders; Brain Diseases; Child; Ele | 2015 |
Inhibitory regulation of the pain gate and how its failure causes pathological pain.
Topics: Animals; gamma-Aminobutyric Acid; Humans; Neural Inhibition; Neurotransmitter Agents; Pain; Pain Mea | 2015 |
Plasticity of inhibition in the spinal cord.
Topics: Animals; gamma-Aminobutyric Acid; Humans; Interneurons; Neural Inhibition; Neuronal Plasticity; Pain | 2015 |
Amygdala pain mechanisms.
Topics: Amygdala; Animals; Calcitonin; Corticotropin-Releasing Hormone; gamma-Aminobutyric Acid; Humans; Neu | 2015 |
Pharmacological treatment for pain in Guillain-Barré syndrome.
Topics: Amines; Analgesics; Carbamazepine; Constipation; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Amin | 2015 |
Therapeutic Basis of Clinical Pain Modulation.
Topics: Adrenergic Neurons; Amygdala; Analgesics; Analgesics, Opioid; Anesthetics; Animals; Autonomic Nervou | 2015 |
Headache and Pain in Guillain-Barré Syndrome.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Guillain-Barre Sy | 2015 |
Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics.
Topics: Amines; Analgesics, Opioid; Animals; Antidepressive Agents; Antineoplastic Agents; Cisplatin; Cycloh | 2016 |
Painful Diabetic Neuropathy: Prevention or Suppression?
Topics: Analgesics; Animals; Calcium Channels, T-Type; Diabetic Neuropathies; gamma-Aminobutyric Acid; Human | 2016 |
Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review.
Topics: Amines; Analgesics; Anticonvulsants; Antidepressive Agents; Chemotherapy, Adjuvant; Cyclohexanecarbo | 2017 |
Analgesia in the surgical intensive care unit.
Topics: Acetaminophen; Amines; Analgesics; Analgesics, Opioid; Anesthesia, Conduction; Anesthetics, Local; C | 2017 |
Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders.
Topics: Analgesics; Central Nervous System Diseases; Choline; Donepezil; Epilepsy; gamma-Aminobutyric Acid; | 2017 |
Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck.
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2016 |
GABA
Topics: Analgesics; Animals; gamma-Aminobutyric Acid; Humans; Pain; Receptors, GABA-A | 2017 |
Practical management strategies for the chronic pain patient.
Topics: Administration, Cutaneous; Amines; Analgesics; Antidepressive Agents, Tricyclic; Carbamazepine; Chro | 2007 |
[Central and peripheral mechanisms in antinociception: current and future perspectives].
Topics: Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Bridged Bicyclo Compounds, Heterocycl | 2008 |
Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain.
Topics: Amines; Analgesics; Analysis of Variance; Bayes Theorem; Cyclohexanecarboxylic Acids; Diabetic Neuro | 2009 |
Pregabalin in the treatment of chronic pain: an overview.
Topics: Amines; Analgesics, Non-Narcotic; Animals; Calcium Channels; Chronic Disease; Cyclohexanecarboxylic | 2009 |
Pregabalin for fibromyalgia: some relief but no cure.
Topics: Analgesics; Evidence-Based Medicine; Fibromyalgia; gamma-Aminobutyric Acid; Humans; Pain; Pain Measu | 2009 |
[GABA(B) receptors and sensitization to pain].
Topics: 14-3-3 Proteins; Allosteric Regulation; Animals; Baclofen; Calcium Channels; Calcium-Binding Protein | 2009 |
Pregabalin for acute and chronic pain in adults.
Topics: Acute Disease; Adult; Analgesics; Chronic Disease; Diabetic Neuropathies; Fibromyalgia; gamma-Aminob | 2009 |
Pregabalin for acute and chronic pain in adults.
Topics: Acute Disease; Adult; Analgesics; Chronic Disease; Diabetic Neuropathies; Fibromyalgia; gamma-Aminob | 2009 |
Pregabalin for acute and chronic pain in adults.
Topics: Acute Disease; Adult; Analgesics; Chronic Disease; Diabetic Neuropathies; Fibromyalgia; gamma-Aminob | 2009 |
Pregabalin for acute and chronic pain in adults.
Topics: Acute Disease; Adult; Analgesics; Chronic Disease; Diabetic Neuropathies; Fibromyalgia; gamma-Aminob | 2009 |
[Role of extracellular nucleotides and their receptors in chronic pain].
Topics: Adenosine Triphosphate; Animals; Brain-Derived Neurotrophic Factor; Chronic Disease; Drug Design; ga | 2009 |
[Pain relief by gabapentin via supraspinal mechanisms in neuropathic conditions].
Topics: Amines; Analgesics; Animals; Brain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid | 2009 |
Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports.
Topics: Analgesics; Dose-Response Relationship, Drug; Fibromyalgia; gamma-Aminobutyric Acid; Humans; Pain; P | 2010 |
WITHDRAWN. Anticonvulsant drugs for acute and chronic pain.
Topics: Acute Disease; Amines; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topic; Cycloh | 2010 |
Lumbar spinal stenosis: a brief review of the nonsurgical management.
Topics: Administration, Intranasal; Alprostadil; Amines; Analgesics, Non-Narcotic; Anesthetics, Local; Anti- | 2010 |
Central sensitization and Ca(V)α₂δ ligands in chronic pain syndromes: pathologic processes and pharmacologic effect.
Topics: Amines; Analgesics; Animals; Calcium Channels; Complex Regional Pain Syndromes; Cyclohexanecarboxyli | 2010 |
Gabapentin for the treatment of cancer-related pain syndromes.
Topics: Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2010 |
An algorithm for the treatment of chronic testicular pain.
Topics: Algorithms; Amines; Analgesics; Anesthetics; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive | 2010 |
Oxycodone combinations for pain relief.
Topics: Acetaminophen; Amines; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Aspi | 2010 |
Pregabalin: an alpha2-delta (alpha2-delta) ligand for the management of fibromyalgia.
Topics: Analgesics; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Fibromyalgia; gam | 2010 |
Treating diabetic peripheral neuropathic pain.
Topics: Analgesics, Opioid; Anticonvulsants; Antidepressive Agents; Complementary Therapies; Diabetic Neurop | 2010 |
Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis.
Topics: Amines; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Fem | 2010 |
[Development of animal models of herpetic pain and postherpetic neuralgia and elucidation of the mechanisms of the onset and inhibition of allodynia].
Topics: Amines; Analgesics; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Cyclooxygenase Inhibitors | 2011 |
WITHDRAWN: Gabapentin for acute and chronic pain.
Topics: Acute Disease; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; ga | 2011 |
Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response.
Topics: Absenteeism; Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Cos | 2011 |
Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response.
Topics: Absenteeism; Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Cos | 2011 |
Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response.
Topics: Absenteeism; Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Cos | 2011 |
Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response.
Topics: Absenteeism; Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Cos | 2011 |
Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response.
Topics: Absenteeism; Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Cos | 2011 |
Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response.
Topics: Absenteeism; Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Cos | 2011 |
Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response.
Topics: Absenteeism; Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Cos | 2011 |
Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response.
Topics: Absenteeism; Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Cos | 2011 |
Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response.
Topics: Absenteeism; Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Cos | 2011 |
[Molecular mechanisms and clinical pharmacology of chronic pain].
Topics: Amines; Animals; Anterior Horn Cells; Antidepressive Agents; Brain; Chronic Disease; Cyclohexanecarb | 2010 |
Anti-epileptic drugs.
Topics: Anticonvulsants; Automobile Driving; Drug Interactions; Epilepsy; Female; GABA Agents; gamma-Aminobu | 2011 |
Fast synaptic inhibition in spinal sensory processing and pain control.
Topics: Animals; gamma-Aminobutyric Acid; Glycine; Humans; Interneurons; Neurotransmitter Agents; Pain; Post | 2012 |
Astrocyte-neuron communication: functional consequences.
Topics: Adenosine Triphosphate; Animals; Astrocytes; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Memory; | 2012 |
Use of anticonvulsants for treatment of neuropathic pain.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; | 2002 |
Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anticonvu | 2003 |
Cellular and molecular action of the putative GABA-mimetic, gabapentin.
Topics: Acetates; Amines; Analgesics; Animals; Anticonvulsants; Anxiety; Brain; Cyclohexanecarboxylic Acids; | 2003 |
The role of gabapentin in treating diseases with cutaneous manifestations and pain.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herp | 2003 |
Gabapentin: a viewpoint by Ian Gilron.
Topics: Acetates; Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; | 2003 |
[Nonorganic pain -- only psychogenic?].
Topics: Acetates; Adult; Amines; Analgesics; Analgesics, Opioid; Anesthetics, Local; Back Pain; Chronic Dise | 2003 |
Gabapentin in the treatment of neuropathic pain.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 2004 |
Pregabalin (Pfizer).
Topics: Analgesics, Non-Narcotic; Animals; Anticonvulsants; Anxiety Disorders; Clinical Trials, Phase II as | 2004 |
Post-herpetic neuralgia case study: optimizing pain control.
Topics: Acetates; Aged; Amines; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2004 |
80-year-old man with fever and ear pain.
Topics: Acetates; Acyclovir; Age Factors; Aged; Aged, 80 and over; Amines; Analgesics; Antiviral Agents; Cyc | 2004 |
GABA puts a stop to pain.
Topics: Afferent Pathways; Animals; Central Nervous System; GABA Agents; GABA Plasma Membrane Transport Prot | 2004 |
[Evidence-based pharmacotherapy of neuropathic pain syndromes].
Topics: Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Antioxidants; Cyclohexanec | 2004 |
[Progress on painful diabetic peripheral neuropathy treated by integrative medicine].
Topics: Amines; Amitriptyline; Analgesics; Animals; Antidepressive Agents, Tricyclic; Blood Glucose; Cyclohe | 2005 |
Role of cation-chloride-cotransporters (CCC) in pain and hyperalgesia.
Topics: Analgesics; gamma-Aminobutyric Acid; Glycine; Hyperalgesia; K Cl- Cotransporters; Pain; Posterior Ho | 2005 |
Anticonvulsant drugs for acute and chronic pain.
Topics: Acute Disease; Amines; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topic; Cycloh | 2005 |
Gabapentin for acute and chronic pain.
Topics: Acute Disease; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; Ga | 2005 |
Pregabalin: a new agent for the treatment of neuropathic pain.
Topics: Analgesics, Non-Narcotic; Animals; Anti-Anxiety Agents; Anticonvulsants; Diabetic Neuropathies; Fibr | 2005 |
Combination pharmacotherapy for neuropathic pain: current evidence and future directions.
Topics: Amines; Analgesics; Animals; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drug Synergism; | 2005 |
Pregabalin: a new neuromodulator with broad therapeutic indications.
Topics: Agoraphobia; Anxiety; Diabetic Neuropathies; Epilepsy; gamma-Aminobutyric Acid; Herpesviridae Infect | 2005 |
The mechanism of action of gabapentin in neuropathic pain.
Topics: Amines; Analgesics, Non-Narcotic; Animals; Binding Sites; Calcium Channels; Cyclohexanecarboxylic Ac | 2006 |
Mechanisms of the antinociceptive action of gabapentin.
Topics: Amines; Analgesics; Animals; Anticonvulsants; Calcium Channels, N-Type; Cyclohexanecarboxylic Acids; | 2006 |
Gabapentin for pain: balancing benefit and harm.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Gabapentin; gamma | 2006 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 2005 |
[Pregabalin. A new treatment for neuropathic pain].
Topics: Analgesics; Animals; Clinical Trials as Topic; Diabetic Neuropathies; gamma-Aminobutyric Acid; Human | 2006 |
Pregabalin: From molecule to medicine.
Topics: Agoraphobia; Animals; Anti-Anxiety Agents; Clinical Trials as Topic; gamma-Aminobutyric Acid; Humans | 2006 |
alpha2delta and the mechanism of action of gabapentin in the treatment of pain.
Topics: Amines; Analgesics; Animals; Brain; Calcium Channels; Cyclohexanecarboxylic Acids; GABA Modulators; | 2006 |
The role of GABA in the mediation and perception of pain.
Topics: Animals; GABA Agonists; GABA Antagonists; gamma-Aminobutyric Acid; Humans; Models, Biological; Nocic | 2006 |
Adjuvant analgesics for the treatment of neuropathic pain: evaluating efficacy and safety profiles.
Topics: Administration, Cutaneous; Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents; Arthritis; | 2007 |
Development of pain: maturation of spinal inhibitory networks.
Topics: Animals; gamma-Aminobutyric Acid; Glycine; Humans; Inhibitory Postsynaptic Potentials; Nerve Net; Pa | 2007 |
Ca2+ channel alpha2-delta ligands for the treatment of neuropathic pain.
Topics: Amines; Analgesics; Animals; Anticonvulsants; Calcium Channels; Carboxylic Acids; Cyclohexanecarboxy | 2007 |
Update on pharmacotherapy guidelines for treatment of neuropathic pain.
Topics: Analgesics; Animals; Cannabidiol; Chronic Disease; Dronabinol; Duloxetine Hydrochloride; gamma-Amino | 2007 |
Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain.
Topics: Adrenergic Uptake Inhibitors; Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tr | 2007 |
Pregabalin: an antiepileptic agent useful for neuropathic pain.
Topics: Animals; Anticonvulsants; Diabetic Neuropathies; Epilepsy, Partial, Sensory; gamma-Aminobutyric Acid | 2007 |
Assessing the impact of pharmacologic intervention on the quality of life in diabetic peripheral neuropathic pain and fibromyalgia.
Topics: Antidepressive Agents; Diabetic Neuropathies; Duloxetine Hydrochloride; Fibromyalgia; gamma-Aminobut | 2007 |
Safety profile of treatment in diabetic peripheral neuropathic pain.
Topics: Administration, Topical; Analgesics; Anesthetics, Local; Anticonvulsants; Antidepressive Agents; Ant | 2007 |
[Pregabalin in the treatment of neuropathic pain].
Topics: Analgesics; Cost-Benefit Analysis; Diabetic Neuropathies; Evidence-Based Medicine; gamma-Aminobutyri | 2007 |
Gabapentin Extended-Release - Depomed: Gabapentin ER, Gabapentin Gastric Retention, Gabapentin GR.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Preparations; Diabetic Neuropathies; | 2007 |
Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate.
Topics: Animals; Brain; Cannabinoid Receptor Modulators; gamma-Aminobutyric Acid; Glutamates; Humans; Models | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Pregabalin: its pharmacology and use in pain management.
Topics: Animals; Disease Management; gamma-Aminobutyric Acid; Humans; Pain; Pregabalin | 2007 |
Pregabalin: its pharmacology and use in pain management.
Topics: Animals; Disease Management; gamma-Aminobutyric Acid; Humans; Pain; Pregabalin | 2007 |
Pregabalin: its pharmacology and use in pain management.
Topics: Animals; Disease Management; gamma-Aminobutyric Acid; Humans; Pain; Pregabalin | 2007 |
Pregabalin: its pharmacology and use in pain management.
Topics: Animals; Disease Management; gamma-Aminobutyric Acid; Humans; Pain; Pregabalin | 2007 |
Pregabalin: its pharmacology and use in pain management.
Topics: Animals; Disease Management; gamma-Aminobutyric Acid; Humans; Pain; Pregabalin | 2007 |
Pregabalin: its pharmacology and use in pain management.
Topics: Animals; Disease Management; gamma-Aminobutyric Acid; Humans; Pain; Pregabalin | 2007 |
Pregabalin: its pharmacology and use in pain management.
Topics: Animals; Disease Management; gamma-Aminobutyric Acid; Humans; Pain; Pregabalin | 2007 |
Pregabalin: its pharmacology and use in pain management.
Topics: Animals; Disease Management; gamma-Aminobutyric Acid; Humans; Pain; Pregabalin | 2007 |
Pregabalin: its pharmacology and use in pain management.
Topics: Animals; Disease Management; gamma-Aminobutyric Acid; Humans; Pain; Pregabalin | 2007 |
[Pregabalin--a neuromodulator for the treatment of neuropathic pain, generalized anxiety disorders and fibromyalgia syndrome].
Topics: Analgesics; Anxiety Disorders; Fibromyalgia; gamma-Aminobutyric Acid; Humans; Pain; Peripheral Nervo | 2007 |
Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome.
Topics: Anticonvulsants; Anxiety Disorders; Cognition Disorders; Depression; Fatigue; Fibromyalgia; gamma-Am | 2007 |
Loss of glycinergic and GABAergic inhibition in chronic pain--contributions of inflammation and microglia.
Topics: Animals; Chronic Disease; Dinoprostone; gamma-Aminobutyric Acid; Glycine; Humans; Inflammation; Micr | 2008 |
[Psychopharmacotherapy in psychiatric comorbidities among patients with chronic pain].
Topics: Amines; Analgesics; Anticonvulsants; Bupropion; Chronic Disease; Cyclohexanecarboxylic Acids; Dopami | 2007 |
Neuropharmacology of depression, anxiety, and pain.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety; Benzodiazepines; Brain; Cat | 1981 |
GABA-ergic analgesia - a naloxone-insensitive system.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Endorphins; gamma-Aminobutyric Acid; Humans; Naloxone | 1982 |
Neurophysiological and nutritional considerations of pain control.
Topics: Analgesia; Brain; Endorphins; gamma-Aminobutyric Acid; Humans; Neurotransmitter Agents; Nociceptors; | 1984 |
Pharmacology of pain and analgesia.
Topics: Amino Acids; Analgesia; Electric Stimulation; Endorphins; Enkephalins; gamma-Aminobutyric Acid; Narc | 1980 |
[Depolarization of primary afferents in the spinal cord. Mechanisms and functions].
Topics: Animals; Brain; Cats; Evoked Potentials; gamma-Aminobutyric Acid; Membrane Potentials; Movement; Mus | 1982 |
Possible involvement of taurine and GABA in morphine-like peptide actions.
Topics: Amino Acids; Analgesia; Animals; Enkephalin, Methionine; gamma-Aminobutyric Acid; Humans; Male; Moto | 1980 |
The dorsal raphe: an important nucleus in pain modulation.
Topics: Animals; gamma-Aminobutyric Acid; Humans; Neurotransmitter Agents; Opioid Peptides; Pain; Raphe Nucl | 1994 |
GABA and its receptors in the spinal cord.
Topics: Animals; GABA Antagonists; gamma-Aminobutyric Acid; Humans; Pain; Receptors, GABA; Spinal Cord | 1996 |
The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord.
Topics: Animals; Excitatory Amino Acids; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Hyperalgesia; Neura | 1997 |
Use of gabapentin in pain management.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic | 1997 |
The neurochemistry of central pain: evidence from clinical studies, hypothesis and therapeutic implications.
Topics: Anesthetics, Intravenous; Baclofen; Cerebral Cortex; GABA Agonists; gamma-Aminobutyric Acid; Glutami | 1998 |
A summary of mechanistic hypotheses of gabapentin pharmacology.
Topics: Acetates; Amines; Analgesics; Animals; Anti-Anxiety Agents; Anticonvulsants; Brain; Calcium Channels | 1998 |
Treatment of chronic pain with antiepileptic drugs: a new era.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapen | 1999 |
Postherpetic neuralgia: role of gabapentin and other treatment modalities.
Topics: Acetates; Administration, Topical; Age Factors; Aged; Ambulatory Care; Amines; Analgesics; Anticonvu | 1999 |
Basic mechanisms of gabitril (tiagabine) and future potential developments.
Topics: Animals; Anticonvulsants; Bipolar Disorder; Carrier Proteins; Epilepsy; GABA Antagonists; GABA Plasm | 1999 |
Interstitial cystitis and the potential role of gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Cystitis, Interstitial; Female; Ga | 2000 |
Gabapentin use in neuropathic pain syndromes.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 2000 |
Gabapentin in pain management.
Topics: Acetates; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric A | 2000 |
[Gabapentin therapy for pain].
Topics: Acetates; Amines; Analgesics; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Diabetic Neurop | 2001 |
Pregabalin (Pfizer).
Topics: Agoraphobia; Animals; Anticonvulsants; Clinical Trials as Topic; Contraindications; GABA Agonists; g | 2001 |
Neurochemical relationships in the action of opioid analgesics on cerebral cortex.
Topics: Afferent Pathways; Analgesics, Opioid; Animals; Cats; Cerebral Cortex; Electric Stimulation; gamma-A | 2001 |
[Modification of morphine dependence under chronic pain and its mechanism].
Topics: Animals; Brain; Chronic Disease; gamma-Aminobutyric Acid; Male; Morphine Dependence; Pain; Rats; Rat | 2001 |
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
Topics: Acetates; Amines; Autoimmune Diseases; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Cannabin | 2001 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Gabapentin: pharmacology and its use in pain management.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2002 |
Background and rationale for use of anticonvulsants in psychiatry.
Topics: Acetates; Amines; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cycloh | 1998 |
Gabapentin. Pfizer.
Topics: Acetates; Amines; Analgesics; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase II | 2002 |
Pain and neurotransmitters.
Topics: Action Potentials; Afferent Pathways; Analgesics; Animals; Animals, Newborn; Enkephalins; GABA Antag | 1990 |
Discharge of noradrenergic locus coeruleus neurons in behaving rats and monkeys suggests a role in vigilance.
Topics: Afferent Pathways; Animals; Arousal; Attention; Behavior, Animal; Efferent Pathways; Frontal Lobe; g | 1991 |
The use of microiontophoresis in the study of the descending control of nociceptive transmission.
Topics: Animals; Brain; gamma-Aminobutyric Acid; Iontophoresis; Pain; Rats; Synaptic Transmission | 1988 |
GABA distribution in a pain-modulating zone of trigeminal subnucleus interpolaris.
Topics: Animals; Axons; Cats; Dendrites; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Immunoenzyme Tech | 1988 |
85 trials available for gamma-aminobutyric acid and Pain
| Article | Year |
|---|---|
Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial.
Topics: Analgesics; Diabetes Mellitus; Diabetic Neuropathies; Double-Blind Method; gamma-Aminobutyric Acid; | 2022 |
Combination analgesic development for enhanced clinical efficacy (the CADENCE trial): a double-blind, controlled trial of an alpha-lipoic acid-pregabalin combination for fibromyalgia pain.
Topics: Analgesics; Double-Blind Method; Fibromyalgia; gamma-Aminobutyric Acid; Humans; Pain; Pregabalin; Th | 2023 |
γ-Aminobutyric acid (GABA) oral rinse reduces capsaicin-induced burning mouth pain sensation: An experimental quantitative sensory testing study in healthy subjects.
Topics: Adult; Analgesics; Capsaicin; Cross-Over Studies; Double-Blind Method; Female; gamma-Aminobutyric Ac | 2018 |
The response of agitated behavior to pain management in persons with dementia.
Topics: Acetaminophen; Aged, 80 and over; Analgesics; Buprenorphine; Delayed-Action Preparations; Dementia; | 2014 |
Duloxetine and pregabalin: high-dose monotherapy or their combination? The "COMBO-DN study"--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain.
Topics: Aged; Analgesics; Diabetic Neuropathies; Double-Blind Method; Drug Therapy, Combination; Duloxetine | 2013 |
Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome.
Topics: Adult; Analgesics; Colon; Compliance; Constipation; Double-Blind Method; Female; gamma-Aminobutyric | 2014 |
Determination of the effective dose of pregabalin on human experimental pain using the sequential up-down method.
Topics: Adult; Analgesics; Capsaicin; Dose-Response Relationship, Drug; Double-Blind Method; Female; gamma-A | 2014 |
Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: a cluster randomized trial.
Topics: Acetaminophen; Activities of Daily Living; Aged; Aged, 80 and over; Analgesics; Buprenorphine; Clini | 2014 |
Analgesic efficacy of prophylactic gabapentin and lornoxicam in preventing postendodontic pain.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2014 |
The effect of a combination of gabapentin and donepezil in an experimental pain model in healthy volunteers: Results of a randomized controlled trial.
Topics: Adolescent; Adult; Amines; Analgesics, Non-Narcotic; Cross-Over Studies; Cyclohexanecarboxylic Acids | 2014 |
Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication.
Topics: Aged; Analgesics; Cross-Over Studies; Disability Evaluation; Dose-Response Relationship, Drug; Doubl | 2015 |
Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil.
Topics: Adult; Carbamates; Dose-Response Relationship, Drug; Double-Blind Method; Female; gamma-Aminobutyric | 2015 |
Clinical Trial Assessing the Efficacy of Gabapentin Plus B Complex (B1/B12) versus Pregabalin for Treating Painful Diabetic Neuropathy.
Topics: Adolescent; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Drug Combinatio | 2016 |
Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer.
Topics: Acetaminophen; Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Carcinoma | 2016 |
A Validated Fluorometric Method for the Rapid Determination of Pregabalin in Human Plasma Applied to Patients With Pain.
Topics: Amines; Analgesics; Chromatography, High Pressure Liquid; Cyclohexanecarboxylic Acids; Data Accuracy | 2016 |
Topical gabapentin in the treatment of localized and generalized vulvodynia.
Topics: Administration, Topical; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; | 2008 |
Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Diabetic Neuropathies; Double-Blind Method; Drug Adminis | 2008 |
Effect of morphine and pregabalin compared with diphenhydramine hydrochloride and placebo on hyperalgesia and allodynia induced by intradermal capsaicin in healthy male subjects.
Topics: Adolescent; Adult; Alkaloids; Analgesics; Analgesics, Opioid; Analysis of Variance; Capsaicin; Cross | 2008 |
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster.
Topics: Acute Disease; Aged; Amines; Analgesics, Opioid; Clinical Trials as Topic; Cyclohexanecarboxylic Aci | 2009 |
Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Analgesics; Antidepressive Agents; Cognitive Behavioral Therapy; Combined M | 2009 |
The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome.
Topics: Analgesics; Double-Blind Method; Female; Fibromyalgia; gamma-Aminobutyric Acid; Humans; Male; Medica | 2009 |
Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; | 2009 |
Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy.
Topics: Aged; Algorithms; Analgesics; Casts, Surgical; Diabetic Neuropathies; Drug Combinations; Female; gam | 2009 |
5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study.
Topics: Aged; Algorithms; Analgesics; Casts, Surgical; Diabetic Neuropathies; Female; gamma-Aminobutyric Aci | 2009 |
Patient-reported outcomes in subjects with painful trigeminal neuralgia receiving pregabalin: evidence from medical practice in primary care settings.
Topics: Analgesics; Disability Evaluation; Evidence-Based Medicine; Female; gamma-Aminobutyric Acid; Humans; | 2009 |
Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial.
Topics: Acupuncture Therapy; Acute Disease; Adult; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxyli | 2009 |
Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial.
Topics: Acupuncture Therapy; Acute Disease; Adult; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxyli | 2009 |
Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial.
Topics: Acupuncture Therapy; Acute Disease; Adult; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxyli | 2009 |
Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial.
Topics: Acupuncture Therapy; Acute Disease; Adult; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxyli | 2009 |
Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial.
Topics: Amitriptyline; Analgesics, Non-Narcotic; Diabetic Neuropathies; Dose-Response Relationship, Drug; Do | 2009 |
A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin.
Topics: Aged; Aged, 80 and over; Analgesics; Analgesics, Opioid; Diabetic Neuropathies; Double-Blind Method; | 2010 |
A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain.
Topics: Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Female; Gabapentin | 2010 |
Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine.
Topics: Aged; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; | 2010 |
A fMRI evaluation of lamotrigine for the treatment of trigeminal neuropathic pain: pilot study.
Topics: Adult; Amines; Anticonvulsants; Brain; Cold Temperature; Cross-Over Studies; Cyclohexanecarboxylic A | 2010 |
Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy.
Topics: Acetaminophen; Adult; Aged; Amines; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Diabetes Mellit | 2010 |
Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analgesics; Anxiety; Depression; Dose-Response Relation | 2010 |
Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures.
Topics: Adult; Aged; Algorithms; Analgesics; Anticonvulsants; Chronic Disease; Databases, Factual; Dose-Resp | 2011 |
Safety and efficacy of pregabalin in patients with central post-stroke pain.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Dose-Response Relationship, Drug; Double-Blind Method; F | 2011 |
Effect of a single dose of pregabalin on herpes zoster pain.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; California; Cross-Over Studies; Do | 2011 |
Pregabalin in severe burn injury pain: a double-blind, randomised placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Analgesics; Analgesics, Opioid; Burns; Dose-Response Relationship, Drug; Do | 2011 |
Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study.
Topics: Adult; Analgesics; Analysis of Variance; Anti-Anxiety Agents; Antidepressive Agents, Second-Generati | 2011 |
Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Cohort Studies; Dose-Response Relationship, Drug; Drug D | 2011 |
[Biological age and the pain syndrome at diabetic polyneuropathy].
Topics: Adult; Aging; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; | 2011 |
Effect of pre-emptive gabapentin on postoperative pain following lower extremity orthopaedic surgery under spinal anaesthesia.
Topics: Adult; Amines; Anesthesia, Spinal; Anesthesiology; Cyclohexanecarboxylic Acids; Double-Blind Method; | 2011 |
Randomised clinical trial: pregabalin attenuates the development of acid-induced oesophageal hypersensitivity in healthy volunteers - a placebo-controlled study.
Topics: Adult; Analgesics; Cross-Over Studies; Double-Blind Method; Esophageal Diseases; Female; gamma-Amino | 2012 |
Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study.
Topics: Adult; Aged; Analgesics; Comorbidity; Cross-Over Studies; Dose-Response Relationship, Drug; Double-B | 2012 |
The effects of low doses of pregabalin on morphine analgesia in advanced cancer patients.
Topics: Analgesics; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; | 2013 |
The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica.
Topics: Adult; Analysis of Variance; Capsaicin; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combi | 2012 |
Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life.
Topics: Aged; Amitriptyline; Diabetic Neuropathies; Double-Blind Method; Duloxetine Hydrochloride; Female; g | 2012 |
Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life.
Topics: Aged; Amitriptyline; Diabetic Neuropathies; Double-Blind Method; Duloxetine Hydrochloride; Female; g | 2012 |
Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life.
Topics: Aged; Amitriptyline; Diabetic Neuropathies; Double-Blind Method; Duloxetine Hydrochloride; Female; g | 2012 |
Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life.
Topics: Aged; Amitriptyline; Diabetic Neuropathies; Double-Blind Method; Duloxetine Hydrochloride; Female; g | 2012 |
Gabapentin reduces preoperative anxiety and pain catastrophizing in highly anxious patients prior to major surgery: a blinded randomized placebo-controlled trial.
Topics: Adult; Amines; Analysis of Variance; Anti-Anxiety Agents; Anxiety; Catastrophization; Cyclohexanecar | 2013 |
Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analysis of Variance; Chi-Square Distribution; Cyc | 2002 |
Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study.
Topics: Acetates; Adult; Aged; Amines; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind Method; | 2002 |
Gabapentin for the treatment of pain in guillain-barré syndrome: a double-blinded, placebo-controlled, crossover study.
Topics: Acetates; Adult; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind M | 2002 |
Gabapentin in the management of pentazocine dependence: a potent analgesic--anticraving agent.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Anti-Anxiety Agents; Clonidine; Cyclohexanecarboxy | 2003 |
Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain.
Topics: Acetates; Activities of Daily Living; Aged; Aged, 80 and over; Amines; Analgesics; Anesthetics, Loca | 2003 |
Gabapentin for painful legs and moving toes syndrome.
Topics: Acetates; Aged; Amines; Cyclohexanecarboxylic Acids; Electromyography; Excitatory Amino Acid Antagon | 2004 |
Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Double-Blind Me | 2004 |
Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Double-Blind Me | 2004 |
Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Double-Blind Me | 2004 |
Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Double-Blind Me | 2004 |
Therapeutic outcome in neuropathic pain: relationship to evidence of nervous system lesion.
Topics: Acetates; Adult; Aged; Amines; Chi-Square Distribution; Cyclohexanecarboxylic Acids; Depression; Dos | 2004 |
Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379].
Topics: Adult; Aged; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind Metho | 2004 |
Treatment of diabetic neuropathic pain with gabapentin alone or combined with vitamin B complex. preliminary results.
Topics: Activities of Daily Living; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropat | 2004 |
Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin.
Topics: Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; | 2005 |
Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Fatigue; Female; Fibr | 2005 |
Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Fatigue; Female; Fibr | 2005 |
Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Fatigue; Female; Fibr | 2005 |
Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Fatigue; Female; Fibr | 2005 |
Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Fatigue; Female; Fibr | 2005 |
Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Fatigue; Female; Fibr | 2005 |
Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Fatigue; Female; Fibr | 2005 |
Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Fatigue; Female; Fibr | 2005 |
Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Fatigue; Female; Fibr | 2005 |
The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit.
Topics: Adult; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Carbamazepine; Conscious Sedation; Crit | 2005 |
Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans.
Topics: Adult; Amines; Analgesics; Analysis of Variance; Capsaicin; Central Nervous System; Cross-Over Studi | 2005 |
Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study.
Topics: Aged; Amines; Analgesics; Analysis of Variance; Cyclohexanecarboxylic Acids; Dose-Response Relations | 2005 |
CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model.
Topics: Adult; Amines; Analgesics; Capsaicin; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind | 2006 |
A randomized study of the effects of gabapentin on postamputation pain.
Topics: Aged; Amines; Amputation Stumps; Amputation, Surgical; Analgesics; Cyclohexanecarboxylic Acids; Fema | 2006 |
Premedication with gabapentin: the effect on tourniquet pain and quality of intravenous regional anesthesia.
Topics: Adult; Amines; Analgesics; Anesthesia, Conduction; Anesthesia, Intravenous; Cyclohexanecarboxylic Ac | 2007 |
[The tebantin use in the complex therapy of pain syndrome during the mixed forms of alcoholic polyneuropathy].
Topics: Alcoholic Neuropathy; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Fe | 2006 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome.
Topics: Administration, Oral; Adolescent; Adult; Analgesics; Double-Blind Method; Female; gamma-Aminobutyric | 2007 |
Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen.
Topics: Central Nervous System Diseases; Double-Blind Method; Female; gamma-Aminobutyric Acid; Humans; Male; | 2008 |
Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia.
Topics: Amines; Cost-Benefit Analysis; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Double-Blind Meth | 2007 |
Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury.
Topics: Adult; Aged; Amines; Amitriptyline; Analgesics; Analysis of Variance; Antidepressive Agents, Tricycl | 2007 |
A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia.
Topics: Adolescent; Adult; Aged; Analgesics; Dose-Response Relationship, Drug; Double-Blind Method; Female; | 2008 |
The effect of gabapentin on neuropathic pain.
Topics: Acetates; Adolescent; Adult; Amines; Analgesics; Child; Cyclohexanecarboxylic Acids; Gabapentin; gam | 1997 |
Open label gabapentin treatment for pain in multiple sclerosis.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gab | 1997 |
Painful and non-painful effects of low doses of morphine in migraine sufferers partly depend on excitatory amino acids and gamma-aminobutyric acid.
Topics: Adult; Cross-Over Studies; Diazepam; Double-Blind Method; Excitatory Amino Acids; gamma-Aminobutyric | 1998 |
Gabapentin for treatment of pain and tremor: a large case series.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Anticonvulsants; Arachnoiditis; Cerebellar Neoplasms; Cyc | 1998 |
Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; D | 1998 |
Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Cyclohexanecarboxylic Acids; Diabetic Neuropathies | 1999 |
Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain.
Topics: Acetates; Adrenergic Uptake Inhibitors; Aged; Amines; Amitriptyline; Analgesics; Cross-Over Studies; | 1999 |
Postherpetic neuralgia: role of gabapentin and other treatment modalities.
Topics: Acetates; Administration, Topical; Age Factors; Aged; Ambulatory Care; Amines; Analgesics; Anticonvu | 1999 |
Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis.
Topics: Acetates; Amines; Anticonvulsants; Circadian Rhythm; Cyclohexanecarboxylic Acids; Gabapentin; gamma- | 2000 |
Gabapentin therapy for diabetic neuropathic pain.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Double-Blind Metho | 2000 |
Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study.
Topics: Acetates; Aged; Aged, 80 and over; Amines; Amitriptyline; Analgesics; Ataxia; Cyclohexanecarboxylic | 2000 |
Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain.
Topics: Acetates; Administration, Oral; Amines; Analgesics; Cyclohexanecarboxylic Acids; Cystitis, Interstit | 2001 |
Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study.
Topics: Acetates; Adolescent; Amines; Analgesics; Antineoplastic Agents; Cyclohexanecarboxylic Acids; Female | 2002 |
527 other studies available for gamma-aminobutyric acid and Pain
| Article | Year |
|---|---|
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzofurans; Carrageenan; Disease Models, Animal; | 2008 |
Prescribing of Gabapentinoids with or without opioids after burn injury in the US, 2012-2018.
Topics: Adult; Analgesics, Opioid; Burns; Cohort Studies; gamma-Aminobutyric Acid; Humans; Pain; Practice Pa | 2022 |
Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy.
Topics: Amines; Analgesics; Cardiovascular Diseases; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Gab | 2022 |
A nigro-subthalamo-parabrachial pathway modulates pain-like behaviors.
Topics: Animals; Electric Stimulation; Female; GABAergic Neurons; gamma-Aminobutyric Acid; Male; Mice; Pain; | 2022 |
A nigro-subthalamo-parabrachial pathway modulates pain-like behaviors.
Topics: Animals; Electric Stimulation; Female; GABAergic Neurons; gamma-Aminobutyric Acid; Male; Mice; Pain; | 2022 |
A nigro-subthalamo-parabrachial pathway modulates pain-like behaviors.
Topics: Animals; Electric Stimulation; Female; GABAergic Neurons; gamma-Aminobutyric Acid; Male; Mice; Pain; | 2022 |
A nigro-subthalamo-parabrachial pathway modulates pain-like behaviors.
Topics: Animals; Electric Stimulation; Female; GABAergic Neurons; gamma-Aminobutyric Acid; Male; Mice; Pain; | 2022 |
Divergent modulation of pain and anxiety by GABAergic neurons in the ventrolateral periaqueductal gray and dorsal raphe.
Topics: Animals; Dorsal Raphe Nucleus; GABAergic Neurons; gamma-Aminobutyric Acid; Mice; Pain; Periaqueducta | 2023 |
Divergent modulation of pain and anxiety by GABAergic neurons in the ventrolateral periaqueductal gray and dorsal raphe.
Topics: Animals; Dorsal Raphe Nucleus; GABAergic Neurons; gamma-Aminobutyric Acid; Mice; Pain; Periaqueducta | 2023 |
Divergent modulation of pain and anxiety by GABAergic neurons in the ventrolateral periaqueductal gray and dorsal raphe.
Topics: Animals; Dorsal Raphe Nucleus; GABAergic Neurons; gamma-Aminobutyric Acid; Mice; Pain; Periaqueducta | 2023 |
Divergent modulation of pain and anxiety by GABAergic neurons in the ventrolateral periaqueductal gray and dorsal raphe.
Topics: Animals; Dorsal Raphe Nucleus; GABAergic Neurons; gamma-Aminobutyric Acid; Mice; Pain; Periaqueducta | 2023 |
Dorsal root ganglia control nociceptive input to the central nervous system.
Topics: Animals; Central Nervous System; gamma-Aminobutyric Acid; Ganglia, Spinal; Mice; Nociception; Pain; | 2023 |
Green light induces antinociception via visual-somatosensory circuits.
Topics: Analgesics; Animals; GABAergic Neurons; gamma-Aminobutyric Acid; Gyrus Cinguli; Mice; Pain | 2023 |
Monoacylglycerol Lipase Protects the Presynaptic Cannabinoid 1 Receptor from Desensitization by Endocannabinoids after Persistent Inflammation.
Topics: Animals; Cannabinoids; Endocannabinoids; Female; gamma-Aminobutyric Acid; Inflammation; Male; Monoac | 2023 |
Loss of bhlha9 Impairs Thermotaxis and Formalin-Evoked Pain in a Sexually Dimorphic Manner.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Female; Formaldehyde; gamma-Aminobutyric Acid | 2020 |
Prescription analgesia and adjuvant use by pain severity at admission among nursing home residents with non-malignant pain.
Topics: Aged; Aged, 80 and over; Analgesia; Analgesics; Anticonvulsants; Antidepressive Agents; Chemotherapy | 2020 |
Inhibition of NADPH oxidase within midbrain periaqueductal gray decreases pain sensitivity in Parkinson's disease via GABAergic signaling pathway.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Male; Medial Forebrain Bundle; NADPH Oxida | 2020 |
Additional considerations for studying brain metabolite levels across pain conditions using proton magnetic resonance spectroscopy.
Topics: Brain; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Pain; Proton Magnetic Resonance Spectroscopy | 2021 |
Rethinking Opioids, Gabapentinoids, and Pain.
Topics: Analgesics, Opioid; Coronavirus Infections; COVID-19; gamma-Aminobutyric Acid; Humans; Opioid Epidem | 2020 |
Transplantation of GABAergic precursors into the spinal cord to alleviate neuropathic pain.
Topics: gamma-Aminobutyric Acid; Humans; Neuralgia; Pain; Spinal Cord | 2020 |
Effects of GABAA receptors in nucleus cuneiformis on the cannabinoid antinociception using the formalin test.
Topics: Animals; Benzoxazines; Bicuculline; Cannabinoids; GABA-A Receptor Agonists; GABA-A Receptor Antagoni | 2021 |
The translocator protein gene is associated with endogenous pain modulation and the balance between glutamate and γ-aminobutyric acid in fibromyalgia and healthy subjects: a multimodal neuroimaging study.
Topics: Brain; Fibromyalgia; gamma-Aminobutyric Acid; Glutamic Acid; Healthy Volunteers; Humans; Neuroimagin | 2022 |
[Analgesic effect and central mechanisms of CQ prescription on cancer invasion induced mirror image pain in model mice].
Topics: Analgesics; Animals; Drugs, Chinese Herbal; gamma-Aminobutyric Acid; Glutamic Acid; Glycine; Male; M | 2017 |
Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study.
Topics: Adult; Aged; Amines; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studi | 2017 |
Gabapentinoid Use in the United States 2002 Through 2015.
Topics: Female; GABA Agents; gamma-Aminobutyric Acid; Health Expenditures; Humans; Male; Middle Aged; Pain; | 2018 |
Metaplasticity within the spinal cord: Evidence brain-derived neurotrophic factor (BDNF), tumor necrosis factor (TNF), and alterations in GABA function (ionic plasticity) modulate pain and the capacity to learn.
Topics: Animals; Brain-Derived Neurotrophic Factor; gamma-Aminobutyric Acid; Humans; Learning; Models, Neuro | 2018 |
Ionic plasticity and pain: The loss of descending serotonergic fibers after spinal cord injury transforms how GABA affects pain.
Topics: Animals; Bicuculline; Capsaicin; Conditioning, Operant; GABA Antagonists; gamma-Aminobutyric Acid; K | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Mechanism of dorsal root ganglion stimulation for pain relief in painful diabetic polyneuropathy is not dependent on GABA release in the dorsal horn of the spinal cord.
Topics: Animals; Diabetic Neuropathies; Electric Stimulation Therapy; Electrodes, Implanted; Female; gamma-A | 2020 |
The glutamate to γ-aminobutyric acid ratio in the posterior insula is associated with pain perception in healthy women but not in women with borderline personality disorder.
Topics: Adolescent; Adult; Borderline Personality Disorder; Brain Mapping; Female; gamma-Aminobutyric Acid; | 2019 |
A study to compare circulating flunixin, meloxicam and gabapentin concentrations with prostaglandin E₂ levels in calves undergoing dehorning.
Topics: Amines; Analgesics; Animals; Area Under Curve; Cattle; Clonixin; Cyclohexanecarboxylic Acids; Dinopr | 2013 |
Quantitative sensory testing predicts pregabalin efficacy in painful chronic pancreatitis.
Topics: Adult; Analgesics; Electric Stimulation; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; | 2013 |
Antiallodynic and analgesic effects of maslinic acid, a pentacyclic triterpenoid from Olea europaea.
Topics: Analgesics; Animals; Capsaicin; gamma-Aminobutyric Acid; Hyperalgesia; Inflammation; Mice; Molecular | 2013 |
Women with scalp dysesthesia treated with pregabalin.
Topics: Adult; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Pain; Paresthesia; Pregabalin; Pruritus; | 2013 |
Antihyperalgesic activity of a novel synthesized analogue of lidocaine in diabetic rats.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Diabetes Complications; | 2013 |
Chronic unilateral eruption of painful, erythematous papules and nodules. Piloleiomyoma.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; | 2013 |
Neurokinin-1 receptor-expressing neurons that contain serotonin and gamma-aminobutyric acid in the rat rostroventromedial medulla are involved in pain processing.
Topics: Animals; Biotin; Cell Count; Dextrans; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamate De | 2013 |
The application of support vector regression for prediction of the antiallodynic effect of drug combinations in the mouse model of streptozocin-induced diabetic neuropathy.
Topics: 4-Butyrolactone; Algorithms; Analgesics; Animals; Computer Simulation; Diabetes Mellitus, Experiment | 2013 |
Impact of a pregabalin step therapy policy among medicare advantage beneficiaries.
Topics: Aged; Aged, 80 and over; Analgesics; Cohort Studies; Drug Administration Schedule; Drug Utilization | 2014 |
Add-on therapy: when two are not better than one.
Topics: Diabetic Neuropathies; Duloxetine Hydrochloride; Female; gamma-Aminobutyric Acid; Humans; Male; Pain | 2013 |
Brain-derived neurotrophic factor-mediated downregulation of brainstem K+-Cl- cotransporter and cell-type-specific GABA impairment for activation of descending pain facilitation.
Topics: Animals; Animals, Newborn; Brain Stem; Brain-Derived Neurotrophic Factor; Down-Regulation; gamma-Ami | 2013 |
The pain of pregabalin prescribing in prisons.
Topics: Analgesics; gamma-Aminobutyric Acid; General Practice; Guideline Adherence; Humans; Inappropriate Pr | 2013 |
Semi-mechanistic modelling of the analgesic effect of gabapentin in the formalin-induced rat model of experimental pain.
Topics: Amines; Analgesics; Animals; Computer Simulation; Cyclohexanecarboxylic Acids; Dose-Response Relatio | 2014 |
Glutamate/GABA balance in ACC modulates the nociceptive responses of vocalization: an expression of affective-motivational component of pain in guinea pigs.
Topics: Animals; Bicuculline; Dizocilpine Maleate; Dose-Response Relationship, Drug; Excitatory Amino Acid A | 2014 |
Peripherally driven low-threshold inhibitory inputs to lamina I local-circuit and projection neurones: a new circuit for gating pain responses.
Topics: Animals; Electric Stimulation; Excitatory Postsynaptic Potentials; gamma-Aminobutyric Acid; Glycine; | 2014 |
Gabapentin hybrid peptides and bioconjugates.
Topics: Acylation; Amines; Analgesics; Animals; Behavior, Animal; Crystallography, X-Ray; Cyclization; Cyclo | 2014 |
Painful traumatic trigeminal neuropathy: an open study on the pharmacotherapeutic response to stepped treatment.
Topics: Amines; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Baclofen; Carbamazepine; Clinical Proto | 2014 |
The effects of Phα1β, a spider toxin, calcium channel blocker, in a mouse fibromyalgia model.
Topics: Animals; Brain; Calcium Channel Blockers; Diclofenac; Disease Models, Animal; Dopamine; Fibromyalgia | 2014 |
Effects of gabapentin enacarbil on restless legs syndrome and leg pain in dementia with Lewy bodies.
Topics: Aged; Carbamates; Dopamine Agonists; Female; gamma-Aminobutyric Acid; Hallucinations; Humans; Japan; | 2014 |
Shift-invariant target in allocation problems.
Topics: Computer Simulation; gamma-Aminobutyric Acid; Humans; Models, Statistical; Neuralgia, Postherpetic; | 2014 |
Effect of gabapentin on swallowing during and after chemoradiation for oropharyngeal squamous cell cancer.
Topics: Amines; Analgesics; Carcinoma, Squamous Cell; Chemoradiotherapy; Cyclohexanecarboxylic Acids; Deglut | 2014 |
Pain reduces sexual motivation in female but not male mice.
Topics: alpha-MSH; Analgesics; Animals; Apomorphine; Carrageenan; Dopamine Agonists; Female; gamma-Aminobuty | 2014 |
Modeling effects of spinal cord stimulation on wide-dynamic range dorsal horn neurons: influence of stimulation frequency and GABAergic inhibition.
Topics: Action Potentials; Animals; Computer Simulation; GABAergic Neurons; gamma-Aminobutyric Acid; Interne | 2014 |
Paroxysmal itch caused by gain-of-function Nav1.7 mutation.
Topics: Adult; Antipruritics; Child, Preschool; DNA Mutational Analysis; Female; gamma-Aminobutyric Acid; Hu | 2014 |
Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain: a potential biomarker of efficacy.
Topics: Amines; Analgesics; Animals; Biomarkers; Cyclohexanecarboxylic Acids; Dopamine; Gabapentin; gamma-Am | 2014 |
Effects of NB001 and gabapentin on irritable bowel syndrome-induced behavioral anxiety and spontaneous pain.
Topics: Adenosine Triphosphate; Amines; Animals; Anxiety; Behavior, Animal; Cyclohexanecarboxylic Acids; Gab | 2014 |
Synergic effects of pregabalin-acetaminophen combination in somatic and visceral nociceptive reactivity.
Topics: Acetaminophen; Acetic Acid; Analgesics; Animals; Drug Combinations; Drug Synergism; gamma-Aminobutyr | 2014 |
Inhibition of mitogen-activated protein kinases phosphorylation plays an important role in the anti-nociceptive effect of pregabalin in zymosan-induced inflammatory pain model.
Topics: Analgesics; Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Male; Mitogen-Activated Protei | 2014 |
Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements?
Topics: Aged; Amines; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Chemotherapy, Adjuvant; C | 2015 |
Development and pharmacological characterization of a model of sleep disruption-induced hypersensitivity in the rat.
Topics: Amines; Animals; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapenti | 2015 |
A high-quality RCT documents that elderly with dementia, the most neglected pain patients, have effective and safe pain relief from paracetamol alone or with buprenorphine patch.
Topics: Acetaminophen; Analgesics; Buprenorphine; Clinical Protocols; Dementia; Female; gamma-Aminobutyric A | 2014 |
Comparison of the effects of gabapentin and pregabalin on wound healing in rats.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Human | 2016 |
[Cardioprotective properties of new glutamic acid derivative under stress conditions].
Topics: Animals; Animals, Outbred Strains; Cardiotonic Agents; Drug Administration Schedule; gamma-Aminobuty | 2014 |
Six cases of (severe) hypoglycaemia associated with gabapentin use in both diabetic and non-diabetic patients.
Topics: Amines; Analgesics; Blood Glucose; Cyclohexanecarboxylic Acids; Diabetes Mellitus; Gabapentin; gamma | 2015 |
BDNF-trkB-KCC2-GABA pathway may be related to chronic stress-induced hyperalgesia at both the spinal and supraspinal level.
Topics: Animals; Brain-Derived Neurotrophic Factor; gamma-Aminobutyric Acid; Gene Expression Regulation; Hum | 2014 |
Enhanced GABAergic synaptic transmission at VLPAG neurons and potent modulation by oxycodone in a bone cancer pain model.
Topics: Analgesics, Opioid; Animals; Bone Neoplasms; Cell Line, Tumor; G Protein-Coupled Inwardly-Rectifying | 2015 |
In vivo two-photon imaging of structural dynamics in the spinal dorsal horn in an inflammatory pain model.
Topics: Acute Disease; Amines; Animals; Calcium Channel Blockers; Calcium Channels; Cyclohexanecarboxylic Ac | 2015 |
Gabapentin for management of recurrent pain in 22 nonverbal children with severe neurological impairment: a retrospective analysis.
Topics: Adolescent; Adult; Amines; Analgesics; Central Nervous System Diseases; Child; Child, Preschool; Cyc | 2015 |
GABA blocks pathological but not acute TRPV1 pain signals.
Topics: Animals; Autocrine Communication; Cells, Cultured; Feedback; Female; gamma-Aminobutyric Acid; Male; | 2015 |
Complete Freund's adjuvant-induced reduction of exploratory activity in a novel environment as an objective nociceptive endpoint for sub-acute inflammatory pain model in rats.
Topics: Adjuvants, Immunologic; Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxy | 2015 |
Pain: Turning down the heat in pain.
Topics: Animals; Autocrine Communication; Female; gamma-Aminobutyric Acid; Male; Neurons; Pain; Receptors, G | 2015 |
Doctors are warned not to prescribe generic pregabalin for pain control.
Topics: Analgesics; Drugs, Generic; England; gamma-Aminobutyric Acid; Humans; Legislation, Drug; Pain; Pain | 2015 |
Brainstem brain-derived neurotrophic factor signaling is required for histone deacetylase inhibitor-induced pain relief.
Topics: Analgesics; Animals; Brain-Derived Neurotrophic Factor; Carbazoles; gamma-Aminobutyric Acid; Glutama | 2015 |
GABA acting on GABAB receptors located in a medullary pain facilitatory area enhances nociceptive behaviors evoked by intraplantar formalin injection.
Topics: Animals; Baclofen; Disease Models, Animal; Formaldehyde; GABA-B Receptor Agonists; GABA-B Receptor A | 2015 |
Margaret McCartney: Second use patents--why do we have to prescribe branded Lyrica for pain?
Topics: Analgesics; Cost-Benefit Analysis; Delivery of Health Care; Drug Industry; Drug Prescriptions; gamma | 2015 |
Chronic progressive polyarthritis in a domestic shorthair cat.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis; Buprenorphine; Cat Diseases; Cats; | 2015 |
Effects of Phenibut and Citrocard on Non-Competitive and Competitive Behavior during Provoked Aggression in Animals.
Topics: Agonistic Behavior; Animal Communication; Animals; Avoidance Learning; Baclofen; Competitive Behavio | 2015 |
The Effect of a Novel form of Extended-Release Gabapentin on Pain and Sleep in Fibromyalgia Subjects: An Open-Label Pilot Study.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Prep | 2016 |
GABAB receptors inhibit low-voltage activated and high-voltage activated Ca(2+) channels in sensory neurons via distinct mechanisms.
Topics: Animals; Baclofen; Calcium Channels, L-Type; Calcium Channels, N-Type; Calcium Channels, T-Type; Dit | 2015 |
Tranexamic acid evokes pain by modulating neuronal excitability in the spinal dorsal horn.
Topics: Animals; Behavior, Animal; Biomarkers; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases | 2015 |
Evaluation of the Percutaneous Absorption of Ketamine HCl, Gabapentin, Clonidine HCl, and Baclofen, in Compounded Transdermal Pain Formulations, Using the Franz Finite Dose Model.
Topics: Administration, Cutaneous; Aged; Amines; Baclofen; Clonidine; Cyclohexanecarboxylic Acids; Drug Comp | 2016 |
Antinociceptive Grayanoids from the Roots of Rhododendron molle.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Diterpenes; Drugs, | 2015 |
Comparative animal study of the antinociceptive efficacy of lamotrigine and gabapentin for the management of pain.
Topics: Analgesics; Animals; Anticonvulsants; Calcium Channel Blockers; gamma-Aminobutyric Acid; Lamotrigine | 2015 |
Pharmacological characterization of intraplantar Complete Freund's Adjuvant-induced burrowing deficits.
Topics: Amines; Analgesics; Animals; Antibodies; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; D | 2016 |
Analysis of the behavioral, cellular and molecular characteristics of pain in severe rodent spinal cord injury.
Topics: Amines; Animals; Calcitonin Gene-Related Peptide; Calcium-Binding Proteins; Carbenoxolone; Connexin | 2016 |
Painless legs and moving toes syndrome associated with a sacral Tarlov cyst: a case report.
Topics: Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Dyskinesias; Female; Gabapentin; gamma-Am | 2016 |
The Effect of Gabapentin Enacarbil on Pain Associated with Moderate-to-Severe Primary Restless Legs Syndrome in Adults: Pooled Analyses from Three Randomized Controlled Trials.
Topics: Adult; Aged; Carbamates; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; F | 2016 |
Cingulate GABA levels inversely correlate with the intensity of ongoing chronic knee osteoarthritis pain.
Topics: Aged; Demography; Female; gamma-Aminobutyric Acid; Gyrus Cinguli; Humans; Magnetic Resonance Imaging | 2016 |
The Association Between Clinical Characteristics of Migraine and Brain GABA Levels: An Exploratory Study.
Topics: Adult; Area Under Curve; Brain; Case-Control Studies; Cross-Sectional Studies; Disability Evaluation | 2016 |
Transcriptomic and behavioural characterisation of a mouse model of burn pain identify the cholecystokinin 2 receptor as an analgesic target.
Topics: Amines; Amitriptyline; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin; Gai | 2016 |
Combined glutamate and glutamine levels in pain-processing brain regions are associated with individual pain sensitivity.
Topics: Adult; Brain; Brain Mapping; Cross-Sectional Studies; Female; gamma-Aminobutyric Acid; Glutamic Acid | 2016 |
Development of putative inhibitory neurons in the embryonic and postnatal mouse superficial spinal dorsal horn.
Topics: Animals; GABAergic Neurons; gamma-Aminobutyric Acid; Interneurons; Mice, Transgenic; Neural Inhibiti | 2017 |
sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain.
Topics: Amides; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin | 2017 |
Compensatory Activation of Cannabinoid CB2 Receptor Inhibition of GABA Release in the Rostral Ventromedial Medulla in Inflammatory Pain.
Topics: Animals; Benzoxazines; Cannabinoids; gamma-Aminobutyric Acid; Male; Medulla Oblongata; Morpholines; | 2017 |
An Improved Rodent Model of Trigeminal Neuropathic Pain by Unilateral Chronic Constriction Injury of Distal Infraorbital Nerve.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Functional Lateral | 2017 |
Oxytocin-induced antinociception in the spinal cord is mediated by a subpopulation of glutamatergic neurons in lamina I-II which amplify GABAergic inhibition.
Topics: Analgesia; Animals; Electrophysiology; GABA Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Neu | 2008 |
Gabapentin for breakthrough pain due to bone metastases.
Topics: Amines; Analgesics; Bone Neoplasms; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid | 2008 |
Peripheral nerve injury alters spinal nicotinic acetylcholine receptor pharmacology.
Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; gamma-Aminobutyric Acid; Male; Nicotine; Pain; Per | 2008 |
GABAergic modulation is involved in the ventrolateral orbital cortex 5-HT 1A receptor activation-induced antinociception in the rat.
Topics: Animals; Frontal Lobe; gamma-Aminobutyric Acid; Male; Pain; Pain Threshold; Rats; Rats, Sprague-Dawl | 2008 |
Antinociceptive action of GLYX-13: an N-methyl-D-aspartate receptor glycine site partial agonist.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Disease Models, Animal; | 2008 |
Gabapentin toxicity in renal failure: the importance of dose adjustment.
Topics: Acute Kidney Injury; Aged; Amines; Animals; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-A | 2009 |
Opioids modulate pain facilitation from the dorsal reticular nucleus.
Topics: Analgesics, Opioid; Animals; Arthritis; Behavior, Animal; Efferent Pathways; Enkephalins; gamma-Amin | 2008 |
The interaction of gabapentin and N6-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA) on mechanical allodynia in rats with a spinal nerve ligation.
Topics: Adenosine; Amines; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug Syne | 2008 |
FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Diabetic | 2008 |
Preproenkephalin mRNA is expressed in a subpopulation of GABAergic neurons in the spinal dorsal horn of the GAD67-GFP knock-in mouse.
Topics: Animals; Enkephalins; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Green Fluorescent Proteins; | 2008 |
Multiplicative interactions to enhance gabapentin to treat neuropathic pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Donepezil; Dose-Response Relationship, Dru | 2008 |
Is there a role for anticonvulsants in the management of rheumatic pain?
Topics: Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Am | 2008 |
Differential regulation of morphine antinociceptive effects by endogenous enkephalinergic system in the forebrain of mice.
Topics: Analgesics; Animals; Enkephalins; gamma-Aminobutyric Acid; Gene Expression Regulation; Mice; Mice, K | 2008 |
Pregabalin: a treatment for fibromyalgia and other painful conditions.
Topics: Analgesics; Anxiety; Depression; Dose-Response Relationship, Drug; Female; Fibromyalgia; gamma-Amino | 2008 |
GABAA receptors in the central nucleus of amygdala (CeA) affect on pain modulation.
Topics: Amygdala; Animals; Bicuculline; Dose-Response Relationship, Drug; GABA Agonists; GABA Antagonists; G | 2008 |
Modulation of gamma-aminobutyric acid on painful sense in central nervous system of morphine-dependent rats.
Topics: Action Potentials; Animals; Bicuculline; Disease Models, Animal; Drug Administration Schedule; Elect | 2008 |
Spinal cord injury-induced attenuation of GABAergic inhibition in spinal dorsal horn circuits is associated with down-regulation of the chloride transporter KCC2 in rat.
Topics: Action Potentials; Animals; Bicuculline; Blotting, Western; Carboxylic Acids; Electric Stimulation; | 2008 |
Role of cholinergic, opioidergic and GABAergic neurotransmission of the dorsal hippocampus in the modulation of nociception in guinea pigs.
Topics: Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Electric Stimulation; GABA Antagonist | 2008 |
Botulinum toxin treatment of epilepsia partialis continua.
Topics: Anticonvulsants; Botulinum Toxins, Type A; Epilepsia Partialis Continua; Fructose; gamma-Aminobutyri | 2009 |
Differential analgesic effects of morphine and gabapentin on behavioural measures of pain and disability in a model of osteoarthritis pain in rats.
Topics: Amines; Analgesics; Analgesics, Opioid; Animals; Behavior, Animal; Cold Temperature; Cyclohexanecarb | 2009 |
Gabapentin reverses microglial activation in the spinal cord of streptozotocin-induced diabetic rats.
Topics: Amines; Analgesics; Animals; Astrocytes; Cell Count; Cyclohexanecarboxylic Acids; Diabetes Mellitus, | 2009 |
Hypothalamospinal oxytocinergic antinociception is mediated by GABAergic and opiate neurons that reduce A-delta and C fiber primary afferent excitation of spinal cord cells.
Topics: Animals; Bicuculline; Efferent Pathways; Electric Stimulation; GABA Antagonists; gamma-Aminobutyric | 2009 |
Contralateral high or a combination of high- and low-frequency transcutaneous electrical nerve stimulation reduces mechanical allodynia and alters dorsal horn neurotransmitter content in neuropathic rats.
Topics: Acupuncture Points; Amino Acids; Animals; Aspartic Acid; Chromatography, High Pressure Liquid; gamma | 2009 |
Neuropathic pain in children after exposure to mercury.
Topics: Amines; Analgesics, Non-Narcotic; Burning Mouth Syndrome; Child; Cyclohexanecarboxylic Acids; Gabape | 2008 |
A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling.
Topics: Adult; Aged; Algorithms; Amines; Area Under Curve; Bayes Theorem; Biological Availability; Cyclohexa | 2009 |
Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; | 2009 |
Painful tonic heat stimulation induces GABA accumulation in the prefrontal cortex in man.
Topics: Adult; Brain Mapping; Female; gamma-Aminobutyric Acid; Hot Temperature; Humans; Image Processing, Co | 2009 |
Pain in the numb chin syndrome.
Topics: Adolescent; Analgesics; Anemia, Sickle Cell; Chin; gamma-Aminobutyric Acid; Humans; Male; Pain; Preg | 2009 |
Actions of propofol on substantia gelatinosa neurones in rat spinal cord revealed by in vitro and in vivo patch-clamp recordings.
Topics: Anesthetics, Intravenous; Animals; Excitatory Postsynaptic Potentials; gamma-Aminobutyric Acid; Inhi | 2009 |
Transient receptor potential vanilloid type 1 receptor regulates glutamatergic synaptic inputs to the spinothalamic tract neurons of the spinal cord deep dorsal horn.
Topics: Animals; Calcium Channels; Capsaicin; Excitatory Postsynaptic Potentials; Female; gamma-Aminobutyric | 2009 |
[Effect of a simple morphine system injection in some aminoacids in the anterior cingulate cortex during acute pain].
Topics: Acute Disease; Amino Acids; Analgesics, Opioid; Animals; Arginine; Aspartic Acid; Cerebral Cortex; D | 2008 |
Oral pregabalin reverses cold allodynia in two distinct models of peripheral neuropathic pain.
Topics: Administration, Oral; Analgesics; Animals; Behavior, Animal; Chronic Disease; Cold Temperature; Dise | 2009 |
Intrathecal gabapentin does not act as a hyperpolarization-activated cyclic nucleotide-gated channel activator in the rat formalin test.
Topics: Amines; Analgesics; Animals; Cardiotonic Agents; Cyclic Nucleotide-Gated Cation Channels; Cyclohexan | 2009 |
Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit.
Topics: Administration, Oral; Amines; Analgesics, Non-Narcotic; Animals; Antineoplastic Agents; Antineoplast | 2009 |
A mouse model of sural nerve injury-induced neuropathy: gabapentin inhibits pain-related behaviors and the hyperactivity of wide-dynamic range neurons in the dorsal horn.
Topics: Amines; Analgesics, Non-Narcotic; Animals; Behavior, Animal; Cold Temperature; Cyclohexanecarboxylic | 2009 |
Etodolac attenuates mechanical allodynia in a mouse model of neuropathic pain.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitor | 2009 |
Neurotensin inhibition of GABAergic transmission via mGluR-induced endocannabinoid signalling in rat periaqueductal grey.
Topics: Adamantane; Animals; Cannabinoid Receptor Modulators; Endocannabinoids; Excitatory Amino Acid Antago | 2009 |
Combined use of pregabalin and memantine in fibromyalgia syndrome treatment: a novel analgesic and neuroprotective strategy?
Topics: Analgesics; Chronic Disease; Drug Therapy, Combination; Fibromyalgia; gamma-Aminobutyric Acid; Human | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Minimal clinically important difference in the fibromyalgia impact questionnaire.
Topics: Analgesics; Disability Evaluation; Female; Fibromyalgia; gamma-Aminobutyric Acid; Health Status; Hum | 2009 |
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
Topics: Analgesics; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Fluoxetine; Formaldehyde; gam | 2009 |
Expression patterns of 5-HT receptor subtypes 1A and 2A on GABAergic neurons within the spinal dorsal horn of GAD67-GFP knock-in mice.
Topics: Animals; Female; Fluorescent Antibody Technique; gamma-Aminobutyric Acid; Gene Expression Regulation | 2009 |
Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Cyclopentanes; Diabetes Mellitus, Experime | 2009 |
Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Drug Synergism; Gabapent | 2009 |
Gabapentin therapy for chronic proctalgia following stapled haemorrhoidopexy.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Hemorrhoids; H | 2009 |
Protein kinase A-dependence of the supraspinally mediated analgesic effects of gabapentin on thermal and mechanical hypersensitivity.
Topics: Amines; Analgesics; Animals; Cyclic AMP-Dependent Protein Kinases; Cyclohexanecarboxylic Acids; Dose | 2009 |
How does gabapentin relieve neuropathic pain?
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Pain; | 2009 |
Arginine vasopressin antinociception in the rat nucleus raphe magnus is involved in the endogenous opiate peptide and serotonin system.
Topics: Analgesics; Animals; Arginine Vasopressin; Choline; Enkephalin, Leucine; Enkephalin, Methionine; gam | 2009 |
Moving from tube to oral feeding in medically fragile nonverbal toddlers.
Topics: Amines; Analgesics; Antidepressive Agents, Tricyclic; Appetite Regulation; Appetite Stimulants; Chil | 2009 |
Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel.
Topics: Adolescent; Adult; Amines; Calcium Channel Blockers; Carbamazepine; Cyclohexanecarboxylic Acids; Dru | 2009 |
Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Deglutition Disorders; Dose-Response Relationship, | 2010 |
Successful pain relief of cutaneous leiomyomata due to reed syndrome with the combination treatment of pregabalin and duloxetine.
Topics: Adult; Analgesics, Non-Narcotic; Duloxetine Hydrochloride; Female; gamma-Aminobutyric Acid; Humans; | 2009 |
Gabapentin therapy for pain and irritability in a neurologically impaired infant.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Infant | 2009 |
Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models.
Topics: Amines; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Axotomy; Carrageenan; | 2009 |
A case of perineal pain related to interstitial cystitis which was supposed to be relieved with gabapentin.
Topics: Amines; Analgesics; Anesthetics, Local; Cyclohexanecarboxylic Acids; Cystitis, Interstitial; Cystosc | 2009 |
Alterations in extracellular levels of gamma-aminobutyric acid in the rat basolateral amygdala and periaqueductal gray during conditioned fear, persistent pain and fear-conditioned analgesia.
Topics: Amygdala; Animals; Behavior, Animal; Conditioning, Psychological; Disease Models, Animal; Electric S | 2009 |
Selective inhibitory effects of pregabalin on peripheral C but not A-delta fibers mediated nociception in intact and spinalized rats.
Topics: Animals; Anticonvulsants; Decerebrate State; Electric Stimulation; gamma-Aminobutyric Acid; Male; Ne | 2009 |
Suppression of formalin-induced nociception by cilnidipine, a voltage-dependent calcium channel blocker.
Topics: Administration, Oral; Amines; Analgesics; Animals; Calcium Channel Blockers; Calcium Channels, N-Typ | 2009 |
Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of stress-induced ultrasonic vocalizations in rats.
Topics: Adrenergic Uptake Inhibitors; Analgesics; Analysis of Variance; Animals; Cyclopropanes; Dose-Respons | 2010 |
Outcome reporting in industry-sponsored trials of gabapentin for off-label use.
Topics: Amines; Bipolar Disorder; Clinical Protocols; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobu | 2009 |
Role of GABAA receptors in cognition.
Topics: Animals; Anxiety; Brain; Cognition; Electroencephalography; gamma-Aminobutyric Acid; Humans; Interne | 2009 |
Pharmacological treatment of fibromyalgia syndrome: new developments.
Topics: Age Factors; Analgesics, Opioid; Calcium Channel Blockers; Clinical Trials as Topic; Cognitive Behav | 2010 |
Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study.
Topics: Aged; Amines; Analgesics; Analgesics, Opioid; Chronic Disease; Cyclohexanecarboxylic Acids; Female; | 2010 |
Tri-partite complex for axonal transport drug delivery achieves pharmacological effect.
Topics: Amines; Analgesics; Animals; Axonal Transport; Cell Line; Cells, Cultured; Cricetinae; Cyclohexaneca | 2010 |
Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy.
Topics: Aged; Amines; Analgesics; Cohort Studies; Cyclohexanecarboxylic Acids; Data Interpretation, Statisti | 2010 |
A new combination cream for the treatment of severe neuropathic pain.
Topics: Administration, Topical; Analgesics; Capsaicin; Diabetic Neuropathies; Drug Combinations; gamma-Amin | 2010 |
Cut-points for the measurement of pain: the choice depends on what you want to study.
Topics: Analgesics; Clinical Trials as Topic; Data Interpretation, Statistical; Diabetic Neuropathies; Endpo | 2010 |
Syringomyelia in the Cavalier King Charles spaniel (CKCS) dog.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents; Arnold-Chiari Malformation; Breeding; Cyclohe | 2010 |
Opioidergic and GABAergic mechanisms in the rostral ventromedial medulla modulate the nociceptive response of vocalization in guinea pigs.
Topics: Analgesics, Opioid; Animals; Bicuculline; GABA Agonists; GABA Antagonists; gamma-Aminobutyric Acid; | 2010 |
Cognitive impairment in pain through amygdala-driven prefrontal cortical deactivation.
Topics: Amygdala; Animals; Arthritis; Cognition Disorders; Decision Making; Disease Models, Animal; gamma-Am | 2010 |
Analgesic effects of gabapentin on mechanical hypersensitivity in a rat model of chronic pancreatitis.
Topics: Amines; Analgesics; Animals; Calcium Channels; Calcium Channels, L-Type; Cyclohexanecarboxylic Acids | 2010 |
Pain, in the boondocks.
Topics: Administration, Topical; Analgesics, Non-Narcotic; Animals; Behavior, Animal; gamma-Aminobutyric Aci | 2010 |
Attenuation of neuropathy-induced allodynia following intraplantar injection of pregabalin.
Topics: Analgesics, Non-Narcotic; Animals; Behavior, Animal; Cold Temperature; Dose-Response Relationship, D | 2010 |
Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain.
Topics: Analgesics; Animals; Calcium Channels; Chronic Disease; Drug Interactions; gamma-Aminobutyric Acid; | 2010 |
Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
Topics: Amines; Analgesics, Opioid; Animals; Carrageenan; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Ex | 2010 |
[Formalin-induced pain stimulation induced expression of GABA in the distal cerebrospinal fluid contacting neurons].
Topics: Animals; Brain; Cerebrospinal Fluid; Formaldehyde; gamma-Aminobutyric Acid; Inflammation; Male; Neur | 2010 |
Synaptic pathways and inhibitory gates in the spinal cord dorsal horn.
Topics: Afferent Pathways; Animals; Electric Stimulation; Evoked Potentials; gamma-Aminobutyric Acid; Hypere | 2010 |
Role of NKCC1 and KCC2 in the development of chronic neuropathic pain following spinal cord injury.
Topics: Animals; Bumetanide; Chronic Disease; gamma-Aminobutyric Acid; Hyperalgesia; Inflammation; K Cl- Cot | 2010 |
Upregulation of the GABA transporter GAT-1 in the gracile nucleus in the spared nerve injury model of neuropathic pain.
Topics: Amino Acid Transport System X-AG; Animals; Astrocytes; Biological Transport; Excitatory Amino Acid T | 2010 |
Selective potentiation of gabapentin-mediated antinociception in the rat formalin test by the nicotinic acetylcholine receptor agonist ABT-594.
Topics: Amines; Analgesics; Animals; Azetidines; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-R | 2010 |
Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy.
Topics: Amines; Analgesics; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2010 |
Lack of analgesic efficacy of spinal ondansetron on thermal and mechanical hypersensitivity following spinal nerve ligation in the rat.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gabapen | 2010 |
[Effects of extremely low frequency sinusoid magnetic field on pain threshold and amine acid neurotransmitter of rats].
Topics: Amino Acids; Animals; Brain; Electromagnetic Fields; Electrophysiological Phenomena; gamma-Aminobuty | 2010 |
Differential distribution of activated spinal neurons containing glycine and/or GABA and expressing c-fos in acute and chronic pain models.
Topics: Animals; Capsaicin; Cell Count; Disease Models, Animal; Formaldehyde; gamma-Aminobutyric Acid; Gene | 2010 |
Characterization of the acute and persistent pain state present in K/BxN serum transfer arthritis.
Topics: Activating Transcription Factor 3; Amines; Analgesics; Analysis of Variance; Animals; Arthritis, Rhe | 2010 |
Dissociation of rewarding, anti-aversive and anti-nociceptive effects of different classes of anti-nociceptives in the rat.
Topics: Analgesics; Animals; Carrageenan; Conditioning, Psychological; Dose-Response Relationship, Drug; gam | 2011 |
[Puncture of the radial vein: a forgotten complication].
Topics: Analgesics, Non-Narcotic; Colonoscopy; Female; gamma-Aminobutyric Acid; Humans; Middle Aged; Nerve B | 2010 |
Potential for pregabalin abuse or diversion after past drug-seeking behavior.
Topics: Adult; Analgesics; Analgesics, Opioid; Behavior, Addictive; Female; gamma-Aminobutyric Acid; Humans; | 2010 |
Evaluation of healthcare resource utilization and costs in employees with pain associated with diabetic peripheral neuropathy treated with pregabalin or duloxetine.
Topics: Adolescent; Adult; Age Factors; Analgesics; Comorbidity; Diabetic Neuropathies; Duloxetine Hydrochlo | 2010 |
[The role of combat stress in the development of chronic pain syndrom in veterans and its treatment by pantogam active].
Topics: Adult; Aged; Chronic Disease; Combat Disorders; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; | 2010 |
Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin.
Topics: Analgesics; Dose-Response Relationship, Drug; Double-Blind Method; Fatigue; Fibromyalgia; gamma-Amin | 2011 |
High-resolution sonography of posttraumatic neuroma of the superficial radial nerve.
Topics: Analgesics; Bone Plates; Female; gamma-Aminobutyric Acid; Humans; Middle Aged; Neuroma; Neurosurgica | 2011 |
Is pregabalin ineffective in poststroke pain?
Topics: Analgesics; gamma-Aminobutyric Acid; Humans; Pain; Pregabalin; Stroke | 2011 |
Metabotropic glutamate receptor subtype 8 in the amygdala modulates thermal threshold, neurotransmitter release, and rostral ventromedial medulla cell activity in inflammatory pain.
Topics: Amino Acids; Amygdala; Animals; Behavior, Animal; Benzoates; Blotting, Western; Carrageenan; Chromat | 2011 |
Kv3.1b and Kv3.3 channel subunit expression in murine spinal dorsal horn GABAergic interneurones.
Topics: Animals; gamma-Aminobutyric Acid; Gene Knock-In Techniques; Glutamate Decarboxylase; Immunohistochem | 2011 |
Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study.
Topics: Aged; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Pain; Peripheral Nervo | 2011 |
[Disease with generalized pain. Guillain-Barré syndrome].
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Female; Gabapentin; | 2011 |
Painful traumatic neuroma of the tongue treated with serial alcohol injections.
Topics: Aged; Amines; Analgesics; Anesthetics, Local; Central Nervous System Depressants; Cyclohexanecarboxy | 2011 |
Pregabalin suppresses spinal neuronal hyperexcitability and visceral hypersensitivity in the absence of peripheral pathophysiology.
Topics: Analgesics; Analgesics, Opioid; Animals; Dilatation; Electrophysiology; gamma-Aminobutyric Acid; Hyp | 2011 |
Off-label prescribing explained. Why your doctor may recommend meds that aren't FDA-approved for your condition.
Topics: Amines; Bipolar Disorder; Clinical Protocols; Cyclohexanecarboxylic Acids; Drug Approval; Drug Label | 2011 |
Effects of inducible nitric oxide synthase blockade within the periaqueductal gray on cardiovascular responses during mechanical, heat, and cold nociception.
Topics: Animals; Blood Pressure; Cold Temperature; Enzyme Inhibitors; Female; gamma-Aminobutyric Acid; Gluta | 2012 |
Chronic Lyme disease: the controversies and the science.
Topics: Amines; Analgesics; Anti-Bacterial Agents; Arthritis, Rheumatoid; Borrelia burgdorferi; Chronic Dise | 2011 |
Gabapentin as part of multi-modal analgesia in two cats suffering multiple injuries.
Topics: Amines; Analgesia; Analgesics; Animals; Buprenorphine; Cat Diseases; Cats; Cyclohexanecarboxylic Aci | 2011 |
Pain-related deactivation of medial prefrontal cortical neurons involves mGluR1 and GABA(A) receptors.
Topics: Action Potentials; Animals; Arthritis, Experimental; Benzoates; Bicuculline; Disease Models, Animal; | 2011 |
Accounting for perception, placebo and unmasking effects in estimating treatment effects in randomised clinical trials.
Topics: Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Pain | 2014 |
Successful treatment of tabetic lightning pain and visceral crisis with gabapentin.
Topics: Amines; Cyclohexanecarboxylic Acids; Extremities; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; | 2011 |
Epigenetic suppression of GAD65 expression mediates persistent pain.
Topics: Animals; Chronic Disease; Epigenesis, Genetic; gamma-Aminobutyric Acid; Gene Expression Regulation, | 2011 |
Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition.
Topics: Analysis of Variance; Animals; Animals, Newborn; Arachidonic Acids; Benzoxazines; Benzoxazoles; Biph | 2011 |
Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Databases, Factual; Diabetic Nephropathies; F | 2012 |
The combined predictive capacity of rat models of algogen-induced and neuropathic hypersensitivity to clinically used analgesics varies with nociceptive endpoint and consideration of locomotor function.
Topics: Amines; Analgesics; Animals; Capsaicin; Cyclohexanecarboxylic Acids; Disease Models, Animal; Duloxet | 2012 |
Spontaneous burrowing behaviour in the rat is reduced by peripheral nerve injury or inflammation associated pain.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Cyclohexanec | 2012 |
Commentary: effect of pregabalin on acid-induced oesophageal hypersensitivity.
Topics: Analgesics; Esophageal Diseases; Female; gamma-Aminobutyric Acid; Humans; Male; Pain | 2012 |
Temperature-dependent enhancement of the antinociceptive effects of opioids in combination with gabapentin in mice.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gam | 2012 |
Gabapentin reduces CX3CL1 signaling and blocks spinal microglial activation in monoarthritic rats.
Topics: Amines; Animals; Arthritis; Calcium Channels, L-Type; Chemokine CX3CL1; CX3C Chemokine Receptor 1; C | 2012 |
Ondansetron reverses antihypersensitivity from clonidine in rats after peripheral nerve injury: role of γ-aminobutyric acid in α2-adrenoceptor and 5-HT3 serotonin receptor analgesia.
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesia; Animals; Clonidine; Disease Models, Animal; gamma-A | 2012 |
Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes.
Topics: Amines; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Dia | 2012 |
Non-surgical therapy for bilateral glossopharyngeal neuralgia caused by Eagle's syndrome, diagnosed by three-dimensional computed tomography: a case report.
Topics: Aged; Amines; Analgesics; Anesthetics, Local; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobu | 2012 |
Antinociceptive effects of gabapentin & its mechanism of action in experimental animal studies.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dinoprostone; Gabapentin; gamma-Aminobutyr | 2012 |
Pregabalin antinociception and its interaction with tramadol in acute model of pain.
Topics: Acute Pain; Analgesics; Analgesics, Opioid; Animals; Disease Models, Animal; Dose-Response Relations | 2012 |
Treatment with gabapentin associated with resolution of apnea in two infants with neurologic impairment.
Topics: Amines; Analgesics; Apnea; Central Nervous System; Cyclohexanecarboxylic Acids; Female; Gabapentin; | 2013 |
Positive allosteric modulation of GABA-A receptors reduces capsaicin-induced primary and secondary hypersensitivity in rats.
Topics: Amines; Analgesics, Opioid; Animals; Behavior, Animal; Benzimidazoles; Capsaicin; Cyclohexanecarboxy | 2012 |
Increased excitability of spinal pain reflexes and altered frequency-dependent modulation in the dopamine D3-receptor knockout mouse.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analgesics; Animals; Animals, Newborn; B | 2012 |
Ameliorative effect of Vernonia cinerea in vincristine-induced painful neuropathy in rats.
Topics: Animals; Behavior, Animal; Calcium; Female; gamma-Aminobutyric Acid; Glutathione; Hyperalgesia; Lipi | 2014 |
Evaluation of the fibromyalgia impact questionnaire at baseline as a predictor for time to pain improvement in two clinical trials of pregabalin.
Topics: Analgesics; Double-Blind Method; Female; Fibromyalgia; gamma-Aminobutyric Acid; Humans; Kaplan-Meier | 2013 |
Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model.
Topics: Amines; Animals; Antioxidants; Calcium Channels; Catalase; Cyclohexanecarboxylic Acids; Drug Combina | 2013 |
Mandatory palliative care education for surgical residents: initial focus on teaching pain management.
Topics: Adult; Amines; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Curriculum; | 2013 |
Dynamic determination and possible mechanism of amino acid transmitter release from rat spinal dorsal horn induced by the venom and a neurotoxin (BmK I) of scorpion Buthus martensi Karsch.
Topics: Animals; Aspartic Acid; gamma-Aminobutyric Acid; Glutamic Acid; Male; Microdialysis; Neurotransmitte | 2002 |
Changes in expression of voltage-dependent ion channel subunits in dorsal root ganglia of rats with radicular injury and pain.
Topics: Acetates; Amines; Analgesics; Animals; Behavior, Animal; Calcium Channels; Cyclohexanecarboxylic Aci | 2002 |
Gabapentin for coeliac plexus pain.
Topics: Acetates; Aged; Amines; Analgesics; Celiac Plexus; Cyclohexanecarboxylic Acids; Female; Gabapentin; | 2002 |
Gabapentin and pregabalin suppress tactile allodynia and potentiate spinal cord stimulation in a model of neuropathy.
Topics: Acetates; Amines; Analgesics; Animals; Anticonvulsants; Calcium Channel Blockers; Cyclohexanecarboxy | 2002 |
SUNCT responsive to gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Conjunctiva; Cyclohexanecarboxylic Acids; Female; Gabapentin; g | 2002 |
Central post-stroke pain syndrome: yet another use for gabapentin?
Topics: Acetates; Activities of Daily Living; Administration, Oral; Amines; Analgesics; Cyclohexanecarboxyli | 2002 |
Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat.
Topics: Analgesics, Opioid; Animals; Chronic Disease; Colon; Colonic Diseases; gamma-Aminobutyric Acid; Hype | 2002 |
Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception.
Topics: Acetates; Acute Disease; Adrenergic alpha-Agonists; Amines; Analgesics, Non-Narcotic; Analgesics, Op | 2002 |
Two major distinct subpopulations of neurokinin-3 receptor-expressing neurons in the superficial dorsal horn of the rat spinal cord.
Topics: Afferent Pathways; Animals; Cell Count; gamma-Aminobutyric Acid; Immunohistochemistry; Nitric Oxide; | 2002 |
Is gabapentin a "Broad-spectrum" analgesic?
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 2002 |
BDNF modulates sensory neuron synaptic activity by a facilitation of GABA transmission in the dorsal horn.
Topics: Afferent Pathways; Animals; Brain-Derived Neurotrophic Factor; Cells, Cultured; gamma-Aminobutyric A | 2002 |
Somatic nociception activates NK1 receptors in the nucleus tractus solitarii to attenuate the baroreceptor cardiac reflex.
Topics: Animals; Baroreflex; Bicuculline; Electrophysiology; GABA Antagonists; gamma-Aminobutyric Acid; Micr | 2002 |
Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain.
Topics: Acetates; Amines; Animals; Benzofurans; Carbamates; Cyclohexanecarboxylic Acids; Diabetes Mellitus, | 2002 |
Anti-allodynic action of the tormentic acid, a triterpene isolated from plant, against neuropathic and inflammatory persistent pain in mice.
Topics: Acetates; Amines; Analgesics; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Female; Freund' | 2002 |
Cavernous angioma in the brachium pontis presenting with trigeminal neuralgia: a case report.
Topics: Acetates; Amines; Analgesics; Central Nervous System Vascular Malformations; Cyclohexanecarboxylic A | 2002 |
Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia.
Topics: Acetates; Adrenergic Uptake Inhibitors; Amines; Aminopyridines; Analgesia; Analgesics; Animals; Cell | 2002 |
Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin.
Topics: Acetates; Amines; Animals; Calcium Channels; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Dis | 2002 |
Anti-nociceptive effects of diazepam binding inhibitor in the central nervous system of rats.
Topics: Animals; Central Nervous System; Diazepam Binding Inhibitor; Dose-Response Relationship, Drug; gamma | 2002 |
Lumbar spinal cord stimulation for cervical-originated central pain: a case report.
Topics: Acetates; Amines; Antidepressive Agents, Tricyclic; Cervical Vertebrae; Cyclohexanecarboxylic Acids; | 2002 |
Plateau properties in pain pathways.
Topics: Action Potentials; Animals; Biological Clocks; GABA-B Receptor Agonists; gamma-Aminobutyric Acid; In | 2003 |
Gabapentin markedly reduces acetic acid-induced visceral nociception.
Topics: Acetates; Amines; Analgesics; Animals; Calcium; Cyclohexanecarboxylic Acids; Excitatory Amino Acids; | 2003 |
[Recognizing the "neck-tongue" syndrome].
Topics: Acetates; Amines; Analgesics; Analgesics, Non-Narcotic; Arthritis; Cervical Vertebrae; Cyclohexaneca | 2003 |
Suppression by gabapentin of pain-related mechano-responses in mice given orthotopic tumor inoculation.
Topics: Acetates; Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Hyperal | 2003 |
Behavioral evidence linking opioid-sensitive GABAergic neurons in the ventrolateral periaqueductal gray to morphine tolerance.
Topics: Analgesics, Opioid; Animals; Drug Tolerance; Efferent Pathways; Excitatory Amino Acid Agonists; GABA | 2003 |
[Case report on a patient with SUNCT-syndrome].
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Functional Laterality; Gabapentin | 2003 |
Bicuculline and strychnine suppress the mesencephalic locomotor region-induced inhibition of group III muscle afferent input to the dorsal horn.
Topics: Afferent Pathways; Animals; Bicuculline; Cats; Efferent Pathways; Female; GABA Antagonists; GABA-A R | 2003 |
Complete vasomotor collapse: an unusual manifestation of the carotid sinus reflex.
Topics: Acetates; Amines; Animals; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gabapenti | 2003 |
Gabapentin blocks and reverses antinociceptive morphine tolerance in the rat paw-pressure and tail-flick tests.
Topics: Acetates; Amines; Analgesics, Opioid; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; | 2003 |
An East-West approach to the management of central post-stroke pain.
Topics: Acetates; Acupuncture; Aged; Amines; Amitriptyline; Analgesics, Opioid; Antidepressive Agents, Secon | 2003 |
ATP-sensitive potassium channels in rat primary afferent neurons: the effect of neuropathic injury and gabapentin.
Topics: Acetates; Amines; Animals; ATP-Binding Cassette Transporters; Basal Ganglia; Cyclohexanecarboxylic A | 2003 |
The trend to move palliative care upstream.
Topics: Acetates; Adult; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; H | 2003 |
Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin.
Topics: Acetates; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Herpes Z | 2003 |
[Effect of anticonvulsant gabapentin on visceral nociception and its relationship with amino acid neurotransmitters released from spinal cord].
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, | 2003 |
Salt and wounds: a new mechanism for neuropathic pain.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Glycine; Humans; K Cl- Cotransporters; Ner | 2003 |
Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain.
Topics: Acetates; Amines; Analgesics; Animals; Anti-Inflammatory Agents; Cyclohexanecarboxylic Acids; Edema; | 2003 |
[Unclear chronic aches. Often depression plays a part therein].
Topics: Acetates; Amines; Analgesics, Opioid; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Age | 2003 |
[Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus].
Topics: Acetates; Aged; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Ty | 2003 |
The pattern of gabapentin use in a tertiary palliative care unit.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; G | 2003 |
Treatment of neuropathic orbital pain with gabapentin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Eye Diseases; Female; Gabapen | 2003 |
Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited.
Topics: Acetates; Amines; Analgesia; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; | 2003 |
The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain.
Topics: Acetates; Amines; Analgesics; Chronic Disease; Clinical Trials, Phase II as Topic; Computer Simulati | 2003 |
A nitric oxide (NO)-releasing derivative of gabapentin, NCX 8001, alleviates neuropathic pain-like behavior after spinal cord and peripheral nerve injury.
Topics: Acetates; Amines; Animals; Aorta, Thoracic; Behavior, Animal; Cyclic GMP; Cyclohexanecarboxylic Acid | 2004 |
GABAergic projection from the ventral tegmental area and substantia nigra to the periaqueductal gray region and the dorsal raphe nucleus.
Topics: Animals; Blood Pressure; Cardiovascular Physiological Phenomena; Cholera Toxin; GABA Antagonists; ga | 2004 |
Myoclonic jerks associated with gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobut | 2003 |
Synergistic interaction between spinal gabapentin and oral B vitamins in a neuropathic pain model.
Topics: Acetates; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug | 2003 |
Dopaminergic input to GABAergic neurons in the rostral agranular insular cortex of the rat.
Topics: Animals; Benzofurans; Cerebral Cortex; Dopamine; gamma-Aminobutyric Acid; Immunohistochemistry; Inte | 2003 |
Reduction by gabapentin of K+-evoked release of [3H]-glutamate from the caudal trigeminal nucleus of the streptozotocin-treated rat.
Topics: Acetates; Amines; Animals; Blood Glucose; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experiment | 2004 |
Painful neuropathy alters the effect of gabapentin on sensory neuron excitability in rats.
Topics: Acetates; Action Potentials; Amines; Analgesics; Analysis of Variance; Animals; Calcium Channels; Cy | 2004 |
Effects of the suppression of acute herpetic pain by gabapentin and amitriptyline on the incidence of delayed postherpetic pain in mice.
Topics: Acetates; Amines; Amitriptyline; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, A | 2004 |
Vulvodynia.
Topics: Acetates; Amines; Anticonvulsants; Antidepressive Agents, Tricyclic; Biofeedback, Psychology; Chroni | 2004 |
Gabapentin (Neurontin) for chronic pain.
Topics: Acetates; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Drug Costs; Drug Interac | 2004 |
The use of gabapentin in a 12-year-old boy with cancer pain.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Child; Cyclohexanecarboxylic Acids; Dose-Response | 2004 |
Successful use of zonisamide for central poststroke pain.
Topics: Anticonvulsants; Calcium Channel Blockers; Calcium Channels, T-Type; Cerebral Infarction; Diabetes C | 2004 |
Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury.
Topics: Amines; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Cyclohexanols; Disease Models, Animal | 2004 |
Differential release of neurotransmitters from superficial and deep layers of the dorsal horn in response to acute noxious stimulation and inflammation of the rat paw.
Topics: Afferent Pathways; Animals; Arginine; Aspartic Acid; Chondrus; Extracellular Fluid; Foot; gamma-Amin | 2004 |
American Chemical Society--227th annual meeting. Neuroprotection. 28 March - 1 April 2004, Anaheim, CA, USA.
Topics: Animals; Antiparkinson Agents; Carbazoles; gamma-Aminobutyric Acid; Humans; Indoles; Neuroprotective | 2004 |
Nicotine differentially activates inhibitory and excitatory neurons in the dorsal spinal cord.
Topics: Action Potentials; Afferent Pathways; Analgesics; Animals; Biomarkers; Calbindins; Dendrites; Excita | 2004 |
Mechanical allodynia following contusion injury of the rat spinal cord is associated with loss of GABAergic inhibition in the dorsal horn.
Topics: Action Potentials; Animals; Bicuculline; Disease Models, Animal; Electric Stimulation; Female; GABA | 2004 |
Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels.
Topics: Acetates; Amines; Anticonvulsants; Calcium Channels; Chronic Disease; Cyclohexanecarboxylic Acids; G | 2004 |
Adenosine inhibits GABAergic and glycinergic transmission in adult rat substantia gelatinosa neurons.
Topics: 4-Aminopyridine; 8-Bromo Cyclic Adenosine Monophosphate; Adenosine; Animals; Colforsin; GABA Antagon | 2004 |
Profiles in patient safety: when an error occurs.
Topics: Acetates; Aged; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Diabetic Neuropath | 2004 |
Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain.
Topics: Animals; Baclofen; Bicuculline; Calcitonin Gene-Related Peptide; gamma-Aminobutyric Acid; Ganglia, S | 2004 |
Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
Topics: Acute Disease; Amines; Amitriptyline; Animals; Conscious Sedation; Cyclohexanecarboxylic Acids; Cycl | 2004 |
Future Pain Drugs - Europe 2003. 15-16 September 2003, London, UK.
Topics: Acetaminophen; Acetates; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, A | 2003 |
Differential analgesic sensitivity of two distinct neuropathic pain models.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Animals; Cold Temperature; Cyclohexanecarboxylic A | 2004 |
Evidence that GABAergic neurons in the spinal trigeminal nucleus are involved in the transmission of inflammatory pain in the rat: a microdialysis and pharmacological study.
Topics: Animals; GABA Agonists; GABA Antagonists; gamma-Aminobutyric Acid; Inflammation; Male; Microdialysis | 2004 |
Treatment of bath PUVA-induced skin pain with gabapentin.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; | 2004 |
Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model.
Topics: Acetates; Acute Disease; Amines; Analgesics; Analgesics, Opioid; Animals; Behavior, Animal; Bradykin | 2004 |
Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents.
Topics: Adrenergic Uptake Inhibitors; Amines; Analgesics; Analgesics, Opioid; Animals; Anti-Inflammatory Age | 2005 |
[Gabapentin (Neurontin) and cancer pain: a pilot study].
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2004 |
Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Bone Neoplasms; Cell Line, Tumor; Cyclohexanecarboxyl | 2005 |
Analysis of interactions between serotonin and gabapentin or adenosine in the spinal cord of rats.
Topics: Adenosine; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Dru | 2005 |
Neutropenia occurring after starting gabapentin for neuropathic pain.
Topics: Adenocarcinoma; Amines; Analgesics; Carcinoma, Non-Small-Cell Lung; Cyclohexanecarboxylic Acids; Gab | 2004 |
Gabapentin-induced myoclonus in end-stage renal disease.
Topics: Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2005 |
Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action.
Topics: Acetates; Acute Disease; Amines; Analgesics; Animals; Benzylamines; Chronic Disease; Cyclohexanecarb | 2005 |
Taste damage: previously unsuspected consequences.
Topics: Burning Mouth Syndrome; Clonazepam; Female; GABA Agonists; gamma-Aminobutyric Acid; Humans; Male; Mo | 2005 |
[Questions to the Drug Committee about administration of Lyrica].
Topics: Anticonvulsants; Denmark; Drug and Narcotic Control; gamma-Aminobutyric Acid; Humans; Neuralgia; Pai | 2005 |
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anxiety; Ataxia; Behavior, Ani | 2005 |
Peptide leads new class of chronic pain drugs.
Topics: Calcium Channel Blockers; Calcium Channels, N-Type; Chronic Disease; gamma-Aminobutyric Acid; Humans | 2005 |
Ionotropic glutamate receptors are expressed in GABAergic terminals in the rat superficial dorsal horn.
Topics: Animals; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Immunohistochemistry; Isoenzymes; Male; M | 2005 |
[Is there any documentation for Lyrica in the treatment of painful diabetic neuropathy?].
Topics: Anticonvulsants; Diabetic Neuropathies; Documentation; Drug Information Services; gamma-Aminobutyric | 2005 |
GABAergic neurons express mu-opioid receptors in the ventrolateral orbital cortex of the rat.
Topics: Animals; Cerebral Cortex; Fluorescent Antibody Technique; gamma-Aminobutyric Acid; Male; Microscopy, | 2005 |
Substance P inhibits progesterone conversion to neuroactive metabolites in spinal sensory circuit: a potential component of nociception.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Male; Models, Neurological; Neurons, Affer | 2005 |
Pregabalin.
Topics: Analgesics; Anticonvulsants; Drugs, Investigational; gamma-Aminobutyric Acid; Humans; Pain; Pregabal | 2005 |
The effect of antinociceptive drugs tested at different times after nerve injury in rats.
Topics: Amines; Analgesics; Animals; Antidepressive Agents, Tricyclic; Cyclohexanecarboxylic Acids; Dose-Res | 2005 |
Computed tomography guided lumbar sympathetic block for complex regional pain syndrome in a child: a case report and review.
Topics: Amines; Amitriptyline; Analgesics; Anesthetics, Local; Antidepressive Agents, Tricyclic; Autonomic N | 2006 |
Effect of morphine on deep dorsal horn projection neurons depends on spinal GABAergic and glycinergic tone: implications for reduced opioid effect in neuropathic pain.
Topics: Administration, Topical; Analgesics, Opioid; Animals; Behavior, Animal; Electrophysiology; gamma-Ami | 2005 |
Morphological evidence for GABA/glycine-cocontaining terminals in synaptic contact with neurokinin-1 receptor-expressing neurons in the sacral dorsal commissural nucleus of the rat.
Topics: Animals; Fluorescent Antibody Technique; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Glycine; | 2005 |
Characterization of pain and pharmacologic responses in an animal model of lumbar adhesive arachnoiditis.
Topics: Amines; Analgesics; Analgesics, Opioid; Animals; Arachnoiditis; Behavior, Animal; Cauda Equina; Cycl | 2005 |
CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats.
Topics: Administration, Oral; Amines; Analgesics; Animals; Behavior, Animal; Capsaicin; Cyclohexanecarboxyli | 2005 |
Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain.
Topics: Amines; Analgesics; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Bupropio | 2005 |
Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin.
Topics: Action Potentials; Amines; Analgesics; Analysis of Variance; Animals; Behavior, Animal; Cell Count; | 2005 |
Development and expression of neuropathic pain in CB1 knockout mice.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2006 |
Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain.
Topics: Ambroxol; Amines; Analgesics; Animals; Behavior, Animal; Constriction, Pathologic; Cyclohexanecarbox | 2005 |
The effects of diacerhein on mechanical allodynia in inflammatory and neuropathic models of nociception in mice.
Topics: Amines; Animals; Anthraquinones; Anti-Inflammatory Agents, Non-Steroidal; Cyclohexanecarboxylic Acid | 2005 |
Postnatal changes in functional activities of the pig's brain: a combined functional magnetic resonance imaging and immunohistochemical study.
Topics: Aging; Animals; Animals, Newborn; Brain; Brain Chemistry; Female; Fluorescent Antibody Technique; ga | 2005 |
Neuroscience: a painful factor.
Topics: Adenosine Triphosphate; Animals; Brain-Derived Neurotrophic Factor; gamma-Aminobutyric Acid; Microgl | 2005 |
The nitric oxide-cyclic GMP-protein kinase G-K+ channel pathway participates in the antiallodynic effect of spinal gabapentin.
Topics: Amines; Analgesics; Animals; Apamin; Carbazoles; Charybdotoxin; Cyclic GMP; Cyclic GMP-Dependent Pro | 2006 |
Inhibition of nociceptive responses of spinal cord neurones during hypertension involves the spinal GABAergic system and a pain modulatory center located at the caudal ventrolateral medulla.
Topics: Animals; Blood Pressure; gamma-Aminobutyric Acid; Gene Expression; Genes, fos; Hindlimb; Hypertensio | 2006 |
[Pregabalin--clinical evidence and experiences].
Topics: Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topic; Drug Interactions; Epilepsy; | 2005 |
Substantia Gelatinosa neurons in defined-medium organotypic slice culture are similar to those in acute slices from young adult rats.
Topics: Action Potentials; Afferent Pathways; Aging; Animals; Chronic Disease; Culture Media; Electric Stimu | 2006 |
Motor cortex stimulation for central pain following a traumatic brain injury.
Topics: Accidental Falls; Adult; Amines; Amitriptyline; Analgesics, Non-Narcotic; Aphasia, Broca; Brain Inju | 2006 |
Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin.
Topics: Amines; Animals; Antineoplastic Agents, Phytogenic; Behavior, Animal; Blotting, Western; Calcium Cha | 2006 |
Protective effect of BR-16A, a polyherbal preparation against social isolation stress: possible GABAergic mechanism.
Topics: Animals; Diazepam; Dose-Response Relationship, Drug; Drug Interactions; Female; Flumazenil; GABA Ago | 2006 |
Gabapentin may cause reversible visual field constriction.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans | 2006 |
Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Cyclohexanols; Dose-Response Relationship, | 2006 |
Does acute pain associated with herpes zoster respond to treatment with gabapentin?
Topics: Acute Disease; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind Met | 2006 |
Inhibition of pain behavior by GABA(B) receptors in the thalamic ventrobasal complex: effect on normal rats subjected to the formalin test of nociception.
Topics: Acute Disease; Analgesics; Animals; Baclofen; Behavior, Animal; Chronic Disease; Disease Models, Ani | 2006 |
Gabapentin enhances the analgesic response to morphine in acute model of pain in male rats.
Topics: Amines; Analgesics, Opioid; Animals; Area Under Curve; Cyclohexanecarboxylic Acids; Disease Models, | 2006 |
Two cases of painful gynecomastia and lower extremity pain in association with pregabalin therapy.
Topics: Adolescent; Anticonvulsants; Edema; Epilepsy; gamma-Aminobutyric Acid; Gynecomastia; Humans; Ilium; | 2006 |
Effects of gabapentin on morphine consumption and pain in severely burned patients.
Topics: Administration, Oral; Amines; Analgesics; Burns; Case-Control Studies; Cyclohexanecarboxylic Acids; | 2007 |
Bilateral hemifacial spasm and trigeminal neuralgia: a unique form of painful tic convulsif.
Topics: Aged; Amines; Amitriptyline; Analgesics; Arachnoid Cysts; Botulinum Toxins, Type A; Cyclohexanecarbo | 2007 |
Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin.
Topics: Amino Acid Sequence; Analgesics; Animals; Arginine; Autoradiography; Base Sequence; Calcium Channels | 2006 |
Increased nociceptive input rapidly modulates spinal GABAergic transmission through endogenously released glutamate.
Topics: Afferent Pathways; Animals; Capsaicin; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; G | 2007 |
Analgesic activity of affinin, an alkamide from Heliopsis longipes (Compositae).
Topics: 4-Butyrolactone; Alkenes; Amides; Analgesics; Animals; Asteraceae; Benzodioxoles; Brain; Dioxoles; F | 2007 |
Neurochemical evidence that supraspinally administered gabapentin activates the descending noradrenergic system after peripheral nerve injury.
Topics: Amines; Analgesics; Animals; Chromatography, High Pressure Liquid; Cyclohexanecarboxylic Acids; Gaba | 2007 |
GABAA but not GABAB receptors in the rostral anterior cingulate cortex selectively modulate pain-induced escape/avoidance behavior.
Topics: Animals; Avoidance Learning; Baclofen; Bicuculline; Escape Reaction; GABA Agonists; GABA Antagonists | 2007 |
Painful pemphigus vulgaris.
Topics: Administration, Cutaneous; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Fentanyl; Gabapen | 2007 |
Subarachnoid transplant of a human neuronal cell line attenuates chronic allodynia and hyperalgesia after excitotoxic spinal cord injury in the rat.
Topics: Animals; Antimetabolites; Bromodeoxyuridine; Cell Differentiation; Cell Line; Cell Transplantation; | 2007 |
A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain.
Topics: Amines; Analgesics; Animals; Anticonvulsants; Cold Temperature; Cyclohexanecarboxylic Acids; Disease | 2007 |
Nociception: Taking the Pain out of Drug Discovery. 28 November 2006, London, UK.
Topics: Amidohydrolases; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2007 |
Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats.
Topics: Analgesics; Animals; Carrageenan; Chronic Disease; Disease Models, Animal; Dose-Response Relationshi | 2007 |
Hydrogen peroxide increases GABAergic mIPSC through presynaptic release of calcium from IP3 receptor-sensitive stores in spinal cord substantia gelatinosa neurons.
Topics: Animals; Calcium; Calcium Channel Blockers; gamma-Aminobutyric Acid; Hydrogen Peroxide; Inhibitory P | 2007 |
Arginine vasopressin induces periaqueductal gray release of enkephalin and endorphin relating to pain modulation in the rat.
Topics: Acetylcholine; Animals; Arginine Vasopressin; beta-Endorphin; Choline; Dopamine; Dose-Response Relat | 2007 |
Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF.
Topics: Acetamides; Amines; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Excitatory Amino Acid An | 2007 |
Isobolographic analyses of the gabapentin-metamizol combination after local peripheral, intrathecal and oral administration in the rat.
Topics: Administration, Cutaneous; Administration, Oral; Amines; Analgesics; Animals; Cyclohexanecarboxylic | 2007 |
Evaluation of gabapentin in the treatment of generalized vulvodynia, unprovoked.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Ad | 2007 |
Pregabalin and duloxetine for the treatment of neuropathic pain disorders.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Duloxetine Hydrochloride; Ga | 2007 |
Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.
Topics: Analgesics; Animals; Anticonvulsants; Disease Models, Animal; gamma-Aminobutyric Acid; Hyperalgesia; | 2007 |
Colocalization and shared distribution of endomorphins with substance P, calcitonin gene-related peptide, gamma-aminobutyric acid, and the mu opioid receptor.
Topics: Animals; Brain; Calcitonin Gene-Related Peptide; gamma-Aminobutyric Acid; Immunohistochemistry; Male | 2007 |
BDNF-mediated modulation of GABA and glycine release in dorsal horn lamina II from postnatal rats.
Topics: Animals; Animals, Newborn; Brain-Derived Neurotrophic Factor; Dendrites; gamma-Aminobutyric Acid; Gl | 2007 |
Oral gabapentin activates spinal cholinergic circuits to reduce hypersensitivity after peripheral nerve injury and interacts synergistically with oral donepezil.
Topics: Administration, Oral; Amines; Analgesics; Animals; Cholinesterase Inhibitors; Cyclohexanecarboxylic | 2007 |
The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy.
Topics: Amides; Amines; Animals; Behavior, Animal; Camphanes; Cyclohexanecarboxylic Acids; Dose-Response Rel | 2007 |
Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial.
Topics: Adverse Drug Reaction Reporting Systems; Analgesics; Anti-Anxiety Agents; Body Weight; Conflict of I | 2007 |
Chronic orchialgia: consider gabapentin or nortriptyline before considering surgery.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Amines; Calcium Channel Blockers; Chronic Disease; Cycloh | 2007 |
c-Fos expression in the periaqueductal gray is induced by electroacupuncture in the rat, with possible reference to GABAergic neurons.
Topics: Acupuncture Points; Animals; Electroacupuncture; gamma-Aminobutyric Acid; Gene Expression Regulation | 2007 |
Gabapentin action and interaction on the antinociceptive effect of morphine on visceral pain in mice.
Topics: Acetic Acid; Amines; Analgesics; Analgesics, Opioid; Analysis of Variance; Animals; Cyclohexanecarbo | 2008 |
Transient allodynia pain models in mice for early assessment of analgesic activity.
Topics: Adrenergic alpha-Antagonists; Amines; Amitriptyline; Analgesics; Animals; Clonidine; Cyclohexanecarb | 2008 |
Spinal GABAergic transplants attenuate mechanical allodynia in a rat model of neuropathic pain.
Topics: Animals; Brain Tissue Transplantation; Cells, Cultured; Disease Models, Animal; Female; Fetal Tissue | 2007 |
Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia.
Topics: Amitriptyline; Analgesics; Anti-Ulcer Agents; Anticoagulants; Antidepressive Agents; Anxiety; Cardio | 2007 |
Pregabalin in patients with antidepressant treatment-resistant somatoform disorders: a case series.
Topics: Adult; Analgesics; Antidepressive Agents; Dose-Response Relationship, Drug; Female; gamma-Aminobutyr | 2007 |
Pregabalin (Lyrica) for fibromyalgia.
Topics: Administration, Oral; Analgesics; Drug Administration Schedule; Drug Costs; Drug Interactions; Fibro | 2007 |
Pregabalin-induced generalized myoclonic status epilepticus in patients with chronic pain.
Topics: Aged, 80 and over; Analgesics; Chronic Disease; Electroencephalography; Epilepsies, Myoclonic; Femal | 2007 |
Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005.
Topics: Adolescent; Adult; Age Distribution; Aged; Amines; Anticonvulsants; Carbamazepine; Catchment Area, H | 2007 |
Acupuncture, ketamine and piriformis syndrome--a case report from palliative care.
Topics: Acupuncture Therapy; Amines; Analgesics; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Gab | 2007 |
Case reports: zoster pain in haematological malignancies: effective pain relief with oxycodone in patients unresponsive to other analgesic measures.
Topics: Acute Disease; Aged; Aged, 80 and over; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic | 2007 |
[Pregabalin in the treatment of neuropathic pain].
Topics: Analgesics; gamma-Aminobutyric Acid; Humans; Neuralgia; Pain; Pregabalin | 2007 |
Antinociceptive action of limonexic acid obtained from Raulinoa echinata.
Topics: Acetaminophen; Analgesics; Animals; Aspirin; Disease Models, Animal; Dose-Response Relationship, Dru | 2007 |
Gestational trophoblastic disease with painful skin metastases.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Fatal Outcome; Female; Gabapentin; gamma-Ami | 2008 |
Evidence for the involvement of glutamatergic and GABAergic systems and protein kinase A pathway in the antinociceptive effect caused by p-methoxy-diphenyl diselenide in mice.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Acetic Acid; Analgesics; Animals; Benzene Derivatives; Capsa | 2008 |
Gabapentin for painful legs and moving toes syndrome.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; | 2007 |
Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways.
Topics: Action Potentials; Animals; Brain Stem; Capsaicin; Diterpenes; Dose-Response Relationship, Drug; gam | 2007 |
Gabapentin produces PKA-dependent pre-synaptic inhibition of GABAergic synaptic transmission in LC neurons following partial nerve injury in mice.
Topics: Amines; Animals; Cyclic AMP-Dependent Protein Kinases; Cyclohexanecarboxylic Acids; Efferent Pathway | 2008 |
Pharmacologic investigation of the mechanism underlying cold allodynia using a new cold plate procedure in rats with chronic constriction injuries.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Calcium Channel Blockers; Chronic Disease; Cold Tempe | 2008 |
Regions of interest analysis in pharmacological fMRI: how do the definition criteria influence the inferred result?
Topics: Adult; Amines; Analgesics; Brain; Capsaicin; Cyclohexanecarboxylic Acids; Echo-Planar Imaging; Gabap | 2008 |
Reduced GABA neurotransmission underlies hyperalgesia induced by repeated forced swimming stress.
Topics: Analysis of Variance; Animals; Diazepam; Flumazenil; GABA Modulators; gamma-Aminobutyric Acid; Hyper | 2008 |
Labetalol facilitates GABAergic transmission to rat periaqueductal gray neurons via antagonizing beta1-adrenergic receptors--a possible mechanism underlying labetalol-induced analgesia.
Topics: Action Potentials; Adrenergic alpha-Antagonists; Adrenergic beta-1 Receptor Antagonists; Analgesics; | 2008 |
Gabapentin evoked changes in functional activity in nociceptive regions in the brain of the anaesthetized rat: an fMRI study.
Topics: Administration, Oral; Amines; Analgesics; Animals; Blood Pressure; Brain; Brain Mapping; Cyclohexane | 2008 |
Rats with chronic post-ischemia pain exhibit an analgesic sensitivity profile similar to human patients with complex regional pain syndrome--type I.
Topics: Amitriptyline; Analgesics; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dos | 2008 |
Mercury intoxication and neuropathic pain.
Topics: Adolescent; Amines; Analgesics, Opioid; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Female | 2008 |
Standard error of measurement as a valid alternative to minimally important difference for evaluating the magnitude of changes in patient-reported outcomes measures.
Topics: Amines; Analgesics; Cohort Studies; Cyclohexanecarboxylic Acids; Data Interpretation, Statistical; G | 2008 |
Propentofylline attenuates allodynia, glial activation and modulates GABAergic tone after spinal cord injury in the rat.
Topics: Animals; gamma-Aminobutyric Acid; Male; Neuroglia; Pain; Rats; Rats, Sprague-Dawley; Spinal Cord Inj | 2008 |
Successful use of gabapentin in acute pain management following burn injury: a case series.
Topics: Adult; Amines; Analgesics; Burns; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyri | 2008 |
Gabapentin therapy for painful, blind glaucomatous eye: case report.
Topics: Aged; Amines; Analgesics; Blindness; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2008 |
The use of gabapentin for recurrent painful attacks with multiple piloleiomyomas.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Leiomy | 2008 |
Pharmacological treatment of neuropathic pain in older persons.
Topics: Aged; Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Chronic Disease | 2008 |
Urinary and rectal incontinence during gabapentin therapy.
Topics: Aged; Amines; Anticonvulsants; Carcinoma, Non-Small-Cell Lung; Cyclohexanecarboxylic Acids; Fecal In | 2008 |
Antinociceptive activity of the S1P-receptor agonist FTY720.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Fingolim | 2008 |
The antinociceptive effects of anticonvulsants in a mouse visceral pain model.
Topics: Acetic Acid; Amines; Analgesics; Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Cyclohex | 2008 |
Ronald Tasker Award: Intrathecal transplantation of a human neuronal cell line for the treatment of neuropathic pain in a spinal cord injury model.
Topics: Animals; Carcinoma, Embryonal; Cell Line, Tumor; gamma-Aminobutyric Acid; Glycine; Injections, Spina | 2007 |
GABAergic mechanisms in antinociception.
Topics: Alkynes; Aminocaproates; Aminooxyacetic Acid; Analgesics; Animals; Baclofen; Bicuculline; Central Ne | 1984 |
Pharmacological studies on stimulation-produced analgesia in mice.
Topics: Adrenalectomy; Analgesia; Animals; Avoidance Learning; Catecholamines; Electric Stimulation; Female; | 1981 |
[GABA-ergic component in the mechanism of action of narcotic analgesics and enkephalin analogs].
Topics: Analgesics, Opioid; Animals; Brain; Drug Interactions; Endorphins; Enkephalins; GABA Antagonists; ga | 1982 |
Participation of GABA in the mechanism of action of psychotropic agents.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Brain Chemistry; Cerebral Cortex; Electric Stimulatio | 1982 |
Psychobiology of opioids.
Topics: Acetylcholine; Animals; Behavior; Brain; Brain Chemistry; Catecholamines; Circadian Rhythm; Consumma | 1984 |
Transmitters involved in central processing of nociceptive information.
Topics: Animals; Enkephalins; gamma-Aminobutyric Acid; Glycine; Humans; Neural Inhibition; Neurons, Afferent | 1982 |
Neurotransmitters and CNS disease. Pain.
Topics: Central Nervous System; Endorphins; GABA Antagonists; gamma-Aminobutyric Acid; Humans; Neurons, Affe | 1982 |
Sensitization produced by repeated administration of naloxone is blocked by food deprivation.
Topics: Animals; Avoidance Learning; Food Deprivation; gamma-Aminobutyric Acid; Male; Mice; Mice, Inbred DBA | 1982 |
Spinal vs supraspinal actions of morphine on cat spinal cord multireceptive neurons.
Topics: Animals; Brain; Cats; Female; gamma-Aminobutyric Acid; Male; Morphine; Neural Inhibition; Pain; Spin | 1983 |
Irreversible inhibitors of GABA transaminase induce antinociceptive effects and potentiate morphine.
Topics: 4-Aminobutyrate Transaminase; Alkynes; Aminocaproates; Animals; Ataxia; Brain Chemistry; Drug Synerg | 1980 |
Interaction between phencyclidine (PCP) and GABA-ergic drugs: clinical implications.
Topics: Aminooxyacetic Acid; Anesthesia; Animals; Baclofen; Dextroamphetamine; Diazepam; Drug Interactions; | 1980 |
The effect of GABAergic agents on opiate analgesia.
Topics: Animals; Drug Interactions; Endorphins; gamma-Aminobutyric Acid; Injections, Intraventricular; Isoni | 1980 |
Chlordiazepoxide and GABA injected into raphé dorsalis release the conditioned behavioural suppression induced in rats by a conflict procedure without nociceptive component.
Topics: Animals; Chlordiazepoxide; Conditioning, Operant; Conflict, Psychological; Diazepam; gamma-Aminobuty | 1980 |
[Effects of neurotropin in pain syndromes].
Topics: Analgesics; Animals; Arthritis, Experimental; gamma-Aminobutyric Acid; Male; Nervous System Diseases | 1995 |
Dorsal column inhibition of nociceptive thalamic cells mediated by gamma-aminobutyric acid mechanisms in the cat.
Topics: Afferent Pathways; Animals; Baclofen; Cats; Dental Pulp; Electric Stimulation; GABA-A Receptor Antag | 1994 |
Glycine and GABAA antagonists reduce the inhibition of primate spinothalamic tract neurons produced by stimulation in periaqueductal gray.
Topics: Animals; Bicuculline; Brain Mapping; Dose-Response Relationship, Drug; Electric Stimulation; GABA-A | 1994 |
Interactions between laudanosine, GABA, and opioid subtype receptors: implication for laudanosine seizure activity.
Topics: Animals; Bicuculline; Binding, Competitive; Brain; Cell Membrane; Cerebral Ventricles; GABA Antagoni | 1994 |
Effects of intrathecal strychnine and bicuculline on nerve compression-induced thermal hyperalgesia and selective antagonism by MK-801.
Topics: Animals; Bicuculline; Dizocilpine Maleate; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid | 1993 |
Postpoliomyelitis pain treated with gabapentin.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Ac | 1996 |
Prostaglandin D2 inhibits prostaglandin E2-induced allodynia in conscious mice.
Topics: Adrenergic Agonists; Animals; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; gamma-Amino | 1996 |
Effects of spinal cord stimulation on touch-evoked allodynia involve GABAergic mechanisms. An experimental study in the mononeuropathic rat.
Topics: Animals; Baclofen; Electric Stimulation; GABA Agonists; GABA Antagonists; GABA-A Receptor Agonists; | 1996 |
Involvement of the frontal ventrolateral orbital cortex in descending inhibition of nociception mediated by the periaqueductal gray in rats.
Topics: Animals; Coloring Agents; Frontal Lobe; gamma-Aminobutyric Acid; Glutamic Acid; Microinjections; Neu | 1997 |
Erythromelalgia pain managed with gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Child; Cyclohexanecarboxylic Acids; Erythromelalgia; Female; Ga | 1997 |
Spinal gabapentin is antinociceptive in the rat formalin test.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, | 1997 |
Loss of GABA-immunoreactivity in the spinal dorsal horn of rats with peripheral nerve injury and promotion of recovery by adrenal medullary grafts.
Topics: Adrenal Medulla; Animals; Behavior, Animal; Cell Transplantation; Chromaffin Cells; gamma-Aminobutyr | 1997 |
[Neurophysiology of pain. Current aspects].
Topics: Enkephalins; gamma-Aminobutyric Acid; Humans; Neural Inhibition; Neurons, Afferent; Nociceptors; Pai | 1980 |
The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain.
Topics: Acetates; Acute Disease; Amines; Analgesics; Animals; Anticonvulsants; Chronic Disease; Cyclohexanec | 1997 |
Gabapentin for idiopathic trigeminal neuralgia: report of two cases.
Topics: Acetates; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapent | 1997 |
Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobut | 1997 |
Involvement of supraspinal GABA-ergic systems in clonidine-induced antinociception in the tail-pinch test in mice.
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics; Animals; Baclofen; Bicuculline; Clonidine; GABA An | 1997 |
Pain in Guillain-Barré syndrome.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 1997 |
Gabapentin reverses the allodynia produced by the administration of anti-GD2 ganglioside, an immunotherapeutic drug.
Topics: Acetates; Amines; Analgesics; Animals; Antibodies, Monoclonal; Blood Pressure; Cyclohexanecarboxylic | 1998 |
The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat.
Topics: Acetates; Amines; Animals; Anticonvulsants; Burns; Cyclohexanecarboxylic Acids; Dose-Response Relati | 1998 |
Supraspinal inhibition of nociceptive dorsal horn neurones in the anaesthetized rat: tonic or dynamic?
Topics: Anesthesia; Anesthetics, Local; Animals; Efferent Pathways; Electromyography; Electrophysiology; Evo | 1998 |
[Preemptive analgesia].
Topics: Animals; Bicuculline; Dose-Response Relationship, Drug; Formaldehyde; GABA Antagonists; gamma-Aminob | 1997 |
Gabapentin induced polyneuropathy.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 1998 |
Gabapentin for lancinating neuropathic pain.
Topics: Acetates; Acquired Immunodeficiency Syndrome; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabap | 1998 |
Attenuation of formalin-induced nociceptive behaviors following local peripheral injection of gabapentin.
Topics: Acetates; Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Dose-Response | 1998 |
Modulation of spinal pain mechanisms by spinal cord stimulation and the potential role of adjuvant pharmacotherapy.
Topics: Adenosine; Animals; Baclofen; Behavior, Animal; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 1997 |
Characteristics of neurons with high-frequency discharge in the central nervous system and their relationship to chronic pain. Experimental and clinical investigations.
Topics: Animals; Calcium Channel Blockers; Chronic Disease; Denervation; Disease Models, Animal; Electric St | 1997 |
A case of spinal cord injury-related pain with baseline rCBF brain SPECT imaging and beneficial response to gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Brain; Cerebrovascular Circulation; Cyclohexanecarboxylic Acids | 1998 |
Symptomatic treatment of painful neuropathy.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; G | 1998 |
Gabapentin for treatment of neuropathic pain in a 12-year-old girl.
Topics: Acetates; Amines; Child; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; H | 1998 |
Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats.
Topics: Acetates; Afferent Pathways; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Disease | 1999 |
Effects of CCK antagonists on GABA mechanism-induced antinociception in the formalin test.
Topics: Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Baclofen; Dose-Response Relationship, Drug; F | 1999 |
Gabapentin for painful diabetic neuropathy.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Double-Blind Metho | 1999 |
Sex differences in pain.
Topics: Adult; Female; gamma-Aminobutyric Acid; Gonadal Steroid Hormones; Humans; Male; Middle Aged; Nerve G | 1997 |
Sex differences in pain.
Topics: Adult; Female; gamma-Aminobutyric Acid; Gonadal Steroid Hormones; Humans; Male; Middle Aged; Nerve G | 1997 |
Sex differences in pain.
Topics: Adult; Female; gamma-Aminobutyric Acid; Gonadal Steroid Hormones; Humans; Male; Middle Aged; Nerve G | 1997 |
Sex differences in pain.
Topics: Adult; Female; gamma-Aminobutyric Acid; Gonadal Steroid Hormones; Humans; Male; Middle Aged; Nerve G | 1997 |
Sex differences in pain.
Topics: Adult; Female; gamma-Aminobutyric Acid; Gonadal Steroid Hormones; Humans; Male; Middle Aged; Nerve G | 1997 |
Sex differences in pain.
Topics: Adult; Female; gamma-Aminobutyric Acid; Gonadal Steroid Hormones; Humans; Male; Middle Aged; Nerve G | 1997 |
Sex differences in pain.
Topics: Adult; Female; gamma-Aminobutyric Acid; Gonadal Steroid Hormones; Humans; Male; Middle Aged; Nerve G | 1997 |
Sex differences in pain.
Topics: Adult; Female; gamma-Aminobutyric Acid; Gonadal Steroid Hormones; Humans; Male; Middle Aged; Nerve G | 1997 |
Sex differences in pain.
Topics: Adult; Female; gamma-Aminobutyric Acid; Gonadal Steroid Hormones; Humans; Male; Middle Aged; Nerve G | 1997 |
Tiagabine antinociception in rodents depends on GABA(B) receptor activation: parallel antinociception testing and medial thalamus GABA microdialysis.
Topics: Abdomen; Animals; Baclofen; Constriction, Pathologic; Dose-Response Relationship, Drug; Escape React | 1999 |
Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat.
Topics: Acetates; Amines; Amitriptyline; Analgesics; Animals; Cyclohexanecarboxylic Acids; Diabetes Mellitus | 1999 |
Gabapentin for painful diabetic neuropathy.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Gabapentin; gamma- | 1999 |
Gabapentin for painful diabetic neuropathy.
Topics: Acetates; Amines; Analgesics; Antidepressive Agents, Tricyclic; Cyclohexanecarboxylic Acids; Diabeti | 1999 |
Behavioral effects of RS-45041-190, a selective I2 imidazoline ligand, in rats.
Topics: Acetates; Amines; Analgesics; Animals; Carrageenan; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 1999 |
The effect of intrathecal gabapentin on pain behavior and hemodynamics on the formalin test in the rat.
Topics: Acetates; Amines; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Dose-Response Relationship | 1999 |
Use of gabapentin to treat taxane-induced myalgias.
Topics: Acetates; Amines; Analgesics; Antineoplastic Agents, Phytogenic; Cyclohexanecarboxylic Acids; Doceta | 1999 |
The race to control pain: more participants, more targets.
Topics: Acetates; Amines; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gabapentin; gamma- | 1999 |
Gabapentin leads to remission of somatoform pain disorder with major depression.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Depressive Disorder; Female; Gabapen | 1999 |
Central GABA activation and behaviors evoked by tail-pinch stress in the rat.
Topics: Animals; Behavior, Animal; Defecation; GABA Agonists; gamma-Aminobutyric Acid; Injections, Intravent | 1999 |
Repeated administration of systemic gabapentin alleviates allodynia-like behaviors in spinally injured rats.
Topics: Acetates; Amines; Analgesics; Animals; Cold Temperature; Cyclohexanecarboxylic Acids; Drug Administr | 2000 |
Synergistic effect between intrathecal non-NMDA antagonist and gabapentin on allodynia induced by spinal nerve ligation in rats.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxy | 2000 |
Immunocytochemical localization of neurokinin B in the rat spinal dorsal horn and its association with substance P and GABA: an electron microscopic study.
Topics: Animals; Axons; gamma-Aminobutyric Acid; Immunohistochemistry; Male; Microscopy, Electron; Neurokini | 2000 |
Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia.
Topics: Adenosine Triphosphate; Animals; Arachidonic Acids; Behavior, Animal; Capsaicin; Carrageenan; Cells, | 2000 |
Gabapentin for treatment of thalamic pain syndrome.
Topics: Acetates; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric | 2000 |
Gabapentin in acute painful diabetic neuropathy.
Topics: Acetates; Acute Disease; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathie | 2000 |
Pharmacological and immunohistochemical characterization of a mouse model of acute herpetic pain.
Topics: Acetates; Amines; Amitriptyline; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; | 2000 |
Painful gynecomastia: an unusual toxicity of gabapentin?
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; | 2000 |
Gabapentin for chronic pain in spinal cord injury: a case report.
Topics: Acetates; Adult; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Female; Gabapenti | 2000 |
Gabapentin, an adjuvant treatment for neuropathic pain in a cancer hospital.
Topics: Acetates; Amines; Analgesics; Cancer Care Facilities; Cyclohexanecarboxylic Acids; Gabapentin; gamma | 2000 |
Antinociceptive effect of systemic gabapentin in mononeuropathic rats, depends on stimulus characteristics and level of test integration.
Topics: Acetates; Amines; Analgesics; Animals; Cold Temperature; Cyclohexanecarboxylic Acids; Gabapentin; ga | 2000 |
Malignant appearing cachexia in an older patient with Bruns-Garland syndrome.
Topics: Acetates; Aged; Amines; Analgesics; Cachexia; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2 | 2000 |
Periaqueductal grey mediated inhibition of responses to noxious stimulation is dynamically activated in a rat model of neuropathic pain.
Topics: Animals; gamma-Aminobutyric Acid; Homocysteine; Ligation; Male; Microinjections; Neural Inhibition; | 2001 |
Gabapentin antinociception in mice with acute herpetic pain induced by herpes simplex virus infection.
Topics: Acetates; Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Drug Tolerance | 2001 |
Electrophysiologic evidence for increased endogenous gabaergic but not glycinergic inhibitory tone in the rat spinal nerve ligation model of neuropathy.
Topics: Animals; Bicuculline; Cold Temperature; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; G | 2001 |
Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin.
Topics: Acetates; Amines; Analgesics; Animals; Behavior, Animal; Chronic Disease; Contusions; Cyclohexanecar | 2000 |
A population of large lamina I projection neurons with selective inhibitory input in rat spinal cord.
Topics: Amino Acid Transport Systems, Neutral; Animals; Carrier Proteins; Cholera Toxin; Female; gamma-Amino | 2001 |
G protein-coupled receptor kinase 2 mediates mu-opioid receptor desensitization in GABAergic neurons of the nucleus raphe magnus.
Topics: Amino Acid Sequence; Analgesics, Opioid; Animals; beta-Adrenergic Receptor Kinases; Binding Sites; C | 2001 |
The behavioural importance of dynamically activated descending inhibition from the nucleus reticularis gigantocellularis pars alpha.
Topics: Animals; Behavior, Animal; Efferent Pathways; gamma-Aminobutyric Acid; Homocysteine; Ligation; Male; | 2001 |
Three-month follow-up of shoulder-hand syndrome induced by phenobarbital and treated with gabapentin.
Topics: Acetaminophen; Acetates; Amines; Analgesics; Anticonvulsants; Arthralgia; Cyclohexanecarboxylic Acid | 2001 |
Gabapentin for opiod-related myoclonus in cancer patients.
Topics: Acetates; Amines; Analgesics, Opioid; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamm | 2001 |
Vincristine-induced allodynia in the rat.
Topics: Acetates; Amines; Analgesics; Animals; Antineoplastic Agents, Phytogenic; Body Weight; Cyclohexaneca | 2001 |
[Role of the GABA-ergic and adrenergic system in transmission and modulation of pain and possibilities of pharmacologic control].
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Animals; Benzodiazepines; gamma-Ami | 2001 |
Treatment of pain with gabapentin in a neonate.
Topics: Acetates; Amines; Analgesics; Arthrogryposis; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobu | 2001 |
Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami | 2001 |
Gabapentin for pain control in cancer patients' wound dressing care.
Topics: Acetates; Amines; Analgesics; Bandages; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric | 2001 |
Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain.
Topics: Alanine; Amidohydrolases; Amino Acids; Animals; Arachidonic Acid; Arachidonic Acids; Brain; Calcium; | 2001 |
NMDA or non-NMDA receptor antagonists attenuate increased Fos expression in spinal dorsal horn GABAergic neurons after intradermal injection of capsaicin in rats.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Blotting, Western; Capsa | 2001 |
Changes in exploratory behavior as a measure of chronic central pain following spinal cord injury.
Topics: Acetates; Amines; Analgesics; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Exploratory Beh | 2001 |
Treating painful diabetic neuropathy with gabapentin.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Dose-Response Rela | 2001 |
Glutamate and GABA: a painful combination.
Topics: Animals; gamma-Aminobutyric Acid; Glutamic Acid; Pain; Posterior Horn Cells; Receptors, Kainic Acid | 2001 |
Spinal GABA(B)-receptor antagonism increases nociceptive transmission in vivo.
Topics: Action Potentials; Animals; Carrageenan; Dose-Response Relationship, Drug; Electric Stimulation; GAB | 2001 |
Synaptic connections between trigemino-parabrachial projection neurons and gamma-aminobutyric acid- and glycine-immunoreactive terminals in the rat.
Topics: Animals; Dendrites; gamma-Aminobutyric Acid; Glycine; Horseradish Peroxidase; Immunohistochemistry; | 2001 |
PGE(2) selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Cholera Toxin; Cyclic AMP-Depende | 2002 |
Stereospecific effect of pregabalin on ectopic afferent discharges and neuropathic pain induced by sciatic nerve ligation in rats.
Topics: Animals; Anticonvulsants; Behavior, Animal; Electrophysiology; gamma-Aminobutyric Acid; Ligation; Ma | 2001 |
[Diabetic neuropathies].
Topics: Acetates; Amines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbamazepine; Controlled Clinic | 2001 |
Gabapentin treatment of multiple piloleiomyoma-related pain.
Topics: Acetates; Administration, Oral; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; | 2002 |
Baclofen inhibits ANP-mediated cyclic GMP synthesis in the rat cervical spinal cord.
Topics: Aging; Animals; Atrial Natriuretic Factor; Baclofen; Cervical Vertebrae; Cyclic GMP; GABA Agonists; | 2002 |
A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Animals; Cyclohexanecarboxylic Acids; Electrophysi | 2002 |
The interaction between gabapentin and amitriptyline in the rat formalin test after systemic administration.
Topics: Acetates; Amines; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Animals; Behavior, Animal; Cy | 2002 |
Pre- and postsynaptic localizations of the CB1 cannabinoid receptor in the dorsal horn of the rat spinal cord.
Topics: Afferent Pathways; Animals; Cannabinoids; gamma-Aminobutyric Acid; Ganglia, Spinal; Immunohistochemi | 2002 |
Effects of analgesics on delayed postherpetic pain in mice.
Topics: Acetates; Acute Disease; Acyclovir; Amines; Analgesics; Analgesics, Opioid; Animals; Antiviral Agent | 2002 |
Spinal GABA(A) and GABA(B) receptor pharmacology in a rat model of neuropathic pain.
Topics: Animals; GABA Agonists; GABA-A Receptor Agonists; GABA-B Receptor Agonists; gamma-Aminobutyric Acid; | 2002 |
Gabapentin potentiates N-methyl-D-aspartate receptor mediated currents in rat GABAergic dorsal horn neurons.
Topics: Acetates; Afferent Pathways; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Fluorescent D | 2002 |
Gabapentin for neuropathic pain following spinal cord injury.
Topics: Acetates; Acute Disease; Adolescent; Adult; Aged; Amines; Chronic Disease; Cyclohexanecarboxylic Aci | 2002 |
Gabapentin (neuronetin) in the treatment of SUNCT syndrome.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Ac | 2002 |
Experimental conditions for the continuous subcutaneous infusion of four central analgesics in rats.
Topics: Acetates; Amines; Analgesics; Anesthetics, Dissociative; Animals; Anticonvulsants; Antidepressive Ag | 2002 |
Constraints on inferring neurochemical involvement in behavior.
Topics: Animals; Behavior; Brain; Brain Mapping; Corpus Striatum; Dopamine; Endorphins; gamma-Aminobutyric A | 1978 |
[Myocardial energy metabolic disorders in emotional-pain stress and the prevention of these disorders by using sodium gamma-oxybutyrate].
Topics: Animals; Citric Acid Cycle; Energy Metabolism; Enzyme Activation; Female; gamma-Aminobutyric Acid; G | 1978 |
[Activation of GABA biosynthesis in the brain as a protective mechanism in emotional pain stress].
Topics: Aminobutyrates; Animals; Brain; Defense Mechanisms; gamma-Aminobutyric Acid; Glutamates; Humans; Hyd | 1978 |
Morphine and pain: effects on aspartate, GABA and glutamate in four discrete areas of mouse brain.
Topics: Aminobutyrates; Animals; Aspartic Acid; Brain; Cerebral Cortex; Dose-Response Relationship, Drug; ga | 1976 |
Widely distributed GABA-mediated afferent inhibition processes within the ventrobasal thalamus of rat and their possible relevance to pathological pain states and somatotopic plasticity.
Topics: Animals; Conditioning, Operant; GABA Antagonists; GABA-A Receptor Antagonists; gamma-Aminobutyric Ac | 1992 |
Role of the deep mesencephalic nucleus in the antinociception induced by stimulation of the anterior pretectal nucleus in rats.
Topics: Animals; Electric Stimulation; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Mesencephalon; Mi | 1992 |
Glutamate-immunoreactive terminals synapse on primate spinothalamic tract cells.
Topics: Animals; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Immunohistochemistry; Macaca fascicular | 1992 |
GABA-immunoreactive terminals synapse on primate spinothalamic tract cells.
Topics: Animals; gamma-Aminobutyric Acid; Immunohistochemistry; Macaca fascicularis; Nerve Endings; Pain; Se | 1992 |
GABAergic and cholinergic mediation in the antinociceptive action of homotaurine.
Topics: Acetates; Acetic Acid; Analgesics; Animals; Baclofen; gamma-Aminobutyric Acid; Immersion; Male; Mice | 1992 |
Light and electron microscope study of GABA-immunoreactive neurones in lamina III of rat spinal cord.
Topics: Animals; gamma-Aminobutyric Acid; Glycine; Male; Microscopy, Electron; Neurons; Neurons, Afferent; P | 1992 |
Inhibition of rubral neurons by noxious and non-noxious pressure.
Topics: Animals; Electrophysiology; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Hindlimb; Ibotenic A | 1991 |
Neuropharmacological studies on the venom of Vipera russelli.
Topics: Aggression; Animals; Behavior, Animal; Body Temperature; Brain; Chlorpromazine; Dose-Response Relati | 1991 |
GABAergic circuitry in the rostral ventral medulla of the rat and its relationship to descending antinociceptive controls.
Topics: Animals; gamma-Aminobutyric Acid; Immunohistochemistry; Male; Medulla Oblongata; Nerve Endings; Neur | 1991 |
[The neural pathway from nucleus accumbens to amygdala in morphine analgesia of the rabbit].
Topics: Amygdala; Analgesics; Animals; gamma-Aminobutyric Acid; Male; Morphine; Naloxone; Neural Pathways; N | 1990 |
Contribution of brainstem GABAergic circuitry to descending antinociceptive controls: I. GABA-immunoreactive projection neurons in the periaqueductal gray and nucleus raphe magnus.
Topics: Animals; Brain Stem; gamma-Aminobutyric Acid; Immunohistochemistry; Male; Medulla Oblongata; Neural | 1990 |
Contribution of brainstem GABAergic circuitry to descending antinociceptive controls: II. Electron microscopic immunocytochemical evidence of GABAergic control over the projection from the periaqueductal gray to the nucleus raphe magnus in the rat.
Topics: Animals; Brain Stem; gamma-Aminobutyric Acid; Immunoenzyme Techniques; Male; Microscopy, Electron; N | 1990 |
Noxious somatic stimuli excite neurosecretory vasopressin cells via A1 cell group.
Topics: Animals; Arginine Vasopressin; Electric Stimulation; gamma-Aminobutyric Acid; Hindlimb; Injections; | 1990 |
[Pain and chemical transmitters].
Topics: Animals; Enkephalins; gamma-Aminobutyric Acid; Ganglia, Spinal; Neurotransmitter Agents; Nociceptors | 1988 |
GABAergic agents-induced antinociceptive effect in mice.
Topics: Analgesics; Animals; Baclofen; Bicuculline; Female; gamma-Aminobutyric Acid; Male; Mice; Morphine; M | 1989 |
[The influence of GABA injected into cerebral ventricle on electrical activities of pain-excitation neurons and pain-inhibition neurons in nucleus parafascicularis of the thalamus of rats].
Topics: Animals; Electrophysiology; Female; gamma-Aminobutyric Acid; Injections, Intraventricular; Male; Neu | 1989 |
Pharmacology of descending control systems.
Topics: Amino Acids; Animals; Biogenic Amines; Cats; Central Nervous System; Efferent Pathways; Endorphins; | 1985 |
[Effect of adrenoblockers on the analgesic effect of GABA-positive preparations].
Topics: Adrenergic alpha-Antagonists; Analgesics; Animals; Dopamine beta-Hydroxylase; Drug Interactions; gam | 1986 |
Endogenous GABA released into the fourth ventricle of the rat brain in vivo is enhanced by noxious stimuli.
Topics: Animals; Cerebral Ventricles; Formaldehyde; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Male | 1988 |
[Progabide treatment of a case of the syndrome of painful legs and moving toes].
Topics: Adult; Female; gamma-Aminobutyric Acid; Humans; Leg; Middle Aged; Movement Disorders; Pain; Receptor | 1985 |
Involvement of the midbrain reticular formation in self-injurious behavior, stereotyped behavior, and analgesia induced by intranigral microinjection of muscimol.
Topics: Animals; Brain Mapping; gamma-Aminobutyric Acid; Male; Mesencephalon; Muscimol; Pain; Rats; Rats, In | 1986 |
The parafasciculus thalami as a site for mediating the antinociceptive response to GABAergic drugs.
Topics: Animals; gamma-Aminobutyric Acid; Isoxazoles; Male; Morphine; Pain; Rats; Rats, Inbred Strains; Rece | 1986 |
Nociceptive responses to altered GABAergic activity at the spinal cord.
Topics: Animals; Bicuculline; Female; gamma-Aminobutyric Acid; Injections, Spinal; Motor Activity; Muscimol; | 1986 |
Neurobehavioral, neuroendocrine and neurochemical effects of zinc supplementation in rats.
Topics: Adrenocorticotropic Hormone; Animals; Baclofen; Behavior, Animal; beta-Endorphin; Brain; Diazepam; E | 1986 |
Barbiturate-induced inhibition of a spinal nociceptive reflex: role of GABA mechanisms and descending modulation.
Topics: Analgesics; Animals; Depression, Chemical; gamma-Aminobutyric Acid; Male; Pain; Pentobarbital; Rats; | 1987 |
[Ontogeny of GABAergic modulation on locomotor activity and pain reactivity in mice].
Topics: Animals; Brain; Drug Tolerance; Female; gamma-Aminobutyric Acid; Male; Mice; Motor Activity; Muscimo | 1988 |
GABAergic modulation of nociceptive threshold: effects of THIP and bicuculline microinjected in the ventral medulla of the rat.
Topics: Animals; Bicuculline; gamma-Aminobutyric Acid; Isoxazoles; Male; Medulla Oblongata; Microinjections; | 1988 |
[Potentiation of acupuncture analgesia by GABA in the dorsal raphe nucleus].
Topics: 3-Mercaptopropionic Acid; Acupuncture Therapy; Animals; Bicuculline; Electric Stimulation Therapy; g | 1986 |
An antinociceptive profile of kojic amine: an analogue of gamma-aminobutyric acid (GABA).
Topics: Animals; Atropine; Atropine Derivatives; Baclofen; gamma-Aminobutyric Acid; Isoxazoles; Male; Mice; | 1987 |
Effects of midbrain stimulation and iontophoretic application of serotonin, noradrenaline, morphine and GABA on electrical thresholds of afferent C- and A-fibre terminals in cat spinal cord.
Topics: Animals; Cats; Electric Stimulation; Female; gamma-Aminobutyric Acid; Male; Morphine; Norepinephrine | 1987 |
Evidence for GABA involvement in midbrain control of medullary neurons that modulate nociceptive transmission.
Topics: Action Potentials; Animals; Bicuculline; gamma-Aminobutyric Acid; Male; Medulla Oblongata; Morphine; | 1986 |
Inhibition of nociceptive responses of laminae V-VII dorsal horn neurones by stimulation of mixed and muscle nerves, in the cat.
Topics: Animals; Cats; Decerebrate State; Electric Stimulation; Endorphins; Female; gamma-Aminobutyric Acid; | 1987 |
Shock controllability and opioid substrates of escape performance and nociception: differential effects of peripherally and centrally acting naltrexone.
Topics: Animals; Brain; Endorphins; Escape Reaction; gamma-Aminobutyric Acid; Male; Naltrexone; Nervous Syst | 1985 |
[Effect of changing the functional state of SII by GABA on the acupuncture effect of PF neurons].
Topics: Acupuncture Therapy; Animals; Cats; Electric Stimulation; Evoked Potentials; gamma-Aminobutyric Acid | 1985 |
GABA uptake inhibitors produce a greater antinociceptive response in the mouse tail-immersion assay than other types of GABAergic drugs.
Topics: Analgesics; Animals; Biological Transport; Brain; Corpus Striatum; GABA Antagonists; gamma-Aminobuty | 1985 |